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This	 thesis	 is	 aimed	at	 gaining	 insight	 into	 the	neural	 and	genetic	mechanisms	underlying	 the	relatively	 common	 neurodevelopmental	 disorders	 attention-deficit/hyperactivity	 disorder	(ADHD),	autism	spectrum	disorder	(ASD),	obsessive	compulsive	disorder	(OCD)	and,	to	a	lesser	extent,	Tourette’s	disorder	(TD).	More	specifically,	the	focus	is	on	shared	and	unique	underlying	mechanisms	related	to	the	fronto-striatal	circuits	and	the	role	of	the	glutamate	neurotransmitter	system.	 In	 the	 following	 sections,	 a	 more	 elaborate	 description	 is	 given	 of	 the	 clinical	manifestation	of	the	disorders	and	their	overlap	as	well	as	an	overview	of	the	current	knowledge	regarding	 their	 neurobiology	 and	 genetics.	 Finally,	 an	 outline	 of	 the	 chapters	 in	 this	 thesis	 is	given.		
ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD) 	ADHD	 is	 one	 of	 the	 most	 common	 neurodevelopmental	 disorders,	 affecting	 around	 5%	 of	children	worldwide	(Polanczyk	et	al.	2007;	Polanczyk	et	al.	2014).	The	core	symptoms	present	in	ADHD	are	inattention	and/or	hyperactivity/impulsivity,	which	lead	to	impairments	in	social,	academic	and/or	occupational	functioning	(American	Psychiatric	Association	2013).	Although	it	is	 characterized	 as	 a	 childhood	 disorder,	 ADHD	 can	 persist	 into	 adulthood,	 with	 estimates	 of	persistence	 up	 to	 60%,	 depending	 on	 the	 criteria	 used	 (Barbaresi	 et	 al.	 2013;	 Faraone	 et	 al.	2015).	 Three	 subtypes	 of	 ADHD	 can	 be	 classified:	 a	 predominantly	 hyperactive/impulsive	subtype,	 a	 predominantly	 inattentive	 subtype,	 and	 the	 combined	 subtype,	 presenting	 both	inattention	 and	 hyperactivity/impulsivity.	 In	 the	 Diagnostic	 and	 Statistical	 Manual	 of	 Mental	Disorders	 5	 (DSM-5)	 these	 subtypes	 are	 now	 called	 presentations	 (American	 Psychiatric	Association	 2013).	 In	 addition	 to	 the	 classical	 symptoms,	 ADHD	 is	 further	 characterized	 by	impairments	 in	 cognitive	 control	 (Sonuga-Barke,	 Bitsakou,	 and	 Thompson	 2010)	 and	 reward	processing	 (Durston,	 van	 Belle,	 and	 de	 Zeeuw	 2011)	 and	 also	motor	 deficits	 are	 reported	 in	children	 with	 ADHD	 (Fliers	 et	 al.	 2010).	 Cognitive	 deficits	 related	 to	 ADHD	 are	 assumed	 to	originate	from	dysfunction	of	certain	neural	circuits,	which	has	led	to	much	research	effort	into	the	 underlying	 neurobiology	 of	 ADHD.	 Key	 regions	 investigated	 in	 ADHD	 –	 but	 also	 other	neurodevelopmental	disorders	–	are	parts	of	the	fronto-striatal	circuit.		
AUTISM SPECTRUM DISORDER (ASD) 	ASDs	 have	 a	 prevalence	 of	 1.5%	 (Baird	 et	 al.	 2006;	 Geschwind	 and	 State	 2015)	 and	 are	characterized	by	deficits	in	reciprocal	social	 interaction	and	communication,	abnormal	sensory	experiences	and	by	restricted,	repetitive	and	stereotypical	patterns	of	behaviour,	 interests	and	activities	(American	Psychiatric	Association	2013).	Symptoms	in	the	latter	domain,	of	particular	
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relevance	 for	 the	current	 thesis,	 include	a	strong	 interest	 in	non-functional	 routines	or	rituals,	preoccupations	 with	 one	 narrow	 topic	 and	 stereotyped	 and	 repetitive	 motor	 behaviours	 and	body	movements.	 ASDs	 are	more	 prevalent	 in	 boys,	 have	 an	 onset	 prior	 to	 age	 3	 years	 and	 a	strong	 persistence	 over	 time	 in	 older	 childhood,	 adolescence	 and	 into	 adulthood	 (Geschwind	and	 State	 2015).	 People	with	 ASD	 also	 show	 other	 phenotypes,	 such	 as	 intellectual	 disability	(35%)	 or	 language	 delay	 (50%).	 Additionally,	 ASD	 is	 highly	 comorbid	 with	 ADHD	 (Matson,	Rieske,	and	Williams	2013)	and	OCD	(Mazzone,	Ruta,	and	Reale	2012;	Russell	et	al.	2005).	The	core	symptoms	of	ASD	are	accompanied	by	changes	in	brain	structure	and	functioning	that	affect	behaviour	across	the	lifespan	(Ecker,	Bookheimer,	and	Murphy	2015).		
OBSESSIVE COMPULSIVE DISORDER (OCD) 	OCD	 is	 characterized	 by	 repetitive	 thoughts,	 impulses	 or	 images	 (obsessions)	 and	 repetitive	behaviours	or	mental	acts	(compulsions)	 that	usually	cause	marked	distress	and/or	 functional	impairment	 (American	 Psychiatric	 Association	 2013).	 Obsessions	 are	 frequent,	 intrusive,	stereotypical	 thoughts.	 They	 are	 recognised	 as	 being	 foreign	 and	 unrealistic	 and	 are	 often	associated	 with	 anxiety.	 Compulsions	 are	 repetitive,	 ritualized	 behaviours,	 usually	 related	 to	specific	obsessions	and	performed	to	alleviate	the	anxiety	caused	by	these	obsessions.	OCD	has	its	onset	 in	 late	childhood	and	 is	present	 in	about	2.5%	of	 the	adult	population	(Nestadt	et	al.	2009;	Abramowitz,	Taylor,	and	McKay	2009).	Notably,	30–50%	of	patients	develop	OCD	starting	in	 childhood	 (Stewart	 et	 al.	 2004),	 and	 early-onset	 OCD	 may	 represent	 a	 more	 severe	developmental	subtype	of	the	disorder	(Rosario-Campos	et	al.	2001;	Taylor	2011).	The	clinical	heterogeneity	of	OCD	is	accompanied	by	a	complex	underlying	neurobiology	(Pauls	et	al.	2014).	The	common	feature	of	OCD,	having	obsessions	and	trying	to	reduce	these	by	performing	certain	compulsive	 behaviours,	 is	 suggested	 to	 be	 regulated	 by	 specific	 brain	 regions	 involved	 in	 the	cortico-striatal	thalamo-cortical	circuits,	in	which	the	prefrontal	cortex	(PFC)	and	striatum	play	key	roles	(Saxena	and	Rauch	2000;	Whiteside,	Port,	and	Abramowitz	2004).			
TOURETTE’S DISORDER (TD) 	TD	is	a	childhood-onset	neuropsychiatric	disorder	characterized	by	multiple	motor	tics	and	one	or	more	 vocal	 tics	 that	 persist	 for	 at	 least	 one	 year	 (Swain	 et	 al.	 2007;	 American	 Psychiatric	Association	2013).	Tics	appear	as	sudden,	rapid,	purposeless	motor	movements	or	sounds	that	involve	discrete	muscle	groups.	They	are	stereotypical	 in	that	they	occur	in	a	similar	way	each	time	they	are	performed	(Cohen,	Leckman,	and	Bloch	2013).	The	prevalence	of	TD	varies	based	on	 study	 design	 and	 location.	 An	 international	 prevalence	 of	 0.6–1%	 has	 been	 reported	 for	
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mainstream	schoolchildren,	with	 the	disorder	being	3–4	times	more	common	 in	males	 than	 in	females	 (Cavanna	 and	 Termine	 2012).	 In	 90%	 of	 the	 cases,	 vocal	 and	 motor	 tics	 are	accompanied	 by	 comorbidities	 such	 as	 ADHD	 and	 OCD	 (Robertson	 2012;	 Robertson	 2008).	Although	still	very	little	is	known	about	the	neurobiology	underlying	TD,	the	involvement	of	the	basal	ganglia	and	the	PFC	has	been	repeatedly	described	(e.g.	Makki	et	al.	2009;	Cavanna,	Eddy,	and	Rickards	2009).		
OVERLAP IN DISORDERS: IMPULSIVITY AND COMPULSIVITY 	ADHD,	 ASD,	 OCD	 and	 TD	 are	 all	 highly	 comorbid.	 For	 instance,	 30-80%	 of	 children	with	 ASD	present	with	 symptoms	 of	 ADHD	 that	 pass	 the	 threshold	 for	 diagnosis	 (Sprenger	 et	 al.	 2013;	Rommelse	et	al.	2011;	Matson,	Rieske,	and	Williams	2013).	Vice	versa,	20-50%	of	children	with	ADHD	show	similar	deficits	 in	social	 interaction	and	communication	as	seen	in	ASD	(Goldstein	and	Schwebach	2004;	Nijmeijer	et	al.	2008;	Kotte	et	al.	2013).	OCD	diagnoses	 in	children	with	ADHD	are	estimated	at	8%	(Geller	et	al.	2000;	Brem	et	al.	2014)	while	OCD	and	ASD	symptom	comparisons	 have	 demonstrated	 more	 similarities	 than	 differences	 (Anholt	 et	 al.	 2010).	 The	most	common	comorbidities	within	TD	are	ADHD	(estimated	at	40%	(Rickards	2011))	and	OCD	(Roessner	et	al.	2007;	Roessner	et	al.	2013),	which	in	turn	are	both	often	associated	with	ASD.	To	 a	more	 or	 lesser	 extent,	 all	 disorders	 have	 commonalities	 (Huisman-van	Dijk	 et	 al.	 2016),	which	 may	 be	 due	 to	 overlapping	 deficits	 in	 the	 brain,	 more	 specifically	 in	 areas	 within	 the	fronto-striatal	circuit,	which	are	described	in	more	detail	in	the	next	section.		The	 main	 traits	 overlapping	 between	 the	 disorders	 are	 impulsivity	 and	 compulsivity.	Impulsivity	can	be	defined	as	a	predisposition	towards	rapid	unplanned	reactions	to	internal	or	external	 stimuli	 with	 diminished	 regard	 for	 the	 potentially	 negative	 consequences	 of	 these	reactions	 (Chamberlain	 and	 Sahakian	 2007;	 Fineberg	 et	 al.	 2010).	 Compulsivity,	 on	 the	 other	hand,	 is	 characterized	 by	 a	 repetitive	 and	 irresistible	 urge	 to	 perform	 certain	 behaviour,	 the	experience	of	loss	of	voluntary	control	over	this	urge,	the	diminished	ability	to	delay	or	inhibit	thoughts/behaviours	 and	 the	 tendency	 to	 perform	 acts	 in	 a	 habitual	 or	 stereotyped	 manner	(Chamberlain	and	Menzies	2009).	Both	impulsivity	and	compulsivity	have	been	hypothesized	to	result	 from	 deficits	 in	 response	 inhibition	 or	 top-down	 cognitive	 control	 (Dalley,	 Everitt,	 and	Robbins	 2011),	 which	 in	 turn	 are	 regulated	 by	 fronto-striatal	 functioning.	 Compulsivity,	 in	contrast	 to	 impulsivity,	 is	 considered	 a	 more	 maladaptive	 perseveration	 of	 behaviour,	 which	does	 not	 fall	 into	 the	 range	 of	 normal	 behaviour	 (Robbins	 et	 al.	 2012).	 In	 chapter	 3	 a	 more	elaborate	description	of	these	traits	as	well	as	of	their	associations	with	the	described	disorders	and	the	involvement	of	fronto-striatal	glutamate	is	given.	
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NEUROBIOLOGY OF DEVELOPMENTAL DISORDERS 	Neuroanatomical	models	have	posited	the	existence	of	separate	but	intercommunicating	fronto-striatal	 circuits	 involved	 in	 behavioural	 regulation	 (Alexander,	 Delong,	 and	 Strick	 1986;	Alexander	 and	 Crutcher	 1990;	 Joel	 and	 Weiner	 1994).	 Several	 circuits	 have	 been	 described,	which	have	been	segregated	based	on	function	(e.g.	Di	Martino	et	al.	2008).	As	indicated	above,	these	 circuits	 have	 been	 associated	 with	 both	 impulsivity	 and	 compulsivity	 (Fineberg	 et	 al.	2010).	 Impulsive	 or	 compulsive	 behaviours	 may	 occur	 when	 there	 is	 an	 imbalance	 between	direct	and	indirect	signalling	pathways	within	these	circuits	(Van	den	Heuvel	et	al.	2010).	In	the	direct	pathway,	the	cortex	controls	the	inhibitory	GABAergic	signal	of	the	striatum	to	the	globus	pallidus	internus	via	glutamatergic	projections.	This	leads	to	a	disinhibition	of	the	thalamus	and	consequently	to	increased	excitation	of	the	(PFC).	Indirectly,	when	the	striatum	is	activated	by	cortico-striatal	 signalling,	 it	 inhibits	 the	 globus	 pallidus	 externus,	 leading	 to	 excitation	 of	 the	globus	pallidus	 internus.	The	effect	of	 these	signals	 is	 inhibition	of	 the	 thalamus	and	therefore	less	 excitation	 in	 the	PFC.	These	pathways	 represent	 a	 self-reinforcing	positive	 feedback	 loop,	contributing	to	the	initiation	and	continuation	of	behaviour,	and	a	mechanism	of	modulation	for	the	output	of	the	direct	pathway,	involved	in	behavioural	inhibition	and	switching	(Bolam	et	al.	2000;	Wise,	Murray,	and	Gerfen	1996).	Aberrant	functioning	of	these	pathways	may	result	in	an	increased	 tendency	 of	 executing	 impulsive	 or	 compulsive	 behaviour,	 depending	 on	 which	components	are	affected	(Figure	1).	Neuroimaging	studies	using	magnetic	resonance	imaging	(MRI;	BOX	1)	have	consistently	provided	 evidence	 for	 fronto-striatal	 alterations	 in	 ADHD,	 ASD,	 OCD	 and	 TD,	 using	 both	structural	and	functional	measures.	Structural	alterations	 include	smaller	volumes	of	 the	basal	ganglia	(including	caudate,	putamen,	and	globus	pallidus)	in	ADHD	(Frodl	and	Skokauskas	2012;	Ellison-Wright,	Ellison-Wright,	and	Bullmore	2008)	as	well	as	smaller	global	grey	matter	volume	(Nakao	 et	 al.	 2011;	 Greven	 et	 al.	 2015);	 larger	 total	 brain	 volume	 and	 larger	 cerebellar	 and	caudate	 volumes	 are	 seen	 in	 ASD	 (Stanfield	 et	 al.	 2008),	 where	 larger	 caudate	 volumes	 have	been	 related	 to	 repetitive	 behaviours	 (Hollander	 et	 al.	 2005);	 smaller	 volumes	of	 frontal	 grey	and	white	matter,	 including	anterior	cingulate	cortex	(ACC)	volumes,	are	observed	in	OCD	(De	Wit	et	al.	2014;	Rotge	et	al.	2009);	age-related	prefrontal	changes	and	smaller	caudate	volumes	are	 linked	 to	 TD	 (Felling	 and	 Singer	 2011).	 Additionally,	 by	 using	 diffusion	 tensor	 imaging,	microstructural	 alterations	 in	 fronto-striatal	 white	 matter	 tracts	 have	 been	 shown	 in	 these	disorders	(Koch	et	al.	2014;	Piras	et	al.	2013;	van	Ewijk	et	al.	2012;	Travers	et	al.	2012;	Felling	and	Singer	2011).		Altered	 activation	 patterns	 in	 fronto-striatal	 regions	 during	 various	 cognitive	 tasks	(Dickstein	et	al.	2013;	Hart	et	al.	2012;	Whiteside,	Port,	and	Abramowitz	2004)	as	well	as	during	
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rest	(Oldehinkel	et	al.	2013;	Beckmann	et	al.	2005)	have	been	reported	in	ADHD,	ASD,	OCD	and	TD.	Several	task-based	functional	MRI	(fMRI:	BOX	2)	studies	focused	on	(deficits	in)	inhibitory	control,	which	 is	 supposed	 to	 follow	 from	alterations	 in	 fronto-striatal	 brain	 regions	 (Arnsten	and	 Rubia	 2012;	 Morris	 et	 al.	 2016).	 In	 TD,	 for	 instance,	 active	 suppression	 of	 tics	 has	 been	associated	with	 increased	activity	 in	 frontal	 regions	and	 the	caudate	(Peterson	et	al.	1998).	 In	ASD,	 aberrant	 fronto-striatal	 activation	 patterns	 have	 been	 shown	 in	 cognitive	 control	 tasks,	which	were	 related	 to	 repetitive	 behaviours	 (Dichter	 2012).	 In	ADHD,	 hypo-activation	 during	inhibitory	 control	 tasks	 has	 been	 repeatedly	 reported	 (Cortese	 et	 al.	 2012;	 Hart	 et	 al.	 2012).	Evidence	 from	 resting	 state	 fMRI	 studies	 suggests	 atypical	 functional	 connectivity	 in	 fronto-striatal	networks	in	ADHD	and	decreased	connectivity	between	subcortical	regions	and	the	ACC	in	OCD	(for	an	overview	see	Oldehinkel	et	al.	2013).	In	ASD,	several	hypotheses	exist,	including	long-range	hypo-connectivity/short-range	hyper-connectivity	(Di	Martino	et	al.	2014)	but	also	changes	in	connectivity	during	development	(Uddin,	Supekar,	and	Menon	2013).	Structural	 and	 functional	 changes	might	 be	 associated	with	 altered	 neurochemistry	 of	the	 fronto-striatal	 brain	 regions.	 At	 the	 neurochemical	 level,	 dopamine	 and	 serotonin	 are	 the	most	 intensively	 investigated	 neurotransmitters	 in	 neurodevelopmental	 disorders	 (e.g.	Vermeire	 et	 al.	 2012;	 Buse	 et	 al.	 2013;	 Swanson	 et	 al.	 2000;	 Muller,	 Anacker,	 and	 Veenstra-VanderWeele	2016).	However,	 glutamate	 is	 the	most	 abundant	excitatory	neurotransmitter	 in	the	 human	 central	 nervous	 system	 (Zhou	 and	 Danbolt	 2014;	 Pittenger,	 Bloch,	 and	 Williams	2011)	and	 is	 involved	 in	many	processes	 in	 the	brain,	 including	plasticity	and	cell	elimination.	Because	of	these	important	roles,	it	is	essential	that	glutamate	is	present	in	the	right	amount	in	the	 right	 places	 at	 the	 right	 time;	 both	 too	much	 and	 too	 little	 glutamate	 can	 be	 detrimental.	Glutamate	projections	participate	in	practically	all	communication	in	the	central	nervous	system	(Shepherd	2004;	Shepherd	2004)	and	are	specifically	relevant	 for	 top-down	projections	 in	the	fronto-striatal	 circuit.	 Impulsivity	 and	 compulsivity,	 associated	 with	 aberrant	 fronto-striatal	functioning,	 may	 be	 partly	 explained	 by	 alterations	 in	 glutamatergic	 signalling.	 Proton	 MR	spectroscopy	(1H-MRS;	BOX	3)	studies	have	shown	altered	glutamate	concentrations	in	several	regions	involved	in	the	fronto-striatal	circuit	in	ADHD,	ASD	and	OCD	(see	chapter	3).	In	TD,	no	MRS	 studies	 to	 date	 have	 reported	 changes	 in	 glutamatergic	 compounds,	 but	 several	 lines	 of	evidence	support	a	role	of	glutamatergic	neurotransmission	(Singer,	Morris,	and	Grados	2010).		In	short,	evidence	for	the	involvement	of	fronto-striatal	changes	in	ADHD,	ASD,	OCD	and	TD	 comes	 from	 neuroimaging	 studies	 showing	 structural,	 functional,	 and	 neurochemical	changes.	 However,	 no	 studies	 to	 date	 have	 examined	 common	 and	 unique	 underlying	 neural	substrates	of	the	overlapping	traits	impulsivity	and	compulsivity	across	these	disorders.			
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		 		Figure	 1	 Cortico-striatal	 thalamo	 cortical	 (CSTC)	 loops	 implicated	 in	 compulsivity	 and/or	 impulsivity	(GPe,	 globus	pallidus	 externus;	GPi,	 globus	pallidus	 internus;	 SNc,	 substantia	 nigra	pars	 compacta;	 SNr,	substantia	nigra	pars	reticulata;	STN,	sub-thalamic	nucleus).	Adapted	from	Pittenger,	Bloch,	and	Williams	2011.			
GENETICS OF NEURODEVELOPMENTAL DISORDERS 	Twin	 and	 family	 studies	 have	 provided	 convincing	 evidence	 for	 the	 involvement	 of	 genetic	factors	in	the	causation	of	neurodevelopmental	disorders.	Having	a	first	degree	family	member	with	for	instance	ADHD	increases	the	risk	for	developing	the	disorder	five	times	compared	with	the	population-wide	risk	(Faraone	et	al.	2005).	Furthermore,	having	family	members	presenting	one	disorder	might	increase	the	risk	for	developing	another.	Children	with	ASD	are,	according	to	a	 recent	 longitudinal	 investigation,	 at	 two-fold	 increased	 risk	 of	 developing	OCD	 (Meier	 et	 al.	2015).	 Investigating	 the	 separate	 roles	of	genetic	 influences	and	environmental	 factors	 can	be	achieved	 via	 adoption	 and	 twin	 studies.	 The	 difference	 in	 concordance	 rate	 between	monozygotic	 (MZ)	 and	 dizygotic	 (DZ)	 twins	 can	 be	 used	 as	 an	 estimate	 for	 the	 amount	 of	phenotypic	 variance	 that	 can	 be	 explained	 by	 genetic	 factors.	 In	 TD	 for	 example,	 the	concordance	 rate	 for	MZ	 twins	was	 found	 to	be	86%,	 compared	with	20%	 for	dizygotic	 twins	(Price	et	al.	1985).	There	 is	also	shared	heritability	 in	neurodevelopmental	disorders,	with	 for	instance	estimates	of	genetic	correlations	to	be	0.87	between	ASD	and	ADHD,	0.60	between	ASD	and	tic	disorders	(including	TD)	and	0.41	between	TD	and	OCD	(Lichtenstein	et	al.	2010;	Davis	et	al.	2013).			 Heritability	 estimates	 for	 neurodevelopmental	 disorders	 are	 relatively	 high,	 but	identification	of	specific	genetic	risk	factors	remains	difficult.	These	complications	can	be	partly	
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explained	 by	 the	 phenotypic	 heterogeneity	 of	 neurodevelopmental	 disorders;	 different	phenotypic	expressions	of	a	disorder	might	be	associated	with	different	underlying	genetic	risk	factors.	On	the	other	hand,	different	combinations	of	genetic	risk	factors	may	be	associated	with	similar	 phenotypic	 expressions	 (Franke,	 Neale,	 and	 Faraone	 2009).	 The	 presence	 of	comorbidities	makes	 this	even	more	complicated.	 In	addition	 to	phenotypic	heterogeneity,	 the	complex	genetic	architecture	of	the	disorders	is	hampering	gene-finding.	In	most	patients	with	neurodevelopmental	disorders,	the	underlying	aetiology	is	likely	to	be	polygenic	(Cross-disorder	group	 of	 the	 Psychiatric	 Genomics	 Consortium	 2013;	 McCarthy	 et	 al.	 2008),	 referring	 to	 the	involvement	 of	 multiple	 genetic	 variants.	 Most	 of	 the	 variants	 investigated	 are	 relatively	common	(present	in	at	least	1%	of	the	population)	and	only	explain	little	variance	on	their	own.			 Common	variants	can	be	investigated	by	using	association	studies,	testing	a	correlation	between	a	certain	phenotype	and	genetic	variation	(Lewis	and	Knight	2012).	One	can	do	this	in	a	hypothesis-free	 way	 by	 using	 genome-wide	 association	 studies	 (GWASs)	 in	 which	 all	 single-nucleotide	polymorphisms	(SNPs)	are	considered.	Another	way	to	investigate	common	variants	is	 by	 using	 candidate	 genes.	 In	 a	 candidate	 gene-approach,	 one	 takes	 the	 polygenic	model	 of	neurodevelopmental	disorders	as	a	 starting	point	and	 investigates	 the	 involvement	of	a	 single	variant	or	a	single	gene	in	a	certain	phenotype.	In	addition	to	single	variant/gene	investigations,	as	described	in	multiple	meta-analyses	and	reviews	before	(e.g.	Gizer,	Ficks,	and	Waldman	2009;	Holt	 et	 al.	 2010;	 Gatt	 et	 al.	 2015;	 Warrier	 et	 al.	 2015),	 one	 can	 consider	 several	 to	 multiple	genetic	variants	in	a	single	analysis.	These	mass-univariate	analyses	can	potentially	increase	the	total	 explained	 phenotypic	 variance	 by	 taking	 into	 account	 allelic	 heterogeneity,	 and	 thereby	may	boost	the	power	of	genetic	studies.	Earlier	studies	focusing	on	multiple	variants	within	one	gene	or	candidate	gene-sets	already	showed	potential	for	the	approach	(e.g.	Bralten	et	al.	2011;	Bralten	et	 al.	 2013;	Walsh	et	 al.	 2008).	This	 aggregation	approach	 is	used	 in	 chapter	7	of	 this	thesis.	 In	 addition	 to	 common	 variation,	 one	 can	 also	 investigate	 rare	 variants.	 Rare	 variants	occur	less	frequent	in	the	population	(<1%)	and	are	therefore	more	difficult	to	detect	(Manolio	et	al.	2009;	McCarthy	et	al.	2008).	However,	 they	also	have	 larger	effect	sizes	explaining	more	variance.	 Several	 studies	 point	 to	 an	 important	 contribution	 of	 these	 rare	 variants	 in	neurodevelopmental	disorders.	For	instance,	a	study	in	ADHD	pointed	to	the	involvement	of	rare	recurrent	copy	number	variants	(CNVs)	affecting	glutamatergic	neurotransmission	genes	 (Elia	et	al.	2012).	Recent	research	 in	mainly	ASD,	but	also	ADHD,	has	established	a	role	 for	de	novo	mutations	 (new	 germline	 mutations	 not	 inherited)	 using	 exome	 sequencing	 (Sanders	 et	 al.	2012;	 Takata	 et	 al.	 2016;	 Hawi	 et	 al.	 2016;	 Iossifov	 et	 al.	 2014).	 Less	 is	 known	 about	 the	involvement	 of	 rare	 variants	 in	 OCD	 and	 TD.	 The	 investigation	 of	 these	 variants,	 however,	 is	beyond	the	scope	of	this	thesis.	
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AIMS AND THESIS OUTLINE 	The	 overall	 aim	 of	 this	 thesis	 is	 to	 gain	 insight	 into	 the	 underlying	 neural	 and	 genetic	mechanisms	 of	 ADHD,	 ASD,	 OCD	 and	 TD	 and	 the	 overlap	 and/or	 differences	 across	 these	neurodevelopmental	 disorders	 with	 a	 specific	 focus	 on	 glutamate.	 The	 literature	 available	 to	date	has	already	provided	us	with	several	studies	investigating	the	role	of	glutamate.	However,	studies	 to	date	 lack	 the	 integration	of	 several	disorders	 in	one	design	 to	 study	specifically	 the	cross-disorder	 traits	 compulsivity	 and	 impulsivity.	 In	 this	 thesis,	 the	 previous	 studies	 are	complemented	 by	 considering	 the	 most	 common	 neurodevelopmental	 disorders	 (partly)	together	using	MR	spectroscopy	and	a	genetic	aggregation	approach	and	by	exploring	the	role	of	compulsivity	 (and	 impulsivity)	 in	 a	more	 dimensional	matter.	 This	 is	 in	 accordance	with	 the	recent	 development	 of	 the	 Research	 Domain	 Criteria	 (RDoC;	 Cuthbert	 2014)	 aiming	 to	 apply	dimensional	 cross-disorder	 constructs	 to	 (neurodevelopmental)	 disorders	 in	 addition	 to	 the	classical	 categorical	 classifications.	 To	 gain	 more	 insight	 into	 the	 role	 of	 glutamate	 in	neurodevelopmental	disorders,	we	conducted	a	series	of	studies	that	are	described	throughout	chapters	4	to	7	within	this	thesis.	Chapter	2	and	3	comprise	a	design-manuscript	and	a	literature	review.	In	chapter	8,	an	overall	summary	and	interpretation	in	the	broader	context	is	provided.	Below,	an	outline	of	each	of	the	chapters	is	given.			In	chapter	2,	an	overview	of	the	COMPULS	study	is	presented,	which	was	designed	as	part	of	the	multi-centre	 EU	 project	 TACTICS	 (Translational	 Adolescence	 and	 Childhood	 Therapeutic	Interventions	 in	 Compulsive	 Syndromes),	 and	 is	 described	 in	 a	 more	 elaborate	 design-manuscript	 of	 the	 sample	 used	 in	 chapters	 4	 and	 5	 and	 partly,	 6.	 This	 chapter	 provides	 an	overview	 of	 the	 participants	 included	 in	 the	 COMPULS	 study	 and	 all	 the	measures	 that	 were	collected	 in	 terms	of	 cognitive	 functioning,	 genetics,	 and	neuroimaging.	Chapter	3	provides	an	extensive	 summary	 of	 the	 current	 literature	 regarding	 1H-MRS	 studies	 on	 glutamate	concentrations	in	the	prefrontal	cortex	and	the	striatum	in	children,	adolescents	and	adults	with	ADHD,	ASD	and	OCD.		Chapter	4	zooms	in	on	the	two	neurodevelopmental	disorders	most	strongly	associated	with	compulsivity,	ASD	and	OCD.	1H-MRS	is	used	to	investigate	glutamate	concentrations	in	the	ACC	 and	 dorsal	 striatum,	 two	 central	 regions	 in	 fronto-striatal	 signalling.	 Children	 with	 ASD,	OCD	and	controls	are	included.	In	addition	to	group	differences	in	this	chapter	we	investigated	whether	 continuous	 measures	 of	 compulsivity	 across	 ASD	 and	 OCD	 are	 associated	 with	glutamatergic	alterations	in	fronto-striatal	areas.	Chapter	5	continues	the	work	in	chapter	4	and	describes	 metabolite	 concentrations	 as	 measured	 with	 MRS	 and	 their	 relation	 with	 dorsal	striatal	volume	in	children	with	ASD	and	OCD.	N-acetylaspartate	(NAA),	a	measure	of	neuronal	
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integrity,	 and	 glutamate	 are	 investigated	 in	 relation	 to	 striatal	 volume.	 In	 addition,	 volume	 of	total	dorsal	striatum	and	volume	and	shape	of	the	caudate	nucleus	and	putamen	separately	are	investigated.	 In	 chapter	 6,	 possible	 glutamatergic	 differences	 and	 overlap	 between	 the	 highly	comorbid	disorders	ADHD	and	TD	are	studied.	Again,	1H-MRS	is	used	to	 investigate	glutamate	concentrations	in	the	ACC	and	dorsal	striatum	of	a	large	sample	of	children	with	ADHD,	TD,	both	ADHD	and	TD	and	 controls.	Here	we	 studied	possible	 associations	with	phenotypic	measures,	such	as	tic	severity,	ADHD	severity	and	compulsivity	as	well.	This	investigation	is	not	part	of	the	multi-centre	study	described	in	chapter	5,	but	uses	similar	approaches.		In	 chapter	 7,	 a	 genetic	 approach	 is	 used	 to	 investigate	 the	 overlap	 in	 ADHD	 and	 ASD	symptom	 severity	 in	 an	 ADHD-only	 sample.	 The	 IMAGE	 cohort	 consists	 of	 a	 large	 group	 of	children	 and	 adolescents	 with	 ADHD	 (combined	 subtype).	 ADHD	 symptom	 severity,	 ASD	symptom	severity	(within	ADHD)	and	inhibitory	control	are	studied	with	a	genetic	association	analysis	 using	 glutamatergic	 and	 GABAergic	 gene-sets.	 The	 role	 of	 a	 possible	 imbalance	 in	excitatory-inhibitory	neurotransmission	in	ADHD	and	ASD	is	investigated.		 Chapter	 8	 provides	 a	 summary	 of	 the	 studies	 described	 in	 this	 thesis	 and	 a	 broader	discussion	of	the	findings	in	relation	to	each	other	and	the	clinical	context.	In	addition,	strengths	and	limitations	are	described	and	implications	for	future	research	are	given.		 	
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BOX 1 MRI 	In	 magnetic	 resonance	 imaging	 (MRI)	 a	 static	 magnetic	 field	 is	 used	 to	 align	 the	 magnetic	 dipoles	 of	protons	 (hydrogen	 nuclei)	 in	 the	 brain.	 In	 addition	 to	 the	 static	 field,	 a	 magnetic	 field	 gradient	 is	generated,	 which	 alters	 the	 precessional	 frequency	 of	 protons	 dependent	 on	 their	 position	 on	 the	gradient.	 By	 transmitting	 radio-frequency	pulses,	 the	 spin	 axis	 of	 the	 protons	will	 flip	 out	 of	 alignment	with	the	static	magnetic	field.	If	the	magnetic	field	gradient	is	turned	off,	protons	will	gradually	return	to	their	normal	alignment.	The	radio-frequency	energy	absorbed	by	the	spin	assemblies	will	be	transmitted	and	can	be	picked	up	by	a	receiving	coil.	This	is	called	the	magnetic	resonance	(MR)	signal.	The	MR	signal	can	be	used	to	generate	an	anatomical	 image	of	the	brain.	The	MR	signal	differs	across	different	tissues.	This	variation	in	signal	is	used	to	infer	the	underlying	anatomy,	used	in	structural	MRI	applications. 	
BOX 2 fMRI 	Functional	 MRI	 (fMRI)	 is	 used	 to	 indirectly	 measure	 neuronal	 activity	 in	 certain	 areas	 of	 the	 brain	dependent	on	task-performance	or	resting-state.	This	is	measured	by	using	the	blood-oxygenation	level-dependent	 (BOLD)	 contrast,	 which	 is	 used	 as	 an	 index	 of	 changes	 in	 neuronal	 activity,	 based	 on	 local	changes	 in	oxygen-levels	(Ogawa	et	al.	1990).	 It	relies	on	the	assumption	that	blood-flow	to	brain	areas	which	 are	 active	 increases	 to	provide	 these	 areas	with	oxygen	and	 that	 cerebral	 blood-flow	and	neural	activity	are	thus	coupled.	As	such,	one	can	use	fMRI	to	identify	brain	regions	involved	in	specific	cognitive	processes.	The	brain	is	never	inactive,	and	it	is	the	assumption	that	any	neural	activity	at	a	given	moment	is	 a	 combination	 of	 stimulus-dependent	 activity	 and	 unrelated	 ongoing	 activity	 (Huettel,	 Song,	 and	McCarthy	2004).	 	
BOX 3 1H-MRS 	Proton	 magnetic	 resonance	 spectroscopy	 (1H-MRS)	 is	 a	 non-invasive	 in	 vivo	 technique	 that	 allows	quantification	of	neuro-metabolite	 concentrations.	 In	 the	brain,	 these	concentrations	 reflect	a	variety	of	mechanisms,	such	as	neurotransmission	and	cellular	functioning.	With	1H-MRS,	one	can	create	resonance	signals	from	hydrogen	nuclei	(protons)	in	neurochemical	molecules,	yielding	a	resonance	spectrum	with	peaks	 for	 each	molecule.	 The	 strength	 of	 the	 resonance	 reflects	 the	 concentration	 of	 the	molecule.	 The	most	 commonly	 reported	 neuro-metabolites	 in	 the	 spectrum	 are	 N-acetylaspartate	 (NAA),	 N-acetylaspartylglutamate	 (NAAG),	 together	 referred	 to	 as	 total	NAA	 (tNAA),	 creatine	+	phosphocreatine	(total	 Cr,	 tCr),	 choline	 (Cho),	 myo-inositol	 (mI),	 the	 amino-acids	 glutamate	 (Glu)	 and	 glutamine	 (Gln),	together	 referred	 to	 as	 Glx,	 and	 gamma-aminobutyric	 acid	 (GABA).	 The	 most	 important	 spectral	resonances	for	this	thesis	are	those	for	tNAA	and	the	glutamatergic	compounds. 	  
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COMPULS: Design of a multi-centre phenotypic, cognitive, genetic 
and magnetic resonance imaging study in children with 
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ABSTRACT 	Background:	 Compulsivity,	 the	 closely	 linked	 trait	 impulsivity	 and	 addictive	 behaviour	 are	associated	with	several	neurodevelopmental	disorders,	including	attention-deficit/hyperactivity	disorder	 (ADHD),	autism	spectrum	disorder	 (ASD),	and	obsessive	compulsive	disorder	 (OCD).	All	 three	disorders	 show	 impaired	 fronto-striatal	 functioning,	which	may	be	 related	 to	altered	glutamatergic	 signalling.	 Genetic	 factors	 are	 also	 thought	 to	 play	 an	 important	 role	 in	 the	aetiology	of	compulsivity-related	disorders.		Methods:	The	COMPULS	 study	 is	 a	multi-centre	 study	designed	 to	 investigate	 the	 relationship	between	the	traits	compulsivity,	impulsivity,	and,	to	a	lesser	extent,	addictive	behaviour	within	and	 across	 the	 neurodevelopmental	 disorders	 ADHD,	 ASD,	 and	 OCD.	 This	will	 be	 done	 at	 the	phenotypic,	 cognitive,	 neural,	 and	 genetic	 level.	 In	 total,	 240	 participants	 will	 take	 part	 in	COMPULS	 across	 four	 different	 sites	 in	 Europe.	 Data	 collection	 will	 include	 diagnostic	interviews,	 behavioural	 questionnaires,	 cognitive	measures,	 structural,	 functional	 and	 spectral	neuroimaging,	and	genome-wide	genetic	information.		Discussion:	 The	 COMPULS	 study	 will	 offer	 the	 unique	 opportunity	 to	 investigate	 several	 key	aspects	of	compulsivity	across	a	large	cohort	of	ADHD,	ASD	and	OCD	patients.					 	
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BACKGROUND 	Compulsivity	 and	 impulsivity	 are	 cross-disorder	 traits	 that	 are	 present	 across	 various	neurodevelopmental	disorders,	such	as	attention-deficit/hyperactivity	disorder	(ADHD)	autism	spectrum	disorder	(ASD)	and	obsessive	compulsive	disorder	(OCD).		Compulsivity	 can	 be	 defined	 as	 the	 repetitive,	 irresistible	 urge	 to	 perform	 certain	behaviour,	 the	 experience	 of	 loss	 of	 voluntary	 control	 over	 this	 intense	 urge,	 the	 diminished	ability	to	delay	or	inhibit	thoughts	and	behaviours,	and	the	tendency	to	perform	repetitive	acts	in	 a	 habitual	 or	 stereotyped	 manner	 (Chamberlain	 et	 al.	 2006;	 Fineberg	 et	 al.	 2014).	Compulsivity	 is	 a	 cross-disorder	 trait	 observed	 in	 the	 phenotypically	 distinct	neurodevelopmental	disorders	ASD	and	OCD.	ASDs	have	a	prevalence	of	1.5%	(Baird	et	al.	2006;	Geschwind	and	State	2015)	and	are	characterized	by	deficits	in	reciprocal	social	interaction	and	communication	 and	 by	 restricted,	 repetitive	 and	 stereotyped	 patterns	 of	 behaviour,	 interests	and	activities	(American	Psychiatric	Association.	2000).	OCD,	on	the	other	hand,	 is	a	relatively	common	 anxiety	 disorder,	 characterized	 by	 repetitive	 thoughts,	 impulses,	 or	 images	(obsessions),	 and	 repetitive	 behaviours	 or	 mental	 acts	 (compulsions)	 that	 cause	 marked	distress	 (American	 Psychiatric	 Association.	 2000).	 OCD	 has	 its	 onset	 in	 late	 childhood	 and	 is	present	 in	about	2.5%	of	 the	adult	population	(Nestadt	et	al.	2009).	Repetitive	behaviours	are	among	the	core	features	of	both	ASD	and	OCD,	and	comparison	of	symptom	characteristics	has	demonstrated	more	 similarities	 than	differences	 (Anholt	 et	 al.	 2010).	 In	 addition	 to	 symptom	overlap,	 similar	 executive	 function	 impairments	 related	 to	 inhibiting	 compulsive	 behaviours	have	been	reported	in	first	degree	relatives	of	people	with	ASD	and	OCD	(Delorme	et	al.	2007).	Compulsivity	can	be	seen	as	an	overarching	concept	 that	 includes	both	 the	 failure	 to	 resist	an	impulse,	which	 links	 it	 to	 impulsivity,	 and	maladaptive	habitual	patterns	of	behaviours,	which	relates	to	addictive	behaviour.		 Impulsivity	is	described	as	a	predisposition	toward	rapid	unplanned	reactions	to	internal	or	 external	 stimuli	 with	 diminished	 regard	 to	 the	 potentially	 negative	 consequences	 of	 these	reactions	 (N.	 A.	 Fineberg	 et	 al.	 2014).	 Impulsivity	 is	 one	 of	 the	 core	 characteristics	 of	 ADHD.	ADHD	 is	 characterized	 by	 clinically	 significant	 levels	 of	 hyperactivity,	 impulsivity	 and/or	inattention	 and	 is	 affecting	 about	 5%	 of	 all	 school-age	 children	 world-wide	 (Polanczyk	 et	 al.	2007;	 Faraone	 et	 al.	 2015).	 About	 40%	 of	 children	 with	 ADHD	 have	 comorbid	 ASD	 (e.g.	(Nijmeijer	et	al.	2008;	Reiersen	et	al.	2007;	Polderman	et	al.	2014)).	Further,	prevalence	of	OCD	in	children	with	ADHD	is	estimated	at	8%,	which	is	a	2-3	fold	increase	compared	to	non-ADHD	children	 (Geller	 et	 al.	 2000;	 Anholt	 et	 al.	 2010).	 There	 are	 strong	 similarities	 between	 the	uncontrollable	behaviour	based	on	impulsivity	(seen	in	ADHD)	and	the	excessive	and	unwanted	rituals	related	to	compulsivity	(Robbins	et	al.	2012).		
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	 Addictive	behaviour	is	characterized	by	both	impulsivity	and	compulsivity	(Koob	and	Le	Moal	1997).	One	shows	compulsive	drug-seeking,	loss	of	control	in	limiting	this	intake,	and	the	emergence	of	a	negative	emotional	state	reflecting	a	motivational	withdrawal	syndrome,	when	access	 to	 the	 drug	 is	 prevented.	 Impulsivity	 often	 dominates	 early	 stages	 of	 addiction,	 while	compulsivity	 becomes	 important	 in	 later	 stages.	 See	 Figure	 1	 for	 the	 relation	 between	compulsivity,	impulsivity	and	addictive	behaviour	in	different	disorders.			
		Figure	 1	 Framework	 for	 understanding	 the	 relationships	 between	 cross-disorder	 traits	 impulsivity,	compulsivity	and	addictive	behaviours,	between	discrete	disorders	and	between	traits	and	disorders	by	adding	 a	 cognitive,	 neural,	 genetic	 and	 biomarker	 level	 of	 understanding.	 (ADHD,	 attention-deficit/hyperactivity	 disorder;	 ASD,	 autism	 spectrum	 disorder;	 ICD,	 impulse	 control	 disorder;	 OCD,	obsessive	compulsive	disorder).			Separate	but	intercommunicating	cortico-striatal	circuits	seem	to	be	involved	in	impulsivity	and	compulsivity	 (Fineberg	 et	 al.	 2010;	 Fineberg	 et	 al.	 2014).	 In	 the	 impulsive	 circuit,	 a	 striatal	component	(nucleus	accumbens)	may	drive	impulsive	behaviours,	and	a	prefrontal	component	(anterior	 cingulate	 (ACC),	 ventromedial	 prefrontal	 cortex)	 exerts	 inhibitory	 control.	 Similarly,	compulsive	 behaviour	 may	 be	 driven	 by	 a	 striatal	 component	 (caudate,	 putamen),	 which	 is	controlled	by	the	orbitofrontal	cortex	(OFC).	Increased	activity	in	the	striatum	and/or	decreased	activity	in	the	prefrontal	cortex	(PFC)	may	alter	the	functioning	of	these	cortico-striatal	circuits	and	 cause	 impulsive	 or	 compulsive	 disorders,	 both	 characterized	 by	 deficits	 in	 response	inhibition.	 Although,	 in	 contrast	 to	 impulsivity,	 compulsivity	 is	 considered	 a	 maladaptive	
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perseveration	of	behaviour	that	does	not	fall	within	the	range	of	normal	behaviour	(Robbins	et	al.	2012),	both	patterns	of	behaviour	often	co-occur	(Grant	et	al.	2010;	Hanna	1995).	Compulsivity-related	disorders	differ	 in	 their	age	of	onset.	ASD	starts	very	early	 in	 life,	ADHD	 in	 early	 childhood,	 and	 OCD	 has	 its	 onset	 in	 late	 childhood	 or	 early	 adolescence.	 This	variation	in	onset	of	 impulsivity/compulsivity	may	be	related	to	variation	in	the	maturation	of	the	 fronto-striatal	 circuits	 and	 the	 role	 of	 glutamate	 within	 these	 circuits.	 Recent	 theories	suggest	that	striatal	brain	regions	underlying	impulsive	and	compulsive	behaviours	may	show	a	nonlinear	developmental	pattern	with	a	peak	inflection	between	13	and	17	years	of	age	(Casey	and	Jones	2010).	The	prefrontal	regions	on	the	other	hand,	which	are	 important	 for	 top-down	regulation	 of	 (striatum-driven)	 impulsive	 and	 compulsive	 behaviour,	 show	 a	 more	 linear	pattern	of	maturation	well	into	young	adulthood.			Glutamate	 is	 the	 major	 excitatory	 neurotransmitter	 in	 the	 human	 brain	 and	 is	 critical	 to	 the	understanding	 of	 the	 top-down	 control	 of	 the	 prefrontal	 cortex	 over	 the	 dorsal	 and	 ventral	striatum	(Arnsten	2009).	The	 impulsivity-	 and	 compulsivity-related	 fronto-striatal	 circuits	 are	notable	for	their	relatively	rich	glutamatergic	receptor	density.	Glutamate	modulates	the	neural	activity	and	metabolism	of	these	circuits,	as	 is	reflected	by	the	effects	of	glutamate	on	synapse	induction	 and	 elimination	 as	 well	 as	 synaptic	 transmission	 via	 ionotropic	 and	 metabotropic	glutamate	 receptors	 (Pittenger,	 Bloch,	 and	Williams	 2011).	 Indeed,	 glutamatergic	 projections	from	the	prefrontal	sub-regions	to	the	striatum	are	already	known	to	play	a	key	role	in	various	compulsive	and	impulsive	behaviours	including	repetitive	behaviours	such	as	stereotypy	seen	in	ASD,	 impulsivity	 seen	 in	 ADHD,	 and	 feelings	 of	 loss	 of	 control	 seen	 in	OCD	 (for	 a	 review,	 see	(Naaijen	et	al.	2015)).		 	The	 study	 of	 genetics	 offers	 an	 opportunity	 to	 gather	 additional	 evidence	 for	 the	 role	 of	glutamate.	Many	compulsivity-	and	impulsivity-related	disorders	are	substantially	heritable	but	genetically	very	complex,	with	multiple	genetic	factors	of	varying	penetrance	implicated	[10,	24,	25].	 A	 number	 of	 candidate	 genes	 have	been	 identified,	 suggesting	 glutamatergic	 pathways	 to	operate	 in	 ASD,	 ADHD,	 and	 OCD.	 For	 example,	 variation	 in	 genes	 encoding	 the	 glutamate	transporters	 SLC1A1,	 SLC1A2,	 and	 SLC1A3	 are	 strong	 candidate	 genes	 for	 both	ASD	 and	OCD	(Rotge	et	al.	2010).	In	addition,	genes	encoding	the	NMDA	receptors	GRIN2A	and	GRIN2B	have	been	 implicated	 in	 ASD	 (Yoo	 et	 al.	 2012),	 and	 GRIN2B	 has	 also	 been	 associated	 with	 ADHD	(Dorval	et	al.	2007)	and	OCD	(Arnold	et	al.	2009).	While	glutamate	has	an	important	role	in	the	neurobiology	 of	 compulsivity	 and	 impulsivity	 and	 the	 related	disorders,	 it	 is	 certainly	 not	 the	only	 biological	 substrate	 involved.	 For	 example,	 we	 have	 recently	 identified	 central	 insulin	signalling	as	an	additional	molecular	cascade	involved	in	OCD	(van	de	Vondervoort	et	al.	2016)	
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and	neurite	outgrowth	as	 a	neurodevelopmental	process	 implicated	 in	ADHD	(Poelmans	et	 al.	2011)	 and	ASD	 (Poelmans	 et	 al.	 2013).	 Genetic	 variation	 in	 such	 genes	 is	 likely	 to	 alter	 their	regulation	and/or	function,	leading	to	changes	in	the	encoded	proteins	and	biological	processes	contributing	 to	 proper	 cell	 function.	 Brain	 structure	 and	 brain	 function,	 also	 highly	 heritable,	may	mediate	 the	 effects	 of	 the	 variation	 in	 genes	 and	 proteins	 on	 compulsive	 and	 impulsive	behaviours	 and	 related	 disorders	 (Glahn	 et	 al.	 2010;	 Peper	 et	 al.	 2007).	 See	 Figure	 2	 for	 a	representation	of	this	relation	between	genes,	cell	functioning,	brain	and	behaviour.		
	Figure	2	Simplified	representation	of	 the	relation	between	genes,	cell	 functioning,	brain	 functioning	and	behaviour.	 Many	 genes	 are	 involved	 in	 causing	 disease	 symptoms,	 but	 reduced	 numbers	 of	 genes	 are	involved	 in	 features	 associated	with	 the	 disease	 symptoms,	 like	 brain	 functioning	 and	 cell	 functioning.	Adapted	from	Franke,	Neale,	and	Faraone	2009.			
METHODS/DESIGN 	
Aims of the study COMPULS	is	a	multi-centre	study	as	part	of	the	overarching	TACTICS	study	(http://www.tactics-project.eu)	investigating	the	relationship	between	the	traits	compulsivity,	impulsivity,	and	-	to	a	lesser	 extent	 -	 addictive	 behaviour	within	 and	 across	 the	 neurodevelopmental	 disorders	 ASD,	ADHD,	and	OCD.	This	will	be	the	first	study	to	integrate	these	different	traits	and	disorders	into	one	design.	The	primary	objectives	are	to	examine	whether	these	traits	are	related	to	structural	
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and	 functional	 connectivity	of	 the	 fronto-striatal	 circuits	 and	whether	 these	behavioural	 traits	are	 predicted	 by	 or	 related	 to	 abnormal	 glutamatergic	 concentrations	 in	 these	 fronto-striatal	circuits.	 Secondary	 objectives	 of	 COMPULS	 are	 to	 explore	 the	 role	 of	 candidate	 genes	 or	candidate	genetic	pathways	involved	in	compulsivity,	and	related	traits	within	these	disorders.	These	 objectives	 will	 be	 investigated	 at	 the	 phenotypic,	 cognitive,	 neural,	 and	 genetic	level	 in	 a	 prospective	 longitudinal	 design.	 This	 paper	 describes	 the	 design,	 measures,	 and	rationale	of	COMPULS.			
Participants Data	collection	occurs	at	four	different	sites	across	Europe	(Radboud	University	Medical	Center	and	the	Donders	Institute	for	Brain,	Cognition	and	Behaviour,	Nijmegen,	The	Netherlands;	Brain	Centre	 Rudolf	 Magnus,	 University	 Medical	 Centre	 Utrecht,	 Utrecht,	 The	 Netherlands;	 King’s	College	 London,	 London,	 United	 Kingdom,	 and	 Central	 Institute	 of	 Mental	 Health,	 Medical	Faculty	Mannheim,	University	of	Heidelberg	Mannheim,	Germany).	We	 include	60	participants	with	ASD,	60	with	OCD,	60	with	ADHD,	and	60	healthy	comparison	participants	in	the	age	range	of	 8	 to	 12	 years.	 Every	 site	 includes	 fifteen	 ASD,	 OCD,	 and	 healthy	 comparison	 participants	(adding	up	 to	a	 total	of	60	per	group).	The	ADHD	sample	 is	 completely	collected	 in	Nijmegen.	The	total	sample	size	consists	of	240	participants.	Setting	alpha	at	 .05	(two-tailed)	our	sample	size	of	N=240	has	80%	statistical	power	to	detect	a	beta	(standardized	regression	coefficient)	of	0.21.	This	sample	size	allows	for	about	15	covariates/predictors	 in	total.	Thus	our	sample	size	will	provide	us	 sufficient	power	 to	establish	predictors	of	 small	 effect	 size.	A	group	 size	of	60	participants	 per	 group	 (OCD,	 ASD,	 ADHD,	 controls)	 further	 allows	 us	 to	 examine	 the	 disease	modifying	effects	in	planned	contrasts	in	these	regression	models	(dummy	variables).		 Inclusion	criteria	 for	all	 groups	are	age	between	8	and	12	years	old,	 IQ	>	70,	ability	 to	speak	and	comprehend	the	native	language	of	the	country	in	which	the	assessment	takes	place,	and	a	signed	informed	consent	by	parents	or	 legal	representatives.	For	the	diagnosis	groups,	a	DSM-IV-TR	or	DSM-5	diagnosis	of	 the	respective	disorder	has	 to	be	present.	Exclusion	criteria	for	the	ASD,	OCD,	and	ADHD	children	are	diagnoses	of	the	other	disorders	(comorbidity),	e.g.	an	OCD	 diagnosis	 in	 an	 ASD	 participant.	 Other	 exclusion	 criteria	 include	 IQ	 <	 70,	major	 physical	illness	of	the	vascular,	endocrine,	pulmonic	or	the	gastrointestinal	system,	all	contra-indications	for	MR	 assessment,	 such	 as	 the	 presence	 of	metal	 objects	 in	 the	 body	 (i.e.	 pacemaker,	 dental	braces),	 and	 a	 history	 or	 presence	 of	 neurological	 disorders.	 For	 the	 healthy	 comparison	participants,	no	first	degree	family	members	are	allowed	to	have	any	psychiatric	disorder.				
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Measures 
Diagnosis To	 determine	 the	 diagnoses	 several	 interviews	 will	 be	 administered,	 depending	 on	 the	symptoms	of	the	participant.	The	autism	diagnostic	interview-revised	(ADI-R	(Lord,	Rutter,	and	Couteur	1994))	is	a	structured	developmental	interview	administered	to	the	parent(s)	to	assess	the	 symptoms	 of	 ASD	 and	 make	 an	 ASD	 DSM-IV-TR	 diagnosis	 in	 the	 child.	 For	 an	 ADHD	diagnosis,	 the	 semi-structured	 Kiddie	 Schedule	 for	 Affective	 Disorders	 and	 Schizophrenia	 (K-SADS	(Kaufman	et	al.	1997))	will	be	administered	 to	 the	parent(s).	The	Children’s	Yale	Brown	Obsessive	Compulsive	Scale	(CYBOCS	(Scahill	et	al.	2014))	is	used	to	interview	the	parent(s)	and	child	 for	 the	presence	of	 obsessions	 and/or	 compulsions	 and	 symptom	 severity,	when	OCD	 is	present.	 This	 interview	will	 be	 performed	 in	 all	 participant	 groups	when	 screening	 questions	confirm	 the	 presence	 of	 obsessions	 or	 compulsions.	 In	 addition,	 all	 parents	 are	 interviewed	using	the	structured	Diagnostic	Interview	Schedule	for	Children	(DISC	(Shaffer	et	al.	2000)),	the	Development	 and	Well-being	 Assessment	 (DAWBA	 (Goodman	 et	 al.	 2000))	 or	 the	 K-SADS	 to	assess	 the	 presence	 of	 possible	 comorbidities	 such	 as	 oppositional	 defiant	 disorder,	 conduct	disorder,	 and	 the	 presence	 of	 tics/Tourette’s	 syndrome	 and	 anxiety	 disorders.	 The	 diagnostic	tools	 provide	 operational	 definitions	 of	 individual	 symptoms	 as	 well	 as	 diagnosis-relevant	questions,	such	as	onset	of	symptoms	and	impairment	in	several	areas	of	life.			
Questionnaires Questionnaires	are	used	to	assess	(a)	symptom	severity	of	possible	comorbid	disorders,	such	as	ADHD	 (Conners’	 Parent	 Rating	 Scale	 (CPRS	 R:L	 (Conners	 et	 al.	 1998))	 and	 ASDs	 (Children’s	Social	 Behavioural	 Questionnaire	 (CSBQ	 (Luteijn	 et	 al.	 2000)),	 (b)	 Substance	 use	 disorders	(SUDs;	 Alcohol	 Use	 Disorders	 Identification	 Test	 (AUDIT	 (Saunders	 et	 al.	 1993)),	 drug	 abuse	(Drug	Abuse	Screening	Test	(DAST	(Gavin,	Ross,	and	Skinner	1989)),	and	nicotine	dependence	(Fagerstrøm	Test	for	Nicotine	Dependence	(FTND	(Heatherton	et	al.	1991)),	(c)	lifetime	alcohol-related	 problems	 (Michigan	 Alcohol	 Screening	 Test	 (MAST	 (Selzer,	 Vinokur,	 and	 van	 Rooijen	1975)),	(d)	gambling	problems	(South	Oaks	Gambling	Screen	(SOGS	(Lesieur	and	Blume	1987)),	(e)	repetitive	behaviour	(Repetitive	Behaviour	Scale-Revised	(RBS-R	(Lam	and	Aman	2007)),	(f)	emotional	and	behavioural	problems	 (Child	Behaviour	Check	List	 (CBCL	 (Bordin	et	al.	2013));	Teacher	 report	 form	 (TRF)	 (Bordin	et	 al.	 2013)),	 and	 (g)	physical	development	 (Williams	and	Dunlop	 1999),	 to	 determine	 the	 developmental	 stage	 at	 the	 time	 of	 assessment.	 All	questionnaires	 are	 completed	 by	 the	 parent(s).	 A	 final	 set	 of	measures	 is	 taken	 to	 determine	patterns	of	use	of	prescribed	medication	(in	house	self-report	for	medication	use).			
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Cognitive assessment All	 children	 complete	 an	 extensive	 protocol	 of	 cognitive	 tasks	 measuring	 (a)	 intellectual	functioning	estimated	from	the	(i)	vocabulary,	(ii)	block	design,	(iii)	similarities,	and	(iv)	picture	completion	subtests	of	the	WISC	(Canivez	and	Watkins	1998),	(b)	motor	inhibition,	(c)	cognitive	flexibility,	and	(d)	motor	speed.	Except	for	the	subtests	of	the	WISC,	all	tests	are	computerized.	For	cognitive	flexibility,	a	timing	task	will	be	administered	(Davidson	et	al.	2004;	Durston	et	al.	2007).	 For	 measuring	 motor	 inhibition	 and	 motor	 speed,	 we	 will	 use	 the	 set-shifting	 and	baseline-speed	tasks	of	the	Amsterdam	Neuropsychological	Tests	(ANT	(de	Sonneville	1999)).		
MR measurements Participating	 children	 complete	 a	 brain	 scan	 session	 in	 a	 magnetic	 resonance	 imaging	 (MRI)	scanner.	At	the	four	different	sites,	comparable	3	Tesla	MRI	scanners	are	used	(Siemens	Trio	and	Siemens	Prisma,	Siemens,	Erlangen,	Germany;	Philips	3T	Achieva,	Philips	Medical	Systems,	Best,	The	Netherlands;	General	Electric	MR750,	GE	Medical	Systems,	Milwaukee,	WI,	USA)	using	a	32	channel	 (Siemens)	 or	 8	 channel	 head	 coil	 (Philips,	 GE).	 A	 scanning	 session	 includes	 an	anatomical	T1	scan,	resting	state	functional	MRI	(R-fMRI),	Diffusion	Tensor	Imaging	(DTI),	and	two	 functional	 imaging	 tasks	 including	a	behavioural	 inhibition	(Stop)	 task	(Rubia	et	al.	2003)	and	a	shortened	monetary	reward	anticipation	task	[54,	55].	COMPULS’	areas	of	interest	are	the	fronto-striatal	circuits,	important	signalling	regions	that	are	undergoing	developmental	changes	in	the	age	range	of	8	to	12	years.	As	described	in	the	introduction,	differences	exist	in	the	onset	of	compulsive	disorders.	In	order	to	capture	glutamatergic	deficits	across	these	disorders,	an	MR	spectroscopy	 session	with	 two	 voxels	 of	 interest	 encompassing	 a	 part	 of	 these	 fronto-striatal	circuits	(left	dorsal	striatum	and	ACC)	is	also	included	in	the	MRI	session.		 The	 structural	 T1	 scanning	 sequences	 are	 based	 on	 the	ADNI	GO	protocols	 (Jack	 et	 al.	2008;	Jack	et	al.	2010)	to	be	matched	as	closely	as	possible	across	the	different	scanning	sites.	For	R-fMRI	we	use	 a	multi-echo	 sequence	 to	be	 able	 to	 separate	BOLD	 from	non-BOLD	 signal	more	accurately	(Kundu	et	al.	2012),	DTI	acquisition	is	chosen	to	better	resolve	crossing	fibres	and	 task-based	 fMRI	acquisition	 is	designed	 for	optimal	 signal	 stability	 and	homogeneity	over	the	 different	 sites	 (see	 Table	 1	 for	 an	 overview	 of	 the	 scan	 sequences).	 In	 order	 to	 perform	quality	assessment	of	the	MR	scanning	sessions	across	four	different	sites,	we	will	make	use	of	phantoms	and	so-called	 ‘travelling	heads’.	By	using	phantoms,	we	can	assess	subtle	changes	 in	scanner	output	over	time	(due	to	scanner	drifts,	system	upgrades,	etc.),	but	we	feel	that	this	 is	not	sufficient	to	allow	for	calibration	of	human	brain	data.	In	order	to	compare	the	quality	of	the	human	brain	scans	across	sites,	the	travelling	heads	are	thus	used,	i.e.	three	adult	volunteers	will	travel	 to	 the	 four	participating	sites	at	 the	start	of	COMPULS,	at	 the	end	of	 the	data	collection,	and	 in-between,	whenever	scanner	upgrades	are	performed.	This	will	allow	us	to	assess	 inter-
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scanner	 reliability	 and	 take	 into	 account	 differences	 between	 scanners.	 These	 travelling	 head	data-sets	will	additionally	be	used	to	compare	intra-	and	inter-site	variability	with	regard	to	the	measurement	 of	 glutamate.	 On-site	 MRS	 training	 will	 be	 provided	 before	 data-collection	 to	assure	similarity	in	terms	of	voxel	placement	across	sites.	
	Table	1	Scan	sequences.	Sequence	 Site	 TR/TE/TI	(ms)	 Flip	angle	 Field	of	view	(mm)	 Matrix	RL/AP	/slices	 Voxel-size	(mm)	 Gap	(%)	 Parallel	Imaging	 b	value	 Directions/	b0’s	 Averages	sup/	unsup	T1	 Nijmegen	(Siemens)	 2300*/2.98/900	 9	 256		 212/256/176	 1.0	*	1.0	*	1.2	 NA	 2	 NA	 NA	 NA		 Mannheim	(Siemens)	 2300*/2.98/900	 9	 270	 212/254/176	 1.1	*	1.1	*	1.2	 NA	 2	 NA	 NA	 NA		 Utrecht	(Philips)	 6.8*/3.10/823	 9	 270	 204/252/170	 1.1	*	1.1	*	1.2	 NA	 1.8	 NA	 NA	 NA		 London	(GE)	 7.31*/3.02/400	 11	 270	 256/256/196	 1.1	*	1.1	*	1.2	 NA	 1.75	 NA	 NA	 NA	MRS	PRESS		 All	 3000/30/-	 NA	 NA	 NA	 20	*	20*	20		 NA	 NA	 NA	 NA	 96/16	R-FMRI#	 All	 2300/12a–13b/-	 80	 240	 240/240/33	 3.8	*	3.8	*	3.8	 11	 2	–	2.5c	 NA	 NA	 NA	Functional	tasks	 All	 2070/35/-	 74	 192	 192/192/36	 3.0	*	3.0	*	3.0	 13	 2	 NA	 NA	 NA	DTI	 All	 12000/103/-	 90	 256	 256/256/72	 2.0	*	2.0	*	2.0	 0	 2	 1500	 60/2	 NA	*	As	provided	by	the	manufacturer.	Philips	and	GE	define	a	TR	as	the	time	an	excitation	pulse	is	given,	while	Siemens	defines	TR	as	the	time	between	inversion	recovery	pulses	a	volume.		#	Multi-echo	resting	state	fMRI:	TE2	is	31	ms	for	London	and	Utrecht,	29	for	Mannheim	and	28.41	for	Nijmegen.	TE3	is	48	for	London,	49	for	Utrecht,	46	for	Mannheim	and	44.82	for	Nijmegen.	a	Nijmegen,	Mannheim	b	Utrecht,	London	c	Utrecht	(sup	=	water	suppressed;	unsup	=	water	unsuppressed)	
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Genetic determinants Participants	will	provide	40	ml	blood	for	DNA-isolation	and	assessment	of	biomarkers	for	which	serum	and	plasma	fractions	will	be	prepared.	The	venapuncture	will	be	performed	by	a	trained	practical	 nurse.	 If	 a	 participant	 refuses	 venapuncture,	 saliva	 will	 be	 used	 for	 DNA-isolation	instead.		 DNA,	RNA,	and	plasma/serum	fractions	will	be	isolated	from	blood/saliva	using	standard	techniques	and	stored	at	the	department	of	Human	Genetics	of	the	Radboud	University	Medical	Center.	MicroRNAs	(miRNA)	will	be	extracted	 from	 total	RNA	 isolated	 from	blood	collected	 in	PAX-gene	 tubes.	 The	DNA	will	 be	 subjected	 to	 genome-wide	 genotyping,	 providing	 a	basis	 for	the	computation	of	polygenic	risk	scores;	such	scores	will	be	incorporated	in	analyses	of	disease	risk,	 and	might	 improve	 phenotypic	 prediction	 (Hamshere	 et	 al.	 2013).	 The	 current	 study	 on	itself	will	have	a	small	sample	size	and	is	of	course	insufficient	to	detect	genome-wide	significant	effects.	However,	by	aggregation	of	multiple	variants	at	the	level	of	individual	genes	or	gene-sets	through	mass-univariate	or	multivariate	methods,	power	may	be	increased	(Bralten	et	al.	2013;	Bralten	 et	 al.	 2011;	 Walsh	 et	 al.	 2008).	 This	 will	 provide	 opportunities	 for	 candidate	gene/pathway	analyses,	which	of	course	will	require	appropriate	correction	for	multiple	testing.	Lastly,	by	contributing	to	international	collaborations	like	the	Psychiatric	Genomics	Consortium	(PGC;	 (Psychiatric,	 Consortium,	 and	Committee	2009)	 and	Enhancing	Neuro	 Imaging	Genetics	through	meta-analysis	(ENIGMA;	(Thompson	et	al.	2014))),	our	data	may	contribute	to	genome-wide	 gene-finding	 studies	 will	 become	 more	 powerful.	 Protein	 and	 miRNA	 levels	 of	 blood-expressed	candidate	genes	will	be	monitored.	In	the	case	of	proteomics,	this	will	 involve	using	multiplex	 immunoassay	profiling	of	 serum.	 In	addition,	determination	of	 glutamate,	 serotonin,	and	insulin	levels	will	be	performed.	This	work	will	be	performed	in	the	laboratory	of	Professor	Bahn	in	Cambridge.			
Somatic and other measures To	 obtain	 an	 estimate	 of	 possible	 abnormal	 growth	 or	 other	 physiological	 abnormalities,	 we	measure	body	length,	weight,	waist	circumference,	and	ask	for	the	presence	of	allergies	or	food	restrictions.		
Procedures 
Ethical approval  The	study	was	approved	by	 the	regional	ethics	committee	of	each	site	(Nijmegen	and	Utrecht:	Commissie	 Mensgebonden	 Onderzoek	 Regio	 Arnhem-Nijmegen,	 2013,	 NL	 nr	 42004.091.12;	Mannheim:	Ethics	committee	of	the	Medical	Faculty	Mannheim,	Heidelberg	University,	2013,	nr	213-616N-MA;	London:	NRES	Committee	London	-	Camberwell	St	Giles,	2013,	nr:	14/LO/1413).	
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We	obtain	written	 informed	consent	 from	 the	parents	of	all	 children	and	oral	assent	 from	 the	children.	When	 children	 are	12	 years	 old	 they	provide	written	 informed	assent	 themselves	 in	addition	 to	 the	 parents.	 In	 case	 a	 participant	 or	 a	 parent	 retracts	 the	 consent,	 all	 data	 and	samples	will	be	withheld	from	further	use	for	analysis	and	removed	from	the	database.	This	is	allowed	 at	 any	 point	 during	 the	 study.	 Participating	 families	 are	 regularly	 informed	 with	 a	newsletter	about	study	progress	and	resulting	publications.		
Assessment After	initial	contact	through	information	packages	(including	general	project	 information)	sent	by	 post,	 the	 parents	 are	 phoned	 to	 check	 interest	 in	 participation.	 In	 case	 of	 interest,	 a	 brief	screening	 will	 be	 conducted	 to	 control	 for	 possible	 exclusion	 criteria.	 If	 the	 child	 meets	 the	inclusion	criteria,	a	questionnaire	package	will	be	sent	via	regular	post,	also	including	informed	consent/assent	forms	and	general	information	about	the	test-location.			 If	 feasible	 according	 to	 the	 child’s	 capability,	 one	 testing	 day	 is	 organised	 covering	 all	assessments.	During	this	day,	parents	will	be	assessed	with	the	interview.	If	screening	questions	are	 answered	 positively,	 screening	 will	 be	 followed	 by	 the	 full	 supplementary	module	 of	 the	specific	disorder.	When	applicable,	CYBOCS	and/or	the	ADI	is	administered.	Cognitive	tests	with	the	child	will	be	administered	in	a	fixed	order	and	-	due	to	the	length	of	the	battery	-	split	in	two	parts,	part	A	and	part	B.	The	order	of	administration	of	 the	 two	parts	will	be	counterbalanced	across	children.	Before	participating	 in	 the	MR	session,	 children	will	be	prepared	 for	scanning	using	 a	 dummy	 scanner.	 In	 this	 dummy	 session,	 children	 are	 presented	with	MR	 sounds,	 the	button	 box	 needed	 for	 task	 completion,	 and	 lying	 in	 a	 tight	 environment.	 In	 addition,	 time	 to	practise	the	MR	tasks	is	provided	during	this	dummy	session.	Should	a	child	(or	his/her	parent)	report	anxiety	to	enter	the	MR	scanner,	the	session	will	be	ended.	The	anxiety	is	monitored	by	using	 a	 visual	 analogue	 scale	 (VAS),	 a	 scale	 from	 1	 to	 10,	 on	 which	 the	 child,	 parent,	 and	researcher	rate	the	anxiety	(1	means	no	anxiety	and	10	means	very	high	anxiety).	If	the	score	is	8	or	higher,	the	scan	will	not	be	performed.	After	the	MR	assessment,	the	blood-sample	will	be	taken	by	trained	professionals	for	biological	analyses.		 A	 monetary	 reward	 is	 granted	 and	 travel	 costs	 will	 be	 reimbursed.	 Children	 who	complete	the	MR	session	(or	at	least	the	anatomical	session)	are	provided	with	a	picture	of	their	anatomical	MR	scan.	Moreover,	all	 children	receive	an	extra	monetary	reward,	which	 they	can	gain	during	the	cognitive	assessments	(inside	or	outside	the	MR	scanner),	and	a	short	report	of	their	performance	on	the	IQ	tests,	if	requested.					 	
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Follow up A	second	wave	data	collection	procedure	will	be	performed	after	the	first	with	an	interval	of	at	least	 one	 year.	 The	 same	measurements	will	 be	 administered,	 except	 for	 the	ADI-R	 interview.	These	two	time-points	together	can	give	insights	in	development	during	an	important	phase	in	life,	when	the	transition	from	childhood	and	adolescence	takes	place.	The	fronto-striatal	circuit	undergoes	 several	 changes	 during	 development	 (Somerville	 and	 Casey	 2010),	 which	 we	 can	map	longitudinally	with	this	study-design.		
Staff training and supervision The	 cognitive	 testing,	 diagnostic	 interview,	 and	 MRI	 scanning	 are	 restricted	 to	 trained	personnel.	This	 includes	 training	 in	Good	Clinical	Practice	(GCP).	For	 the	diagnostic	 interview,	staff	members	have	to	attend	interview	sessions	 led	by	a	trained	interviewer.	When	practicing	interviews,	one	will	be	under	supervision	of	a	clinician	or	trained	professional.	The	ADI-R	is	an	interview	 that	 requires	 an	 official	 certificate	 and	will	 only	 be	 administered	 by	 those	 officially	trained.	 For	 the	 diagnostic	 interviews	 quality	 control	 meetings	 will	 be	 held	 to	 discuss	controversial	cases	and	to	maintain	agreement.		To	standardize	cognitive	testing	and	neuroimaging	sessions	as	much	as	possible,	written	standard	operating	procedures	(SOPs)	were	developed	for	administration	of	cognitive	tests	and	MR	assessments.	All	 researchers	are	 trained	 to	administer	 the	 test	battery	using	 the	SOPs	and	under	supervision	before	 they	can	administer	 tests	on	 their	own.	The	MRI	 training	consists	of	practicing	 to	 operate	 the	 scanner	 computer,	 learning	 security	 procedures,	 and	 monitoring	quality	of	the	data	(i.e.	motion	artefacts,	spike	identification).			
Data management and quality control Every	participant	is	coded	with	an	anonymous	identifier	number	to	separate	personal	data	from	scientific	data.	Data	acquisition	will	be	documented	in	a	case	report	listing	all	data	available	for	that	person.	Notes	regarding	factors	that	may	influence	the	data	(analysis)	are	provided.	Every	note,	questionnaire,	informed	consent	form,	etc.	will	be	kept	together	in	a	dossier.		 All	 digital	data	 will	 be	 stored	 on	 the	 device,	 on	 which	 it	 is	 administered	 (laptops),	 and	 then	 securely	uploaded	 to	 a	 central	 storage	 server.	 This	 server	 backs-up	 to	 tape	 daily.	 Researchers	 at	 the	Radboud	 University	 Medical	 Center	 are	 also	 obligated	 to	 archive	 raw	 data	 on	 at	 least	 two	different	archiving	disks.		All	 data,	 except	 for	 the	MRI	 data,	will	 be	 uploaded	 to	 a	 central	 SQL	 (Structured	Query	Language)	database.	This	database	meets	the	acquired	safety	regulations	per	participating	site,	and	 only	 assigned	 researchers	 will	 have	 access	 across	 the	 four	 sites.	 Data	 integrity	 will	 be	controlled	 by	 comparing	 uploaded	 data	 to	 descriptions	 in	 the	 dossier.	 For	 MRI	 data,	 quality	
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checks	are	also	performed.	T1	anatomical	scans	are	quality-rated	on	a	4-point	scale,	MR	spectra	undergo	 visual	 inspection	 for	 each	 participant,	 and	 various	 quantitative	 parameters	 are	calculated	for	the	functional	and	diffusion	imaging	data,	such	as	spatial	and	temporal	signal-to-noise-ratios	and	realignment	parameters.		
DISCUSSION 	The	 COMPULS	 database	 will	 offer	 the	 unique	 opportunity	 to	 study	 several	 key	 aspects	 of	compulsivity	 in	 a	 large	 cohort	 of	 ASD,	 ADHD,	 and	 OCD	 patients.	 By	 assessing	 neural	 and	cognitive	systems	during	the	critical	period	of	transition	from	childhood	to	adolescence	across	disorders,	we	can	investigate	stability	and	changes	of	neural	systems,	which	seem	to	be	critical	in	the	development	of	compulsive	behaviour.	Integrating	data	from	cognitive,	neural,	and	genetic	markers	 linked	 to	 compulsivity	 can	 largely	 increase	 our	 understanding	 of	 neural	mechanisms	involved	in	compulsivity	and	related	disorders.	Additionally,	by	using	a	dimensional	approach	of	compulsive	and	impulsive	behaviour	in	several	different	disorder	groups,	we	can	find	differing	and	overlapping	deficits,	which	may	explain	the	high	comorbidity	rates.	At	the	clinical	level,	this	would	 provide	means	 for	 identifying	 children	 at	 risk	 for	 poor	 clinical	 outcome	 and	 provide	 a	basis	for	the	development	of	better	treatment	strategies	that	take	into	account	this	dimensional	nature	of	neurodevelopmental	disorders.	COMPULS	will	contribute	its	data	to	meta-	and	mega-analyses	 in	 international	 initiatives	 like	 the	 Psychiatric	 Genomics	 Consortium	 (Psychiatric,	Consortium,	 and	 Committee	 2009)	 and	 the	 ENIGMA	 Consortium	 (Thompson	 et	 al.	 2014)	 and	will	 collaborate	 with	 other	 large	 international	 project	 with	 a	 focus	 on	 neurodevelopmental	disorders	(i.e.	EU	AIMS:	http://www.eu-aims.eu/).		 At	 the	 more	 technical	 and	 logistic	 level,	 the	 COMPULS	 database	 will	 provide	opportunities	 to	 thoroughly	 investigate	 the	 effect	 of	 acquiring	 data	 at	 different	 centres	 on	outcome	variables	during	analyses.	It	can	examine	which	types	of	data	are	most	sensitive	to	the	effect	 of	multi-centre	 collection,	 and	 can	 thus	 provide	 input	 for	 future	multi-centre	 studies.	 It	will	form	an	international	scientific	resource,	which	may	be	accessed	by	other	researchers	in	the	field	on	request.		  
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ABSTRACT 	Compulsivity	 and	 impulsivity	 are	 cross-disorder	 traits	 observed	 in	 autism	 spectrum	disorders	(ASD),	 attention-deficit/hyperactivity	 disorder	 (ADHD)	 and	 obsessive	 compulsive	 disorder	(OCD).	 Aberrant	 fronto-striatal	 glutamatergic	 signalling	 is	 core	 to	 the	 understanding	 of	compulsive	 and	 impulsive	 disorders.	 In	 this	 review,	 the	 glutamate	 (Glu)	 neurochemistry	 of	fronto-striatal	circuits	in	paediatric	and	adult	ASD,	ADHD	and	OCD,	as	described	in	59	studies,	is	outlined	from	the	perspective	of	proton	magnetic	resonance	spectroscopy	(1H	MRS).	Despite	the	methodological	inconsistencies	between	studies,	two	observations	stand	out	that	form	possible	hypotheses	for	future	studies.	Firstly,	a	possible	increase	in	Glx	(combination	of	Glu,	glutamine	and	GABA)	in	the	striatum	across	ADHD,	OCD	and	ASD.	Secondly,	an	increased	Glx	signal	in	the	anterior	cingulate	cortex	 in	paediatric	ASD	and	ADHD	but	a	 lower	Glx	 signal	 in	adult	ASD	and	ADHD.	 This	 suggests	 neurodevelopmental	 changes	 in	 fronto-striatal	 glutamatergic	 circuits	across	 the	 lifespan.	 Future	 studies	 should	 incorporate	 more	 homogeneous	 samples,	 perform	MRS	 at	 field	 strengths	 of	 at	 least	 3	 Tesla	 and	 provide	 much	 more	 precise	 and	 standardized	information	 on	 methods	 to	 improve	 our	 understanding	 of	 fronto-striatal	 glutamatergic	transmission	in	compulsive	and	impulsive	syndromes.			 	
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INTRODUCTION 	Autism	 spectrum	 disorder	 (ASD),	 attention-deficit/hyperactivity	 disorder	 (ADHD),	 and	obsessive	 compulsive	disorder	 (OCD)	 are	 rather	 common	neurodevelopmental	 disorders	with	prevalence	rates	of	about	1%	for	ASD,	5.3%	for	ADHD,	and	between	2	and	3	%	for	OCD	(Baird	et	al.	2006;	Polanczyk	et	al.	2007;	Ruscio	et	al.	2010).	The	aim	of	the	current	study	is	to	review	the	role	 of	 glutamate	 (Glu)	 (and	 GABA)	 in	 fronto-striatal	 circuits	 in	 ASD,	 ADHD	 and	 OCD	 and	 to	examine	 possible	 overlap	 and	 differences	 between	 these	 disorders	 based	 on	 their	 underlying	traits.	Before	describing	the	methods	and	findings,	we	will	elaborate	more	on	the	relationships	between	the	three	disorders.	While	the	origin	of	symptoms	starts	very	early	in	life	(ASD),	in	early	childhood	(ADHD)	or	 in	 late	childhood	(OCD),	many	patients	with	these	disorders	have	persistent	symptoms	and	impairment	well	into	adulthood	(Faraone	et	al.	2006;	Bloch	et	al.	2009).	ASD	is	characterized	by	impairments	 in	 social	 interaction,	 both	 verbal	 and	 nonverbal	 communication,	 restricted	 and	stereotyped	 interests	and	behaviours;	ADHD	by	 inattentiveness,	 impulsivity	and	hyperactivity,	and	OCD	by	repetitive	 thoughts,	 impulses	or	 images	(obsessions)	and	repetitive	behaviours	or	mental	acts	(compulsions)	that	cause	distress	(Hanna	1995;	Perlov	et	al.	2009).	Despite	the	fact	that	 these	 disorders	 clearly	 differ	 by	 their	 defining	 characteristics,	 they	 also	 have	 a	 strong	clinical	overlap.	Between	25	and	50	%	of	patients	with	ASD	show	clinically	impairing	symptoms	of	 impulsivity,	 inattentiveness	 and	hyperactivity	 that	 pass	 the	 threshold	 for	 diagnosing	ADHD	(Rommelse	et	al.	2010).	In	turn,	the	prevalence	of	comorbid	social	dysfunction	up	to	full	ASD	in	ADHD	 children	 is	 between	 20	 and	 50	 %	 (Rommelse	 et	 al.	 2010).	 Both	 ASD	 and	 OCD	 show	repetitive	behaviours	among	their	core	features	and	comparison	of	ASD	and	OCD	symptoms	has	shown	more	similarities	 than	differences	 (Anholt	et	al.	2010).	Elevated	ADHD	symptoms	have	been	 reported	 in	 up	 to	 30	 %	 of	 patients	 with	 OCD.	 Conversely,	 8	 %	 of	 children	 with	 ADHD	demonstrate	 comorbid	 OCD	 symptoms	 (Geller	 et	 al.	 2000).	 These	 findings	 suggest	interrelatedness	between	ASD,	ADHD	and	OCD.	One	study	to	date	has	examined	ADHD	and	ASD	symptoms	 within	 an	 adult	 OCD	 patient	 group,	 and	 reported	 an	 increase	 in	 ASD	 and	 ADHD	symptoms	 in	 patients	 compared	 to	 non-affected	 controls	 (Anholt	 et	 al.	 2010).	 Autism-related	attention	switching	problems	and	ADHD	inattention	proved	to	be	the	most	significant	predictor	for	 OCD	 symptom	 dimensions	 and	 severity.	 It	 can	 be	 assumed	 therefore	 that	 attentional	problems	reflect	symptom	overlap	and	a	common	etiological	factor	underlying	ASD,	ADHD,	and	OCD.	However,	no	other	studies	so	far	have	further	characterized	the	relationship	between	ASD,	ADHD,	and	OCD.	Contemporary	 neuroscience	 stresses	 the	 importance	 of	 endophenotypes	 to	 elucidate	commonalities	 across	disorders	 (Robbins	et	 al.	 2012).	 In	 this	 context,	 endophenotypes	 can	be	
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described	as	heritable	objectively	measurable	traits	associated	with	a	disorder	in	the	population.	These	can	be	well-defined	behavioural	or	cognitive	processes	associated	with	deficits	in	defined	neural	 circuits.	 These	 deficits	 are	 predicted	 to	 be	 present	 in	 first	 degree	 relatives,	 even	when	unaffected,	to	a	higher	degree	than	in	the	general	population	and	may	enable	early	detection	of	a	possible	disorder	(Gottesman	and	Gould	2003).	If	these	endophenotypes	are	investigated	across	disorders,	this	would	highlight	commonalities	between	seemingly	different	pathologies.	Possible	endophenotypes	for	ASD,	ADHD	and	OCD	are	the	underlying	mechanisms	of	the	cross-disorder	traits	 impulsivity	 and	 compulsivity.	 Impulsivity	 is	 defined	 as	 a	 predisposition	 toward	 rapid	unplanned	 reactions	 to	 internal	 or	 external	 stimuli	 with	 diminished	 regard	 to	 the	 potentially	negative	 consequences	 of	 these	 reactions	 (Chamberlain	 and	 Sahakian	 2007;	 Fineberg	 et	 al.	2010).	 Compulsivity	 on	 the	 other	 hand,	 is	 characterized	 by	 a	 repetitive,	 irresistible	 urge	 to	perform	 certain	 behaviour,	 the	 experience	 of	 loss	 of	 voluntary	 control	 over	 this	 urge,	 the	diminished	 ability	 to	 delay	 or	 inhibit	 thoughts	 and	 behaviours,	 and	 the	 tendency	 to	 perform	repetitive	 acts	 in	 a	 habitual	 or	 stereotyped	 manner	 (Chamberlain	 and	 Menzies	 2009).	Compulsivity	 and	 impulsivity	 have	 been	 associated	 with	 deficits	 in	 response	 inhibition	 and	cognitive	control	(Dalley	et	al.	2011).	Similarly,	they	are	both	evident	in	substance	dependence.	ASD	 and	OCD	both	 show	 compulsive	 symptoms,	while	ADHD	 is,	 initially,	more	 impulsive.	 The	impulsivity	 of	 ADHD	 patients	 places	 them	 at	 risk	 for	 developing	 substance	 use	 disorders.	Addictive	 behaviour	 is	 at	 first	 associated	 with	 impulsivity,	 but	 becomes	 more	 related	 to	compulsivity	 at	 later	 stages	 (Koob	 and	 Le	 Moal	 1997;	 Grant	 and	 Potenza	 2006).	 All	 three	disorders	 thus	 show	compulsivity-related	 symptomatology,	 though	 in	different	ways.	ADHD	 is	related	 to	 more	 addictive	 compulsive	 behaviour,	 ASD	 to	 stereotyped	 behaviour,	 and	 OCD	 to	more	anxiety-based	obsessions	and	compulsions.	The	nature	of	the	relationship	between	these	different	compulsive	(and	impulsive)	disorders	is	less	clear,	particularly	in	terms	of	underlying	mechanisms.	 The	 impulsivity	 seen	 in	 ADHD	 constitutes	 vulnerability	 for	 compulsive	 drug	seeking	 but	 does	 not,	 for	 instance,	 contribute	 to	 anxiety-based	 compulsivity	 seen	 in	 OCD	 or	stereotyped	 behaviour	 seen	 in	 ASD.	 However,	 it	 is	 known	 that	 the	 presence	 of	 one	 of	 these	disorders	often	 co-occurs	with	one	or	 even	both	of	 the	other	disorders.	Therefore,	 it	 could	be	argued	 that	 a	 construct	 shared	by	 all	 three	disorders	may	be	 that	of	 altered	value	 estimation.	The	 compulsivity,	 reflecting	 fear,	 seen	 in	OCD	 is	 overvalued	 in	 a	 similar	way	as	 the	overvalue	prescribed	 to	 stereotyped	 behaviour	 in	 ASD	 and	 to	 reward	 (and	 undervalue	 to	 possible	consequences)	in	impulsivity	and	compulsivity	in	ADHD.	Neuroanatomical	models	posit	the	existence	of	separate	but	intercommunicating	fronto-striatal	 circuits	 involved	 in	 behavioural	 regulation	 (Alexander	 et	 al.	 1986).	 In	 these	 circuits,	 a	striatal	 component	 may	 drive	 impulsive	 or	 compulsive	 behaviour	 while	 a	 frontal	 component	exerts	control	over	it.	An	imbalance	within	these	fronto-striatal	circuits	can	lead	to	impulsivity	
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or	compulsivity.	 In	ASD	and	ADHD	dorsal	 fronto-striatal	 circuits	have	been	 linked	 to	cognitive	control	 while	 connections	 between	 orbitofrontal	 cortex	 (OFC)	 and	 ventral	 striatum	 are	associated	with	reward	and	motivation	(Alexander	et	al.	1986;	Langen	et	al.	2012).	Repetitive	behaviours	 common	 in	ASD	and	OCD	have	been	 linked	 to	executive	 functioning	deficits	 in	 the	frontal	cortex	and	its	connections	to	striatal	regions	as	well	(Thakkar	et	al.	2008).	This	suggests	that	the	tendencies	to	perform	impulsive	behaviour	(especially	present	in	ADHD)	or	compulsive	behaviour,	 like	 the	repetitive	acts	among	ASD	and	OCD,	are	driven	by	striatal	brain	areas.	The	loss	 of	 control	 or	 the	 deficit	 in	 behavioural	 inhibition	 involves	 prefrontal	 cortex	 regions	regulating	monoamines	within	fronto-striatal	circuits	(Del	Campo	et	al.	2013;	Silvetti	et	al.	2013;	Chantiluke	 et	 al.	 2015).	 Impulse	 control	 deficits	 usually	 involve	 aberrant	 dopaminergic	functioning	(Fineberg	et	al.	2010).	Whether	dopamine	dysregulation	reflects	a	primary	deficit	or	is	secondary	to	fronto-striatal	glutamatergic	deficits	remains	unclear.	The	glutamate-dopamine	interaction	is	critical	for	the	top-down	control	from	prefrontal	regions	to	the	striatum	(Arnsten	2009).	Fronto-striatal	circuits	such	as	those	implicated	in	regulating	compulsive	and	impulsive	behaviour	 have	 a	 high	 glutamatergic	 receptor	 density	 (Monaghan	 et	 al.	 1985).	 Glutamatergic	receptors	 modulate	 the	 metabolism	 and	 function	 of	 fronto-striatal	 circuits	 by	 influencing	synapse	 induction	 and	 elimination,	 cell	 migration,	 and	 ionotropic	 and	 metabotropic	 synaptic	transmission.	 Dysregulation	 in	 dopamine	 associated	with	 ASD,	 ADHD	 and	OCD	may	 therefore	reflect	 abnormalities	 in	 glutamatergic	 functioning	 which	 in	 turn	 alters	 monoaminergic	transmission	(Carrey	et	al.	2007;	Fatemi	2008;	Pittenger	et	al.	2011).	Additional	insights	in	the	neurobiology	of	ASD,	ADHD	and	OCD	and	their	overlap	can	be	found	 by	 investigating	 the	 neurochemistry	 of	 the	 brain.	 Proton	 magnetic	 resonance	spectroscopy	 (1H	 MRS)	 allows	 for	 non-invasive	 in	 vivo	 quantification	 of	 specific	 neuro-metabolites	such	as	N-Acetylaspartate	(NAA),	creatine	and	phosphocreatine	(tCr),	choline	(Cho),	myo-inositol	 (mI),	 glutamate	 (Glu)	 and	 gamma	 aminobutyric	 acid	 (GABA).	 Glutamate	 and	glutamine	 are	 together	 referred	 to	 as	 Glx.	 Although	 some	 studies	 of	 ASD,	 ADHD	 and	 OCD	examined	 glutamatergic	 changes	 (Pittenger	 et	 al.	 2011),	 most	 studies	 focus	 on	 monoamines.	However,	 the	role	of	neuronal	Glu	(even	 if	glial	and	metabolic	Glu	 transmission	 is	discounted)	remains	 highly	 relevant	 even	 though	 it	 is	 representing	 only	 a	 portion	 of	 total	 brain	 Glu	 as	measured	by	1H	MRS	(Pittenger	et	al.	2011).	GABA	is	even	less	well	studied,	despite	its	dominant	inhibitory	role	in	the	central	nervous	system.		Thus,	 the	 aim	 of	 the	 current	 manuscript	 is	 to	 review	 the	 role	 of	 glutamatergic	compounds	 in	 fronto-striatal	 circuits	 in	ASD,	ADHD	and	OCD	and	 to	 examine	possible	overlap	and	 differences	 between	 these	 disorders	 based	 on	 their	 underlying	 traits.	 Further,	 we	summarize	 the	 current	 knowledge	 on	 1H	 MRS	 studies	 measuring	 Glu	 and	 Glu-related	
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neurochemicals	 in	 regions	 encompassing	 the	 fronto-striatal	 circuits.	 Methodological	 issues	explaining	inconsistent	findings	and	future	study	suggestions	are	also	discussed.		
METHODS 	With	the	key	words	“proton	magnetic	resonance	spectroscopy”	in	combination	with	respectively	“attention	deficit	hyperactivity	disorder”,	“autism	spectrum	disorder”	or	“obsessive	compulsive	disorder”	we	searched	the	PubMed	 library	(http://www.ncbi.nlm.nih.gov/pubmed)	 for	studies	in	English	using	1H	MRS	to	compare	Glu-related	levels	in	patients	with	ASD,	ADHD	or	OCD	versus	healthy	 subjects.	 Studies	 examining	 changes	 in	 glutamatergic	 levels	 after	 administration	 of	medication	 or	 psychosocial	 treatment	 were	 also	 included.	 Both	 paediatric	 and	 adult	 studies	were	accepted,	regardless	of	sample	size.	In	addition,	we	only	included	studies	examining	brain	regions	in	the	fronto-striatal	circuit	or	areas	that	have	proven	to	be	closely	related	to	prefrontal	and	striatal	brain	regions,	such	as	thalamus,	amygdala	and	cerebellum	(Durston	et	al.	2011).	Due	to	 the	nature	of	Glu	and	 the	developmental	changes	within	 the	 fronto-striatal	 circuit,	different	patterns	of	the	metabolite	levels	can	be	expected	between	children	and	adult	patients	(Pouwels	et	 al.	 1999).	 The	 findings	 of	 children	 and	 adult	 studies	 will	 be	 discussed	 separately	 where	applicable.	We	 abstained	 from	performing	 a	meta-analysis,	 since	 the	 underlying	 studies	 differ	too	much	 in	 design,	 selection	 of	 participants	 and	methods,	which	makes	 it	 impossible	 to	 pool	data	 in	 an	 appropriate	 matter	 (Crowther	 et	 al.	 2010).	 However,	 we	 checked	 whether	 study	results	were	 dependent	 on	 sample	 size	 by	 comparing	 sample	 sizes	 of	 studies	 that	 did	 report	differences	in	Glu	or	Glx	signal	to	those	that	did	not	find	differences.				  
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RESULTS 	Fifty-nine	 studies	 examining	 glutamatergic	 levels	 with	 1H	 MRS	 in	 ASD,	 ADHD,	 or	 OCD	 were	included	 for	 further	 examination.	 Forty-three	 studies	 investigated	 either	 one	 of	 the	 three	disorders	 (ADHD,	 ASD,	 OCD)	 compared	 to	 healthy	 controls;	 Sixteen	 examined	 changes	 after	treatment	administration	in	either	ADHD	or	OCD.	Sixteen	studies	compared	Glu	or	Glx	in	ADHD	patients	versus	healthy	 individuals	 (Table	1;	Figure	1),	 seven	 studied	 changes	after	 treatment	administration	 in	 ADHD	 (Table	 2).	 Sixteen	 compared	 ASD	 with	 healthy	 individuals	 (Table	 3;	Figure	1).	Eleven	studies	compared	OCD	patients	versus	healthy	controls	(Table	4;	Figure	1)	and	nine	 studies	 examined	 glutamatergic	 changes	 after	 treatment	 in	 OCD	 (Table	 5).	 Three	 of	 the	ADHD	and	 four	of	 the	OCD	studies	 examining	 changes	after	 treatment	 also	 included	a	healthy	comparison	group	to	assess	differences	in	metabolite	levels	at	baseline.	No	studies	were	found	in	 which	 treatment	 changes	 in	 ASD	 were	 examined,	 possibly	 due	 to	 the	 fact	 that	 no	 specific	pharmacological	 treatment	 is	 currently	 available	 for	 ASD	 core	 symptoms.	 An	 overview	 of	 the	results	from	the	studies	comparing	patients	with	healthy	control	subjects	can	be	found	in	Figure	1	and	2.		 Thirty	of	59	studies	examined	paediatric	patients	and	24	examined	adults.	Five	studies	examined	 adolescents	 (mean	>=	12	 years).	 Twelve	 out	 of	 43	 studies	 that	 compared	 patients	with	 healthy	 controls	 included	 patients	who	were	medication	 naïve	 or	medication	 free	 for	 at	least	six	weeks.	The	16	studies	in	which	metabolite	changes	after	treatment	administration	were	studied	 examined	 the	 effects	 of	 the	 psychostimulant	 methylphenidate	 (MPH)	 or	 the	noradrenaline	 reuptake	 inhibitor	 atomoxetine	 in	 ADHD,	 and	 selective	 serotonin	 reuptake	inhibitors	 (SSRIs)	 or	 cognitive	 behavioural	 therapy	 in	 OCD.	 All	 studies	 excluded	 neurological	disorders	but	only	fourteen	studies	excluded	all	axis-I	DSM-IV	comorbidities.			 In	 terms	 of	 the	 spectroscopy	 techniques	 utilized,	 only	 sixteen	 of	 59	 studies	 used	 field	strengths	 ≥	 3	 Tesla.	 Almost	 all	 studies	 used	 single	 voxel	 spectroscopy	 with	 point	 resolved	spectroscopy	(PRESS).	Seventeen	studies	used	internal	references	to	tCr,	tCho	or	mI	as	the	main	quantification	 method.	 Regions	 of	 interest	 (ROIs)	 were	 described	 in	 the	 papers	 with	accompanying	pictures	in	most	cases	but	unfortunately	no	exact	coordinates	were	provided.	The	tables	1	to	5	provide	information	on	ROIs	of	the	different	studies.	
 
Attention-deficit/hyperactivity disorder  Among	the	16	studies	comparing	ADHD	with	healthy	 individuals,	11	 investigated	Glu	or	Glx	 in	prefrontal	regions.	Six	of	these	11	studies	did	not	report	any	differences	between	ADHD	patients	and	 healthy	 control	 individuals	 in	 dorsolateral	 prefrontal	 cortex	 (DLPFC)	 (Hesslinger	 et	 al.	2001;	Soliva	et	al.	2010;	BenAmor	2014),	ventromedial	prefrontal	cortex	(VMPFC)	(Ferreira	et	
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al.	 2009)	 and	middle	 frontal	 gyrus	 (MFG)/anterior	 cingulate	 cortex	 (ACC)	 (Yang	 et	 al.	 2010;	Tafazoli	 et	 al.	 2013).	 Three	 studies	 found	 increased	 Glx	 levels	 in	 the	 PFC	 (MacMaster	 et	 al.	2003),	superior	frontal	gyrus	(SFG)	(Courvoisie	et	al.	2004)	and	ACC	(Moore	et	al.	2006).	These	studies	 were	 all	 performed	 in	 children.	 Contrarily,	 three	 adult	 studies	 found	 decreased	glutamatergic	 levels	 in	 the	 ACC	 (Perlov	 et	 al.	 2007;	 Dramsdahl	 et	 al.	 2011)	 and	 the	 DLPFC	(Maltezos	 et	 al.	 2014),	 although	 the	 result	 in	 this	 last	 study	 did	 not	 survive	 Bonferroni	correction.	In	addition,	one	study	reported	decreased	GABA	levels	in	the	motor	cortex	(PFC)	in	ADHD	 children	 (Edden	 et	 al.	 2012).	 The	 study	 by	 Dramsdahl	 et	 al.	 and	 Edden	 et	 al.	 were	performed	at	3	T,	all	others	at	1.5	T.		 Six	studies	investigated	striatal	glutamatergic	compounds.	Three	studies	did	not	find	any	differences	 between	 ADHD	 patients	 and	 controls	 (Hesslinger	 et	 al.	 2001;	 Sun	 et	 al.	 2005;	BenAmor	2014)	and	one	adult	study	reported	increased	Glx	levels	in	the	left	putamen	(Ferreira	et	 al.	 2009).	 Another	 adult	 study	 found	 decreased	 Glx	 in	 the	 basal	 ganglia	 comprising	 the	caudate	and	putamen	(Maltezos	et	al.	2014).	One	additional	study	reported	increased	Glx	levels	in	 the	 striatum	 approaching	 statistical	 significance	 after	 correcting	 for	 multiple	 comparisons	(MacMaster	et	al.	2003).	Additional	findings	were	increased	Glx	levels	in	adult	ADHD	patients	in	the	cerebellum	(Perlov	et	al.	2010)	and	the	posterior	cingulate	(Arcos-Burgos	et	al.	2012).	Three	 of	 seven	 studies	 that	 investigated	 glutamatergic	 changes	 after	 treatment	 also	included	 a	 healthy	 comparison	 group.	 In	 two	 of	 them,	 baseline	 Glx	 was	 increased	 in	 ADHD	compared	to	controls	in	the	striatum	(Carrey	et	al.	2007)	and	ACC	(Hammerness	et	al.	2012).	No	Glx	reductions	were	found	after	treatment	with	MPH,	although	one	study	found	a	trend	towards	post-treatment	 reductions	 at	 3	 T	 (Hammerness	 et	 al.	 2012).	 The	 third	 study	 did	 not	 find	differences	 between	 ADHD	 and	 controls	 in	 the	 globus	 pallidus	 (Jin	 et	 al.	 2001).	 Four	 studies	investigated	 glutamatergic	 changes	 after	MPH	or	 atomoxetine	 treatment	 and	did	not	 compare	them	with	healthy	 controls.	All	 but	 one	of	 these	 studies	 found	decreases	 in	 the	 striatum	after	treatment,	with	respectively	56.1%	and	35	%	reductions	(Carrey	et	al.	2002;	Carrey	et	al.	2003)	and	a	PFC	Glu	reduction	of	15%	(Wiguna	et	al.	2012).	The	study	by	Husarova	et	al.	(2014)	found	increased	 Glx	 in	 the	 white	 matter	 behind	 the	 DLPFC	 after	 treatment	 with	 MPH	 (right	hemisphere)	 or	 atomoxetine	 (left	 hemisphere)	 (Husarova	 et	 al.	 2014).	 All	 treatment	 studies	except	the	one	by	Hammerness	et	al.	(2012)	were	performed	in	paediatric	ADHD	cohorts.		 	
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Table	1	Proton	magnetic	resonance	spectroscopy	studies	reporting	glutamate	(and	GABA)	differences	between	ADHD	patients	and	healthy	controls.	Reference	 Subjects	 Comorbidities	 Medication		Status	 Field	strength	 MRS	Sequence	 TR/TE/	averages	 Scan	time	 Coil	type	 Voxel	size	 Regions	of	interest	 Quantification	method	 Reported	results	(calculated	effect	sizes,	cohen’s	d)	Hesslinger	et	al.	(2001)		 5	ADHD,	5	ADD,	5	HC	Adults	 3	avoidant	and	1	antisocial	personality	
Psychotropic	free	 2	T	 PRESS	 3000/30/	N.A	 N.A	 Quadrature	headcoil	 2	x	2	x	2	cm	 Left	DLPFC	Left	Striatum	 Absolute	concentrations	 No	differences	between	ADHD,	ADD	and	HC	MacMaster	et	al.	(2003)		 9	ADHD,	9	HC	Children	 6	ODD	 Med	free	>48	hours	 1.5	T	 1H	MRS	spin	echo	 1500/135/256	 ~	6.5	min	per	voxel	
N.A	 4	cm3	6	cm	3	 Right	PFC	Left	Striatum	 Cre	ratios	 Increased	Glx/Cre	in	Right	PFC	(1.47);	trend	for	Left	striatum	()	In	controls	positive	correlation	for	age	and	Glx/Cre	and	in	ADHD	positive	correlation	for	onset	age	and	Glx/Cr	Courvoisie	et	al.	(2004)		 8	ADHD,	8	HC	Children	 None	 Mostly	stimulants	(MPH)	 1.5	T	 STEAM	 1600/20/128	 ~3.5	min		 Standard	MR	headcoil	 2	x	2	x	2	cm	 Bilateral	frontal	lobe	(including	SFG)	 Cre	ratios	 Increased	Glu/Cre	in	right	frontal	lobe	(1.83)	and	left	frontal	lobe	(1.57)	Sun	et	al.	(2005)		 10	ADHD-C,	10	ADHD-I,	10	HC	Adolescents	 1	CD,	2	ODD,	3	Tic	disorder	 All	med	naïve	 1.9	T	 PRESS	 1500/35.5/200	 ~	5	min	per	voxel	
Circularly	polarized	headcoil	 2	x	2	x	2	cm	 Bilateral	lenticular	nuclei	 Cre	ratios	 No	differences	between	ADHD-C,	ADHD-I	and	HC	(left:	-	0.36,	right	0,17)	Moore	et	al.	(2006)		 23	ADHD,	8	HC		Children	 8	ADHD	+	bipolar	ODD	 Amphetamine,	Bupropion,	atomoxetine	
1.5	T	 PRESS	 2000/30/128	 ~	4	min		 N.A	 2	x	2	x	1.2	cm	 Anterior	Cingulate	 mI	ratios	Cre	ratios	 Increased	Glx/mI	in	ADHD	(0.89)	compared	to	both	ADHD+bipolar	and	HC;	same	for	Glx/Cre		Perlov	et	al.	(2007)		 28	ADHD,	28	HC	Adult	 Depression,	Borderline,	SUD	and	neurological	disorders	excluded	
All	med	free	>	6	months	 1.5	T	 CSI	PRESS	 1500/30/4		 30	min	in	total	 Quadrature	headcoil	 16x16	voxels	6	x	11	x	1.5	VOI	
Bilateral	ACC	 Cre	ratios	 Decreased	Glx/Cre	in	Right	ACC	(-	0,60	)	
Ferreira	et	al.	(2009)		 10	ADHD-C,	9	ADHD-I,	12	HC		Adult		 Dysthymia,	ODD	 Psychotropic	med	naïve	 1.5	T	 PRESS	 1500/30/256	 6:36	min	per	voxel	
N.A	 16x16	voxels	 Bilateral	VMPFC	Bilateral	pulvinar	Bilateral	putamen	Bilateral	head	caudate	
Cre	ratios	 Increased	Glx/Cre	in	left	putamen	in	ADHD-C	compared	to	both	ADHD-I	(1,17)	and	HC	(1,27)		
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Table	1	(continued).	Reference	 Subjects	 Comorbidities	 Medication		Status	 Field	strength	 MRS	Sequence	 TR/TE/	averages	 Scan	time	 Coil	type	 Voxel	size	 Regions	of	interest	 Quantification	method	 Reported	results	(calculated	effect	sizes,	cohen’s	d)	Soliva	et	al.	(2010)		 21	ADHD,	21	HC	Children	 All	axis	I	and	neurological	disorders	excluded	(ODD	too)		
All	stimulants	(MPH)	 1.5	T	 PRESS	 2000/30	/256	 ~	8.5	min	per	voxel	
N.A	 2	x	2	x	2	cm	 Right	DLPFC	Left	cerebellar	hemisphere	 Absolute	concentrations	 No	differences	between	ADHD	and	HC(cerebellum:	0.02)	
Yang	et	al.	(2010)		 15	ADHD,	22	HC	Adolescents	 6	ODD,	3	mood/anxiety	disorder	 11	MPH,	1	bupropion	 1.5	T	 PRESS	 1600/35/128	 ~	3.5	min	 N.A	 2	x	2	x	2	cm	 Bilateral	frontal	lobe	(ACG	+	MFG)	 Absolute	concentrations	(i.u.)	Cre	ratios	
No	differences	between	ADHD	and	HC	(left	0.71,	right	0.04)	Perlov	et	al.	(2010)		 30	ADHD,	30	HC	Adults	 Depression,	Borderline,	SUD	and	neurological	disorders	excluded	
All	med	free	>	6	months	 1.5	T	 CSI	PRESS	 1500/30/4	 30	min	in	total	 Quadrature	headcoil	 16x16	voxels	6	x	11	x	1.5	VOI	
Bilateral	cerebellar	hemispheres	 Cre	ratios	 Increased	Glx/Cre	in	left	cerebellar	hemisphere	(0.74)	
Dramsdahl	et	al.	(2011)		 29	ADHD,	38	HC		Adults	 All	axis	I	and	neurological	disorders	excluded	(epilepsy	too)	
15	stimulants,	1	atomoxetine	
3	T	 PRESS	 1500/35/N.A	 N.A	 8	channel	coil	 2	x	2	x	2	cm	 Bilateral	midfrontal	region	including	ACC	
Cre	ratios	 Decreased	Glu/Cre	in	left	midfrontal	region	();	without	comorbidity	the	difference	with	controls	was	larger	Negative	correlation	with	inattentive	symptoms	Arcos-Burgos	et	al.	(2012)		 14	ADHD,	20	HC	Adults	 ODD,	CD	1	anxiety,	5	depression	 All	med	naïve	 1.5	T	 PRESS	 1500/30/3	 6:05	and	10:23	min	
8	channel	coil	 CSI	 14	regions	 Cre	ratios	 Increased	Glx/Cre	in	right	posterior	cingulate	
Edden	et	al.	(2012)		 13	ADHD,	19	HC	Children	 5	ODD	 7	stimulants	 3	T	 PRESS	 1800/68/N.A	 10	min	 N.A	 3	x	3	x	3	cm	 Motor	cortex	(hand	knob)	 Absolute	concentrations	(i.u.)	 Decreased	GABA	in	ADHD	compared	to	HC	Tafazoli	et	al.	(2013)		 13	ADHD,	13	HC	Children	 Psychiatric	and	neurological	excluded	
1	MPH,	2	amphetamines	 1.5	T	 PRESS	 1500/30/4	 N.A	 Quadrature	headcoil	 MRSI	voxels	 Bilateral	middle	frontal	gyrus	 Absolute	concentrations	(i.u.)	 No	differences	between	ADHD	and	HC	(left	-0.13,	right	-0,42)	Benamor	et	al.	(2014)	 102	ADHD,	38	HC	Children	 PDD,	psychosis	and	IQ	<	70	excluded	
57	stimulants	 1.5	T	 PRESS	 1500/30/128	 40	min	in	total	 N.A	 8	cm3	 Bilateral	PFC	Bilateral	striatum	Left	cerebellum	
Cre	ratios	 Increased	Glx/Cre	in	cerebellum	(0.44)	with	highest	levels	in	medication	naive	patients	Maltezos	et	al.	(2014)	 40	ADHD,	20	HC	Adults	 All	axis	I	and	neurological	 24	naïve,	16	MPH	or	 1.5	T	 PRESS	 3000/30/N.A	 45	min	in	total	 N.A	 2	x	2	x	2	2	x	2	x	1.5	 Left	parietal	(med)	 Absolute	concentratio Decreased	Glx	in	basal	ganglia	and	in	DLPFC	(this	
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disorders	excluded	 dextramphetamine	 	1.6	x	2.4	x	2	 Left	basal	gang	(caudate/putamen)	Left	DLPFC	
ns	 did	not	survive	correction)	(-1,05)	No	differences	medicated/unmedicated		ACC,	anterior	cingulate	cortex;	ACG,	anterior	cingulate	gyrus;	ADD,	attention-deficit	disorder;	ADHD,	attention-deficit/hyperactivity	disorder;	ADHD-c,	combined	subtype;	ADHD-I,	inattentive	subtype;	CD,	conduct	disorder;	CSI,	chemical	shift	imaging;	Cr,	creatine;	DLPFC,	dorsolateral	prefrontal	cortex;	GABA,	gamma-aminobutyric	acid;	Glx,	glutamate	and	glutamine;	Glu,	glutamate;	HC,	healthy	controls;	i.u.,	institutional	 units;	MFG,	middle	 frontal	 gyrus;	mI,	myo-inositol;	MPH,	methylphenidate;	MRSI,	magnetic	 resonance	 spectroscopic	 imaging;	N.A,	 not	 applicable;	ODD,	 oppositional	 defiant	disorder;	 PDD,	pervasive	developmental	disorder;PFC,	prefrontal	cortex;	SFG,	superior	frontal	gyrus;	SUD,	substance	use	disorder;	T,	tesla;	TE,	echo	time;	TR,	repetition	time;	VMPFC,	ventromedial	prefrontal	cortex;	VOI,	volume	of	interest.	PRESS	and	STEAM	are	single	voxel	spectroscopy	acquisition	methods.	
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Table	2	Proton	magnetic	resonance	spectroscopy	studies	reporting	glutamate	changes	with	treatment	in	ADHD	patients.	Reference	 Subjects	 Comorbidities	 Treatment	administered	 Field	strength	 MRS	sequence	 TR/TE/	averages	 Scan	time	 Coil	type	 Voxel	size	 ROI(s)	 Quantification	method	 Reported	results	(calculated	effect	sizes,	cohen’s	d)	Jin	et	al.	(2001)		 12	ADHD,	10	HC	Children	 Psychiatric	or	neurological	disorder	excluded	
MPH	(10	mg)	 1.9	T	 PRESS	 1500/35.5/200	 ~	5	min	per	voxel	
Circularly	polarized	head	coil	 2	x	2	x	2	cm	 Bilateral	globus	pallidus	 Cre	ratios	 No	differences	between	ADHD	and	HC	before	and	after	treatment	(left	-0.1,	right	0.41)	Carrey	et	al.	(2002)			 	4	ADHD		Children	 ODD	 MPH	and	atomoxetine	 1.5	T	 PRESS	 1500/135/256	 10	min	in	total	 N.A.	 7	cm
3	4	cm3	 Left	striatum	Right	PFC	 Cre	ratios	 Reduction	of	Glx/Cre	in	striatum	(mean	change	56.1	%)	after	treatment	Carrey	et	al.	(2003)		 14	ADHD		Children		 3	ODD	 MPH	(10-15	mg),	Dexedrine	(2,5-15	mg),	atomoxetine	(20-30	mg)	
1.5	T	 Long	echo	sequence	 1500/135/256	 7	min	per	voxel	 N.A.	 4	cm
3	 Left	striatum	Right	PFC	 Cre	ratios	 Reduction	of	Glx/Cre	(35	%)	in	striatum	after	treatment	(0.27)		
Carrey	et	al.	(2007)		 13	ADHD-C,	10	HC	Children	 Psychiatric	or	neurological	disorder	excluded	
MPH	(0.3-0.6	mg/kg)	 1.5	T	 PRESS	 2000/30/256	 ~8	min	per	voxel	
N.A.	 4	cm3	 Left	Striatum	Right	PFC		 Absolute	concentrations	 Baseline	Glu	/	Glx	increased	in	striatum.	(0.92)	No	reduction	after	treatment	
Hammerness	et	al.	(2012)		 10	ADHD,	12	HC	Adolescents	 None	 MPH	(up	to	1.5	mg/kg)	 4	T	 PRESS	 2000/30/128	 ~4	min		 Proton	volumetric	headcoil	 2	x	2	x	2	cm	 ACC	 mI	ratios	 Baseline	Glu,	Gln,	Glx	increased	(0.60,	0.46,	0.25),	correlated	with	ADHD	rating	scale.	Trend	towards	reduction	after	treatment			Wiguna	et	al.	(2012)		 21	ADHD	Children	 None	 MPH	(20	mg	long	action	p/d,	12	weeks(	
1.5	T	 Unknown	 1000/30/N.A	 N.A	 Circularly	polarized	headcoil	 2	x	2	x	2	cm	 Bilateral	PFC	 Cre	ratios	 Reduction	Glu/Cre	(15	%	in	R,	14	%	in	L	PFC)	(0.694)	after	treatment		Husarova	et	al.	(2014)	 21	ADHDChildren	 Current	MDD,	anxiety,	neurological	disorders,	
10	used	MPH	(18	mg	for	5	days	and	then	36	or	
1.5	T	 PRESS	 3000/30/128	 ~	6.5	min	per	voxel	
N.A	 8	mL	 Bilateral	DLPFC	and	the	white	matter	behind	it	 Absolute	concentrations	+	Cre	ratios	
Increased	WM	Glx	in	the	right	hemisphere	after	MPH	Increased	WM	Glx	in	the	left	hemisphere	after	ATX	(-	0.74)	
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learning	disorders	and	tics	excluded	
54)	12	used	ATX	(0.5	mg	for	5	days	and	then	12	or	1.4)		ACC,	 anterior	 cingulate	 cortex;	 ADHD,	 attention-deficit/hyperactivity	 disorder;	 ADHD-c,	 combined	 subtype;	 ATX,	 atomoxetine;	 Cr,	 creatine;	 Glu,	 glutamate;	 Glx,	 glutamate	 and	 glutamine;	 HC,	 healthy	controls;	MDD,	major	depressive	disorder	mI,	myo-inositol;	MPH,	methylphenidate;	N.A,	not	applicable;	ODD,	oppositional	defiant	disorder;	PFC,	prefrontal	cortex;	T,	tesla;	TE,	echo	time;	TR,	repetition	time;	VMPFC,	ventromedial	prefrontal	cortex;	WM,	white	matter.	PRESS	is	a	single	voxel	spectroscopy	acquisition	method.		 	
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Autism spectrum disorder Sixteen	 studies	 discussed	 glutamatergic	 differences	 between	 ASD	 patients	 and	 healthy	individuals.	Twelve	of	sixteen	examined	regions	within	the	PFC.	 In	four	of	these	12	studies,	no	differences	were	 found	 between	 ASD	 patients	 and	 healthy	 individuals	 in	 the	 ACC	 (Aoki	 et	 al.	2012)	and	DLPFC	(Horder	et	al.	2013)	and	two	other	unspecified	frontal	regions	(Friedman	et	al.	2003;	Harada	et	al.	2011).	Three	childhood	studies	and	one	adolescent	study	demonstrated	increased	Glu	and	Glx	levels	in	ASD	in	the	ACC	(Bejjani	et	al.	2012;	Hassan	et	al.	2013;	Joshi	et	al.	2013).	Decreased	levels	of	Glx	were	found	in	frontal	grey	matter	(Devito	et	al.	2007)	in	children,	in	 the	 ACC	 in	 adults	 (Bernardi	 et	 al.	 2010;	 Tebartz	 Van	 Elst	 et	 al.	 2014)	 and	 in	 the	 OFC	 in	children	 (Kubas	et	 al.	 2012).	Additionally,	 three	 studies	 found	 reduced	GABA	 levels	 in	 several	frontal	 areas	 (Harada	 et	 al.	 2011;	 Kubas	 et	 al.	 2012;	 Gaetz	 et	 al.	 2013).	 Only	 four	 studies	examined	 striatal	 glutamatergic	 levels.	 Three	 found	 no	 differences	 although	 in	 the	 study	 by	Harada	et	al	(2011)	a	trend	for	elevated	Glu	was	found	in	the	lenticular	nuclei	(Friedman	et	al.	2003;	Harada	et	al.	2011;	Corrigan	et	al.	2013).	One	study	found	increased	Glu	 in	the	striatum	(Hassan	et	al.	2013).	Other	 areas	 examined	 in	 ASD	 were	 amygdala-hippocampal	 complex	 in	 which	 Glx	increases	were	found	in	an	adult	ASD	study	(Page	et	al.	2006)	but	no	differences	were	found	in	adults	with	Asperger	syndrome	(O'Brien	et	al.	2010).	Further,	no	differences	were	reported	 in	the	 thalamus	 (Friedman	 et	 al.	 2003;	 Hardan	 et	 al.	 2008;	 Bernardi	 et	 al.	 2010);	 one	 study	examining	 the	 cerebellum	 showed	 elevated	 levels	 of	 Glu	 in	 children	 with	 ASD	 (Hassan	 et	 al.	2013)	while	another	found	no	differences	between	adult	ASD	patients	and	controls	(Tebartz	Van	Elst	et	al.	2014).	Of	all	studies,	seven	used	field	strengths	of	3	T	and	these	studies	were	all	able	to	find	 differences	 across	 ASD	 patients	 and	 controls	 (Devito	 et	 al.	 2007;	 Bernardi	 et	 al.	 2010;	Harada	et	al.	2011;	Gaetz	et	al.	2013;	Joshi	et	al.	2013;	Tebartz	Van	Elst	et	al.	2014)	except	for	the	study	by	Aoki	et	al.	(2012).		
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Table	3	Proton	magnetic	resonance	spectroscopy	studies	reporting	glutamate	differences	between	ASD	patients	and	healthy	controls.	Reference	 Subjects	 Comorbidities	 Medication		status	 Field	strength	 MRS	Sequence	 TE/TR/	averages	 Scan	time	 Coil	type	 Voxel	size	 ROI(s)	 Quantification	method	 Reported	results	(calculated	effect	sizes,	cohen’s	d)	Friedman	et	al.	(2003)		 45	ASD,	15	DD,13	HC	Children	 Neurological	disorders,	genetic	syndromes	excluded	
Psychoactive	excluded	 1.5	T	 PEPSI	 2000/20	and	272/N.A	 20	min	per	volume	
Receive	only	linear	bird-cage	coil	
CSI	 Frontal	Striatum	Thalamus	 Absolute	concentrations	 No	differences	between	ASD,	DD	and	HC	(overall	-0.94,	not	specified	per	region)	
Page	et	al.	(2006)		 25	ASD,	21	HC		Adults	 Neurological	disorders,	genetic	syndromes	excluded	
Psychotropic	excluded	 1.5	T	 PRESS	 3000/35/160	 ~	8	min	per	voxel	
N.A	 6	cm3	8	cm3	 Amygdala-hippo-campal	complex		 Absolute	concentrations	and	Cre	ratios	
Increased	Glx	in	amygdala	(0.92)	
DeVito	et	al.	(2007)		 26	ASD	,	29	HC	♂		Children	 Neurological	disorders,	genetic	syndromes	excluded	
Stimulants,	SSRI,	risperidone,	choline	sterase	inhib	
3	T	 1H	MRSI	sequence	 1800/135/N.A	 30	min	in	total	 Quadrature	RF	headcoil	 0.8	x	0.8	x	0.9	cm	 Grey	and	white	matter	in	cerebrum	 Absolute	concentrations	(i.u.)	 Decreased	Glx	in	grey	matter	(frontal	(-0.15	left	and	–	0.66	right),	cerebellum		
Hardan	et	al.	(2008)		 18	ASD,	16	HC	♂	Children	 Genetic	and	metabolic,	TS,	fragile	X	excluded	
No	information	 1.5	T	 STEAM	 1600/20/4	 N.A	 N.A	 CSI	 Bilateral	thalamus	 Absolute	concentrations	 Trend	towards	a	decrease	in	left	thalamus	(-0.62)	O’Brien	et	al.	(2010)		 22	Asperger,	22	HC		Adults	
Neurological	disorders,	genetic	syndromes	excluded	
Psychotropic	free	 1.5	T	 PRESS	 3000/35/160	 ~	8	min	per	voxel	
Quadrature	headcoil	 2	x	2	x	1.5	cm	 Amygdala-hippocampal	complex	 Absolute	concentrations	and	Cre	ratios	
No	differences	between	Asperger	and	HC	
Bernardi	et	al.	(2011)		 14	ASD,	14	HC		Adults	 All	axis	I	and	neurological	disorders	excluded	
All	med	free	 3	T	 PRESS	 2000/30/1	per	encoding	step	 N.A	 N.A	 1	x	0.75	x	0.75	cm	 ACC	Thalamus		 Absolute	concentrations	 Decreased	Glx	in	ACC	(-1.30)	Aoki	et	al.	(2012)		 24	ASD,	25	HC	♂	Adults		
Neurological	disorders,	brain	injury,	addiction	excluded	
All	med	free	 3	T	 Unknown	 3000/15/136	 ~	7	min		 8	channel	coil	 2	x	2	x	2	cm	 ACC	 Unknown	 No	differences	between	ASD	and	HC	
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Table	3	(continued).	Reference	 Subjects	 Comorbidities	 Medication		status	 Field	strength	 MRS	Sequence	 TR/TE/averages	 Scan	time	 Coil	type	 Voxel	size	 ROI(s)	 Quantification	method	 Reported	results	(calculated	effect	sizes,	cohen’s	d)	Harada	et	al.	(2011)		 12	ASD,	10	HC	Children	 Authors	do	not	report	any	exclusion	criteria	
Authors	do	not	provide	information	on	medication	
3	T	 STEAM	(MEGA)	PRESS	 2500/68/256	 ~	10.5	min	per	voxel	
Birdcage	headcoil	 3	x	3	x	3	cm	 Lenticular	nuclei	Left	frontal	lobe	 Absolute	concentrations	and	ratios	 Trend	towards	increased	Glu/NAA	in	both	regions	(0.42	and	0.67)	Decreased	GABA	in	the	frontal	lobe	Bejjani	et	al.	(2012)		 8	ASD,	10	HC			26	ASD,	16	HC		Children	
Medical	and	neurological	disorders	excluded	
1	fluoxetine	1	MPH	5	stimulants	1	atomoxetine	Anti-depress	+	anti-psychotic	
1.5	T	 PRESS	 1500/25/256	 ~	6.5	min		 Quadrature	headcoil	 2.4	–	3.6	cm3	4	x	4	voxels	0.9	x	1.1	x	1.1	cm	
pACC		pACC	 Absolute	concentrations	 Increased	Glx	(1,03)		Increased	Glx	(0.98)	
Joshi	et	al.	(2012)		 7	ASD,	7	HC	Adolescents	 Yes	(no	information	on	which)	 SSRI,	stimulant,	antidepressants	and	psychotics	
4	T	 2DJ	PRESS	 2000/20	to	250/16	and	32	 ~	7	min		 N.A	 8	cm
3	3.375	cm3	 ACC		 Absolute	concentrations	(i.u.)	 Increased	Glu	in	ACC	(2.47)		
Corrigan	et	al.	(2013)	 53	ASD,	20	DD,	49	HC	Children	 Genetic,	sensory	and	motor	impairments,	CVD	excluded	
Stimulants,	antidepressants,antipsychotics	and	anticonvulsant	
1.5	T	 PRESS	 2000/20/	N.A	 N.A	 Birdcage	RF	headcoil	(receive	only)	
1	cm3	 Anterior	commisure		Basal	ganglia		(GM	and	WM)	
Absolute	concentrations	 Decreased	Glx	in	WM	in	3-4	year	old	ASD	patients	(-1.43)	but	no	(longitudinal)	differences	across	the	three	age	groups	(3-4,	6-7	and	9-10)		Kubas	et	al.	(2013)		 12	ASD,	16	HC	Children	 Authors	do	not	provide	information	on	comorbidities	
Authors	do	not	provide	information	on	medication	
1.5	T	 PRESS	 1500/35/192	 ~	5	min		 N.A	 	 Frontal	lobe	(OFC)	 Absolute	concentrations	(i.u.)	 Decreased	Glx	(-1.07)	Decreased	GABA		
Gaetz	et	al.	(2013)	 17	ASD,	17	HC	Children	 Genetic,	neurological,	 13	medication	 3	T	 MEGA	PRESS	 1500/68/N.A	 ~	7	min	 32	channel	coil	 3	x	3	x	3	cm	 Motor	Visual	 Cre	ratios		 	 Decreased	GABA	in	ASD	in	motor	and	auditory	cortex	
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	 sensory	and	motor	impairments	excluded	
free,	2	SSRI’s,	1	mood	disorder	treatment	and	1	atypical	antipsychotics	
per	voxel	 (receive	only)	 4	x	3	x	2	 Auditory	
Horder	et	al.	(2013)		 28	ASD,	14	HC		Adults	 Psychiatric	or	medical	disorder	affecting	brain	development	excluded	
Naïve	 1.5	T	 PRESS	 3000/30/N.A	 N.A	 N.A	 2	x	2	x	1.5	1.6	x	2.4	x	2			
Left	Basal	ganglia	Left	DLPFC		
Absolute	concentrations	(i.u.)	 Decreased	Glx	in	basal	ganglia	(-1.48)	
Hassanet	al.	(2013)		 10	ASD,	10	HC	Children	 Neurological	and	metabolic	disorders	excluded	
Authors	do	not	provide	information	on	medication	
1.5	T	 PRESS	 1500/30/3	 N.A	 N.A	 0.2	x	0.2	x	0.2	cm	 Bilateral	ACC	Left	striatum	Left	cerebellum	Left	frontal	lobe	
Absolute	concentrations	(i.u.)	 Increased	Glu	in	all	regions	(1.83	in	striatum,	1.93	in	ACC)	
Tebartz	van	Elst	et	al.	(2014)	 29	ASD,	29	HC		Adults	 Axis	I	excluded	(except	depression	&	anxiety)	
SSRI’s	and	neuroleptics	 3	T	 PRESS	 3000/30/N.A	 N.A	 12	channel	coil	 2.5	x	1.6	x	2	2	x	2	x	2	cm	
ACC	Left	cerebellum	 Absolute	concentrations	(i.u.)	 Decreased	Glu	and	Glx	in	the	ACC	(-0.9)	
	ACC,	anterior	cingulate	cortex;	ASD,	autism	spectrum	disorder;	CSI,	chemical	shift	imaging;	Cr,	creatine;	CVD,	cardiovascular	disease;	DD,	delayed	development;	DLPFC,	dorsolateral	prefrontal	cortex;	Glx,	glutamate	and	glutamine;	Glu,	glutamate;	GABA,	gamma-aminobutyric	acid;	GM,	grey	matter;	HC,	healthy	controls;	i.u.,	institutional	units;	MPH,	methylphenidate;	MRSI,	magnetic	resonance	spectroscopic	imaging;	 N.A,	 not	 applicable;	 NAA,	 N-Acetylaspartate;	 OFC,	 orbitofrontal	 cortex;	 pACC,	 pregenual	 anterior	 cingulate	 cortex;	 PEPSI,	 proton	 echo-planar	 spectroscopic	 imaging;	 SSRI,	 selective	 serotonin	reuptake	inhibitor;	T,	tesla;	TE,	echo	time;	TR,	repetition	time;	TS,	tuberous	sclerosis;	WM,	white	matter.	PRESS	and	STEAM	are	single-voxel	spectroscopy	acquisition	methods.	♂,	male	participants.	
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Obsessive compulsive disorder Among	eleven	studies	comparing	OCD	patients	with	healthy	control	individuals,	ten	investigated	prefrontal	 regions.	 In	 seven	 of	 these	 studies	 no	 differences	were	 reported	 (Ebert	 et	 al.	 1997;	Starck	et	al.	2008;	Bédard	and	Chantal	2011;	Simpson	et	al.	2012).	These	were	all	adult	cohort	studies	 investigating	 different	 PFC	 regions	 such	 as	 ACC,	 OFC,	 MPFC	 and	 DLPFC.	 Two	 studies	found	 increased	 Glx	 in	 respectively	 the	 right	 OFC	 and	 the	 ACC	 in	 an	 adult	 patient	 group	(Whiteside	 et	 al.	 2006;	 Gnanavel	 et	 al.	 2014).	 One	 adolescent	 study	 found	 no	 significant	differences	 between	 patients	 and	 controls	 but	 a	 trend	 towards	 increased	 Glx	 in	 the	 right	prefrontal	white	matter	behind	the	ACC	(p	.07)	(Weber	et	al.	2014).	Decreases	in	Glx	were	found	in	 one	 adult	 study	 examining	 only	 female	 patients	 and	 one	 paediatric	 study	 in	 the	 ACC	(Rosenberg	et	al.	2004;	Yücel	et	al.	2008).	One	additional	study	found	a	trend	towards	decreased	Glx	in	the	dorsal	ACC,	but	only	in	patients	that	were	using	SSRIs	(Yücel	et	al.	2007).	One	study	reported	 reduced	 GABA	 in	 the	 MPFC	 in	 an	 adult	 OCD	 group,	 while	 Glu	 differences	 were	 not	found	(Simpson	et	al.	2012).	Five	of	11	studies	examined	glutamatergic	levels	in	the	striatum	of	which	one	found	increased	Glx	levels	in	the	caudate	nucleus	in	an	adult	sample	(Gnanavel	et	al.	2014).	The	other	studies	found	no	differences	between	patients	and	controls	(Ebert	et	al.	1997;	Bartha	et	al.	1998;	Whiteside	et	al.	2006;	Starck	et	al.	2008).	In	one	study,	a	positive	correlation	between	 obsessive	 compulsive	 symptom	 severity,	 as	 measured	 by	 the	 Children’s	 Yale-Brown	Obsessive	 Compulsive	 Scale	 (CYBOCS),	 and	 Glx	 levels	 in	 the	 caudate	was	 found	 (Starck	 et	 al.	2008).	 In	 four	 of	 nine	 studies	 that	 examined	 glutamatergic	 changes	 after	 treatment,	 an	additional	control	group	was	used.	Three	of	these	studies	did	not	find	any	differences	between	OCD	patients	and	controls	in	any	region	(O’Neill	et	al.	2012;	Whiteside	et	al.	2012;	Zurowski	et	al.	2012).	One	study	found	increased	baseline	Glx	in	the	head	of	the	left	caudate	nucleus	that	was	reduced	following	treatment	with	paroxetine	(Rosenberg	et	al.	2000).	Of	the	five	studies	that	did	not	include	a	control	group,	two	examined	the	ACC	(Lázaro	et	al.	2012;	Neill	et	al.	2013).	O’Neill	et	 al	 (2013)	 found	 reduced	 ACC	 Glx	 levels	 after	 four	 weeks	 of	 daily	 cognitive	 behavioural	therapy	 (CBT).	 The	 study	 by	 Lazaro	 et	 al	 (2012)	 examined	 both	 the	 effect	 of	 SSRIs	 and	behavioural	counselling	but	no	differences	were	reported.	Four	of	 these	 five	studies	examined	striatum	as	well.	In	two	studies	reduced	Glx	levels	after	12	weeks	of	paroxetine	treatment	were	reported	 (Moore	et	 al.	 1998;	Bolton	et	 al.	 2001)	and	 in	 the	other	 two	no	 changes	were	 found	after	treatment	with	CBT	or	SSRIs	(Benazon	et	al.	2003;	Lázaro	et	al.	2012).			 	
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Table	4	Proton	magnetic	resonance	spectroscopy	studies	reporting	glutamate	differences	between	OCD	patients	and	healthy	controls.	Reference	 Subjects	 Comorbidities	 Medication		status	 Field	strength	 MRS	Sequence	 TR/TE/	averages	 Scan	time	 Coil	type	 Voxel	size	 ROI(s)	 Quantification	method	 Reported	results	(calculated	effect	sizes,	cohen’s	d)	Ebert	et	al.	(1997)		 12	OCD,	6	HC		Adults	 Medical	illness,	schizoaffective	and	dementia	excluded	
10	med	free	>	6	months,	2	clomipramine	or	fluvoxamine	
2	T	 PRESS	 1500/30/256	 ~	6.5	min	per	voxel	
N.A	 2	x	2	x	2	cm	 Bilateral	anterior	cingulate	Right	striatum		
Relative	to	pCr/Cr	 No	differences	between	OCD	and	HC	(striatum	–	0.35)	
Bartha	et	al.	(1998)		 13	OCD,	13	HC		Adults	 Schizoaffective	disorders	excluded	 Med	free	>	6	wk		 4	T	 STEAM	 1500/20/N.A	 N.A	 N.A	 1.5	x	2	x	1.5	cm	 Left	striatum	(caudate	+	putamen)	
Unknown	 No	differences	between	OCD	and	HC	
Rosenberg	et	al.	(2004)		 20	OCD,	14	MDD,	14	HC		Children	 2	OCD	anxiety,	1	ADD,	1	ODD,	1	dysthymia	
All	med	naïve	 1.5	T	 PRESS	 3000/30/512	 60	min	in	total	 N.A	 2	x	1.5	x	1	cm	 ACC	 Absolute	concentrations	(mmol)	 Decreased	Glx	in	OCD	and	MDD	compared	to	HC	(No	difference	between	OCD	and	MDD)	(-1.06)	Whiteside	et	al.	(2006)		 15	OCD,	15	HC		Adults	 Substance	abuse,	medical/neurological/	psychosis	excluded	
Stable	doses	of	psychotropic	medication	
1.5	T	 PRESS	 2000/35/128	 ~	4	min	per	voxel	
N.A	 2	x	2	x	1	cm	 Bilateral	head	caudate	Bilateral	OFC	
Cre	ratios	 Increased	Glx/Cre	in	right	OFC	(1.12)		
Yucel	et	al.	(2007)		 19	OCD,	19	HC	Adults	 All	axis	I	disorders	excluded	 Stable	doses	of	SSRI,	venlafaxine	etc	
3	T	 PRESS		 3000/30/128	 ~	6.5	min	per	voxel	
N.A	 6.5	cm3	 Dorsal	ACC	 Absolute	concentrations	(i.u.)	 Trend	towards	decreased	Glx	in	medicated	patients	
Starck	et	al.	(2008)		 9	OCD,	16	HC		Adults	 Mild	depression	dysthymia	1	GAD	
SSRI’s,	hypnotics	etc	 1.5	T	 PRESS	 2000/30/256	 ~	8.5	min	per	voxel	
Birdcage	headcoil	 1.5	cm3	3.6	cm3	4	cm3	 Right	caudate	Bilateral	ACC		
Absolute	concentrations	(i.u.)	 No	differences	between	OCD	and	HC	Positive	correlation	between	symptom	severity	and	caudate	Glx	in	OCD		Yucel	et	al.	(2008)		 20	OCD,	26	HC	♀	Adults	 All	axis	I	disorders	excluded	 Stable	doses	of	psychotropic	medication	
3	T	 PRESS	 3000/30/N.A	 30	min	in	total	 N.A	 6.5	cm3	 Bilateral	dorsal	ACC	Bilateral	rostral	ACC	
Absolute	concentrations	(i.u.)	 Decreased	Glx	in	bilateral	rostral	and	left	dorsal	ACC	in	♀	(-1.03)	Correlation	Glx	and	symptom	severity	Bedard	&	Chantal		 13	OCD,	12	HC			Adults	 Active	axis	I	disorders	 2	med	free,	11	SSRI,	 1.5	T	 PRESS	 1500/30/128	 45	min	in	total	 Proton	head	coil	 8	cm3	to	9.6	cm3	 Bilateral	OFC	 Relative	to	Cr	 No	differences	between	OCD	and	HC	(ACC	-0.45,	left	OFC	-
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(2011)		 excluded	 clompipramine	or	venlafaxine	
Bilateral	thalamus	ACC	 0.01,	right	OFC	-0.6,	right	thalamus	0,44)	Simpson	et	al.		(2012)		 24	OCD,	22	HC		Adults	 Tics	(2)	and	MDD	(4)	 Med	free	>	10	wk	 3	T	 PRESS	 1500/68/256	 ~	6.5	min	per	voxel	
8	channel	headcoil	 2.5	x	3	x	2.5	cm	1	x	2	x	4.8	cm	
MPFCDLPFC	 Brain	water	ratios	(i.u.)	 No	differences	between	OCD	and	HC	in	Glx	(MPFC	0.03,	DLPFC	-0.12)	Decreased	GABA	in	MPFC	Gnanavel	et	al.	(2013)		 26	OCD,	15	unaffected	relatives,	16	HC	Adults	
Axis	I	disorders	excluded	 Authors	do	not	provide	information	on	medication	
1.5	T	 PRESS	 2000/30/256	 ~	8.5	min	per	voxel	
Phase-array	headcoil	 1	x	1	x	1	cm	 Caudate	nucleus	ACC	Medial	thalamus	
Absolute	concentrations	 Increased	Glx	in	caudate	(3.81)	and	ACC	(5.74)	in	OCD	patients	>	unaffected	siblings	>	HC	
Weber	et	al.	(2014)	 15	OCD,	18	HC	(after	dropout)	Adolescents	 Psychosis,	Bipolar	disorder,	CD,	substance	or	eating	disorder	excluded	
Medication	naïve	 3	T	 PRESS	 2500/30/192	 ~	8	min	per	voxel	
8	channel	headcoil	(receive	only)	
2	x	2	x	2.5	 Bilateral	PFC	white	matter	next	to	ACC	
Absolute	concentrations	 No	differences	between	OCD	and	HC	except	for	a	trend	towards	increased	Glx	in	the	right	PFWM	(p	.07)	(0.37)	
	ACC,	 anterior	 cingulate	 cortex;	 ADD,	 attention-deficit	 disorder;	 CD,	 conduct	 disorder;	 Cr,	 creatine;	 DLPFC,	 dorsolateral	 prefrontal	 cortex;	 GABA,	 gamma-aminobutyric	 acid;	 GAD,	 generalized	 anxiety	disorder;	 Glx,	 glutamate	 and	 glutamine;	 HC,	 healthy	 controls;	 i.u.,	 institutional	 units;	MDD,	major	 depressive	 disorder;	MPFC,	middle	 prefrontal	 cortex;	 N.A,	 not	 applicable;	 OCD,	 obsessive-compulsive	disorder;	ODD,	oppositional	defiant	disorder;	OFC,	orbitofrontal	cortex;	pCr,	phosphocreatine;	SSRI,	selective	serotonin	reuptake	inhibitor;	T,	Tesla;	TE,	echo	time;	TR,	repetition	time.	PRESS	and	STEAM	are	all	single-voxel	spectroscopy	acquisition	methods.	♀,	female	participants.		
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Table	5	Proton	magnetic	resonance	studies	reporting	glutamate	changes	with	treatment	in	OCD	patients.	Reference	 Subjects	 Comorbidities	 Treatment	administered	 Field	strength	 MRS	sequence	 TR/TE/	averages	 Scan	time	 Coil	type	 Voxel	size	 ROI(s)	 Quantification	method	 Reported	results	(calculated	effect	sizes,	cohen’s	d)	Moore	et	al.	(1998)			 1	OCD	Children	 None	 Paroxetine	(10-20	mg/day)		 1.5	T	 PRESS	 3000/30/512	 27	min		 N.A	 0.7	cm3	 Head	left	caudate	 Brain	water	ratios	 Reduced	Glx	after	12	weeks	of	treatment	Rosenberg	et	al.	(2000)		 11	OCD,	11	HC	Children	 4	anxiety,	1	dysthymia,	2	ODD	 Paroxetine	(10-60	mg/day,	M	=	45)	
1.5	T	 PRESS	 N.A/	N.A/N.A	 60	min	in	total	 Quadrature	headcoil	 0.7	cm3	 Head	left	caudate	 Brain	water	ratios	 Increased	baseline	Glx,	reduction	after	treatment,	correlated	with	symptoms	Bolton	et	al.	(2001)			 1	OCD	Children	 None	 Paroxetine	(10-40	mg/day)	 1.5	T	 PRESS		 3000/30/512	 27	min		 Quadrature	headcoil	 0.7	cm
3	 Head	left	caudate	 Brain	water	ratios	 Reduced	Glx	after	12	weeks	of	treatment		Benazon	et	al.	(2003)		 23	OCD		Children	 ODD,	ADD,	Dysthymia,	GAD,	SAD	 CBT	(12	weeks)	 1.5	T	 PRESS	 3000/30/512	 60	min	in	total	 N.A	 0.7	cm
3	 Head	left	caudate	 Brain	water	ratios	 No	changes	after	12	weeks	of	CBT	(-0.47)	Lazaro	et	al.	(2012)		 11	OCD	Children	 All	psychiatric	and	neurological	disorders	excluded	
SSRI	(20-60	mg/day)	and	behavioural	counseling	
1.5	T	 PRESS	 1500/35/N.A	 N.A	 Quadrature	headcoil	 2	x	3	x	2	cm	2	x	2	x	2	cm	
Anterior	cingulate/	medial	frontal	lobe	Bilateral	striatum	
Absolute	concentrations	(mmol)	 No	changes	after	treatment	(left	striatum	-0.09,	right	striatum	-0.1,	ACC	-1.4)	
O’Neill	et	al.	(2012)		 5	OCD,	9	HC		Children	 Authors	do	not	report	any	exclusion	criteria	
CBT	 1.5	T	 PRESS	 1500/30/N.A	 90	min	in	total	 Quadrature	headcoil	 0.9	x	1.1	x	1.1	cm	 pACC	Putamen	Thalamus	 Absolute	concentrations	(i.u.)	 No	differences	between	OCD	and	HC	before	and	after	treatment	Whiteside	et	al.	(2012)		 15	OCD,	15	HC	Children	 5	GAD,	2	ADHD,	specific	phobia	and	depression	
16	sessions	of	BT,	2nd	scan	4	months	later	
1.5	T	 PRESS	 2000/35/128	 60	min	in	total	 N.A	 4	cm3	 Head	caudate	pACC	 Absolute	concentrations	and	Cre	ratios	 No	baseline	differences	between	OCD	and	HC	but	reduced	Glx	in	caudate	after	treatment	(excluded	ADHD	patients)	(1.71)	Zurowski	et	al.	(2012)		 16	OCD,	9	HC	Adults	 1	ADHD,	2	mild	depressive	episode	
CBT	(3	months)	 3	T	 PRESS	 3000/30/128	 ~	6.5	min	per	voxel	
8	channel	headcoil	 2	cm3	 Right	lateral	OFC	Rostral	ACC	Right	ventral	striatum	
Absolute	concentrations	(i.u.)	 No	differences	between	OCD	and	HC	before	and	after	treatment	
O’Neill	et	al.	 10	OCD	 All	excluded	 CBT	(4	 1.5	T	 PRESS	 1500/30/N.A	 N.A	 Quadratur 0.9	x	1.1	x	 pACC	 Absolute	 Reduced	Glx	in	left	AMCC	
	72		
(2013)		 Adults	 except	depression	 weeks,	daily)	 e	headcoil	 1.1	cm	 aMCC	 concentrations	(i.u.)	 with	CBT	(1.14)		ACC,	anterior	cingulate	cortex;	ADD,	attention-deficit	disorder;	ADHD,	attention-deficit/hyperactivity	disorder;	aMCC,	anterior	middle	cingulate	cortex;	BT,	behavioural	therapy;	CBT,	cognitive	behavioural	therapy;	 Cr,	 creatine;	 GAD,	 generalized	 anxiety	 disorder;	 Glx,	 glutamate	 and	 glutamine;	 HC,	 healthy	 controls;	 i.u.,	 institutional	 units;	 N.A,	 not	 applicable;	 OCD,	 obsessive-compulsive	 disorder;	 ODD,	oppositional	defiant	disorder;	pACC,	pregenual	anterior	cingulate	cortex;	SAD,	separation	anxiety	disorder;	SSRI,	selective	serotonin	reuptake	inhibitor;	T,	tesla;	TE,	echo	time;	TR,	repetition	time.	PRESS	is	a	single-voxel	spectroscopy	acquisition	method.	
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Studies	that	compared	Glx	levels	in	the	ACC	mainly	found	increased	levels	across	ASD	and	ADHD	in	children	and	adolescent	 samples	and	decreases	across	adult	 samples.	Since	 there	were	also	several	studies	that	did	not	report	differences,	we	compared	the	sample	sizes	of	positive	versus	negative	studies	with	an	independent	samples	t	test.	Children	studies	finding	increases	did	not	significantly	 differ	 in	 sample	 size	 from	 children	 studies	 finding	 no	 differences	 (t(7)=0.033,	p=0.864).	Adult	studies	finding	decreases	also	did	not	significantly	differ	from	studies	finding	no	differences	 (t(9)=-2.146,	 p=0.585).	 There	 were	 no	 adult	 studies	 finding	 increases	 and	 no	children	studies	finding	decreases	(see	Figure	1).		 In	the	striatum,	the	findings	were	more	inconsistent.	We	therefore	performed	analysis	of	variance	(ANOVA)	to	compare	sample	size	across	studies	finding	decreases,	no	differences	and	increases.	No	significant	differences	in	sample	sizes	were	found	(F(2,17)=2.178,	p=0.144).			
		Figure	 1	 Proton	 magnetic	 resonance	 studies	 of	 patients	 with	 attention-deficit/hyperactivity	 disorder	(ADHD),	 autism	 spectrum	 disorders	 (ASD)	 and	 obsessive	 compulsive	 disorder	 (OCD)	 using	 a	 healthy	comparison	group.	Measures	of	Glx	(and	Glu)	in	prefrontal	brain	areas.	The	width	of	each	study	block	is	proportional	 to	 the	 square	 root	 of	 the	 total	 sample	 size	 (number	 of	 patients	 plus	 number	 of	 healthy	controls).	ACC,	anterior	 cingulate	cortex;	 ↓,	decrease	 (patients	<	controls);	=,	no	difference	 (patients	=	controls)	↑,	increase	(patients	>	controls);	*,	trend	towards	increase	or	decrease.	
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 	Figure	 2	 Proton	 magnetic	 resonance	 studies	 of	 patients	 with	 ADHD,	 ASD	 and	 OCD	 using	 a	 healthy	comparison	 group.	 Measures	 of	 Glx	 (and	 Glu)	 in	 the	 striatum.	 The	 width	 of	 each	 study	 block	 is	proportional	 to	 the	 square	 root	 of	 the	 total	 sample	 size	 (number	 of	 patients	 plus	 number	 of	 healthy	controls).	Abbreviations	as	in	Figure	1.	
 
 
The relationship between Glx levels and behavioural measures Several	studies	performed	additional	correlation	analyses	to	examine	the	relationship	between	Glx	levels	and	behavioural	findings.	In	one	ADHD	children	study	a	positive	correlation	was	found	between	Glx	levels	in	the	frontal	lobe	(SFG)	and	memory	disability	(Courvoisie	et	al.	2004).	Two	adult	studies	found	a	negative	correlation	between	Glx	levels	and	inattentive	symptoms	in	that	lower	Glx	levels	were	paired	with	higher	inattentiveness	(Dramsdahl	et	al.	2011;	Maltezos	et	al.	2014).		 In	ASD	negative	correlations	were	found	between	Glx	levels	in	the	ACC	and	basal	ganglia	and	 communication	 skills,	 with	 lower	 Glx	 leading	 to	 worse	 communication	 skills	 in	 adult	patients	 (Horder	et	al.	2013;	Tebartz	Van	Elst	 et	 al.	2014).	 In	addition,	Hassan	and	colleagues	found	a	strong	correlation	between	blood	and	brain	glutamate	(Hassan	et	al.	2013).		 In	several	OCD	studies,	correlations	were	found	between	Glx	levels	in	frontal	brain	areas	and	 symptom	 severity	 as	 measured	 by	 (C)YBOCS	 (Whiteside	 et	 al.	 2006;	 Yücel	 et	 al.	 2008;	Gnanavel	 et	 al.	 2014);	 a	 reduction	 in	 Glx	 after	 treatment	 with	 paroxetine	 correlated	 with	 a	reduction	 in	 YBOCS	 severity	 scores	 as	 well	 (Rosenberg	 et	 al.	 2000).	 These	 findings	 form	interesting	 perspectives	 for	 future	 studies	 to	 further	 examine	 the	 relationship	 between	 ASD,	ADHD	and	OCD	in	terms	of	their	underlying	traits.		
Glx changes after treatment administration Studies	examining	Glx	changes	after	treatment	were	only	performed	in	ADHD	and	OCD	patients.	Most	studies	performed	in	ADHD	patients	found,	compared	to	controls,	increased	baseline	levels	
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of	 Glx	 in	 the	 striatum	 and	 ACC	 (Carrey	 et	 al.	 2007;	 Hammerness	 et	 al.	 2012)	 which	 tend	 to	reduce	after	treatment	with	either	MPH	or	atomoxetine	(Carrey	et	al.	2002;	Carrey	et	al.	2003;	Hammerness	et	al.	2012;	Wiguna	et	al.	2012).	One	study,	however,	found	increases	in	prefrontal	white	 matter	 after	 treatment	 with	 MPH	 and	 atomoxetine	 (Husarova	 et	 al.	 2014).	 All	 other	studies	were	performed	in	gray	matter.		 In	 OCD,	 baseline	 Glx	 levels	 were	 mostly	 similar	 in	 patients	 and	 controls	 in	 PFC	 and	striatum	 (O’Neill	 et	 al.	 2012;	Whiteside	 et	 al.	 2012;	 Zurowski	 et	 al.	 2012)	but	 after	 treatment	with	paroxetine	or	behavioural	therapy	reductions	in	Glx	levels	were	found	(Moore	et	al.	1998;	Rosenberg	et	al.	2000;	Bolton	et	al.	2001;	Whiteside	et	al.	2012;	Neill	et	al.	2013).	In	one	study,	a	reduction	 in	 Glx	 levels	 in	 the	 caudate	 nucleus	 was	 correlated	 with	 a	 significant	 reduction	 in	symptom	severity	(Rosenberg	et	al.	2000).		 Treatment	 studies	 show	 that	 in	most	 cases	 Glx	 levels	 decrease	 after	 administration	 of	either	 a	 drug	 or	 therapy.	 Almost	 all	 treatment	 studies	 were	 performed	 in	 children	 and	unfortunately	not	always	with	a	comparison	group	to	see	whether	baseline	Glx	levels	differ	from	Glx	levels	in	control	children.	Future	studies	should	take	medication	levels	carefully	into	account	because	medication	may	influence	metabolite	levels	significantly.		
DISCUSSION 	The	 current	 review	 investigated	59	 studies	 that	 examined	Glu-related	neurochemistry	 in	ASD,	ADHD	and	OCD	patient	groups	compared	to	healthy	controls	or	after	treatment	administration.	Many	studies	were	very	heterogeneous;	for	example,	only	a	few	studies	excluded	all	axis-I	DSM-IV	comorbidities.	Most	of	the	studies	allowed	for	anxiety	and	mood	disorders,	which	are	known	to	 influence	neurochemistry	 themselves	 (Yildiz-Yesiloglu	 and	Ankerst	2006).	 In	 addition,	 only	16	 of	 59	 used	 field	 strengths	≥	 3	 Tesla	 and	were	 thus	 able	 to	 report	 the	 less	 ambiguous	 Glu	signal	 instead	 of	 the	 combined	 Glx	 signal.	 In	 addition,	 the	 interpretation	 of	 Glu	 levels	 in	spectroscopy	 is	 problematic.	 Glu	 is	 present	 in	 both	 intra-	 and	 extracellular	 stores,	 not	 only	 in	neurons	 but	 also	 in	 glia	 (influencing	 neurotransmission)	 as	 well	 as	 being	 a	 derivative	 of	metabolic	processes.	This	means	that	the	measurement	of	Glu	levels	by	MRS	do	not	reflect	one	specific	 function	(Pittenger	et	al.	2011).	The	combined	Glx	signal	 is	even	less	 informative.	This	should	be	taken	into	account	when	interpreting	1H	MRS	studies	examining	Glu,	especially	when	they	 use	 lower	 field	 strengths,	 which	 have	 less	 spectral	 resolution	 to	 accurately	measure	 Glx	levels.	 All	 these	 issues	 make	 it	 difficult	 to	 detect	 differences	 between	 patients	 and	 healthy	individuals.	 In	 addition	 to	 the	 heterogeneity,	 many	 studies	 were	 very	 explorative	 in	 nature	because	of	the	relatively	new	application	of	spectroscopy	within	these	disorders.	
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Nevertheless,	 we	 were	 able	 to	 find	 some	 consistent	 findings	 across	 and	 between	disorders	 within	 our	 study	 selection:	 1)	 Possible	 increased	 Glx	 in	 the	 striatum	 across	 ADHD,	OCD	 and	 ASD;	 2)	 Increased	 Glx	 in	 the	 ACC	 in	 paediatric	 and	 adolescent	 ADHD	 and	 ASD;	 3)	Decreased	Glx	in	the	ACC	in	adult	ASD	and	adult	ADHD.	These	findings	are	discussed	in	greater	detail	below;	because	the	studies	performing	1H	MRS	in	ASD,	ADHD	and	OCD	so	 far	have	been	limited	 in	 their	 methodologies	 and	 sample	 selection,	 the	 findings	 must	 be	 interpreted	 with	caution.	They	nevertheless	may	form	preliminary	hypotheses	for	future	testing.		
Possible increased Glx in striatum across ADHD, OCD and ASD Several	studies	showed	increased	Glx	in	striatal	areas	(Rosenberg	et	al.	2000;	Carrey	et	al.	2007;	Ferreira	et	al.	2009;	Hammerness	et	al.	2012;	Hassan	et	al.	2013;	Gnanavel	et	al.	2014)	which	in	ADHD	seem	to	decline	after	treatment	with	MPH	(Carrey	et	al.	2002;	Carrey	et	al.	2003),	and	in	OCD	with	paroxetine	(Moore	et	al.	1998;	Rosenberg	et	al.	2000;	Bolton	et	al.	2001).	The	findings	must	 be	 interpreted	 with	 caution	 given	 that	 other	 studies	 failed	 to	 find	 differences	 between	patient	groups	and	controls	(Ebert	et	al.	1997;	Bartha	et	al.	1998;	Hesslinger	et	al.	2001;	Jin	et	al.	2001;	Friedman	et	al.	2003;	Sun	et	al.	2005;	Whiteside	et	al.	2006;	O’Neill	et	al.	2012;	Whiteside	et	al.	2012;	Zurowski	et	al.	2012)	and	 that	some	studies	even	 found	decreases	(Corrigan	et	al.	2013;	 Horder	 et	 al.	 2013;	Maltezos	 et	 al.	 2014).	 Hassan	 et	 al	 (2013),	 however,	 reported	 also	increased	blood	Glu	levels	in	paediatric	ASD,	a	finding	that	was	positively	correlated	with	brain	Glu.	A	previous	study	showed	elevated	serum	Glu	levels	in	autism	as	well	(Shinohe	et	al.	2006).		There	 is	 evidence	 that	 the	 dorsal	 striatum	 (caudate	 and	 putamen)	 is	 involved	 in	compulsivity,	 while	 the	 ventral	 striatum	 (mainly	 nucleus	 accumbens)	 is	 associated	 with	impulsive	behaviour	(Fineberg	et	al.	2010).	The	fact	that	many	studies	did	not	find	differences	may	be	explained	by	their	choice	of	striatal	area,	leading	to	a	heterogeneous	data	set.			 Ferreira	 et	 al	 (2009)	 have	 suggested	 a	 relationship	 between	 dopamine,	 Glu	 and	acetylcholine	that	results	 in	elevated	Glu	levels	 in	the	striatum	in	ADHD	patients.	The	striatum	itself	 is,	 in	 fact,	 not	 glutamatergic.	 Striatal	Glu	 is	 derived	 from	afferent	 connections,	metabolic	pools	 and	 precursors	 into	 GABA	 (Pittenger	 et	 al.	 2011).	 Tonic	 Glu	 activity	 in	 the	 PFC	 has	 an	inhibitory	effect	on	phasic	Glu	in	the	striatum.	Because	tonic	Glu	in	frontal	regions	seems	to	be	disturbed	 in	 ASD,	 ADHD	 and	 OCD,	 the	 phasic	 Glu	 in	 the	 striatum	 may	 be	 altered	 as	 well.	Preclinical	 studies	 of	 glutamatergic	 neural	 activity	 suggest	 a	 parallel	 with	 brain	 glucose	metabolism.	 Increased	 caudate	 Glx	 concentrations	 in	 OCD	 may	 be	 consistent	 with	 previous	reports	 of	 increased	 glucose	 metabolism	 in	 the	 same	 brain	 region	 (Baxter	 et	 al.	 1992).	 In	paediatric	 ASD,	 increased	 caudate	 volumes	 have	 been	 reported	 that	 might	 influence	 the	concentration	 of	 metabolites	 (Anagnostou	 and	 Taylor	 2011).	 Furthermore,	 increased	 striatal	volumes	 seem	 to	 be	 correlated	with	OCD	 and	 repetitive	 symptom	 severity,	 a	 key	 symptom	of	
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both	 ASD	 and	 OCD	 that	 is	 representative	 of	 cognitive	 inflexibility	 (Hollander	 et	 al.	 2005).	 In	general,	data	suggest	increased	values	of	Glx	in	the	dorsal	striatum,	given	that	many	studies	find	these	increased	levels.	Future	studies	should	confirm	this	hypothesis	by	using	larger	and	more	homogeneous	sample	sizes.	
 
Increased Glx in ACC in paediatric ADHD and ASD Children	 and	 adolescents	 with	 ADHD	 and	 ASD	 demonstrate	 increased	 Glx	 levels	 in	 the	 ACC	region	(Moore	et	al.	2006;	Hammerness	et	al.	2012;	Bejjani	et	al.	2012;	Hassan	et	al.	2013;	Joshi	et	 al.	 2013).	Although	 there	are	also	 studies	 that	do	not	demonstrate	 this	 finding,	 sample	 size	comparison	showed	no	significant	differences	between	studies	that	find	no	differences	and	the	ones	that	do.	Glutamatergic	transmission	from	the	ACC	is	assumed	to	be	involved	in	exerting	control	over	 the	 impulsive	 ventral	 striatum.	 Hammerness	 et	 al	 (2012)	 reported	 a	 trend	 towards	 Glx	reductions	 after	 MPH	 treatment	 in	 adolescents	 with	 ADHD	 with	 baseline	 increased	 Glx	compared	 to	 controls.	 In	 addition,	 two	 studies	 found	 increased	 Glx	 levels	 in	 other	 prefrontal	areas,	such	as	the	superior	frontal	gyrus	(SFG)	(MacMaster	et	al.	2003;	Courvoisie	et	al.	2004).	Several	studies	failed	to	find	differences	between	paediatric	patients	and	controls	(Friedman	et	al.	2003;	Carrey	et	al.	2007;	Soliva	et	al.	2010;	Yang	et	al.	2010;	Tafazoli	et	al.	2013),	which	may	result	 from	 inclusion	 of	 diverse	 PFC	 regions	 such	 as	 DLPFC	 (Soliva	 et	 al.	 2010)	 and	 MFG	(Tafazoli	et	al.	2013)	which	have	different	functionalities.	It	is	possible	that	the	difference	in	Glx	levels	between	patients	and	controls	may	be	ACC	specific	and	may	not	generalize	to	other	PFC	regions	 but	 this	 needs	 to	 be	 further	 demonstrated.	 The	 study	 by	 Friedman	 et	 al	 (2003)	investigated	 preschool	 ASD	 children	 and	 found	 no	 differences	 in	 Glx.	 According	 to	 Joshi	 et	 al	(2013)	school-aged	children	show	elevated	Glx	levels	because	of	stress-related	release	of	Glu	in	the	prefrontal	cortex,	which	is	not	present	at	younger	ages.		Abnormal	 Glu	 functioning	 in	 dopaminergic	 prefrontal	 areas	 may	 be	 involved	 in	 the	pathophysiology	of	ADHD.	Dopamine	 levels	 in	 the	striatum	are	 lower	 in	ADHD	patients,	which	co-occur	with	increased	PFC	Glu	levels	(Russell	2003).	MPH	blocks	dopamine	reuptake,	leading	to	 an	 increase	 in	 dopamine	 levels	 following	 Glu-stimulated	 release	 in	 the	 nucleus	 accumbens	(NAc)	(Russell	2003).	Dopamine	acting	on	inhibitory	dopamine	D4	receptors	blocks	Glu	release	from	the	PFC	afferents	to	the	NAc.	Moore	et	al	(2006)	suggest	that	reduced	NAc	dopamine	levels	in	untreated	paediatric	ADHD	patients	could	lead	to	increased	Glu	in	the	ACC.	Evidence	from	several	studies	also	points	to	ACC	involvement	in	ASD	(Jiao	et	al.,	2011),	such	as	deficits	in	joint	attention	and	social	orienting	(Mundy	2003).	Increased	Glx	levels	in	the	ACC	 in	 paediatric	 ASD	 support	 this	 hyper-glutamatergic	 hypothesis	 in	 ASD	 (Fatemi	 2008).	Excessive	Glu	levels	in	the	brain	of	patients	with	ASD	may	be	the	result	of	decreased	amounts	of	
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the	 enzymes	 glutamic	 acid	 decarboxylase	 (GAD)	 65	 and	 67,	 which	 convert	 Glu	 into	 GABA	(leading	to	an	excitatory-inhibitory	imbalance)	and	altered	glial	Glu	regulation	in	ASD.	
 
Decreased Glx in ACC in adult ASD and adult ADHD 
In contrast	to	paediatric	ASD	and	ADHD,	adults	mainly	showed	decreased	Glx	 levels	 in	the	ACC	(Perlov	et	al.	2007;	Bernardi	et	al.	2010;	Dramsdahl	et	al.	2011;	Tebartz	Van	Elst	et	al.	2014).	The	studies	performed	in	OCD	are	less	supportive	of	either	increases	or	decreases	because	most	adult	studies	were	not	able	to	find	differences	between	patients	and	control	participants	(Ebert	et	 al.	 1997;	 Starck	 et	 al.	 2008;	 Bédard	 and	 Chantal	 2011;	 O’Neill	 et	 al.	 2012;	Whiteside	 et	 al.	2012;	 Zurowski	 et	 al.	 2012).	 Also	 in	 this	 comparison,	 no	 sample	 size	 differences	 were	 found	across	 studies	 finding	 decreases	 and	 studies	 finding	 no	 differences.	 It	 also	 seems	 that	 studies	finding	 differences	 across	 ASD	 and	 ADHD	 patients	 and	 controls	 are	 more	 represented	 by	 3T	studies	than	studies	finding	no	differences.	A	 glutamatergic	 deficit	 in	 the	ACC	 region	 supports	 the	 postulate	 of	 impaired	 cognitive	control	 in	 adult	 ADHD	 and	 the	 hypothesis	 of	 hypo-glutamatergic	 function.	 In	 children	 with	ADHD	hyper-glutamatergic	functioning	in	the	ACC	was	found.	Metabolite	levels	change	with	age	(Horska	 et	 al.	 2002),	 which	 could	 be	 related	 to	 differences	 between	 paediatric	 and	 adult	symptomatology.	In	adults,	for	example,	the	hyperactive	symptoms	seem	less	abundant	than	in	children	and	inattention	becomes	more	dominantly	present	(Faraone	et	al.	2006).	According	to	Perlov	et	al.	(2007),	hyperactivity	may	be	caused	by	excessive	Glu	transmission	in	the	PFC	which	can	 be	 attenuated	 by	 NMDA	 Glu	 receptor	 antagonists.	 This	 suggests	 an	 overactive	 PFC	 in	hyperactive	children	and	may	explain	the	lower	levels	of	Glu	in	adults	with	ADHD,	who	seem	to	show	 less	hyperactive	symptoms.	 In	adult	ASD,	decreased	metabolism	and	smaller	volumes	of	the	ACC	have	been	reported	(Haznedar	et	al.	1997).	Di	Martino	et	al.	 (2009)	reported	 in	 their	review	hypo-activation	of	 the	ACC	 in	 individuals	with	ASD	during	 fMRI	measurements	as	well	(Di	 Martino	 et	 al.	 2009).	 In	 addition,	 in	 a	 very	 recent	 activation	 likelihood	 estimation	 (ALE)	meta-analysis	 by	 Dickstein	 et	 al.	 (2013),	 hyper-activation	 in	 children	 with	 ASD	 in	 prefrontal	regions	compared	to	adults	were	reported	(Dickstein	et	al.	2013).	An	 alternative	 explanation	 for	 the	 reversed	 pattern	 of	 adult	 ASD	 and	 ADHD	 patients	compared	 to	children	 is	 changes	 in	synaptic	pruning	over	 time.	Synaptic	pruning	refers	 to	 the	regulatory	process	in	which	an	overall	number	of	neurons	and	connections	is	reduced	(Iglesias	et	 al.	 2005).	 In	 normal	 development,	 pruning	 leads	 to	 a	 better	 connected	brain,	 but	 there	 are	hypotheses	 concerning	 excessive	 pruning,	 which	 may	 lead	 to	 clinical	 disorders	 such	 as	schizophrenia	 (Keshavan	 et	 al.	 1994).	 In	 children	with	 ASD	 cortical	 grey	matter	 seems	 to	 be	increased	 compared	 to	 controls	 but	 it	 decreases	 with	 age,	 possibly	 reflecting	 the	 effects	 of	excessive	pruning.		
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Three	studies	reported	reduced	ACC	Glx	levels	in	OCD	patients	while	other	studies	reported	increases	in	Glx	in	the	ACC	and	OFC.	Because	OCD	is	a	very	heterogeneous	disorder	with	many	different	compulsive	subtypes,	one	explanation	may	be	that	certain	subgroups	of	OCD	patients	show	 reduced	 Glx	 levels	 based	 on	 mutations	 in	 genes	 affecting	 glutamatergic	 transmission	(Brennan	et	al.	2013).	Another	 cause	of	 the	different	 findings	 could	be	 the	variability	 in	voxel	location	 in	 the	ACC.	Differences	across	 children	and	adults	were	not	 found	 in	OCD	although	 it	may	seem	that	Glu	levels	are	normalized	in	adult	OCD	patients,	given	the	fact	that	several	studies	did	not	 find	differences	across	OCD	patients	and	controls	 in	 the	ACC,	 even	when	studies	were	performed	at	3	T	(Zurowski	et	al.	2012;	Simpson	et	al.	2012;	Weber	et	al.	2014).	
 
Glx changes in other brain regions In	 addition	 to	 the	 general	 findings	 described	 in	 the	 previous	 sections	 involving	 ACC	 and	striatum,	other	regions,	like	the	cerebellum	and	amygdala,	also	showed	elevated	Glx	levels	in	the	patient	groups,	especially	in	ASD	and	to	a	lesser	extent	in	ADHD	(Page	et	al.	2006;	Perlov	et	al.	2010;	Hassan	 et	 al.	 2013;	 BenAmor	 2014).	 Studies	 examining	 other	 prefrontal	 areas	 than	 the	ACC	reported	less	consistent	results.	Only	five	studies	reported	on	levels	of	GABA	and	all	found	decreased	levels	in	PFC	areas	(Harada	et	al.	2011;	Edden	et	al.	2012;	Kubas	et	al.	2012;	Simpson	et	al.	2012;	Gaetz	et	al.	2013).	This	 finding	was	 evident	 across	 all	 patient	 and	 age	 groups.	 According	 to	 Edden	 et	 al.	 (2012)	altered	GABA	levels	reflect	deficits	in	inhibitory	control	of	the	PFC,	which	can	be	related	to	ASD,	ADHD	 and	 OCD	 such	 that	 the	 PFC	 has	 a	 lack	 of	 control	 over	 the	 compulsivity	 or	 impulsivity	regulated	by	the	striatum.	Based	on	the	studies	described	in	the	current	review	paper,	it	becomes	clear	that	more	work	is	needed	in	the	field	of	spectroscopy.	Studies	that	have	been	performed	so	far	were	very	different	 in	patient	groups,	specified	regions	of	 interest	and	1H	MRS	techniques,	which	make	it	difficult	to	draw	general	conclusions.	The	most	striking	finding	was	the	difference	between	ACC	Glx	 levels	 in	 paediatric	 and	 adult	 ADHD	 and	 ASD,	 which	 gives	 us	 greater	 insight	 in	 the	developmental	trajectory	of	these	disorders.	Secondly,	the	similarities	across	OCD	patients	and	adult	ADHD	and	ASD	may	suggest	that	in	childhood,	ADHD	and	ASD	are	more	alike,	while	they	both	become	more	compulsive	when	growing	older	and	thus	resembling	OCD	patients.	Thirdly,	ASD,	ADHD,	and	OCD	all	 show	deficits	 in	 striatal	areas	 that	 seem	to	be	 related	 to	elevated	Glx	levels.	 The	 findings	 reported	 in	 this	 review	 show	 that	 ASD,	 ADHD	 and	 OCD	 indeed	 show	similarities,	 but	 also	 differences	 that	 need	 more	 investigation.	 Studying	 the	 underlying	mechanisms	of	 impulsivity	 and	 compulsivity	 instead	 of	 the	 disorders	 separately	may	 assist	 in	improving	their	biological	understanding	and	consequent	clinical	management.		
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Study limitations and challenges Despite	 our	 general	 findings	 across	 the	 59	 studies,	 the	 existing	 spectroscopy	 literature	 in	 the	compulsive	and	impulsive	disorders	ASD,	ADHD	and	OCD	remains	limited	and	ambiguous.	This	is	 likely	 due	 to	 very	 small	 and	 heterogeneous	 study	 samples	 and	 varying	 methodologies.	Samples	differed,	besides	age,	in	illness	severity,	comorbidity	and	medication	use,	which	can	all	influence	neurochemistry	on	itself.	In	addition,	only	sixteen	of	59	studies	used	field	strengths	of	3	 Tesla	 and	 higher.	 With	 field	 strengths	 below	 3	 Tesla	 it	 is	 very	 difficult	 to	 unambiguously	separate	Glu	from	overlapping	spectral	peaks.	This	means	that	all	these	studies	reported	results	on	 combined	 Glx	 signal,	 which	 is	 less	 specific.	 Glx	 is	 often	 treated	 as	 a	 reflection	 of	 the	neurotransmitter	Glu	but	it	is	actually	a	composite,	something	that	should	be	kept	in	mind	when	interpreting	Glx	results.	Several	studies	were	however	able	to	disambiguate	the	Glx	signal	in	the	separate	Glu	and	glutamine	spectra.	A	number	of	studies	quantified	Glu	concentrations	as	ratios	with	creatine	or	choline	as	internal	references.	This	approach	assumes	that	no	Cre	and	Cho	differences	are	present	between	patients	 and	 controls.	 There	 are	 however	 studies	 reporting	 differences	 in	 these	 metabolites	between	ASD,	ADHD	and	OCD	patients	and	controls	(Mirza	et	al.	2006;	Colla	et	al.	2008;	Suzuki	et	al.	2010)	suggesting	that	using	these	metabolites	as	internal	references	results	in	confounded	findings,	 especially	 in	 comparing	 them	 with	 studies	 that	 use	 absolute	 concentrations.	Furthermore,	the	choice	of	voxel	location	was	very	variable	across	studies,	especially	concerning	the	ACC.	This	makes	it	difficult	to	compare	these	results	as	well.	In	addition	to	the	limitations	of	the	reviewed	studies,	1H	MRS	has	its	own	limitations	in	terms	of	spectral	and	spatial	resolution	and	the	inability	to	distinguish	between	intra-	and	extracellular	neuronal	and	glial	and	metabolic	Glu	levels.	Despite	these	limitations,	the	assessment	of	glutamate-related	metabolites	is	for	now	best	done	with	relatively	cheap,	fast	and	non-invasive	1H-MRS.	The	 main	 limitation	 of	 current	 neuroscience	 is	 that	 disorder	 groups	 are	 examined	separately.	The	existence	of	commonalities	across	ASD,	ADHD	and	OCD	is	well	known	(Anholt	et	al.	2010)	and	one	should	take	advantage	of	that	in	creating	more	clarity	among	the	underlying	mechanisms	of	these	disorders.	
 
Future directions The	 aim	 of	 the	 current	 review	 was	 to	 highlight	 commonalities	 and	 differences	 between	 the	developmental	disorders	ADHD,	ASD,	and	OCD.	Based	on	the	disparities	in	the	described	studies	it	is	very	difficult	to	draw	definitive	conclusions	upon	this.	What	is	clear	from	previous	studies	is	that	there	indeed	seem	to	be	similarities	across	the	three	disorders	and	that	it	is	worthwhile	to	examine	their	underlying	traits.	This	may	be	particularly	helpful	in	improving	diagnosis	further	
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as	 these	 traits	 form	 an	 essential	 part	 of	 the	 disease	 dimensions	 as	 described	 in	 the	 NIMH	Research	 Domain	 Criteria	 (RDoC)	 (Cuthbert	 2014).	 At	 present,	 DSM	 based	 diagnosis	 is	dependent	on	subjective	observations	whereby	experienced	clinical	personnel	are	key.	Instead,	biomarkers	 such	 as	 those	 from	 neuroimaging	 and	 neurochemistry	 studies	may	 provide	more	objective	 criteria	 in	 time.	 Examining	 the	 neurobiology	 of	 underlying	 traits	 of	 psychiatric	disorders	using	techniques	such	as	MRS	will	shed	more	light	on	their	commonalities	and	makes	it	possible	 to	go	beyond	separate	 clinical	diagnoses.	 Since	patients	 can	have	 similar	diagnoses	based	on	different	criteria,	subtyping	of	patients	should	not	be	based	on	diagnostic	criteria	alone	(Robbins	 et	 al.	 2012).	 Differences	 across	 younger	 and	 older	 patients,	 especially	 in	 the	 ACC,	should	also	be	 further	 investigated	because	 this	may	clarify	developmental	changes	across	 the	disorders	based	on	possible	underlying	changes	in	the	fronto-striatal	circuit.		Methodologically,	 future	 studies	 should	 consider	 (i)	 resolving	 Glu	 signal	 instead	 of	reporting	 Glx,	 e.g.	 by	 acquiring	 data	 at	 higher	 field	 strengths;	 (ii)	 using	 multiple	 voxels,	 for	instance	by	performing	MRS	imaging;	(iii)	combining	MRS	with	other	neuroimaging	techniques	to	 assess	 neurochemistry	 simultaneously	 with	 structural	 or	 functional	 abnormalities;	 (iv)	incorporating	 glutamatergic	 genotype	 data	 as	 it	 is	 well	 known	 that	 neurodevelopmental	disorders	are	highly	heritable	(Manolio	et	al.	2008);	and	(v)	longitudinal	studies	that	might	help	in	exploring	the	early	onset	of	disorders	and	the	developmental	issues	regarding	ASD,	ADHD	and	OCD	as	became	evident	from	the	comparison	of	children	and	adults	in	the	current	review.	
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ABSTRACT		Autism	spectrum	disorders	(ASD)	and	obsessive	compulsive	disorder	(OCD)	are	often	comorbid	with	 the	 overlap	 based	 on	 compulsive	 behaviours.	 Although	 previous	 studies	 suggest	glutamatergic	 deficits	 in	 fronto-striatal	 brain	 areas	 in	 both	 disorders,	 this	 is	 the	 first	 study	 to	directly	 compare	 the	glutamate	 concentrations	across	 the	 two	disorders	with	 those	 in	healthy	control	 participants	 using	 both	 categorical	 and	 dimensional	 approaches.	 In	 the	 current	multi-centre	study	(four	centres),	we	used	proton	magnetic	resonance	spectroscopy	(1H	MRS)	in	51	children	with	 ASD,	 29	with	 OCD,	 and	 53	 healthy	 controls	 (aged	 8	 to	 13	 years)	 to	 investigate	glutamate	 (Glu)	 concentrations	 in	 two	 regions	 of	 the	 fronto-striatal	 circuit:	 midline	 anterior	cingulate	 cortex	 (ACC)	 and	 left	 dorsal	 striatum.	 Spectra	 were	 processed	 with	 Linear	Combination	Model	 (LCModel).	Group	comparisons	were	performed	with	one-way	analyses	of	variance	including	sex,	medication	use,	and	scanner	site	as	covariates.	Additionally,	dimensional	analyses	were	performed,	 linking	glutamate	with	continuous	measures	related	to	compulsivity	and	repetitive	behaviour.	There	was	a	main	group	effect	for	ACC	glutamate	(p=0.019).	Contrast	analyses	showed	increased	glutamate	both	in	children	with	ASD	and	OCD	compared	to	controls	(p=0.007),	 but	 no	 differences	 between	 the	 two	 disorders	 (p=0.770).	 Dimensional	 analyses	revealed	 a	 positive	 correlation	 between	 limited	 interests	 (measured	 with	 the	 Repetitive	Behaviour	 Scale)	 and	 ACC	 glutamate	 (rho=0.24,	 p=0.03).	 These	 findings	 were	 robust	 across	sites.	No	differences	were	found	in	the	striatum.	The	current	findings	confirm	overlap	between	ASD	and	OCD	in	terms	of	glutamate	involvement.				 	
 93		
INTRODUCTION 	Autism	spectrum	disorders	(ASD)	are	characterized	by	deficits	 in	reciprocal	social	 interaction,	impairments	 in	 communication,	 and	 by	 restricted,	 repetitive,	 and	 stereotyped	 patterns	 of	behaviour,	 and	 interests.	 Similarly,	 obsessive	 compulsive	 disorder	 (OCD)	 is	 characterized	 by	repetitive	thoughts,	impulses,	or	images	(obsessions),	and	repetitive	behaviours	or	mental	acts	(compulsions)	 that	 cause	 marked	 distress	 and/or	 impairment	 of	 functioning	 (American	Psychiatric	Association.	2000).	Despite	the	diagnostic	differences	between	these	disorders,	there	is	also	strong	clinical	overlap	and	comorbidity.	Both	ASD	and	OCD	show	repetitive	behaviours	among	 their	 core	 features,	 and	 comparison	 of	 their	 symptoms	 has	 shown	more	 overlap	 than	differences	 (Anholt	 et	 al.	 2010).	 A	 recent	 longitudinal	 investigation	 showed	 that	 individuals	diagnosed	with	ASD	were	at	two-fold	increased	risk	of	developing	OCD,	and	vice	versa,	that	OCD	patients	 were	 at	 a	 four-fold	 increased	 risk	 of	 having	 ASD,	 compared	 to	 people	 with	 no	 prior	diagnosis	(Meier	et	al.	2015).	Compulsivity	 is	 a	 cross-disorder	 trait	 that	 appears	 to	 overlap	 between	 ASD	 and	 OCD.	Compulsivity	is	defined	as	the	repetitive	and	irresistible	urge	to	perform	certain	behaviours,	the	experience	of	loss	of	voluntary	control	over	this	urge,	the	diminished	ability	to	delay	or	inhibit	thoughts	 and	 behaviours,	 and	 the	 tendency	 to	 perform	 repetitive	 acts	 in	 a	 habitual	 or	stereotyped	manner	 (Chamberlain	and	Menzies	2009).	Although	 the	psychological	mechanism	underlying	 the	 compulsive	 behaviour	 is	 different	 for	 ASD	 (self-soothing)	 and	 OCD	 (reducing	stress),	poor	behavioural	inhibition	has	been	linked	to	both	disorders	(Robbins	et	al.	2012).	The	prefrontal	 cortex	 (PFC)	 acts	 in	 coordination	 with	 the	 striatum	 to	 implement	 the	 control	 of	behaviour.		It	 has	 therefore	 been	 suggested	 that	 changes	 in	 this	 fronto-striatal	 circuit	 may	 be	involved	in	the	compulsivity	seen	in	ASD	and	OCD	(Voon	et	al.	2014;	Fuccillo	2016).	According	to	neuroanatomical	models,	the	fronto-striatal	circuit	includes	a	compulsivity	route,	in	which	the	dorsal	striatum	drives	the	compulsive	behaviour,	while	the	PFC	exerts	control	over	it	(Alexander	et	 al.	 1986).	 A	 recent	 network	 analysis	 provided	 evidence	 that	 the	 overlap	 between	 ASD	 and	OCD	was	mainly	related	to	repetitive	behaviours	(Ruzzano	et	al.	2015),	which	have	been	linked	to	deficits	in	executive	functioning	of	the	fronto-striatal	circuit	(Thakkar	et	al.	2008).		An	 important	neurotransmitter	 involved	 in	 the	 functioning	of	 fronto-striatal	 circuits	 is	glutamate.	 Glutamate	 is	 the	most	 abundant	 excitatory	 neurotransmitter	 in	 the	 human	 central	nervous	system,	 involved	 in	processes	such	as	synaptic	 transmission,	plasticity,	and	 long-term	potentiation	(Pittenger	et	al.	2011).	Proton	magnetic	resonance	spectroscopy	(1H-MRS)	is	a	non-invasive	 method	 allowing	 for	 in	 vivo	 quantification	 of	 several	 neuro-metabolites,	 including	glutamate	 (Glu).	 Although	 MRS	 is	 not	 suitable	 for	 distinguishing	 glial,	 metabolic	 and	
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neurotransmitter	 glutamate,	 there	 is	 evidence	 suggesting	 that	 the	 glutamate-glutamine	 cycle,	responsible	 for	 glutamate	 supply	 as	 a	 neurotransmitter,	 accounts	 for	 around	 80	 %	 of	 the	glutamate	 trafficking	 in	 the	 brain	 (Hyder	 et	 al.	 2013).	 Previous	MRS	 studies	 in	 ASD	 and	OCD	have	shown	alterations	in	glutamate	in	fronto-striatal	circuits	(for	an	overview,	see	(Naaijen	et	al.	 2015)).	However,	many	of	 these	previous	 studies	were	based	on	 rather	 small	 sample	 sizes	and	used	low	field	strengths	that	did	not	allow	accurate	separation	of	Glu	from	glutamine	(Gln);	those	studies	therefore	reported	the	combined	Glu	+	Gln	signal	(the	so-called	Glx),	which	is	less	informative.	Although	studies	differed	greatly,	many	of	them	found	increased	glutamate	levels	in	prefrontal	 brain	 areas	 in	 ASD	 compared	with	 controls.	 This	 increase	was	 age-dependent,	 and	present	 in	 children,	whereas	 a	 reversed	pattern	was	 observed	 in	 adults	 (Naaijen	 et	 al.	 2015).	Striatal	findings	have	been	more	inconsistent,	but	so	far	increased	striatal	glutamate	levels	have	been	found	in	neurodevelopmental	disorders	(including	ASD	and	OCD)	compared	with	controls	as	well	(i.e.	(Rosenberg	et	al.	2000;	Hassan	et	al.	2013)).		In	the	present	study	we	investigated	whether	glutamatergic	concentrations	in	the	fronto-striatal	circuit	differed	in	children	with	compulsivity	disorders	relative	to	healthy	controls.	We	specifically	focused	on	the	age	range	between	8	and	13	years,	as	the	transition	from	childhood	to	adolescence	 begins	 in	 this	 period,	 in	which	 proper	 functioning	 of	 the	 fronto-striatal	 circuit	 is	essential	 (Somerville	 and	 Casey	 2010).	 Additionally,	 as	 a	 dimensional	 cross-disorder	comparison,	 we	 investigated	 whether	 glutamate	 concentrations	 were	 associated	 with	continuous	 measures	 of	 compulsivity	 and	 repetitive	 behaviour.	 Because	 prefrontal	 glutamate	has	been	associated	with	anxiety	before	(Klumpp	et	al.	2011;	Modi	et	al.	2014),	we	also	included	an	association	with	a	continuous	measure	for	anxiety	to	investigate	whether	possible	relations	are	compulsivity	specific.	We	focused	on	two	regions	of	interest,	the	midline	anterior	cingulate	cortex	(ACC)	and	the	left	dorsal	striatum	(covering	caudate	and	putamen)	to	be	able	to	compare	our	results	with	several	previous	studies	performed	in	ASD	and	OCD.	We	expected	ASD	patients	to	 show	higher	 glutamate	 levels	 compared	with	 healthy	 controls	 in	 both	 regions.	 Although	 to	date	 the	 findings	 in	OCD	have	been	 less	 robust,	we	expected	changes	 to	be	 comparable	 to	 the	ASD	group,	because	of	the	overlap	of	the	two	disorders	in	compulsive	behaviour.		  
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MATERIALS AND METHODS 	
Participants We	 included	 68	 paediatric	 participants	 with	 ASD,	 34	 with	 OCD,	 and	 61	 healthy	 controls.	Participants	(aged	8-13	years)	were	recruited	across	four	sites	in	Europe	(Radboud	University	Medical	 Center	 and	 the	 Donders	 Institute	 for	 Brain,	 Cognition	 and	 Behaviour,	 Nijmegen,	 The	Netherlands;	 Brain	 Center	 Rudolf	 Magnus,	 University	 Medical	 Center	 Utrecht,	 Utrecht,	 The	Netherlands;	King’s	College	London,	London,	United	Kingdom;	Central	Institute	of	Mental	Health	(CIMH),	 Mannheim,	 Germany).	 The	 measures	 used	 here	 were	 part	 of	 a	 larger	 test	 battery	including	questionnaires,	neuropsychological	testing,	and	MR	scanning,	as	described	in	Naaijen	et	al.	(in	press).	Exclusion	criteria	for	all	participants	were	the	presence	of	any	contraindications	for	MRI,	an	IQ	<	70,	and	the	presence	or	history	of	neurological	disorders.	Additionally,	the	ASD	and	OCD	patients	were	not	allowed	to	have	comorbidity	of	the	other	disorder	of	interest.	For	the	healthy	 comparison	 group,	 no	 DSM	 axis	 I	 disorders	 were	 allowed	 in	 any	 relatives	 up	 to	 two	generations	 back.	 Ethical	 approval	 for	 the	 study	 was	 obtained	 for	 all	 sites	 separately.	 After	description	of	the	study,	parents	gave	written	informed	consent,	children	aged	12	years	or	older	gave	written	informed	assent	and	children	younger	than	12	gave	oral	informed	assent.		
Phenotypic information Diagnoses	 of	 ASD	 and	 OCD	 were	 informed	 by	 pre-assessment	 questionnaires	 including	 the	Repetitive	 Behaviour	 Scale	 (RBS)	 filled	 in	 by	 parents	 (Lam	 and	 Aman	 2007).	 Anxiety	 was	measured	 by	 using	 a	 sub-scale	 of	 the	 Child	 Behaviour	 Checklist	 (CBCL	 (Bordin	 et	 al.	 2013)).	Additionally,	 we	 used	 structured	 diagnostic	 interviews	 to	 confirm	 the	 diagnosis.	 The	 autism	diagnostic	interview	revised	(ADI-R	(Lord	et	al.	1994)),	a	structured	developmental	interview	to	assess	 the	 symptoms	 of	 ASD	 and	 classify	 ASD	 DSM-IV-TR	 diagnosis,	 was	 administered.	 The	Children’s	Yale-Brown	Obsessive	Compulsive	Scale	(CY-BOCS	(Scahill	et	al.	1997))	was	used	as	a	severity	 scale	 for	 obsessions	 and	 compulsions	 for	 all	 OCD	 patients	 and	 whenever	 screening	questions	pointed	to	the	presence	of	obsessions/compulsions	in	the	other	participant	groups.	In	addition,	 all	 parents	were	 interviewed	using	 the	 structured	Diagnostic	 Interview	 Schedule	 for	Children	 (DISC	 (Shaffer	 et	 al.	 2000)),	 the	 Development	 and	Well-being	 Assessment	 (DAWBA	(Goodman	et	 al.	 2000)),	 or	 the	Kiddie	 Schedule	 for	Affective	Disorders	 and	Schizophrenia	 (K-SADS	(Kaufman	et	al.	1997),	dependent	on	site,	to	assess	the	presence	of	possible	comorbidities,	such	 as	 attention-deficit/hyperactivity	 disorder	 (ADHD),	 a	 very	 common	 comorbidity	 in	 both	ASD	 and	 OCD	 (Torres	 et	 al.	 2016).	 This	 interview	 was	 also	 conducted	 in	 parents	 of	 control	children	to	rule	out	the	presence	of	DSM	axis	I	diagnoses.	Full	scale	IQ	was	estimated	from	four	subtests	 (Vocabulary,	 Similarities,	 Block	 design,	 and	 Picture	 completion)	 of	 the	 Wechsler	
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Intelligence	 Scale	 for	 Children	 (Wechsler	 2002).	 Medication	 information	 was	 collected	 via	parental	report.		
MR acquisitions All	scans	were	acquired	on	3T	scanners	(see	Table	S1	for	scanner	information	across	sites).	The	scanning	 protocol	 included	 a	 structural	 T1-weighted	 MRI	 scan	 for	 the	 localization	 of	 the	spectroscopy	voxels	for	each	participant	and	the	two	spectroscopy	sequences.	The	structural	T1-weighted	scanning	sequence	was	based	on	 the	ADNI	GO	protocols	(Jack	et	al.	2008)	and	were	matched	 as	 closely	 as	 possible	 across	 the	 different	 scanning	 sites	 (see	 Table	 S1	 for	 the	 T1-weighted	scan	parameters).	Proton	spectra	were	acquired	using	a	point	resolved	spectroscopy	(PRESS)	sequence,	similar	across	sites,	with	the	chemically	selective	suppression	(CHESS)	water	suppression	 technique	 (Haase	 et	 al.	 1985).	 One	 8	 cm3	 voxel	 (2×2×2	 cm)	 was	 placed	 on	 the	midline	pregenual	ACC	anterior	to	and	slightly	superior	of	the	genu	of	the	corpus	callosum,	the	other	was	placed	in	the	left	dorsal	striatum	covering	caudate	and	putamen	(TR	=	3000	ms,	TE	=	30	ms,	 number	 of	 averages	=	 96,	 bandwidth	=	 5	 kHz,	 number	 of	 points	=	 4096).	 Additional	unsuppressed	water	 reference	 spectra	 (16	averages)	were	acquired.	The	voxel	 locations	were	adjusted	to	maximize	their	grey	matter	content,	see	Figure	1	for	locations	of	the	voxels	as	set	by	the	experimenters	across	the	different	sites	and	Figure	2	for	an	example	spectrum.	Both	voxels	were	 placed	 to	 cover	 a	 maximum	 amount	 of	 grey	 matter	 and	 a	 minimum	 amount	 of	cerebrospinal	 fluid	 (CSF).	 T1-weighted	 images	 were	 used	 for	 voxel	 placement	 and	 tissue	segmentation.	 On-site	 training	 was	 provided	 prior	 to	 this	 study	 to	 minimize	 across-site	variability	 in	voxel	placement.	Additionally,	phantom	(General	Electric	MRS	phantom)	and	 so-called	‘travelling-head’	data	from	all	sites	were	collected	to	assure	spectral	quality	and	reliability	across	sites.	Figure	S4	shows	the	spectra	for	one	of	the	travelling	heads.					
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Figure	1	Superposition	of	all	individual	midline	ACC	(A)	and	left	dorsal	striatum	voxels	(B)	on	the	MNI152	template	 from	 London	 (blue),	 Mannheim	 (red),	 Nijmegen	 (yellow)	 and	 Utrecht	 (green).	 Note	 the	consistent	placement	across	the	different	sites	and	experimenters,	as	 indicated	by	the	 large	overlap	and	narrow	spatial	confinement	of	the	colours.	 Individual	positions	of	voxels	per	site	can	be	found	in	Figure	S1.	 	
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Figure	2	Representative	example	spectra	of	a	3	Tesla	proton	magnetic	resonance	spectroscopy	(1H-MRS)	Linear	Combination	Model	(LCModel)	spectral	fit	in	the	ACC	and	the	striatum,	with	a	visualization	of	the	fits	 for	 glutamate	 only.	 The	 thin	 black	 line	 represents	 the	 frequency-domain	 data,	 the	 red	 line	 is	 the	LCModel	fit.	In	the	top	panel	the	residuals	are	plotted	(the	data	minus	the	fit).		
 
 
MR processing and modelling Analysis	 of	 acquired	 spectra	 was	 conducted	 using	 the	 Linear	 Combination	 Model	 (LCModel),	version	 V6.03-0I	 (Provencher	 2001).	 LC	model	 fits	 a	 linear	 combination	 of	model	metabolite	spectra	 to	 the	 in	 vivo	 spectrum.	 The	 analyses	were	 restricted	 to	 spectra	with	 linewidth	 (full-width	at	half-maximum;	FWHM)	≤	0.1	ppm,	Cramér-Rao	lower	bounds	(CRLB)	for	glutamate	≤	20	%,	 signal	 to	 noise	 ratio	 ≥	 5,	 and	 concentrations	within	 two	 standard	 deviations	 from	 the	mean.		 Eddy	 current	 corrections	 were	 performed	 and	 water-referenced	 metabolite	concentrations	were	automatically	calculated	in	institutional	units	(i.u.)	(Gasparovic	et	al.	2006).	Institutional	units	are	presented,	since	no	T1	and	T2	relaxation	time	corrections	of	the	metabolite	concentrations	were	performed.	The	T2	of	tissue	water	was	corrected	for	by	assuming	the	signal	had	decayed	by	30%	at	 the	 echo	 time.	 In	 addition,	 there	 are	 other	 scanner-dependent	 factors	
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that	 can	 affect	 the	 absolute	 scaling	 (e.g.	 details	 of	 coil	 combination	 and	 differences	 in	 the	radiofrequency	pulse	 shapes,	 flip	angles	and	bandwidths)	 such	 that	metabolite	 concentrations	measured	in	i.u.	are	preferred	over	attempting	to	scale	to	absolute	concentrations	in	millimolar	(mM).		 The	 unified	 segmentation	 procedure	 within	 the	 VBM8	 toolbox	 of	 SPM8	 (Statistical	Parametric	Mapping	 release	 8,	 London,	 UK)	was	 used	 to	 process	 the	 T1	 images	 and	 generate	grey	matter	(GM),	white	matter	(WM),	and	CSF	probability	maps	in	conjunction	with	non-linear	transformations	 to	 the	MNI	152	template	space.	Spectroscopy	voxels	were	mapped	onto	 these	probability	maps	 as	well	 as	 onto	 the	MNI	 152	 template,	 to	 provide	 the	 partial	 volume	 of	 GM,	WM,	 and	 CSF	 within	 each	 spectroscopy	 voxel	 (fGM,	 fWM,	 and	 fCSF),	 and	 to	 allow	 for	 group	comparisons	of	 the	anatomical	placement	of	 the	spectroscopy	voxels.	Additionally,	 the	amount	of	water	in	grey	matter,	white	matter,	and	CSF	in	each	voxel	was	taken	into	account.	To	correct	for	 differing	 amounts	 of	 water	 in	 each	 tissue	 and	 partial	 volume	 confounds	 (possible	 group	differences	in	proportions	of	GM,	WM,	and	CSF	in	the	voxels)	we	corrected	individual	absolute	metabolite	concentrations	with	the	following	formula:		ÑÖÜáàâäãÜÖåçééèåêèë = ÑÖÜáàâäãÜÖéíì ∗ 43300 ∗ ïñó + 35880 ∗ ïòó + 55556 ∗ ïôöõ35880 ∗ (1/(1 − ïôöõ)		where	 43300,	 35880,	 and	 55556	 are	 the	 water	 concentrations	 in	 mM	 for	 GM,	WM,	 and	 CSF,	respectively.	This	includes	a	correction	for	the	fraction	of	the	voxel	occupied	by	CSF,	along	with	corrections	 for	 the	 water	 concentration	 in	 each	 of	 the	 tissue	 types.	 The	 factor	 35880	 in	 the	denominator	is	included	since	the	initial	LCModel	analysis	was	carried	out	under	the	assumption	of	a	pure	WM	voxel	(LC	model	manual;	(Provencher	2014)).		
Statistical analysis All	statistical	analyses	were	performed	with	SPSS	release	21	(SPSS,	Inc.,	Chicago,	Illinois).	First,	demographic	 information	 was	 compared	 across	 groups.	 Sex	 was	 tested	 with	 Pearson’s	 chi-squared	test.	Group	differences	in	continuous	measures	(age,	IQ,	and	RBS	score)	were	assessed	with	 one-way	 analyses	 of	 variance	 (ANOVAs)	 if	 assumptions	 of	 homogeneity	 of	 variance	 and	normality	 of	 distributions	were	met	 (p>0.05	 in	 Levene’s	 test	 of	 homogeneity	 of	 variance	 and	Shapiro-Wilk	 normality	 test).	 If	 these	 assumptions	 were	 violated	 a	 non-parametric	 Kruskal-Wallis	 rank	 sum	 test	 (for	 three	groups)	or	 a	Mann-Whitney	U	 test	 (for	 two	groups)	was	used	instead.	Glutamate	 levels	were	normalized	using	Blom	 transformations	 (also	 called	 rank-based	inverse	 normal	 transformations)	 (Conover	 and	 Iman	 1981)	 because	 of	 their	 non-normal	
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distribution	which	allowed	the	use	of	subsequent	parametric	testing.	Group	differences	in	these	glutamate	levels	were	analysed	using	an	ANCOVA	with	scanner	site	(including	major	hardware	upgrades	on	scanners	across	sites),	medication	use,	sex,	and	age	as	covariates.	Covariates	were	removed	 from	analysis,	 if	 they	did	not	significantly	contribute	 to	 the	explained	variance	of	 the	model.	 Subsequently,	 contrast	 analyses	were	 performed	 to	 compare	 the	 two	 disorder	 groups	with	 controls	 and	 with	 each	 other.	 A	 p-value	 of	 <	 0.025	 after	 correction	 for	 multiple	comparisons	(two	voxels	of	interest)	was	considered	statistically	significant.	We	used	the	same	analysis	for	Glx	in	the	supplementary	material.		 For	metabolites	 that	were	 significantly	 different	 across	 the	 groups	 per	 voxel,	 post-hoc	correlation	analyses	with	the	RBS	subscales	and	CBCL	anxiety	scores	were	performed	using	non-parametric	 correlation	 analyses	 (Spearman’s	 rho)	 due	 to	 the	 nonlinear	 relationship	 between	glutamate	levels	and	these	behavioural	measures.	The	correlation	analyses	were	performed	for	the	disorder	groups	only,	as	scores	were	≤	1	for	the	controls.		
RESULTS 	
Demographics MR	spectra	were	 acquired	 for	143	of	 the	original	 163	participants.	Thirteen	participants	with	ASD,	 two	 participants	 with	 OCD,	 and	 five	 healthy	 controls	 were	 excluded	 due	 to	 excessive	movement,	anxiety	in	the	scanner,	or	not	meeting	full	diagnostic	criteria	after	inspection	of	the	ADI-R	 scores.	 Due	 to	 spectral	 or	 segmentation	 quality	 concerns,	 ten	 additional	 spectra	 were	excluded	from	ACC	analysis	(n=133)	and	29	from	striatal	analysis	(n=114).	Table	1	provides	a	summary	of	the	demographic	information.	Sex	and	IQ	differed	between	the	three	groups.	Table	S2	provides	demographic	 information	across	the	four	sites.	The	exclusion	of	more	participants	from	 the	 striatal	 analyses	did	not	 influence	demographic	distributions	 in	 the	group,	 regarding	sex	(χ2=6.88,	p=0.032),	age	(F=0.60,	p=0.55)	and	RBS-scores	(Stereotypes:	U=590.0,	p=0.299;	Self-harm:	 U=506.5,	 p=0.932;	 Compulsions:	 U=348.0,	 p=0.028;	 Rituals:	 U=528.0,	 p=0.834;	Insisting	on	sameness:	U=619.5,	p=0.154;	Limited	 interests:	U=695.5,	p=0.012;	Total:	U=581.5,	
p=0.361)	and	CBCL-anxiety	(U=430,	p=0.34).	However,	 the	difference	 in	 IQ	became	trend-level	in	this	group	(K-Wχ2	=5.42,	p=0.07).		 Children	both	on	and	off	medication	were	included.	Within	the	ASD	group,	three	children	used	stimulants,	 two	used	stimulants	and	antipsychotics,	 two	stimulants	and	atomoxetine,	one	antipsychotics,	 and	 one	 child	 used	 naltrexone.	 From	 the	 children	 with	 OCD,	 five	 used	antipsychotics,	one	used	antipsychotics	and	atomoxetine,	 three	used	stimulants,	and	two	were	on	 anti-depressants.	 Participants	 were	 asked	 to	 abstain	 from	 medication	 48	 hours	 prior	 to	scanning.	
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	 Several	 comorbidities	 were	 present	 across	 disorder	 groups,	 with	 ASD	 participants	showing	 comorbid	 ADHD	 (n=13),	 ODD	 (n=7),	 CD	 (n=1),	 and	 tic	 disorder	 (n=5).	 In	 the	OCD	group,	 the	 following	 comorbidities	 were	 present:	 ADHD	 (n=10),	 ODD	 (n=2),	 CD	 (n=3),	 tic	disorder	 (n=3),	 social	 anxiety	 disorder	 (n=1),	 generalized	 anxiety	 disorder	 (n=4),	 major	depression	(n=1),	and	dysthymia	(n=1).			Table	1	Demographic	characteristics	(based	on	the	group	for	the	ACC	analysis).			 ASD	(n=51)		 OCD	(n=29)	 Control	(n=53)	 Test	statistic	 p-value		 N	 	 N	 	 N	 	 	 	Sex,	m/f	 39/12	 	 13/16	 	 36/17	 	 χ2	=8.39	 0.015*		 	 	 	 	 	 	 	 		 Mean	 SD	 Mean	 SD	 Mean	 SD	 	 	Age	 10.78	 1.31	 10.72	 1.51	 10.45	 1.20	 F	=0.90	 0.409	IQ	 107.89	 14.69	 102.17	 14.42	 111.40	 10.32	 K-Wχ2=8.18	 0.017*	ADI-Revised		 	 	 	 	 	 	 	 	-Reciprocal	interaction	 17.22	 7.05	 -	 -	 -	 -	 -	 -	-Communication		 12.96	 5.09	 -	 -	 -	 -	 -	 -	-Repetitive	behaviour	 3.46	 2.71	 -	 -	 -	 -	 -	 -	CYBOCS	Total	score	 -	 -	 17.45	 7.09	 -	 -	 -	 -	-	Obsessions	 -	 -	 8.80	 4.51	 -	 -	 -	 -	-	Compulsions	 -	 -	 10.21	 3.49	 -	 -	 -	 -	RBS	 	 	 	 	 	 	 	 	-	Stereotypes	 3.26	 3.14	 2.83	 2.90	 -	 -	 U=792.0	 0.490	-	Self-harm	 1.60	 2.34	 1.90	 2.97	 -	 -	 U=696.5	 0.755	-	Compulsions	 3.38	 4.54	 5.21	 4.44	 -	 -	 U=505.5	 0.024*#	-	Rituals	 4.46	 5.02	 3.97	 4.40	 -	 -	 U=795.5	 0.722	-	Insisting	on	sameness	 8.52	 7.28	 6.10	 6.58	 -	 -	 U=881.0	 0.111	-	Limited	interests	 2.94	 2.83	 1.41	 1.80	 -	 -	 U=955.0	 0.016*#	-	Total	score	 24.18	 21.27	 21.38	 19.65	 -	 -	 U=787.5	 0.525	
CBCL	anxiety	score	 4.04	 2.52	 4.97	 3.34	 -	 -	 U=595.0	 0.229	ADI,	Autism	Diagnostic	Interview	(Lord	et	al.	1994);	ASD,	autism	spectrum	disorder;	CBCL;	Child	Behaviour	Checklist	(Bordin	 et	 al.	 2013)	 CYBOCS,	 children’s	 Yale-Brown	 Obsessive	 Compulsive	 scale	 (Scahill	 et	 al.	 1997);	 m/f,	male/female;	 OCD,	 obsessive	 compulsive	 disorder;	 RBS,	 Repetitive	 Behaviour	 Scale	 (Lam	 and	 Aman	 2007);	 SD,	standard	deviation;	*	significant	at	p<0.05;	#	difference	between	the	two	diagnostic	groups	only.			
Spectral quality assurance Voxel	 composition	 did	 not	 differ	 between	 ASD,	 OCD,	 and	 controls	 in	 either	 ACC	 or	 striatum	(Table	2),	supporting	that	our	results	were	not	confounded	by	partial	volume	effects.	To	confirm	that	spectral	quality	did	not	differ	between	groups,	we	compared	the	CRLB-estimated	standard	deviations	in	both	voxels	using	a	one-way	ANOVA	across	the	three	groups.	CRLBs	did	not	differ	between	 groups	 in	 ACC	 (F(2,130)=0.41,	 p=0.67)	 or	 striatum	 (F(2,111)=0.02,	 p=0.99),	 confirming	
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that	possible	differences	in	glutamate	levels	were	not	due	to	differences	in	CRLBs	(Kreis	2015).	Also,	 we	 did	 not	 find	 any	 differences	 in	 FWHM	 (ACC:	 F(2,130)=0.52,	 p=0.60;	 striatum:	F(2,111)=0.25,	 p=0.78	 )	 or	 SNR	 (ACC:	 F(2,130)=1.54,	 p=0.22;	 striatum:	 F(2,111)=0.57,	 p=0.57).	Glutamate	 closely	 interacts	 with	 glutamine	 and	 it	 is	 suggested	 that	 glutamine	 concentrations	may	 be	 additionally	 informative	 about	 possible	 glutamate	 dysfunction	 (Bak	 et	 al.	 2006).	 LC	model	fits	for	glutamine	were	poor,	showing	high	CRLBs.	We	therefore	did	not	include	glutamine	or	the	combined	Glx	signal	in	analysis.		Since	this	was	the	first	multi-centre	MRS	study	investigating	ASD	and	OCD	together,	we	also	investigated	 whether	 any	 site	 differences,	 present	 because	 of	 the	 different	 scanners,	 affected	glutamate	 levels	differently	across	the	three	groups.	The	interaction	term	of	site	and	diagnosis	did	 not	 affect	 glutamate	 levels	 in	 ACC	 or	 striatum	 (both	 p-values	 >	 0.1).	 Also,	 voxel	 tissue	composition	did	not	differ	between	groups	across	sites	(all	p-values	>	0.1).	The	supplementary	material	provides	additional	information	about	voxel	placement	across	sites	and	site/diagnosis	interaction	plots	in	terms	of	partial	volumes.	It	provides	additional	visual	representation	of	the	spectra	across	the	four	sites	for	a	travelling	head.		
Group comparisons A	 group	 difference	 was	 found	 in	 corrected	 glutamate	 levels	 in	 ACC,	 while	 including	 sex,	medication	use,	and	scanner	site	as	covariates	(F(2,127)=4.12,	p=0.019)	(see	Table	2	and	Figure	3).	Age	did	not	influence	the	ANCOVA	model	and	was	therefore	excluded.	Although	there	were	differences	 in	 sex	 between	 groups	 (with	more	males	 in	 the	ASD	 and	 control	 group	 compared	with	 the	OCD	group),	 they	did	not	significantly	 influence	 the	Glu	 levels	(F(1,127)=1,92,	p=0.17).	Post-hoc	between-group	contrasts	were	performed	to	obtain	a	more	detailed	understanding	of	the	nature	of	the	effect.	Indeed,	these	tests	showed	higher	Glu	levels	in	ACC	of	the	two	disorder	groups	(combined)	compared	with	controls	(t=2.85,	p=0.007),	while	 the	 two	disorder	groups	did	 not	 differ	 from	each	 other	 (t=0.29,	 p=0.77).	 Separately,	 both	ASD	 (t=2.52,	 p=0.014)	 and	OCD	(t=2.36,	p=0.02)	showed	increased	Glu	levels	in	the	ACC	compared	with	controls	as	well,	demonstrating	that	it	was	not	driven	by	either	one	of	the	disorders.	We	subsequently	compared	Glu	 levels	 in	a	restricted	set	of	patients	with	ASD	and	OCD	with	no	prior	or	current	use	of	any	medication	(ASD	n=39,	OCD	n=20)	and	separately	for	patients	without	any	comorbidities	(ASD	n=33,	OCD	n=15).	Glu	levels	also	differed	between	the	groups	in	these	more	limited	samples	of	medication-free	 participants	 (F(2,107)=4.13,	 p=0.019)	 and	 comorbidity-free	 participants	(F(2,94)=4.65,	p=0.012);	post-hoc	 across	 group	 tests	 revealed	 the	 same	 results	 as	 in	 the	 larger	sample.	Dimensional	analysis	showed	a	positive	correlation	between	Glu	 levels	 in	the	ACC	and	limited	 interests	as	measured	with	the	RBS	(rho=0.24,	p=0.03;	Figure	4).	The	correlation	was	not	present	when	we	investigated	ASD	and	OCD	separately	(both	p-values	>	0.05),	possibly	due	
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to	 the	smaller	samples.	No	significant	correlation	was	observed	between	Glu	 levels	 in	 the	ACC	and	 other	 subscales	 of	 the	 RBS	 (stereotypes	 (rho=0.18,	 p=0.11),	 self-harming	 behavior	(rho=0.12,	p=0.29,	compulsions	(rho=-0.01,	p=0.93),	rituals	(rho=-0.01,	p=0.90)	and	insisting	on	sameness	(rho=0.01,	p=0.91)).	Also	no	correlation	was	found	with	anxiety	(rho=-0.12,	p=0.30).	We	 additionally	 calculated	 the	 difference	 between	 the	 correlations	 (Lee	 and	 Preacher	 2013).	The	 correlation	 between	 limited	 interests	 and	 glutamate	 and	 anxiety	 and	 glutamate	 differed	significantly	 from	 each	 other	 (p=0.005)	 (Lee	 and	 Preacher,	 2013),	 as	 did	 the	 correlations	between	 limited	 interests	 and	 glutamate	 the	 compulsions,	 rituals	 and	 insisting	 on	 sameness	subscales	 of	 the	RBS	 and	 glutamate	 (all	p-values	 <0.05).	 No	 group	differences	 in	 absolute	Glu	levels	were	found	in	the	striatum	(F(2,108)=1.19,	p=0.31;	Figure	3).	We	additionally	found	group	differences	 in	 ACC	 Glx	 concentrations,	 but	 not	 in	 striatum	 Glx	 concentrations	 (see	supplementary	material).			Table	2	Voxel	composition	(partial	volumes)	and	glutamate	concentrations.			 ASD		 	 OCD	 	 Control	 	 F	statistic	 p-value		 Mean	 SE	 Mean	 SE	 Mean	 SE	 	 	ACC	 	 	 	 	 	 	 	 	%	grey	matter	 67.8	 1.4	 67.8	 1.9	 67.0	 1.4	 0.98	 0.91	%	white	matter	 11.6	 0.5	 11.3	 0.7	 12.5	 0.5	 1.17	 0.32	%	CSF	 20.5	 1.4	 20.9	 1.8	 20.5	 1.3	 0.02	 0.98		 	 	 	 	 	 	 	 	Normalized	Glu1	 0.17	 0.13	 0.23	 0.17	 -0.29	 0.13	 4.11	 0.019*	Striatum	 	 	 	 	 	 	 	 	%	grey	matter	 56.0	 1.4	 57.3	 1.8	 58.1	 1.3	 0.58	 0.56	%	white	matter	 43.3	 1.4	 42.3	 1.8	 40.9	 1.3	 0.77	 0.47	%	CSF	 0.7	 0.2	 0.4	 0.3	 1.0	 0.2	 1.71	 0.19		Normalized	Glu1	 	-0.09	 	0.15	 	0.26	 	0.19	 	-0.06	 	0.14	 	1.19	 	0.31	ACC,	anterior	cingulate	cortex;	ASD,	autism	spectrum	disorder;	CSF,	cerebrospinal	 fluid;	OCD,	obsessive	compulsive	disorder;	SD,	 standard	deviation;	Glu,	glutamate;	 *	 significant	at	p<0.05.	1	Based	on	 the	estimated	marginal	means	(adjusted	for	covariate	use).				 	
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		Figure	3	Glutamate	in	the	anterior	cingulate	cortex	(ACC;	left)	and	the	dorsal	striatum	(right)	across	the	three	 groups.	 Glutamate	 is	 plotted	 as	 a	 normalized	 value	 (using	 Blom	 transformation).	 The	 asterisk	indicates	 the	 significant	 difference	 between	 the	 disorder	 groups	 and	 controls.	 (ASD,	 autism	 spectrum	disorder;	OCD,	obsessive	compulsive	disorder).			
		Figure	4	Relation	between	anterior	cingulate	cortex	(ACC)	glutamate	 levels	and	 limited	 interests	scores	for	participants	with	autism	spectrum	disorder	(ASD;	purple)	and	obsessive	compulsive	disorder	(OCD;	red),	with	fit-lines	per	group.	The	solid	black	line	represents	the	total	fit-line.	 	
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DISCUSSION 	 	This	is	the	first	study	to	assess	glutamate	levels	in	the	fronto-striatal	circuit	in	two	compulsivity	disorders,	 ASD	 and	 OCD,	 and	 in	 healthy	 controls.	 We	 conducted	 both	 categorical	 analyses	contrasting	 diagnostic	 groups	 and	 dimensional	 analyses	 using	 continuous	 measures	 of	compulsivity	and	repetitive	behaviour,	and	anxiety.	 	We	 observed	 glutamate	 levels	 in	 the	 ACC	 to	 be	 significantly	 higher	 in	 children	 with	compulsivity	disorders	(ASD	and	OCD)	compared	to	controls.	No	difference	was	found	between	the	two	disorder	groups.	ACC	Glx	levels	were	increased	in	children	with	compulsivity	disorders	as	well.	Several	previous	studies	investigating	children	with	ASD	have	found	increased	Glu	or	Glx	levels	in	ACC	(Joshi	et	al.	2012;	Bejjani	et	al.	2012;	Hassan	et	al.	2013).	Adults	with	ASD,	on	the	other	 hand,	 tend	 to	 show	 decreased	 levels	 of	 glutamatergic	 compounds	 in	 prefrontal	 brain	regions	(see	(Naaijen	et	al.	2015)).	It	thus	seems	that	glutamatergic	over-activity	in	the	ACC	may	be	specific	for	children	with	ASD.	This	over-activity	may	not	be	limited	to	the	ACC,	as	previous	studies	 also	 reported	 increased	 glutamate	 levels	 within	 the	 amygdala-hippocampal	 complex	(Page	et	al.	2006)	as	well	as	in	the	cerebellum	and	striatum	(Hassan	et	al.	2013).	The	latter	was	not	 confirmed	 in	 the	 current	 study.	 The	 pattern	 of	 higher-than-normal	 glutamate	 metabolite	levels	 in	early	 stages	of	development	and	 lower-than-normal	 levels	 in	adulthood	may	point	 to	excitotoxicity	 in	 youth	 attenuating	 glutamate	 signalling	 in	 adulthood	 (Joshi	 et	 al.	 2012).	However,	also	in	controls,	metabolite	levels	are	known	to	change	with	age	(Horska	et	al.	2002).		 In	 OCD	 the	 findings	 have	 been	 less	 robust	 so	 far,	 with	 studies	 showing	 increased	 Glx	levels	in	the	caudate	(Gnanavel	et	al.	2014)	and	orbitofrontal	cortex	(Whiteside	et	al.	2006)	but	also	decreased	levels	across	different	brain	regions,	including	ACC	(Rosenberg	et	al.	2004;	Yücel	et	al.	2008).	Most	studies	to	date	have	been	performed	in	adults	and	most	were	unable	to	find	any	differences	between	patients	and	controls	(Brennan	et	al.	2013;	Naaijen	et	al.	2015).	Here	we	specifically	focused	on	an	important	age-range	of	8-13	years	within	neurodevelopment.	Our	data	thus	fills	an	important	void	in	current	research,	especially	given	the	knowledge	about	age-specific	effects	in	the	overlapping	disorder	ASD	(Naaijen	et	al.	2015).	The	 most	 important	 result	 of	 the	 current	 study	 is	 that	 there	 was	 no	 difference	 in	glutamate	 levels	 in	 the	 ACC	 between	 the	 two	 disorders,	 while	 both	 disorders	 differed	significantly	 from	 controls.	 This	 similarity	 across	 the	 two	 disorders	might	 be	 due	 to	 common	underlying	 mechanisms	 of	 compulsivity-related	 behaviours.	 This	 is	 also	 consistent	 with	 the	result	 of	 the	 correlation	 analysis,	 where	 increased	 limited	 interests	 were	 associated	 with	increased	ACC	glutamate	 levels	 across	 the	disorders,	 although	 the	 correlation	was	quite	 small	and	not	 corrected	 for	multiple	 comparisons.	This	 correlation	was	not	 found	 for	 the	other	RBS	subscales	 or	 a	 measure	 of	 anxiety.	 This	 cross-disorder	 analysis	 of	 the	 dimensional	 measure	
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provides	 more	 insights	 into	 the	 underlying	 mechanism	 of	 compulsivity	 in	 ASD	 and	 OCD,	 in	concordance	with	the	approach	of	the	Research	Domain	Criteria	(RDoC;	(Cuthbert	2014)).	Increased	Glu	levels	in	ACC	suggest	a	hyper-glutamatergic	brain	state,	as	previously	has	been	 hypothesized	 in	 ASD	 (Fatemi	 2008).	 This	 is	 supported	 by	 genetic	 studies	 pointing	 to	involvement	of	GRIN2B,	a	gene	encoding	the	glutamate	NMDA	receptor	2B,	in	both	ASD	and	OCD	(e.g.	 (Alonso	 et	 al.	 2012)).	 Also,	 the	 proteins	 GAD65kDA	 and	 GAD67kDA,	 responsible	 for	converting	 glutamate	 to	 GABA,	 have	 been	 shown	 to	 be	 reduced	 in	 ASD,	 which	 may	 result	 in	elevated	 glutamate	 levels	 by	 reducing	 inhibitory	 GABAergic	 tone	 (Pizzarelli	 and	 Cherubini	2011).	 Future	 studies	 should	 incorporate	 the	 influence	 of	 glutamate	 genes	 on	 the	 brain	glutamate	 signal	and	 investigate	 the	 influence	of	glutamatergic	medication	on	brain	glutamate	levels.	We	did	not	find	any	differences	in	striatal	glutamate,	which	was	not	due	to	differences	in	quality	 across	 the	 disorders.	 Striatal	 spectra,	 however,	 are	 very	 hard	 to	 acquire	 (Hess	 et	 al.	2013)	and	we	may	have	had	reduced	power	to	detect	differences	because	of	the	lower	spectra	quality.	However,	 the	 fronto-striatal	deficits	described	 in	 compulsivity	disorders	may	also	 just	be	due	more	to	deficits	in	self-control	and	regulation	of	compulsive	behaviour	performed	by	the	frontal	areas	and	less	to	the	more	subcortical	functions	driving	the	compulsivity	or	the	habitual	behaviours	(e.g.	(Fineberg	et	al.	2010;	Dalley	et	al.	2011)).	Strengths	of	the	current	study	are	the	combination	of	a	categorical	(two	disorder	groups	in	 one	 comparison)	 and	 a	 dimensional	 approach	 to	 investigate	 the	 relation	 between	compulsivity	 disorders	 and	 glutamate.	 Employing	 1H-MRS	 at	 3	 Tesla	 enabled	 us	 to	 reliably	measure	 glutamate	 separately	 from	 the	 combined	Glx	 signal.	 There	were,	 however,	 also	 some	limitations.	First,	 compulsivity	 is	 also	often	associated	with	dysfunctions	of	 (glutamate	 in)	 the	orbitofrontal	cortex	(OFC;	(Brennan	et	al.	2013;	Naaijen	et	al.	2015))	which	we	did	not	include	in	 the	 current	 study.	 Pilot	 spectral	 acquisitions	 in	 this	 region	were	 of	 low	quality	 due	 to	 field	inhomogeneity	 and	 lipid	 contamination.	 Second,	 our	 post-hoc	 correlation	 analyses	 were	 not	corrected	for	multiple	comparisons.	These	results	should	therefore	be	interpreted	with	caution.	Third,	 the	OCD	group	was	 smaller	 than	 the	ASD	and	 control	 group	due	 to	 recruitment	difficulties.	This	resulted	in	less	power	and	may	have	led	to	false	negative	results	in	the	striatum.	However,	the	continuous	measures	of	compulsivity	and	repetitive	behaviour	confirmed	the	link	between	ACC	glutamate	and	 limited	 interests	 in	 compulsivity	disorders.	Last,	 the	groups	were	quite	 heterogeneous	 in	 terms	 of	medication	 use	 and	 comorbidities.	 The	 group	 difference	was	retained,	however,	when	we	investigated	only	participants	that	did	not	use	any	medication.	In	 conclusion,	 the	 current	 study	 showed	 increased	 glutamate	 levels	 in	 the	 ACC	 of	children	with	compulsivity	disorders	compared	to	controls	and	a	small	relation	between	limited	interests	 and	 the	 ACC	 glutamate	 levels	 across	 the	 disorders.	 Although	 there	 were	 effects	 of	scanner	sites	on	glutamatergic	metabolites,	these	effects	did	not	differ	between	or	interact	with	
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diagnostic	 group	 status,	 showing	 the	 robustness	 of	 these	 findings	 across	 different	 sites	 and	scanners.	 These	 results	 need	 replication	 in	 an	 independent	 sample	 but	 nevertheless	 provide	insights	into	the	involvement	of	glutamate	in	paediatric	ASD	and	OCD	and	the	need	for	further	exploration	of	glutamatergic	interventions	in	these	disorders.		  
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SUPPLEMENTARY MATERIAL CHAPTER 4 
	Table	S1	Scan	parameters	for	the	structural	MRI	across	the	different	sites.	Site	 TR/TE/TI	(ms)	 Flip	angle	 Field	of	view	(mm)	 Matrix	RL/AP	/slices	 Voxel-size	(mm)	 Parallel	Imaging	Nijmegen	(Siemens	Prisma)	 2300
*/2.98/900	 9	 256		 212/256/176	 1.0	×	1.0	×	1.2	 2	Utrecht	(Philips	Achieva)	 6.8
*/3.10/823	 9	 270	 204/252/170	 1.1	×	1.1	×	1.2	 1.8	
London	(GE	MR750)	 7.31*/3.02/400	 11	 270	 256/256/196	 1.1	×	1.1	×	1.2	 1.75	Mannheim	(Siemens	Trio)	 2300*/2.98/900	 9	 270	 212/254/176	 1.1	×	1.1	×	1.2	 2	*	As	provided	by	the	manufacturer.	Philips	and	GE	define	a	TR	as	the	time	between	excitation	pulses,	while	Siemens	defines	TR	as	the	time	between	inversion	recovery	pulses.			 	
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Table	 S2	 Distribution	 of	 disorders	 and	 demographic	 details	 across	 sites.	 The	 distribution	 of	 diagnoses	across	 sites	 differed	 significantly	 due	 to	 the	majority	 of	 OCD	 participants	 being	 in	 one	 site	 (χ2=14.84,	p=0.02).	(ASD,	autism	spectrum	disorder;	OCD,	obsessive	compulsive	disorder).		 	 ASD		n=51	 OCD	n=29	 Control		n=53	 	Nijmegen	(n=54)	 Age	 11.22	(1.12)	 10.58	(1.41)	 10.37		(1.14)	 		 	IQ	 	105.17	(14.59)	 	102.92	(15.97)	 	111.67		(11.55)	 		 	Sex,	m/f	 	6/10	 	11/8	 	14/5	 		Utrecht	(n=31)	 Age	 10.21	(1.00)	 10.48	(1.33)	 10.46		(1.28)	 		 	IQ	 	108.30	(15.97)	 	100.27	(9.49)	 	109.70		(9.47)	 		 	Sex,	m/f	 	10/2	 	1/3	 	11/4	 		London	(n=21)	 Age	 10.45	(1.63)	 11.02	(2.49)	 9.97		(1.37)	 		 	IQ	 	108.74	(14.00)	 	101.39	(18.75)	 	110.81		(18.32)	 		 	Sex,	m/f	 	13/0	 	0/3	 	4/1	 		Mannheim	(n=27)	 Age	 11.16	(1.28)	 11.60	(1.88)	 10.71		(1.23)	 		 	IQ	 	110.94	(15.81)	 	100.00	(3.92)	 	113.07		(5.93)	 		 	Sex,	m/f	 	10/0	 	1/2	 	7/7	 				 				
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Figure	S1	shows	 the	voxel	placement	distribution	 for	 the	 two	areas	of	 interest	across	 the	 four	different	 scanner	 sites.	This	 shows	 that	 the	placement	was	very	 consistent	but	 that	 there	was	more	variability	in	the	ACC	compared	to	the	striatum.	There	was	an	effect	of	scanner	site	on	the	brain	 glutamate	 levels	 measured,	 as	 was	 expected	 based	 on	 the	 great	 difference	 between	scanner	 apparatuses	 used.	 However,	 site	 by	 diagnosis	 interaction	 analyses	 revealed	 no	differences,	meaning	that	the	effects	of	diagnosis	that	we	found	existed	on	top	of	the	site	effects	reported.	 Table	 S2	 shows	 the	 distribution	 of	 the	 disorders	 across	 sites	 including	 their	demographic	details.	To	show	that	the	main	effects	were	not	due	to	effects	of	one	site	or	to	the	non-similarity	 in	number	of	participants,	we	 include	Figure	S2	 in	which	ACC	glutamate	overall	findings	are	shown,	and	for	each	site	separately.	Directions	of	the	effect	are	similar	across	sites	(showing	 the	normalized	values).	Figure	S3	 shows	 the	grey	matter	partial	 volumes	across	 the	sites	and	diagnoses.	 In	 line	with	Figure	S1,	partial	volumes	were	very	similar	across	 sites,	but	there	was	more	variability	in	the	striatum,	also	due	to	the	smaller	number	of	participants	for	the	analyses	of	 this	voxel.	All	 site	×	diagnosis	 interactions	were	non-significant	 in	 terms	of	partial	volumes	of	the	voxels,	FWHM,	SNR	and	CRLBs.				
		Figure	 S1	 Distribution	 of	 the	 individual	 voxel	 placements	 for	 the	 anterior	 cingulate	 cortex	 (ACC)	 and	striatum	across	the	different	sites.	Note	that	the	voxel	placement	was	very	similar	for	the	striatum	across	all	 sites,	 whereas	 for	 the	 ACC	 the	 placement	 was	 slightly	 more	 posterior	 and	 superior	 in	 Mannheim	compared	with	Utrecht,	London	and	Nijmegen.		 	
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			Figure	 S2	 Glutamate	 in	 the	 anterior	 cingulate	 cortex	 (ACC)	 for	 the	 disorder	 groups	 compared	 with	controls	 (A)	 and	 separately	 per	 site	 (B).	 Glutamate	 is	 plotted	 as	 a	 normalized	 value	 (using	 Blom	transformation).	Note	that	the	pattern	of	increased	glutamate	in	the	disorders	compared	with	controls	is	similar	for	all	sites	separately.	(ASD,	autism	spectrum	disorder;	OCD,	obsessive	compulsive	disorder).		 	
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		Figure	 S3	 Mean	 percentage	 grey	 matter	 in	 the	 anterior	 cingulate	 cortex	 (ACC)	 and	 striatum	 across	disorders	 and	 sites.	 Error-bars	 represent	 the	 standard	 error.	 (ASD,	 autism	 spectrum	 disorder;	 OCD,	obsessive	compulsive	disorder).						
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	Figure	S4	Spectral	fit	for	the	ACC	of	the	same	“travelling	head”	across	sites.	All	sites	show	a	spectral	fit	and	CRLB,	S/N,	and	FWHM	values	within	the	range	of	good	quality.	(CRLB,	Cramér-Rao	lower	bounds;	FWHM,	full-width	at	half-maximum;	S/N,	signal	to	noise	ratio).	
	
	
Group differences in Glx concentrations As	 in	 glutamate	 concentrations,	 we	 also	 found	 a	 group	 difference	 in	 ACC	 Glx	 (F(2,126)=3.87,	p=0.023).	 Post-hoc	 between	 group	 contrasts	 showed	 higher	 Glx	 levels	 in	 the	 ACC	 of	 the	 two	disorder	groups	(combined)	compared	with	controls	(t=2.70,	p=0.008),	while	the	two	disorder	groups	did	not	differ	from	each	other	(t=0.08,	p=0.94).	Separately,	both	ASD	(t=2.57,	p=0.011)	and	OCD	(t=2.07,	p=0.040)	showed	increased	Glx	levels	in	the	ACC	compared	with	controls	as	well.	We	found	no	differences	in	striatum	Glx	(F(2,103)=1.30,	p=0.28).						
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CHAPTER 5 
 
Striatal structure and its association with N-Acetylaspartate and 
glutamate in ASD and OCD 
 
 
 
 
 
 
 
 
 
 
 
 
 										Under	review	as:		Jilly	Naaijen,	Marcel	P	Zwiers,	Natalie	J	Forde,	Steven	CR	Williams,	Sarah	Durston,	Daniel	Brandeis,	Jeffrey	C	Glennon,	The	TACTICS	consortium,	Barbara	Franke,	David	J	Lythgoe,	Jan	K	Buitelaar.	Striatal	structure	and	its	association	with	N-Acetylaspartate	and	glutamate	in	autism	and	obsessive	compulsive	disorder.	 	
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ABSTRACT 	Background:	 Autism	 spectrum	 disorders	 (ASD)	 and	 obsessive	 compulsive	 disorder	 (OCD)	 are	often	 comorbid	 and	 are	 associated	 with	 changes	 in	 striatal	 volumes	 and	 N-Acetylaspartate	(NAA)	and	glutamate	 levels.	Here,	we	 investigated	the	relation	between	dorsal	striatal	volume	and	NAA	 and	 glutamate	 levels.	We	 additionally	 compared	 striatal	 volume	 and	 shape	 between	ASD,	OCD	and	controls.	Methods:	 T1-weighted	magnetic	 resonance	 (MR)	 images,	 proton	 spectra	 (1H-MRS)	 in	 the	 left	striatum,	and	phenotypic	 information	were	collected	from	54	children	with	ASD,	32	with	OCD,	and	56	controls	 (aged	8-13	years)	 in	a	 four-site	 study.	Dorsal	 striatal	volume	and	shape	were	determined	 using	 the	 FMRIB	 integrated	 registration	 and	 segmentation	 tool	 (FIRST).	 Spectra	were	 processed	with	 Linear	 Combination	Model.	 The	 relationship	 of	 left	 striatal	 volume	with	NAA	 and	 glutamate	was	 investigated,	 and	 group	 comparisons	were	 performed	 for	NAA	 levels	and	for	bilateral	striatal	volume	and	shape.	Results:	NAA	levels	were	lower	in	subjects	with	ASD	compared	with	controls	(t=2.86,	p=0.005)	and	were	associated	with	striatal	volume	(β=0.37,	t=2.78,	p=0.008).	Glutamate	levels	were	also	associated	with	volume	in	the	ASD	group	(β=0.38,	t=2.46,	p=0.018).	No	group	differences	were	found	 for	 striatal	 volume	 or	 shape,	 but	 a	 post-hoc	 diagnosis-by-hemisphere	 interaction	(F(2,129)=3.86,	 p=0.024)	 revealed	 greater	 asymmetry	 (right>left)	 in	 striatal	 volume	 for	 the	disorder-groups	compared	with	controls.	Conclusions:	Our	findings	show	involvement	of	NAA	and	glutamate	in	striatal	volume	in	ASD	and	suggest	 greater	 asymmetry	 in	 paediatric	 ASD	 and	 OCD	 compared	 with	 controls,	 pointing	 to	overlapping	 subcortical	 abnormalities.	 The	 lower	 NAA	 in	 ASD	 reflects	 reduced	 neuronal	integrity	or	impaired	neuronal	functioning.			 	
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INTRODUCTION 	Autism	 spectrum	 disorders	 (ASD)	 and	 obsessive	 compulsive	 disorder	 (OCD)	 are	neurodevelopmental	 disorders,	 which	 are	 often	 comorbid	 and	 are	 both	 characterized	 by	compulsive	 behaviors	 (American	 Psychiatric	 Association	 2013).	 Structural	 neuroimaging	studies	 investigating	 these	 disorders	 have	 highlighted	 alterations	 in	 similar	 brain	 regions	 (	Hrdlicka	 2008;	 Radua	 &	Mataix-Cols	 2009).	 Among	 the	most	 investigated	 areas	 is	 the	 dorsal	striatum,	as	are	 the	caudate	nucleus	and	putamen	separately.	These	regions	are	central	 to	 the	functioning	of	 the	 fronto-striatal	circuits	(e.g.	Walhovd	et	al.,	2015;	Morris	et	al.,	2016),	which	have	been	shown	to	be	affected	in	ASD	and	OCD	(Langen	et	al.	2012;	Melloni	et	al.	2012).	Several	studies	 found	 increased	 caudate	 volume	 (Hollander	 et	 al.	 2005;	 Voelbel	 et	 al.	 2006;	Qiu	 et	 al.	2016)	and	increased	putamen	volume	(Sato	et	al.	2014)	in	participants	with	ASD	compared	with	controls.	 However,	 elevated	 repetitive	 behavior	 has	 been	 shown	 to	 correlate	 with	 decreased	bilateral	 putamen	 volumes	 as	well	 in	 children	with	ASD	 (Estes	 et	 al.	 2011).	 In	 a	 shape	 study,	which	 is	more	 sensitive	 to	 subtle	morphological	 changes,	 a	 steeper	 increase	 in	 concavity	with	age	in	both	caudate	and	putamen	of	participants	with	ASD	was	found	(Schuetze	et	al.	2016).	In	OCD,	increased	putamen	(Real	et	al.	2016)	and	caudate	and	putamen	volumes	(Zarei	et	al.	2011)	have	also	been	reported,	but	other	studies	did	not	show	differences	in	both	regions	(Szeszko	et	al.	 2004)	 or	 decreased	 left	 putamen	 volume	 (Hoexter	 et	 al.	 2012).	 Additionally,	 positive	correlations	 between	 putamen	 volume	 and	 obsessive-compulsive	 symptoms	 in	 the	 healthy	population	(Kubota	et	al.	2015),	but	also	negative	correlations	between	contamination/washing	symptoms	 (Van	 Den	 Heuvel	 et	 al.	 2009),	 total	 Children’s	 Yale-Brown	 Obsessive	 Compulsive	Scale	(CYBOCS)	(Scahill	et	al.	2006)	scores,	and	caudate	volume	(Narayanaswamy	et	al.	2013)	have	been	reported.	One	shape	study	found	deformity	of	the	caudate	in	OCD	(Choi	et	al.	2007).	There	 have	 also	 been	 studies	 in	 both	 disorders	 reporting	 regional	 asymmetries	 in	 subcortical	volumes	 (Kang	 et	 al.	 2008;	 Dougherty	 et	 al.	 2016),	 which	 may	 suggest	 deficits	 in	 regional	specialization.		Structural	 abnormalities	 may	 be	 related	 to	 neurochemical	 abnormalities.	 N-Acetylaspartate	 (NAA),	 which	 reflects	 neuronal	 density	 and	 viability,	 indicating	 neuronal	integrity	(Moffett	et	al.	2007),	may	be	a	marker	for	structural	abnormalities.	NAA	concentrations	can	be	measured	with	proton	magnetic	 resonance	 spectroscopy	 (1H-MRS),	 and	both	ASD	and	OCD	 have	 been	 associated	 with	 decreased	 NAA	 concentrations	 in	 several	 brain	 regions,	including	 the	 striatum	 (Aoki	 et	 al.	 2012;	 Aoki	 et	 al.	 2012;	 Ford	 &	 Crewther	 2016).	 NAA	 is	metabolically	connected	with	glutamate,	 the	most	abundant	excitatory	neurotransmitter	 in	the	human	central	nervous	system	(Pittenger	et	al.	2011;	Mehta	et	al.	2013);	mitochondrial	energy	production	from	glutamate	is	enhanced	through	NAA,	making	both	viable	markers	for	neuronal	
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health	(Moffett	et	al.	2007;	Moffett	et	al.	2013).	Glutamate	has	also	been	 found	altered	 in	OCD	and	ASD	(Naaijen	et	al.	2015).	The	relation	between	these	metabolites	and	measures	of	brain	structure	has	hardly	been	investigated	in	ASD	or	OCD.	In	ASD,	a	single	study	investigated	thalamic	volume	and	metabolites	(Say	 et	 al.	 2014);	 they	 found	 increased	 lateralization	 in	 ASD	 for	 thalamic	 volume	 and	 no	differences	in	metabolite	concentrations.	They	did	not	relate	the	two	measures.	An	early	study	in	OCD	with	a	limited	sample	size	found	no	association	between	caudate	volumes	and	metabolites	(Bartha	 et	 al.	 1998).	 In	 another	 neurodevelopmental	 disorder,	 schizophrenia,	 glutamate-mediated	excitotoxicity	in	subcortical	regions	(for	an	overview,	see	Plitman	et	al.	2014)	as	well	as	decoupling	of	NAA	and	glutamate	(Coughlin	et	al.	2015)	have	been	observed.	In	Huntington’s	disease,	correlations	between	caudate	volume	and	both	NAA	and	glutamate	concentrations	have	also	been	 found	(Padowski	et	al.	2014).	This	association	between	volume	and	neurochemistry	may	reflect	neuronal	integrity	and	functioning	of	this	region.			 In	 the	 present	 study	 we	 investigated	 whether	 ASD	 and/or	 OCD	 were	 associated	 with	changes	 in	 total	NAA	(tNAA,	consisting	of	NAA	and	N-Acetylaspartylglutamate)	concentrations	and	whether	 these	 changes	 and	glutamate	 concentrations	were	 related	 to	 striatal	 volume.	We	further	 investigated	 possible	 differences	 between	 the	 disorder	 groups	 and	 controls	 in	 total	striatal	 volume	 (to	 align	 volumetric	 analyses	 with	 spectroscopy	 analyses).	 Post-hoc	 we	investigated	caudate	and	putamen	separately	 including	both	volume	and	shape-analysis	 to	see	whether	observed	differences	were	due	to	region-specific	effects.	Based	on	previous	findings,	we	expected	 lower	 striatum	 tNAA	 concentrations	 within	 the	 disorder	 groups	 compared	 with	controls,	and	an	association	of	neurochemical	concentrations	with	striatal	volume.		
METHOD 	
Participants We	included	68	participants	with	ASD,	33	with	OCD,	and	61	healthy	controls.	Participants	(aged	8-13	years)	were	recruited	across	four	sites	in	Europe	(Radboud	University	Medical	Center	and	the	 Donders	 Institute	 for	 Brain,	 Cognition	 and	 Behaviour,	 Nijmegen,	 The	 Netherlands;	 Brain	Center	 Rudolf	 Magnus,	 University	 Medical	 Center	 Utrecht,	 Utrecht,	 The	 Netherlands;	 King’s	College	London,	London,	United	Kingdom;	Central	Institute	of	Mental	Health	(CIMH),	Mannheim,	Germany).	The	measures	used	here	were	part	of	a	larger	test	battery	including	questionnaires,	neuropsychological	 testing,	 and	 MR	 scanning,	 as	 described	 in	 Naaijen	 et	 al.,	 2016.	 Exclusion	criteria	for	all	participants	were	any	contraindications	for	participating	in	MRI,	IQ<70,	and	the	presence/history	 of	 neurological	 disorders.	 ASD	 and	 OCD	 participants	 were	 not	 allowed	comorbidity	of	 the	other	disorder	of	 interest.	 In	 the	healthy	 comparison	group,	no	DSM	axis	 I	
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disorder	 was	 allowed	 in	 any	 relatives	 up	 to	 two	 generations.	 Participants	 both	 on	 and	 off	medication	were	 included	but	they	were	asked	to	abstain	 for	48	hours	prior	to	testing.	Ethical	approval	 for	 the	 study	 was	 obtained	 for	 all	 sites	 separately.	 After	 description	 of	 the	 study,	parents	gave	written	informed	consent,	children	aged	12	years	or	older	gave	written	informed	assent	and	children	younger	than	12	gave	oral	informed	assent.		
Phenotypic information Clinical	 diagnoses	 of	 ASD	 and	 OCD	 were	 confirmed	 by	 structured	 diagnostic	 interviews.	 The	Autism	Diagnostic	Interview	Revised	(ADI-R	(Lord	et	al.	1994))	and	the	CY-BOCS	(Scahill	et	al.	2006)	were	used	for	ASD	and	OCD	respectively.	In	addition,	all	parents	were	interviewed	using	the	 structured	 Diagnostic	 Interview	 Schedule	 for	 Children	 (DISC	 (Shaffer	 et	 al.	 2000)),	 the	Development	 and	 Well-being	 Assessment	 (DAWBA	 (Goodman	 et	 al.	 2000)),	 or	 the	 Kiddie	Schedule	for	Affective	Disorders	and	Schizophrenia	(K-SADS	(Kaufman	et	al.	1997)),	dependent	on	site,	to	assess	the	presence	of	possible	comorbidities,	such	as	attention	deficit	hyperactivity	disorder	(ADHD),	a	comorbidity	very	common	in	both	ASD	and	OCD	(van	Steensel	et	al.	2013;	Torres	 et	 al.	 2016).	 Repetitive	 behavior	was	 assessed	 by	 the	 Repetitive	 Behavior	 Scale	 (RBS)	filled	in	by	parents	(Lam	and	Aman	2007).	Full-scale	IQ	was	estimated	from	four	subtests	of	the	Wechsler	Intelligence	Scale	for	Children	(Wechsler	2002).	Information	about	use	of	medication	was	collected	via	parental	report.		
MR acquisitions The	scanning	protocol	included	a	structural	MRI	and	the	spectroscopy	sequence.	The	structural	T1-weighted	sequence	was	based	on	the	ADNI	GO	protocols	(Jack	et	al.,	2008;	Jack	et	al.,	2010)	and	was	matched	 closely	 across	 the	 different	 scanning	 sites	 (see	Table	 1	 for	 the	T1-weighted	scan	parameters).	 Proton	 spectra	were	 acquired	using	 a	point-resolved	 spectroscopy	 (PRESS)	protocol,	similar	across	sites,	with	chemically	selective	suppression	(CHESS)	water	suppression	(Haase	et	al.	1985).	One	2×2×2	cm	voxel	was	placed	on	the	left	striatum	covering	caudate	and	putamen	 (TR=3000	 ms,	 TE=30	 ms,	 number	 of	 averages	 =96,	 bandwidth=5	 kHz,	 number	 of	points	=	4096).	Additional	unsuppressed	water	reference	spectra	(16	averages)	were	acquired.	The	voxel	location	was	adjusted	to	maximize	its	gray	matter	content.	T1-weighted	images	were	used	 for	 voxel	 placement	 and	 tissue	 segmentation.	We	 only	measured	metabolites	 in	 the	 left	striatum,	due	to	time-constraints	of	the	scan-protocol,	which	was	part	of	a	larger	study	protocol.	Voxel	 location	 of	 the	 striatum	 across	 the	 different	 sites	 is	 presented	 in	 Figure	 1B,	 showing	consistent	placement.			
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Table	1	Scan	parameters	for	the	structural	MRI	across	the	different	sites.	Site	 TR/TE/TI	(ms)	 Flip	angle	 Field	of	view	(mm)	
Matrix	RL/AP	/slices	 Voxel-size	(mm)	 Parallel	Imaging	 Coil:	#	of	channels		
Nijmegen	(Siemens	Prisma)	
2300*/2.98/900	 9	 256		 212/256/176	 1.0	×	1.0	×	1.2	 2	 32	
Utrecht	(Philips	Achieva)	
6.8*/3.10	/823	 9	 270	 204/252/170	 1.1	×	1.1	×	1.2	 1.8	 8	
London	(GE	MR750)	 7.31*/3.02	/400	 11	 270	 256/256/196	 1.1	×	1.1	×	1.2	 1.75	 8	Mannheim	(Siemens	Trio)	 2300*/2.98/900	 9	 270	 212/254/176	 1.1	×	1.1	×	1.2	 2	 32	*	As	provided	by	the	manufacturer.	Philips	and	GE	define	a	TR	as	the	time	between	excitation	pulses,	while	Siemens	defines	TR	as	the	time	between	inversion	recovery	pulses.				
MR processing and modelling T1-weighted	images	were	processed	with	the	FMRIB	Software	Library	(FSL)	(Smith	et	al.	2004;	Woolrich	 et	 al.	 2009).	 Segmentation	 was	 performed	 with	 the	 automated	 FMRIB	 integrated	registration	 and	 segmentation	 tool	 (FIRST)	 (Patenaude	 et	 al.	 2011).	 The	 FIRST	 procedure	included	 affine	 registration	 to	 MNI	 space	 (MNI152,	 1×1×1mm	 template)	 followed	 by	 a	segmentation	 procedure	 that	 integrates	 both	 shape	 and	 intensity	 information	 for	 accurate	segmentation	 of	 subcortical	 structures,	 including	 the	 striatal	 structures	 (caudate	 nucleus	 and	putamen	bilaterally).	 FIRST	generated	volumetric	data	 and	 surface	meshes	 for	 each	 structure.	Volumes	of	these	respective	nuclei	were	extracted	for	statistical	analysis.		 First_utils	 was	 used	 to	 reconstruct	 the	 caudate	 nucleus	 and	 putamen	 in	 native	 space	(useReconNative).	We	applied	 commands	 to	 align	 each	 structure	 to	 the	 average	 shape	 for	 the	cohort	(useRigidAlign)	and	to	remove	global	scaling	to	account	for	differences	in	size	(useScale).	Vertex-wise	statistical	analyses	of	the	structure	shapes	were	then	conducted.	Statistical	analyses	are	further	described	below	in	section	2.6.		 The	 unified	 segmentation	 procedure	 within	 the	 VBM8	 toolbox	 of	 SPM8	 (Statistical	Parametric	Mapping	release	8,	London,	UK)	was	used	to	process	the	T1	images	and	produce	gray	matter	(GM),	white	matter	(WM),	and	cerebrospinal	fluid	(CSF)	probability	maps	in	conjunction	with	 non-linear	 transformations	 to	 the	 MNI152	 template	 space.	 Total	 brain	 volume	 was	calculated	as	the	voxel-wise	sum	of	the	GM	and	WM	maps.	
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	 Spectral	 analysis	 was	 conducted	 using	 the	 Linear	 Combination	 (LC)	 Model,	 version	V6.03-0I	(Provencher	2001).	The	MRS	processing	has	been	described	in	detail	in	(Naaijen	et	al.	2016);	 briefly,	 it	 included	 eddy	 current	 correction	 and	 calculation	 of	 water-referenced	concentrations	 in	 institutional	units	 (i.u.).	The	 striatal	 voxel	was	 subsequently	mapped	on	 the	above	described	probability	maps	as	well	as	on	the	MNI152	template	to	provide	partial	volumes	of	 GM,	WM	 and	 CSF	 within	 the	 voxel.	 Total	 NAA	 (tNAA)	 and	 glutamate	 concentrations	 were	corrected	for	these	partial	volume	effects	and	for	water-levels	in	the	different	tissue-types	using	the	following	formula:		 ÑÖÜáàâäãÜÖåçééèåêèë = ÑÖÜáàâäãÜÖéíì ∗ 43300 ∗ ïñó + 35880 ∗ ïòó + 55556 ∗ ïôöõ35880 ∗ (1/(1 − ïôöõ)		where	43300,	35880	and	55556	are	the	water	concentrations	(in	millimolar)	 for	GM,	WM	and	CSF,	respectively.			
Quality control Structural	 datasets	 were	 visually	 inspected	 and	 evaluated.	 Segmentation	 of	 the	 striatal	structures	 was	 also	 visually	 examined	 for	 processing	 errors	 and	 accuracy	 of	 segmentation.	Spectra	 with	 line-width	 (full-width	 at	 half-maximum)	 >0.1	 ppm,	 Cramér-Rao	 lower	 bounds	(CRLB)	>20%,	 signal	 to	 noise	 ratio	 <5,	 and	 concentrations	more	 than	 2	 standard	 deviations	from	the	mean	were	excluded.	Thirteen	participants	with	ASD,	three	participants	with	OCD,	and	five	healthy	controls	were	excluded	due	to	excessive	movement,	anxiety	 in	the	scanner,	or	not	meeting	full	diagnostic	criteria	after	inspection	of	the	ADI-R	scores.	Quality	and	reliability	across	sites	was	 assured	by	making	use	of	 so-called	 travelling	heads	and	phantoms	 (General	Electric	MRS	phantom;	 see	also	 (Naaijen	et	 al.	2016).	This	data	 showed	reliable	measures	across	 sites	and	can	be	found	in	Figure	S1).	Striatum	voxel	composition	did	not	differ	between	ASD,	OCD,	and	controls	 (GM,	 F(2,138)=0.59,	 p=0.56;	 WM,	 F(2,138)=0.79,	 p=0.46;	 CSF,	 F(2,138)=1.8,	 p=0.17).	Although	tNAA	CRLBs	differed	between	groups	(F(2,129)=8.34,	p	<0.001),	all	were	in	a	very	low	range	 (Mean	 controls=3.1%,	 OCD=4.4%,	 ASD=3.3%).	 We	 therefore	 assumed	 reliable	measurement	of	tNAA	levels	(Kreis	2015).	Differences	in	scanners	(because	of	the	multi-center	nature	of	this	study)	did	not	differentially	affect	the	tNAA	levels	across	the	three	groups	(p-value	>0.05).		
Statistical analysis Statistical	 analyses	 were	 performed	 with	 SPSS	 release	 21	 (SPSS,	 Inc.,	 Chicago,	 Illinois).	 First,	demographic	 information	was	compared	across	groups.	Group	distributions	in	sex	were	tested	
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with	 Pearson’s	 chi-squared	 test.	 Group	 differences	 in	 continuous	 measures	 (age,	 IQ,	 and	compulsivity	score)	were	assessed	with	one-way	analyses	of	variance	(ANOVAs)	if	assumptions	of	homogeneity	of	variance	and	normality	of	distributions	were	met	(p>0.05	in	Levene’s	test	of	homogeneity	of	variance	and	Shapiro-Wilk	normality	test).	If	these	assumptions	were	violated	a	non-parametric	 Kruskal-Wallis	 rank	 sum	 test	 was	 used	 instead.	 Results	 were	 considered	statistically	 significant	 at	 p<0.05,	 two-sided.	 Group	 differences	 in	 tNAA	 concentrations	 were	analyzed	using	an	ANCOVA	with	scanner-site,	current	medication	use,	sex	and	age	as	covariates;	total	 brain	 volume	was	 not	 included	 in	 this	 analysis	 because	metabolite	 concentrations	were	corrected	 for	 partial	 volume	 effects.	 Covariates	 were	 removed	 from	 analysis	 if	 they	 did	 not	significantly	 contribute	 to	 the	 explained	 variance	 of	 the	 model.	 Additionally,	 we	 investigated	whether	 striatal	 tNAA	 and	 glutamate	 concentrations	were	 associated	with	 left	 striatal	 volume	using	regression	analysis.		
Volume analysis A	 repeated	measures	 analysis	 of	 co-variance	 (ANCOVA)	 was	 used	 to	 investigate	 the	 effect	 of	diagnostic	group	on	dorsal	striatal	volume	(combination	of	caudate	and	putamen	volumes).	We	first	investigated	total	volume	to	allow	for	direct	comparison	with	the	MRS	data,	which	included	a	 region	 of	 interest	 covering	 both	 striatal	 regions.	 Hemisphere	 was	 included	 as	 the	 repeated	measures	 factor,	 and	 total	 brain	volume,	 sex,	 age,	 IQ,	 current	medication-use	and	 scanner-site	were	included	as	covariates.	Secondary,	post-hoc	analyses	were	performed	for	the	caudate	and	putamen	separately	to	establish,	whether	the	observed	group	differences	were	due	to	regional	effects.		When	 asymmetry	 differences	 between	 groups	 were	 observed	 in	 the	 main	 analysis,	 we	calculated	an	asymmetry	index	with	the	following	formula:	¶ß®©©ÖÜ™®	´¨≠ÖÆ	 ¶´ = Øã∞ℎÜ≤ç≥¥µè − ∂ÖïÜ≤ç≥¥µèØã∞ℎÜ≤ç≥¥µè + ∂ÖïÜ≤ç≥¥µè	This	 AI	 was	 used	 in	 Spearman’s	 rank-correlation	 analysis	 to	 investigate	 association	 with	phenotypic	measures	separately	for	the	groups	and	with	a	continuous	measure	of	compulsivity	across	the	two	disorder	groups.			
Shape analysis Shape	 analysis	 of	 the	 caudate	 and	 putamen	 structures	 was	 performed	 using	 FSL	 randomise	(Winkler	 et	 al.	 2014)	 with	 5000	 random	 permutations.	 Threshold-free	 cluster	 enhancement	(TFCE	(Smith	and	Nichols	2009))	was	used	 to	detect	 spatially	adjacent	areas.	Sex,	age,	 IQ	and	scanner-site	 were	 used	 as	 covariates.	 Contrasts	 to	 investigate	 shape	 difference	 between	 the	three	 diagnostic	 groups	 were	 used.	 Separate	 models	 were	 included	 for	 possible	 associations	
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with	 the	 continuous	 measure	 of	 compulsivity	 (RBS)	 as	 well	 as	 associations	 with	 tNAA	 and	glutamate	levels	including	the	same	covariates.	Statistical	significance	was	determined	by	means	of	a	family-wise	error	(FWE)	threshold	of	p<0.05.		
RESULTS 	
Demographics Table	 2	 shows	 a	 summary	 of	 the	 demographic	 information;	 Table	 S1	 provides	 demographic	information	across	the	four	sites	separately.	Of	the	original	162	participants,	141	had	MR	data-sets	available	for	analysis.	Sex	differed	between	the	three	groups	with	a	male/female	imbalance	in	the	ASD	and	control	group	compared	with	the	OCD	group.	Due	to	spectral	or	segmentation	quality	concerns,	29	and	10	participants	were	excluded	for	 association	 analyses	 of	 glutamate	 and	 NAA	 concentrations	 and	 of	 brain	 structure,	 leaving	n=112	 and	 n=131	 participants,	 respectively.	 The	 exclusion	 of	 these	 participants	 did	 not	influence	demographic	 distributions	 in	 the	 group	 regarding	 sex	 (χ2=8.4,	 p=0.015),	 IQ	 (K-Wχ2	=4.74,	p=0.09),	age	(F=0.652,	p=0.52),	and	RBS-scores	(Stereotypes:	U=570.0,	p=0.205;	Self-harm:	 U=469.5,	 p=0.877;	 Compulsions:	 U=	 481.5,	 p=0.983;	 Rituals:	 U=510.0,	 p=0.674;	Insisting	on	sameness:	U=588.5,	p=0.129;	Limited	interests:	U=655.5,	p=0.012;	Total:	U=559.5,	p=0.270).	Several	comorbidities	were	present	in	the	disorder	groups.	ASD	participants	showed	comorbid	ADHD	(n=15),	ODD	(n=9),	CD	(n=1),	and	tic	disorder	(n=5).	In	the	OCD	group,	the	following	comorbidities	were	present:	ADHD	(n=11),	oppositional	defiant	disorder	(ODD;	n=2),	conduct	 disorder	 (CD;	 n=3),	 tic	 disorder	 (n=3),	 social	 anxiety	 disorder	 (n=1),	 generalized	anxiety	disorder	(n=4),	major	depression	(n=2),	and	dysthymia	(n=1).			 	
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Table	2	Demographic	characteristics	(n=141).		 ASD	(n=54)		 OCD	(n=31)	 Control	(n=56)	 Test	statistic	 p-value		 N	 	 N	 	 N	 	 	 	Sex,	m/f	 43/11	 	 15/16	 	 38/18	 	 χ2	=8.85	 0.012*		 	 	 	 	 	 	 	 		 Mean	 SD	 Mean	 SD	 Mean	 SD	 	 	Age	 10.72	 1.33	 10.87	 1.62	 10.44	 1.20	 F	=1.15	 0.318	IQ	 108.75	 14.59	 104.72	 15.37	 111.51	 11.01	 K-Wχ2=4.32	 0.115	ADI-Revised		 	 	 	 	 	 	 	 	-Reciprocal	interaction	 17.28	 6.97	 -	 -	 -	 -	 -	 -	-Communication		 12.96	 4.96	 -	 -	 -	 -	 -	 -	-Repetitive	behavior	 3.60	 2.72	 -	 -	 -	 -	 -	 -	CYBOCS	Total	score	 -	 -	 18.65	 7.26	 -	 -	 -	 -	-	Obsessions	 -	 -	 9.25	 4.53	 -	 -	 -	 -	-	Compulsions	 -	 -	 10.63	 3.55	 -	 -	 -	 -	RBS	 	 	 	 	 	 	 	 	Stereotypes	 3.15	 3.11	 2.58	 2.74	 0.21	 0.76	 U=908.5	 0.414#	Self-harm	 1.58	 2.29	 2.00	 2.85	 0.18	 0.54	 U=745.5	 0.454#	Compulsions		 2.91	 2.71	 3.55	 3.56	 1.30	 2.74	 U=762.5	 0.580#	Rituals	 4.38	 4.92	 3.94	 4.31	 0.07	 0.26	 U=850.5	 0.785#	Insisting	on	sameness	 8.34	 7.16	 6.10	 6.45	 0.23	 0.83	 U=991.0	 0.114#	Limited	interests	 2.92	 2.78	 1.42	 1.75	 0.16	 0.37	 U=1084	 0.013#*	Total	score	 23.58	 20.79	 21.29	 19.20	 1.09	 2.28	 U=883.5	 0.565#		 N	 	 N	 	 	 	 	 	Medication	use	-	Stimulant	-	Atomoxetine	-	Antipsychotic	-	Antidepressant	-	Other	
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	-	-	-	-	-	
	-	-	-	-	-	ADI,	Autism	Diagnostic	Interview	(Lord	et	al.	1994);	ASD,	autism	spectrum	disorder;	CYBOCS,	children’s	Yale-Brown	Obsessive	Compulsive	scale	(Scahill	et	al.	1997);	HC,	healthy	controls;	m/f,	male/female;	OCD,	obsessive	compulsive	disorder;	RBS,	Repetitive	Behavior	 Scale	 (Lam	and	Aman	2007);	 SD,	 standard	deviation;	 *	 significant	 at	 p<0.05;	#	difference	between	the	two	diagnostic	groups	only.		
N-Acetylaspartate  A	group	difference	was	found	in	tNAA	levels	in	the	left	striatum,	while	including	scanner	site	as	covariate	 (F(2,124)=4.29,	 p=0.016).	Medication	 use,	 sex	 and	 age	 did	 not	 influence	 the	ANCOVA	model	and	were	therefore	excluded.	Post-hoc	between-group	comparisons	revealed	lower	tNAA	levels	 in	 the	ASD	 group	 compared	with	 controls	 (t=2.84,	 p=0.005).	No	 significant	 differences	were	found	in	other	group	comparisons.	Highest	CRLB	values	were	found	for	the	OCD	group,	and	ASD	and	controls	did	not	differ	on	this	measure.	We	are	therefore	confident	that	our	results	are	not	driven	by	differences	in	spectral	quality.	Figure	S2shows	group	differences	in	tNAA	overall	and	separately	per	site.			
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Association between striatal volume and metabolite concentrations We	have	shown	earlier	in	an	overlapping	sample	(n=114)	that	glutamate	was	not	significantly	different	across	ASD,	OCD	and	controls	(Naaijen	et	al.	2016).	Since	tNAA	concentrations	differed	between	 groups,	we	 investigated	 associations	 between	metabolite	 concentrations	 and	 striatal	volume	 separately	 for	 each	 group.	We	 found	 a	 significant	 relationship	 of	 both	 tNAA	 (β=0.37,	t=2.78,	p=0.008;	Figure	1A)	and	glutamate	(β=0.38,	t=2.46,	p=0.018;	Figure	1C)	with	striatal	volume	for	children	with	ASD,	which	were	still	(trend)-significant	after	correcting	for	total	brain	volume	 (βtNAA=0.25,	 t=2.28,	 p=0.027	 and	 βglutamate=0.22,	 t=1.92,	 p=0.06,	 respectively).	 The	tNAA	and	glutamate	concentrations	were	associated	with	each	other	as	well	(β=0.88,	t=10.84,	p<0.001;	Figure	1D).	Graphically	(as	apparent	from	Figure	1D),	the	ASD	group	is	divided	in	two	groups.	This	is	due	to	the	relatively	higher	neurochemical	concentrations	for	GE	scanners	(one	of	 the	 sites)	 than	 Siemens	 and	 Philips.	 After	 removal	 of	 this	 group	 (n=7),	 a	 significant	association	 between	 the	metabolites	 was	 still	 found	 (β=0.6,	 t=4.06,	 p<0.001).	 No	 significant	associations	between	neurochemicals	 and	 striatal	 volumes	were	 found	 for	 the	OCD	or	 control	groups	(see	Figure	S5).		 	
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																												Figure	1	Association	between	striatal	N-Acetylaspartate	and	volume	(A),	glutamate	levels	and	volume	(C)	and	between	 the	 two	metabolites	 (D)	 in	 the	autism	spectrum	disorder	 (ASD)	group.	Panel	B	shows	 the	anatomically	 defined	 caudate	 and	 putamen	 regions	 used	 in	 the	 volume	 and	 shape	 analyses	 and	 the	striatum	voxel	(superposition	of	all	participants’	voxels	separately	per	site	on	the	MNI152	template;	note	the	consistent	placement).			
Striatal volume There	was	no	main	effect	of	diagnosis	(F(2,129)=0.97,	p=0.39)	on	striatal	volume,	and	no	effects	of	IQ,	sex,	age,	medication	use	or	scanner-site	were	found	(all	p-values	>0.1).	There	was	a	main	effect	of	total	brain	volume	(F(1,131)=32.48,	p<0.001)	on	striatal	volume,	which	on	itself	did	not	differ	between	the	three	diagnostic	groups	(F(2,132)=0.51,	p=0.60).	The	effect	of	hemisphere	was	at	trend	level	(F(1,129)=3.49,	p=0.064).		A	hemisphere	by	diagnosis	interaction	(F(2,129)=3.86,	p=0.024)	suggested	differences	in	left-right	asymmetry	in	striatal	volume	across	the	three	groups.	Post-hoc,	we	therefore	investigated	this	 interaction	 more	 closely,	 by	 comparing	 the	 three	 groups	 with	 each	 other	 in	 three	 2×2-designs,	which	 showed	 the	 same	 diagnosis	 by	 hemisphere	 interactions,	when	 comparing	 ASD	with	controls	(F(1,99)=7.95,	p=0.006)	and	OCD	with	controls	(F(1,76)=3.99,	p=0.049),	but	not	ASD	
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with	OCD	(F(1,74)=0.03,	p=0.86).	Figure	2	 shows	striatal	volumes	across	 the	diagnostic	groups	and	 hemispheres;	 Figure	 S3	 shows	 these	 results	 separately	 per	 site.	 After	 removal	 of	participants	 using	medication	 and	 those	with	 comorbidities,	 the	 asymmetry	 finding	 remained	significant	 (F(2,111)=3.507,	 p=0.033	 and	 F(2,97)=3.706,	 p=0.028,	 respectively).	 When	investigating	 the	 caudate	 nucleus	 and	 putamen	 separately	 (Figure	 S4),	 likely	 due	 to	 power	restrictions,	 the	 hemisphere	 by	 diagnosis	 interaction	was	 no	 longer	 seen,	 nor	were	 any	main	effect	of	diagnosis	or	hemisphere	(p-values	>0.05).			 Because	of	the	significant	group	difference	in	striatal	volume	asymmetry,	we	conducted	further	 analysis	 using	 the	 asymmetry	 index	 (AI).	 Within	 the	 ASD	 group,	 there	 were	 no	significant	 associations	 between	 striatal	 AI	 and	 any	 phenotypic	 measure	 of	 the	 ADI-R:	 social	interaction	 (rho=0.10,	 p=0.47),	 communication	 and	 language	 (rho=0.04,	 p=0.76),	 and	restricted	 and	 repetitive	 behaviours	 (rho=-0.11,	 p=0.42).	 For	 the	 OCD	 group	 we	 found	 no	significant	 associations	 for	 CYBOCS-obsessions	 (rho=0.07,	 p=0.72)	 or	 CYBOCS-compulsions	(rho=0.08,	p=0.66).	For	the	groups	pooled	together,	no	associations	with	any	of	the	subscales	as	measured	 with	 the	 RBS	 (all	 p-values	 >	 0.1)	 were	 observed.	 These	 were	 all	 uncorrected	 for	multiple	comparisons.		 	
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		Figure	 3	 Left	 and	 right	 striatal	 volume	 for	 each	 group.	 There	 was	 a	 significant	 interaction	 between	diagnosis	and	hemisphere	showing	asymmetry	in	ASD	and	OCD	compared	with	controls.	ASD	and	OCD	did	not	 differ	 from	 each	 other	 in	 asymmetry	 (ASD,	 autism	 spectrum	 disorder;	 OCD,	 obsessive	 compulsive	disorder).	The	error-bars	represent	the	standard-error.			
Striatal shape Shape	analysis	of	 the	caudate	and	putamen	did	not	reveal	any	differences	related	to	diagnosis,	nor	any	association	with	RBS	measures,	tNAA	or	glutamate	concentrations	(all	p-values	>0.05).		 	
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DISCUSSION 	Here	we	investigated	dorsal	striatal	structure	in	relation	to	levels	of	tNAA	and	glutamate	in	ASD	and	OCD	 children.	 In	 children	with	 ASD	 only,	 an	 association	 between	 left	 striatal	 volume	 and	both	 tNAA	 and	 glutamate	 concentrations	 was	 found.	 Volume	 and	 shape	 analyses	 showed	 no	structural	 changes	 of	 the	 striatum	 associated	 with	 ASD,	 OCD,	 compulsivity,	 or	 metabolite	concentrations.	 However,	we	 found	 hemispheric	 asymmetry	 (right>left)	 in	 striatal	 volume	 in	ASD	and	OCD	compared	with	controls,	while	 the	 two	disorder	groups	did	not	differ	 from	each	other.	This	asymmetry	was	not	associated	with	any	phenotypic	measures	in	either	of	the	groups	nor	with	total	brain	volume.	Total	NAA	concentrations	were	lower	in	the	left	striatum	of	children	with	ASD	compared	with	controls.	This	is	in	line	with	previous	studies	(e.g.	see	Ford	&	Crewther	2016).	In	the	same	group,	 striatal	 volume	 positively	 correlated	with	 tNAA	 concentrations.	 Studies	 of	 the	 relation	between	subcortical	volume	and	NAA	 in	other	disorders	(Padowski	et	al.	2014;	Coughlin	et	al.	2015)	 have	 suggested	 NAA	 to	 be	 an	 underlying	 measure	 of	 neuronal	 integrity.	 Since	 NAA	 is	mainly	 found	 in	neurons	 in	 the	brain	 (Urenjak	et	 al.	 1992),	 reductions	 in	 this	metabolite	may	point	 to	 decreased	 neuronal	 density	 within	 the	 region	 of	 interest.	 Compared	 with	 controls,	children	with	ASD	may	 therefore	have	reduced	neuronal	 integrity	 in	 the	striatum.	However,	 it	has	 also	 been	 suggested	 that	 reductions	 in	 NAA	 reflect	 impaired	 neuronal	 functioning	 rather	than	a	reduced	number	of	neurons	per	se	(Devito	et	al.	2007).	Glutamate	 and	 striatal	 volume	 were	 associated	 in	 ASD	 as	 well,	 but	 were	 only	 trend-significant	after	correcting	for	total	brain	volume.	Previous	studies,	for	instance	in	schizophrenia	(Plitman	 et	 al.	 2014),	 suggest	 that	 neuronal	 loss	 in	 the	 striatum	 may	 be	 the	 result	 of	excitotoxicity	 (Engelsen,	 1986;	 Choi,	 1988)	 caused	 by	 increased	 afferent	 glutamatergic	projections	 from	 the	 prefrontal	 cortex.	 Here,	 we	 found	 a	 positive	 relation	 between	 both	glutamate	 and	 striatal	 volume	 and	 tNAA	 and	 striatal	 volume	 in	 children	 with	 ASD,	 which	contradicts	 this	 hypothesis	 of	 excitotoxicity.	Glutamate	 as	measured	with	MRS,	 however,	 does	not	 only	 reflect	 glutamate	 as	 a	 neurotransmitter	 (Govindaraju	 et	 al.	 2000),	 which	 may	 be	responsible	 for	excitotoxicity,	but	also	glial	and	metabolic	concentrations.	Glutamate	and	tNAA	concentrations	were	correlated	as	well,	confirming	an	earlier	report	(Devito	et	al.	2007)	and	is	suggested	to	be	a	marker	of	impairment	in	neuronal	metabolism.	Children	with	ASD	thus	show	possibly	impaired	neuronal	metabolism	in	the	striatum,	concomitant	with	alterations	in	volume.	Both	 ASD	 and	 OCD	 have	 been	 associated	 with	 striatal	 alterations	 before,	 but	 findings	have	 been	 inconsistent.	 In	 ASD,	 mainly	 increased	 volumes	 of	 caudate	 (Hollander	 et	 al.	 2005;	Voelbel	et	al.	2006;	Qiu	et	al.	2016)	and	putamen	(Sato	et	al.	2014)	have	been	found,	which	we	could	not	 replicate	here.	 In	OCD,	 the	 findings	have	been	 less	 consistent	 so	 far,	with	 increased	
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(Real	 et	 al.	 2016),	 decreased	 (Zarei	 et	 al.	 2011)	 and	 no	 differences	 (Szeszko	 et	 al.	 2004)	 in	striatal	volumes	observed,	mainly	with	a	focus	on	putamen.	Asymmetry	was	reported	in	controls	but	not	in	participants	with	ASD	in	one	study	(Hollander	et	al.	2005),	which	is	in	contrast	with	our	results.	The	previous	study,	however,	was	performed	in	a	small	sample	of	adults,	while	ours	included	a	paediatric	sample	with	a	restricted	age-range.	 Investigation	of	other	regions	 in	ASD	(Say	et	al.	2014)	showed	asymmetry	of	the	thalamus	compared	with	controls	as	well.	No	studies	in	 OCD	 have	 shown	 regional	 volumetric	 asymmetry	 before.	 The	 current	 finding	 of	 striatal	asymmetry,	which	was	present	 in	both	ASD	and	OCD,	has	not	been	reported	before	and	could	point	 to	 similarities	 in	 altered	 striatal	 structure	 in	 both	 disorders	within	 children.	 This	 cross-disorder	finding	needs	replication	in	an	independent	sample	but	may	provide	more	insight	into	the	 underlying	 neurobiology	 of	 both	 disorders,	 supporting	 the	 approach	 adopted	 by	 the	Research	Domain	Criteria	(RDoC	(Cuthbert	2014)).	Strengths	of	the	current	study	are	the	use	of	the	complementary	analyses	of	volume	and	in	 relation	 to	neuro-metabolites,	 the	 combination	of	 the	 two	disorder	groups	 in	one	 relatively	large	study	and	additional	approaches	investigating	shape	and	the	relation	between	the	striatal	volume	 asymmetry	 and	 phenotypic	measures.	 Additionally,	 combining	 volumetric	 and	 neuro-metabolite	data	gave	us	the	opportunity	to	more	specifically	investigate	underlying	mechanisms	of	 volume	 alterations	 in	 ASD	 and	OCD.	 There	were,	 however,	 also	 some	 limitations.	 First,	 the	OCD	 group	was	 smaller	 than	 the	ASD	 and	 control	 groups	 due	 to	 recruitment	 difficulties.	 This	resulted	 in	 less	 statistical	 power.	 Second,	 the	 groups	 were	 quite	 heterogeneous	 in	 terms	 of	medication-use	and	comorbidities,	although	the	results	remained	stable	after	removal	of	 these	participants.	Additionally,	 the	ASD	 group	 consisted	of	 only	high-functioning	ASD	patients.	Our	results	 are	 therefore	 not	 generalizable	 to	 all	 children	 with	 ASD.	 Third,	 our	 striatum	 voxel	contains	a	significant	amount	of	white	matter	(from	the	internal	capsule)	and	some	gray	matter	from	 the	 globus	 pallidus.	 We	 corrected	 for	 partial	 volumes	 to	 address	 the	 WM	 contribution,	however,	 it	 was	 not	 possible	 to	 eliminate	 the	 possible	 slight	 contribution	 from	 the	 globus	pallidus.	This	is	a	common	limitation	across	MRS	studies	given	the	size	and	shape	restrictions	of	voxels.	Last,	we	did	not	measure	metabolite	concentrations	from	the	striatum	bilaterally,	which	limits	us	 in	 further	 investigating	the	striatal	asymmetry	we	found	in	relation	to	the	metabolite	concentrations.	 Additionally,	 the	 striatal	 volume	 and	 the	MRS-voxel	 location	 are	 not	 perfectly	matched,	but	since	both	voxel	positioning	and	volumes	did	not	differ	between	the	groups,	 this	may	have	had	minimal	effects.	Using	multi-centre	data	was	both	a	strength	and	a	 limitation;	 it	allowed	 us	 to	 have	 a	 larger	 study	 sample	 but	 at	 the	 same	 time	 adds	 a	 lot	 of	 variance	 which	needed	to	be	accounted	for	in	our	analyses.	In	conclusion,	the	current	study	showed	that	glutamate	concentrations	and	lower	tNAA	levels	in	ASD	compared	with	controls	were	both	positively	associated	with	left	striatal	volume.	
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In	 addition,	we	 found	 asymmetry	 in	 striatal	 volume	 in	 children	with	 ASD	 and	OCD	 compared	with	controls,	which	was	not	region-specific.	These	results	need	replication	 in	an	 independent	sample,	but	nevertheless	provide	 insights	 in	 the	 involvement	of	NAA	and	glutamate	 in	 striatal	volume	in	ASD	and	the	overlap	in	asymmetry	in	striatal	volume	in	paediatric	ASD	and	OCD.							 	
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SUPPLEMENTARY MATERIAL CHAPTER 5 	Table	S1	Distribution	of	disorders	and	demographic	details	across	sites.	(ASD,	autism	spectrum	disorder;	OCD,	obsessive	compulsive	disorder).			 	 ASD	(n=54)	 OCD	(n=31)	 control	(n=56)	Nijmegen	(n=56)	 Age	 11.11	(1.31)	 	10.49	(1.43)	 10.42	(1.12)		 IQ	 105.17	(14.59)	 104.09	(16.41)	 110.40	(12.61)		 Sex,	m/f	 7/9	 12/8	 15/5	Utrecht	(n=32)	 Age	 10.16	(0.97)	 10.87	(1.32)	 10.35	(1.31)		 IQ	 109.90	(16.35)	 101.36	(11.31)	 110.74	(10.05)		 Sex,	m/f	 11/2	 0/3	 11/5	London	(n=25)	 Age	 10.35	(1.62)	 11.93	(2.17)	 10.14	(1.29)		 IQ	 109.70	(13.93)	 111.09	(18.79)	 113.63	(17.79)		 Sex,	m/f	 14/0	 2/3	 5/1	Mannheim	(n=28)	 Age	 11.30	(1.30)	 11.60	(1.88)	 10.71	(1.23)		 IQ	 111.38	(14.33)	 101.72	(4.06)	 113.07	(5.93)		 Sex,	m/f	 11/0	 1/2	 7/7		 	
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	Figure	S1	Spectral	fit	for	the	left	striatum	of	the	same	“travelling	head”	across	sites.	All	sites	show	a	good	spectral	 fit	 and	CRLB,	 S/N,	 and	 FWHM	values	within	 the	 range	 of	 good	quality.	 Although	 the	Nijmegen	spectrum	shows	high	FWHM,	the	S/N	is	highest	of	all	example	spectra.	Participants	with	a	FWHM	>	0.1	were	removed	from	analyses.	(CRLB,	Cramér-Rao	lower	bounds;	FWHM,	full-width	at	half-maximum;	S/N,	signal	to	noise	ratio).		 	
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	Figure	S2	N-Acetylaspartate	(NAA)	in	the	left	striatum	for	the	different	groups	(A)	and	separately	per	site	(B).	Note	the	similar	pattern	for	all	sites.	(ASD	=	autism	spectrum	disorder,	OCD	=	obsessive	compulsive	disorder).	The	error-bars	represent	the	standard-error.		 	
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		Figure	 S3	 Bilateral	 striatal	 volumes	 of	 the	 diagnostic	 groups	 across	 the	 different	 sites.	 The	main	 result	(increased	asymmetry	 in	ASD	and	OCD	compared	with	controls)	 is	 replicated	 for	 three	out	of	 four	sites	separately	 (ASD,	 autism	 spectrum	 disorder;	 OCD,	 obsessive	 compulsive	 disorder).	 The	 error	 bars	represent	the	standard-error.		 	
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		Figure	S4	Left	and	right	caudate	(A)	and	putamen	(B)	volume	for	each	group.	There	were	no	significant	differences	 across	 groups,	 hemispheres	 or	 their	 interaction	 when	 investigating	 the	 striatal	 areas	separately	 (ASD,	 autism	 spectrum	 disorder;	 OCD,	 obsessive	 compulsive	 disorder).	 The	 error	 bars	represent	the	standard-error.		 	
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	Figure	S5	Association	between	 striatal	N-Acetylaspartate	and	volume	 (β=-0.13,	 t=-0.90)	and	glutamate	and	volume	(β=0.86,	 t=0.59)	 in	controls	(panel	A	and	B)	and	 in	 the	OCD	group	(N-Acetylaspartate	and	volume:	 β=0.46,	 t=0.24;	 glutamate	 and	 volume:	 β=0.20,	 t=0.95)	 (panel	 C	 and	 D).	 No	 significant	associations	were	found.							
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CHAPTER 6 
 
Fronto-striatal glutamate in children with Tourette’s disorder and 
ADHD 																					Published	as:		Jilly	Naaijen*,	Natalie	J	Forde*	David	J	Lythgoe,	Sophie	EA	Akkermans	Thaira	JC	Openneer,	Andrea	Dietrich,	Marcel	P	Zwiers,	Pieter	J	Hoekstra#	&	Jan	K	Buitelaar#	(2016).	Fronto-striatal	glutamate	in	children	with	Tourette’s	disorder	and	ADHD.	Neuroimage	clinical,	13,	16-23.	*	shared	first	authorship,	#	shared	last	authorship	 	
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ABSTRACT 	Objective:	 Both	 Tourette’s	 disorder	 (TD)	 and	 attention-deficit/hyperactivity	 disorder	 (ADHD)	have	 been	 related	 to	 abnormalities	 in	 glutamatergic	 neurochemistry	 in	 the	 fronto-striatal	circuitry.	TD	and	ADHD	often	co-occur	and	the	neural	underpinnings	of	this	co-occurrence	have	been	insufficiently	investigated	in	prior	studies.		Method:	We	used	proton	magnetic	resonance	spectroscopy	(1H-MRS)	in	children	between	8-12	years	of	age	(TD	n=15,	ADHD	n=39,	TD+ADHD	n=29,	and	healthy	controls	n=53)	as	an	in	vivo	method	 of	 evaluating	 glutamate	 concentrations	 in	 the	 fronto-striatal	 circuit.	 Spectra	 were	collected	 on	 a	 3	 Tesla	 Siemens	 scanner	 from	 two	 voxels	 in	 each	 participant:	 the	 anterior	cingulate	cortex	(ACC)	and	the	 left	dorsal	striatum.	LC-model	was	used	to	process	spectra	and	generate	 glutamate	 concentrations	 in	 institutional	 units.	 A	 one-way	 analysis	 of	 variance	 was	performed	to	determine	significant	effects	of	diagnostic	group	on	glutamate	concentrations.	Results:	We	 did	 not	 find	 any	 group	 differences	 in	 glutamate	 concentrations	 in	 either	 the	 ACC	(F(3,132)=0.97,	p=0.41)	or	striatum	(F(3,121)=0.59,	p=0.62).	Furthermore,	variation	 in	glutamate	concentration	 in	 these	 regions	 was	 unrelated	 to	 age,	 sex,	 medication	 use,	 IQ,	 tic,	 or	 ADHD	severity.	Obsessive-compulsive	(OC)	symptoms	were	positively	correlated	with	ACC	glutamate	concentration	within	the	participants	with	TD	(rho=0.35,	puncorrected=0.02).	Conclusion:	We	found	no	evidence	for	glutamatergic	neuropathology	in	TD	or	ADHD	within	the	fronto-striatal	 circuits.	 However,	 the	 correlation	 of	 OC-symptoms	 with	 ACC	 glutamate	concentrations	 suggests	 that	 altered	 glutamatergic	 transmission	 is	 involved	 in	 OC-symptoms	within	TD,	but	this	needs	further	investigation.	
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INTRODUCTION 	Tourette’s	 disorder	 (TD)	 and	 attention-deficit/hyperactivity	 disorder	 (ADHD)	 are	 early	 onset	neurodevelopmental	 disorders	 affecting	 approximately	 1%	 (Robertson	 2008)	 and	 5%	(Polanczyk	et	al.	2007)	of	children	and	adolescents,	respectively.	While	TD	 is	characterized	by	the	 presence	 of	 motor	 and	 vocal	 tics	 (American	 Psychiatric	 Association	 2013)	 there	 are	 also	psychiatric	 comorbidities	 present	 in	 up	 to	 86%	 of	 those	 with	 TD	 during	 their	 lifetime	(Hirschtritt	 et	al.	2015).	ADHD	 is	 the	most	 common,	occurring	 in	approximately	40%	of	 cases	(Rickards	 2011)	 and	 even	 more	 TD	 patients	 have	 ADHD	 symptoms	 that	 do	 not	 meet	 the	threshold	for	diagnosis	(Robertson	2000).	Conversely,	the	presence	of	tics	within	patients	with	ADHD	has	been	 estimated	 at	 20%	 (Roessner	 et	 al.	 2007).	ADHD	 itself	 is	 characterized	by	 age	inappropriate	 inattention	 and/or	 hyperactivity/impulsivity	 leading	 to	 impaired	 functioning	(American	Psychiatric	Association	2013).	Both	disorders	have	been	associated	with	abnormalities	in	fronto-striatal	circuits	(Mink	2006;	Leisman	and	Melillo	2013),	although	the	overlap	in	conditions	has	confounded	research	to	date.	 Structural	 and	 functional	 neuroimaging	 studies	 have	 reported	 alterations	 in	 the	 caudate	nuclei,	 putamen,	 and	 anterior	 cingulate	 cortex	 (ACC)	 in	TD	 (Peterson	 et	 al.	 2003;	Ganos	 et	 al.	2013)	and	ADHD	(Nakao	et	al.	2011;	Frodl	and	Skokauskas	2012;	Hart	et	al.	2013)	relative	 to	controls,	although	not	always	consistently.	It	has	been	proposed	that	excitatory	abnormalities	in	the	striatum	cause	erroneous	inhibition	of	neurons	in	the	globus	pallidus	(GP)	internus,	which	in	turn	leads	to	disinhibition	of	prefrontal	neurons	which	results	in	tic	phenomena	(Albin	and	Mink	2006).	These	 striatal	 abnormalities	may	also	underlie	 the	high	 rate	of	 comorbidity	with	other	disorders,	 like	ADHD	and	obsessive	compulsive	disorder	(OCD)	(Hirschtritt	et	al.	2015)	due	to	the	aberrant	integrative	interplay	of	different	fronto-striatal	circuits	including	connections	with	the	 ACC	 (Mink	 2001;	 Albin	 and	Mink	 2006).	 Dopamine	 dysfunction	within	 the	 fronto-striatal	circuit	 has	 long	 been	 considered	 the	 primary	 cause	 of	 tics	 (Singer	 et	 al.	 1982)	 and	 has	 been	related	 to	 difficulties	 with	 attention	 and	 impulsivity	 (Swanson	 et	 al.	 2007).	 However,	 as	glutamatergic,	GABAergic,	serotonergic,	cholinergic,	and	opioid	as	well	as	dopaminergic	systems	all	 operate	 within	 the	 fronto-striatal	 circuits	 it	 is	 plausible	 that	 multiple	 neurotransmitter	systems	 may	 be	 involved	 in	 TD	 and	 ADHD	 (Singer	 et	 al.	 2010).	 Glutamate	 is	 the	 primary	excitatory	 neurotransmitter	 found	 in	 the	 brain	 (Monaghan	 et	 al.	 1985;	 Pittenger	 et	 al.	 2011),	essential	in	fronto-striatal	transmission	and	often	co-transmitted	with	dopamine	(Chuhma	et	al.	2009).	Post-mortem	analysis	of	a	small	number	of	brains	from	people	who	had	TD	corroborate	the	view	that	glutamate	is	involved	in	TD	as	reduced	levels	of	glutamate	were	seen	in	the	GP	and	substantia	nigra	of	the	TD	brains	compared	to	control	brains	(Anderson	et	al.	1992).	
	150		
Additional	 insights	 into	 the	underlying	neurobiology	of	TD	and	ADHD	can	be	 found	by	investigating	brain	neurochemistry.	This	 can	be	achieved	by	using	proton	magnetic	 resonance	spectroscopy	(1H-MRS)	which	allows	 for	non-invasive	 in	vivo	quantification	of	 specific	neuro-metabolites.	 There	 have	 been	 just	 four	MRS	 studies	 of	 TD	 to	 date,	 three	 of	which	 focused	 on	GABA	concentrations	either	 in	the	primary	and	secondary	motor	areas	(Draper	et	al.	2014)	or	the	sensory	motor	cortex	(Tinaz	et	al.	2014;	Puts	et	al.	2015).	DeVito	and	colleagues	(DeVito	et	al.	2005)	on	 the	other	hand	 investigated	multiple	neurochemicals	 including	Glx,	 the	combined	signal	 from	 glutamatergic	 compounds	 (Glu	 +	 Gln),	 within	multiple	 regions;	 premotor	 cortex,	caudate	nucleus,	putamen	and	 thalamus	with	a	3	Tesla	 scanner	 in	a	 sample	of	25	 (male	only)	children	and	adolescents	with	TD	in	comparison	to	controls.	No	group	differences	were	seen	in	Glx	in	any	of	the	regions.	Within	the	putamen	lower	creatine	(Cre)	levels	bilaterally	and	lower	N-acetyl	 aspartate	 and	 choline	 in	 the	 left	 putamen	 were	 found.	 Reduced	 Cre	 bilaterally	 in	 the	caudate	nucleus	was	also	seen	but	this	did	not	reach	significance.	Many	more	MRS	studies	of	disorders	related	 to	TD,	such	as	ADHD	and	OCD,	have	been	conducted.	For	a	review	of	these	studies	in	ADHD,	OCD	and	autism	spectrum	disorder	(ASD)	see	(Naaijen	 et	 al.	 2015).	 However,	 findings	 were	 inconsistent,	 plagued	 by	 heterogeneous	methodologies,	 sample	 selection	 (i.e.,	 child	 or	 adult,	 inclusion	 or	 exclusion	 of	 comorbidities),	voxel	placement,	and	often	 inadequate	 field	strengths	 to	distinguish	glutamate	 from	glutamine	(Naaijen	et	al.	2015).	Despite	these	issues	the	review	tentatively	summarized	increased	striatal	Glx	levels	are	associated	with	both	ADHD	and	OCD	and	increased	ACC	Glx	levels	with	paediatric	ADHD.		 In	 the	current	 study	we	assessed	a	 large	number	of	 children	between	 the	ages	of	8-12	years	which	 allowed	us	 to	 focus	 on	 a	 group	where	 tics	 are	most	 frequently	 observed	 and	not	limit	ourselves	to	the	subset	of	patients	whose	tics	persist	 into	adulthood	(Bloch	and	Leckman	2009).	 Furthermore	we	directly	 addressed	 the	 confounds	of	 comorbidity	 rampant	 in	previous	studies	 by	 including	 a	 TD+ADHD	 group	 in	 addition	 to	 ADHD,	 TD,	 and	 healthy	 control	 (HC)	groups.	 Based	 on	 previous	 findings	 in	 childhood	 ADHD	 (Naaijen	 et	 al.	 2015),	 we	 expected	increased	 glutamate	 concentrations	 in	 both	 regions	 of	 interest.	 This	 is	 the	 first	 study	 to	investigate	 fronto-striatal	 glutamate	 in	 children	 with	 TD.	 Given	 the	 theory	 that	 excitatory	abnormalities	 in	 the	 striatum	 result	 in	 tics,	 we	 expected	 to	 observe	 raised	 glutamate	 in	 the	striatum	of	TD	patients.			  
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METHOD 	
Participants Participants	 with	 TD	 and/or	 ADHD:	 TD	 with/without	 ADHD	 n=60,	 ADHD	 without	 TD	 n=60	were	 recruited	 via	 child	 and	 adolescent	 psychiatry	 departments	 and	 patient	 associations	throughout	 the	 Netherlands,	 while	 healthy	 controls	 (HC;	 n=60)	 were	 found	 mainly	 through	schools.	The	final	numbers	included	for	analysis	(i.e.	with	usable	data)	can	be	found	in	section	3.1	and	Table	1	(n=136	for	the	ACC	and	n=125	for	the	striatum).	Written	informed	consent	was	provided	 by	 the	 parents/guardians	 of	 all	 participants	 and	 written	 assent	 was	 also	 given	 by	participants	who	were	12	years	of	 age.	This	 study	was	 approved	by	 the	 regional	 ethics	board	(CMO	Regio	Arnhem-Nijmegen,	numbers:	NL42004.091.12	&	NL48377.091.14).	Inclusion	criteria	 for	all	participants	 included	being	aged	8-12	years,	 IQ>70,	Caucasian	decent,	 no	 previous	 head	 injuries	 or	 neurological	 disorders,	 no	 contra	 indications	 for	 MRI	assessment,	 and	 no	major	 physical	 illness.	 Inclusion	 criteria	 for	 ADHD	 and	 TD	were	meeting	DSM-5	 criteria	 for	 these	 disorders.	 Those	 with	 sub-threshold	 ADHD	 (Kiddie	 Schedule	 for	Affective	Disorders	and	Schizophrenia	(K-SADS	(Kaufman	et	al.	1997))	score	of	4	or	5	on	either	subscale)	 were	 also	 included.	 Persistent	 Motor	 or	 Vocal	 Tic	 Disorder	 (Motor	 type)	 was	 also	allowed	for	the	TD	group.	Common	psychiatric	comorbidities	like	oppositional	defiant	disorder	were	not	excluded.	Within	the	TD	group,	ADHD,	and	OCD	were	not	excluded,	while	in	the	ADHD	group	those	with	tics	and/or	OCD	were	excluded.	Within	the	HC	group	no	psychiatric	disorders	were	 allowed,	 as	 determined	 by	 screening	 questionnaires	 (Child	 Behaviour	 CheckList	 [CBCL]	and	Teacher	Report	Form	[TRF]	(Bordin	et	al.	2013)).	Subjects	were	divided	 into	 four	groups;	HC,	 TD,	 ADHD,	 and	 TD+ADHD,	 see	 Table	 1	 for	 demographics.	 Participants	 were	 required	 to	refrain	 from	 consuming	 caffeine	 on	 the	 day	 of	 testing.	Medications	 for	 tics	were	 continued	 as	normal	while	stimulant	medication	was	withheld	for	48	hours	before	testing.		
Phenotypic information TD	diagnosis	was	confirmed,	and	tic	severity	rated,	by	diagnostic	interview	with	parent(s)	and	child	 present	 using	 the	 Yale	 Global	 Tic	 Severity	 Scale	 (YGTSS	 (Leckman	 et	 al.	 1989)).	 To	determine	the	presence	of	ADHD	and/or	other	psychiatric	disorders	the	K-SADS	(Kaufman	et	al.	1997)	 interview	 was	 administered	 to	 the	 parent(s).	 All	 interviews	 were	 conducted	 by	experienced	researchers	who	were	trained	and	overseen	by	a	child-	and	adolescent	psychiatrist	(JKB).	 The	 screening	 module	 was	 used,	 followed	 if	 needed	 by	 disorder-specific	 modules.	 If	participants	 screened	 positive	 for	 possible	 OCD	 the	 Children’s	 Yale-Brown	 Obsessive	Compulsive	 Scale	 (CY-BOCS	 (Scahill	 et	 al.	 1997))	 was	 administered	 with	 both	 parent(s)	 and	
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child	present.	The	CY-BOCS	interview	was	conducted	with	each	participant	of	the	TD	group	due	to	the	relatedness	of	symptoms	and	common	co-occurance	of	OCD	and	TD.			 Full-scale	 IQ	 was	 estimated	 by	 four	 subtests	 of	 the	 Wechsler	 Intelligence	 Scale	 for	Children-III	 (WISC-III	 (Wechsler	 2002)):	 Vocabulary,	 Similarities,	 Block	 design,	 and	 Picture	completion.	Questionnaires	were	further	used	to	assess	phenotypic	traits.	The	Conners’	Parent	Rating	 Scale	 –	Revised	Long	 version	 (CPRS-RL	 (Conners	 et	 al.	 1997))	was	used	 to	 rate	ADHD	severity.	Additional	questionnaires	were	used	to	assess	the	presence	of	autistic	symptoms	and	compulsive	 behaviours;	 the	 Children’s	 Social	 Behavioural	 Questionnaire	 (CSBQ	 (Luteijn	 et	 al.	2000))	 and	 Repetitive	 Behaviour	 Scale	 (RBS-R	 (Lam	 and	 Aman	 2007)).	 Information	 about	medication	 history	 was	 gathered	 from	 parental	 report	 which	 has	 previously	 been	 shown	 to	correlate	well	with	pharmacy	records	(Kuriyan	et	al.	2014).	Interviews	on	psychiatric	symptoms	were	conducted	about	an	unmedicated	period.			
 T1-weighted MRI acquisition All	MRI	datasets	were	acquired	on	the	same	3T	Siemens	Prisma	(Siemens,	Erlangen,	Germany)	scanner	 located	 in	 the	 Donders	 Institute	 for	 Brain,	 Cognition	 and	 Behaviour,	 Nijmegen,	 the	Netherlands.	 T1-weighted	 anatomical	 images	 were	 acquired	 with	 a	 transversal,	 3D	magnetization	 prepared	 rapid	 gradient	 echo	 (MPRAGE)	 parallel	 imaging	 sequence	 with	 the	following	parameters:	TR	=	2300	ms,	TE	=	2.98	ms,	TI	=	900	ms,	FoV	=	256	mm,	slice	thickness	=	 1.20	mm,	 Flip	 angle	 9	 degrees,	 in	 plane	 resolution	=	 1.0×1.0	mm,	 acceleration	 factor	=	 2,	acquisition	time	=	5:30	min.	Each	participant	also	had	their	head	stabilized	with	cushions	during	scanning	and	had	a	piece	of	tape	across	their	foreheads	to	help	awareness	of	possible	movement	while	 scanning.	 All	 participants	 were	 first	 familiarized	 with	 the	 MRI	 procedure	 in	 a	 mock	scanner	where	the	importance	of	lying	still	was	explained.			
MRS acquisition Proton	 spectra	 were	 acquired	 using	 a	 point	 resolved	 spectroscopy	 (PRESS)	 sequence	 in	 two	regions	of	interest,	with	chemically	selective	suppression	(CHESS)	water	suppression	(Haase	et	al.	1985).	A	single	8	cm3	voxel	was	centred	on	the	midline	covering	the	pregenual	ACC	anterior	and	slightly	superior	to	the	genu	of	the	corpus	callosum	(TR	=	3000	ms,	TE	=	30	ms,	number	of	averages	 =	 96,	 bandwidth	 =	 5	 kHz,	 number	 of	 points	 =	 4096).	 A	 second,	 similar	 voxel	 was	located	 in	 the	 left	 dorsal	 striatum	 covering	 the	 caudate	 nucleus	 and	 putamen.	 Unsuppressed	water	 reference	 spectra	 (16	 averages)	were	 also	 acquired	 as	part	 of	 the	 standard	 acquisition.	See	 Figure	 1	 for	 location	 of	 the	 voxels	 and	 an	 example	 spectrum.	 Both	 voxels	were	 placed	 to	include	a	maximum	amount	of	grey	matter	and	a	minimum	amount	of	cerebrospinal	fluid	(CSF).	
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T1-weighted	 images	 were	 used	 for	 voxel	 placement	 and	 later	 for	 tissue	 segmentation	 during	processing.	Acquisition	time	was	six	minutes	per	voxel.				
		Figure	1	Location	of	the	two	voxels	are	shown	on	a	T1-weighted	anatomical	image	for	the	pregenual	ACC	including	 an	 example	 spectrum	 (top)	 and	 the	 left	 dorsal	 striatum	 including	 an	 example	 spectrum	(bottom).	Peaks	corresponding	 to	 individual	metabolites	are	highlighted.	The	 thin	black	 line	 represents	the	frequency-domain	data,	the	red	line	is	the	LCModel	fit.	In	the	top	panel	the	residuals	are	plotted	(the	data	minus	 the	 fit).	 (Cho,	Choline;	Cre,	Creatine;	Gln,	Glutamine;	Glu.	Glutamate;	Glx,	Glu+Gln;	mI,	Myo-inositol;	NAA,	N-Acetylaspartate).				  
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Processing LCModel,	version	V6.03-0I	(Provencher	1993;	Provencher	2001),	was	used	to	conduct	spectral	analysis.	LCModel	uses	a	linear	combination	of	simulated	or	in	vitro	metabolite	solution	spectra	as	a	reference	to	identify	and	quantify	the	major	resonance	of	in	vivo	spectra.			 Water	 referenced	 metabolite	 concentrations	 were	 automatically	 calculated	 in	institutional	units	(i.u.).	Institutional	units	are	presented	since	we	did	not	correct	for	the	T1	and	T2	relaxation	times	of	the	metabolites	or	the	T1	relaxation	time	of	water.	The	T2	of	tissue	water	was	corrected	for	assuming	the	signal	had	decayed	by	30%	at	the	echo	time	(Lu	et	al.	2005).	No	correction	 was	 made	 for	 the	 T2	 decay	 of	 metabolites.	 In	 addition,	 there	 are	 other	 scanner-dependent	factors	that	can	affect	the	absolute	scaling	(e.g.,	details	of	coil	combination),	such	that	metabolite	 concentrations	measured	 in	 i.u.	 are	 preferred	 over	 attempting	 to	 scale	 to	 absolute	concentrations	 in	 millimolar	 (mM).	 The	 unified	 segmentation	 procedure	 within	 the	 VBM8	toolbox	of	SPM8	(Statistical	Parametric	Mapping	release	8,	London,	UK)	was	used	to	process	the	T1	 images	 and	 produce	 grey	 matter	 (GM),	 white	 matter	 (WM),	 and	 CSF	 probability	 maps.	Spectroscopy	voxels	were	mapped	onto	 these	maps	 to	provide	 the	partial	volume	of	GM,	WM,	and	CSF	within	each	spectroscopy	voxel	(fGM,	fWM,	and	fCSF),	and	to	allow	for	group	comparisons	of	 the	 placement	 of	 the	 spectroscopy	 voxels.	 Additionally,	 to	 correct	 for	 differing	 amounts	 of	water	 in	 each	 tissue	 and	 for	 partial	 volume	 effects	 we	 corrected	 individual	 metabolite	concentrations	for	water	concentrations	with	the	following	formula	(Gasparovic	et	al.	2006):		 ÑÖÜáàâäãÜÖåçééèåêèë = ÑÖÜáàâäãÜÖéíì ∗ 43300 ∗ ïñó + 35880 ∗ ïòó + 55556 ∗ ïôöõ35880 ∗ (1/(1 − ïôöõ)		where	 43300,	 35880,	 and	 55556	 are	 the	 water	 concentrations	 in	 mM	 for	 GM,	 WM,	 and	 CSF	(Ernst	et	al.	1993),	respectively,	as	described	by	the	LCModel	manual	(Provencher	2014).	These	concentrations	 correspond	 to	 77.9,	 64.4	 and	 100%,	 respectively,	 assuming	 that	 CSF	 is	 pure	water	(Ernst	et	al.	1993).	This	includes	a	correction	for	the	fraction	of	the	MRS	voxel	occupied	by	CSF,	 along	with	 corrections	 for	 the	water	 concentration	 in	each	of	 the	 tissue	 types.	The	 factor	35880	 in	 the	 denominator	 is	 included	 since	 the	 initial	 LCModel	 analysis	 was	 carried	 out	assuming	the	voxel	was	pure	WM.		
Quality control Statistical	 analyses	 were	 restricted	 to	 spectra	 with	 linewidth	 (full-width	 at	 half-maximum;	FWHM)	 ≤0.1	 ppm,	 Cramér-Rao	 lower	 bounds	 (CRLB)	 ≤20%,	 signal	 to	 noise	 ratio	 ≥5	 or	corrected	 glutamate	 concentrations	 less	 than	 two	 standard	 deviations	 from	 the	 mean.	Furthermore,	 anatomical	 scan	 quality	 was	 visually	 checked	 as	 these	 were	 used	 for	 voxel	
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placement	and	tissue	segmentation.	Fifteen	participants	were	excluded	from	both	analyses	due	to	poor	structural	scan	quality.	A	 further	seven	spectra	 from	the	ACC	(n=136)	and	20	spectra	from	the	striatal	analyses	(n=125)	were	excluded	based	on	spectral	quality.	 In	addition	to	the	exclusion	of	those	with	≥20%	CRLB	values,	we	investigated	group	differences	in	CRLBs	to	verify	that	possible	differences	in	glutamate	levels	were	not	due	to	differences	in	CRLBs	(Kreis	2015).		
Statistics Statistical	 analyses	 were	 conducted	 with	 the	 R	 statistical	 program	 (R	 Core	 Team	 2013).	Differences	 between	 the	 four	 groups	 in	 categorical	measures	were	 tested	with	 Pearson’s	 chi-squared	tests.	Group	differences	in	continuous	measures	were	assessed	with	a	one	way	analysis	of	variance	(ANOVA)	or	Welch	Two	Sample	t-test	if	assumptions	of	homogeneity	of	variance	and	normality	 of	 distributions	 were	met	 (p>0.05	 in	 Bartlett	 test	 of	 homogeneity	 of	 variance	 and	Shapiro-Wilk	 normality	 test).	 If	 these	 assumptions	 were	 violated	 a	 non-parametric	 Kruskal-Wallis	 rank	 sum	 test	 was	 used.	 ADHD	 severity	 was	 only	 tested	 between	 the	 ADHD	 and	TD+ADHD	 group.	 Similarly	 measures	 related	 to	 tics	 and	 OC-symptoms	 were	 only	 tested	between	the	TD	and	TD+ADHD	groups.		 Group	differences	in	voxel	tissue	composition	and	spectral	quality	were	assessed	with	a	ANOVA.	 Group	 differences	 in	 glutamate	 were	 analysed	 first	 with	 age	 and	 sex	 included	 as	covariates.	These	covariates	were	removed	from	analysis	as	they	did	not	significantly	contribute	to	 the	 model.	 This	 resulted	 in	 the	 use	 of	 an	 ANOVA	 followed	 if	 appropriate	 by	 Bonferroni	corrected	 post-hoc	 pairwise	 t-tests.	 The	 influence	 of	 IQ,	 ADHD	 severity,	 ASD	 symptoms,	repetitive	and	compulsive	behaviours,	and	medication	status	were	also	examined	by	inclusion	in	an	ANCOVA.	Correlations	between	glutamate	levels	and	phenotypic	measures	of	those	with	TD	(tic	severity,	age	of	onset	and	duration	since	 tic	onset,	and	OC-symptoms)	were	assessed	with	Pearson’s	correlation	tests	if	normally	distributed	or	Spearman’s	rank	correlation	rho	test	if	not.	Tests	were	then	Bonferroni	corrected	for	multiple	comparisons.	In	the	supplementary	material	we	added	the	same	analysis	for	Glx.		 	
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RESULTS 	
Demographics MR	spectra	were	acquired	for	a	total	of	162	of	the	original	180	participants.	Three	participants	from	 the	ADHD	group	were	 found	not	 to	 have	ADHD	 (K-SADS	<4	 in	 both	 subscales)	 and	one	presented	with	tics	but	did	not	meet	criteria	for	TD	or	Chronic	Motor	Tic	disorder	(CMT).	These	four	 participants	 were	 thereafter	 excluded	 from	 analysis.	 Due	 to	 spectral	 or	 segmentation	quality	 concerns	 22	 spectra	 were	 excluded	 from	 the	 ACC	 analysis	 (n=136)	 and	 35	 from	 the	striatal	 analysis	 (n=125).	 The	 TD	 group	 was	 subdivided	 into	 those	 that	 also	 had	 ADHD	(TD+ADHD;	 n=29,	 27	 for	 the	 ACC	 and	 striatal	 analyses,	 respectively)	 and	 those	 that	 did	 not	(TD;	n=15,	17	 for	 the	ACC	and	striatal	analyses,	respectively).	Participants	with	sub-threshold	ADHD	were	 included	 in	 either	 the	ADHD	group	or	 the	TD+ADHD	group	 if	 comorbid	with	TD.	Details	of	the	groups	used	for	analysis	of	the	ACC	are	reported	in	Table	1	(n=136).				 	
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Table	1	Demographic	description	of	participants	included	in	the	ACC	analysis.				 Control	(n=53)	 TD		(n=15)	 ADHD	(n=39)	 TD+ADHD	(n=29)	 Test	statistic	 p-value	Age	years,	mean	(SD)	 10.0(1.0)	 10.4(1.2)	 10.7(1.2)	 10.7(1.6)	 K-W	χ2=2.98	 0.40	Sex,	m/f	 38/15	 13/2	 21/18	 25/4	 χ2=10.70	 0.01*	aIQ,	mean	(SD)	Range	 109(11),	86	–	133	 105(12),	81	–	126	 103(13),	71	–	137	 106(11),	85	–	124	 F=2.47	 0.06	Handed,	r/l	 48/5	 14/1	 36/3	 25/4	 χ2=0.90	 0.82	bADHD	severity,	mean	(SD)	 T=45.5(4.9)		I=45.5(6.0)		H=46.1(3.7)	 T=51.7(7.0)		I=50.9(8.2)	H=52.2(8.5)		 T=71.9(9.7)		I=69.3(10.0)		H=71.2(11.1)	 T=68.7(9.1)	I=65.2(9.8)	H=70.0(10.4)	 t=1.37	t=1.69	t=-0.44	 0.18†	0.10†	0.66†	CSBQ	core	autism	score,	mean	(SD)	 1.42(1.89)	 9.53(10.58)	 12.46(7.78)	 17.66(9.40)	 	 	RBS	compulsivity	score,	mean	(SD)	
0.09(0.35)	 1.67(1.59)		 0.69(1.24)	 2.55(3.00)	 	 	
cTic	dx,	n	 -	 TD=14	
CMT=1	 -	 TD=29	 	 	cTic	severity,	mean	(SD)	 -	 T=20.4(7.9)	M=13.6(4.3)	V=6.8(4.7)	 -	 T=20.8(9.2)	M=13.1(5.5)	V=7.7(5.7)	 t=-0.13	t=0.33	K-W	χ2=0.22	
0.89	0.75	0.64	
cAge	tic	onset	years,	mean	(SD)	 -	 5.3(1.7)	 -	 5.7(1.7)	 t=-0.75	 0.46	cDuration	since	tic	onset	years,	mean	(SD)	 -	 5.0(1.8)	 -	 5.0(2.0)	 t=0.06	 0.95	dOCD	dx,	n	 -	 3	 -	 6	 	 	dOC-symptoms,	mean	(SD)	 -	 8.47(8.6)	 -	 6.75(8.4)	 K-W	χ
2	=0.78	 0.38	
eMedication		Stimulant	Strattera	Antipsychotic	Clonidine	
-	 	0	0	2	0	
	24	1	1	0	
	9	0	7	2	
	 	
aIQ	 estimated	 from	 a	 subtest	 of	 the	Wechsler	 Intelligence	 Scale	 for	 Children-III	 (WISC-III(Wechsler	 2002))	 rating.	bADHD	severity	ratings	reflect	T-scores	from	the	Conners’	Parent	Rating	Scale	–	Revised	Long	version	(Conners	et	al.	1997).	cTic	diagnosis	and	severity	were	determined	and	rated	with	the	Yale	Global	Tic	Severity	Scale	(Leckman	et	al.	1989).	Tic	severity	is	reported	excluding	impairment	score.	dOCD	diagnosis	was	determined	as	a	total-score	of	≥16	on	the	Children’s	Yale-Brown	Obsessive	Compulsive	Scale	(Scahill	et	al.	1997).	 eCurrent	medication	status,	determined	from	parental	report	of	current	and	previous	medication	use.	†Statistics	refer	to	an	ADHD	versus	TD+ADHD	contrast.	*p<0.05,	 **p<0.01.	 ADHD,	 attention-deficit/hyperactivity	 disorder;	 CSBQ,	 Children’s	 Social	 Behavioural	Questionnaire;	CMT,	Chronic	Motor	Tic;	dx,	diagnosis;	H,	hyperactive;	I,	inattentive;	C,	combined;	K-W,	Kruskal-Wallis;	M,	motor;	m/f,	male/female;	OCD,	Obsessive	Compulsive	Disorder;	r/l,	right/left;	RBS,	Repetitive	Behaviour	Scale;	SD,	standard	deviation;	t,	Welch	Two	sample	t-test;	T,	total;	TD,	Tourette’s	disorder;	V,	vocal.			
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Analysis	of	the	striatum	included	fewer	participants	(n=125)	due	to	exclusion	based	on	spectral	quality	 (n=22).	This	did	not	 significantly	 alter	 the	demographic	distributions	between	groups	(n=48,	17,	33,	and	27	for	the	HC,	TD,	ADHD,	and	TD+ADHD	groups,	respectively)	regarding	age	(K-W	 χ2=1.64,	 p=0.65),	 sex	 (χ2=8.09,	 p=0.04),	 IQ	 (F(3,117)=2.25,	 p=0.09)	 and	 handedness	(χ2=0.82,	 p=0.84).	 ADHD	 severity	 between	 the	ADHD	 and	TD+ADHD	groups	 differed	 slightly	but	 not	 significantly	 with	 respect	 to	 total	 and	 inattentive	 scores	 (t=1.90,	 p=0.06;	 t=1.84,	p=0.07;	t=0.99,	p=0.33	for	total,	 inattentive,	and	hyperactive	CPRS	scores,	respectively)	while	tic	 severity	 (t=0.31,	 p=0.76;	 t=-0.54,	 p=0.59;	K-W	 χ2=~0,	 p=0.99	 for	 total,	motor,	 and	 vocal	YGTSS	scores	respectively)	and	OC-symptoms	(K-W	χ2=1.52,	p=0.22)	remained	similar	between	the	TD	and	TD+ADHD	groups.		Age	 of	 tic	 onset	 (t=-0.51,	 p=0.62)	 and	duration	 since	 tic	 onset	 (t=-0.06,	 p=0.95)	did	not	differ	 significantly	 between	 the	 TD	 and	 the	 TD+ADHD	 group.	 For	 both	 analyses	 sex	 was	 not	balanced	between	groups,	mainly	due	 to	a	 low	number	of	girls	with	TD	having	been	 included.	This	reflects	the	proportionately	fewer	girls	affected	by	TD	compared	to	boys.(Robertson	2015)	Sex	was	included	in	the	model	to	account	for	this	imbalance,	however,	it	was	found	not	to	affect	the	model	significantly	and	was	therefore	subsequently	removed.		
Spectral quality Groups	 did	 not	 differ	 significantly	 in	 mean	 voxel	 percentage	 GM,	 WM	 or	 CSF	 in	 either	 ACC	(F(3,132)=0.30,	p=0.83,	F(3,132)=0.61,	p=0.61	and	F(3,132)=0.26,	p=0.85,	respectively)	or	striatum	(F(3,121)=1.77,	p=0.16,	F(3,121)=1.77,	p=0.16	and	F(3,121)=1.73,	p=0.16,	 respectively).	 In	 the	ACC	voxel	across	all	groups	the	tissue	percentages	were:	GM	70	(7)%,	WM	11	(2)%	and	CSF	18	(7)%.	For	the	striatal	voxel	these	were	GM	58	(7)%,	WM	42	(7)%	and	CSF	1	(1)%.		To	verify	 that	 the	spectral	quality	did	not	differ	between	 the	groups,	we	compared	 the	CRLB	estimated	 standard	deviations	 in	both	of	 the	voxels,	using	a	one-way	ANOVA	across	 the	four	 groups.	 CRLB’s	 did	 not	 differ	 between	 groups	 in	 the	 ACC	 (F(3,132)=1.35,	 p=0.26)	 or	 the	striatum	 (F(3,121)=0.37,	 p=0.77).	 Furthermore	 all	 CRLB’s	were	 in	 the	 range	 3-7%	SD,	 all	 SNRs	were	>	20	and	all	FWHM	were	 in	 the	 range	of	0.02-0.09	reflecting	overall	good	quality	of	 the	ACC	spectrum	in	all	four	groups.	For	the	striatum,	CRLB’s	were	in	the	range	5-17%,	SNR	were	>	11	and	FWHM	were	in	the	range	of	0.04-0.09.				  
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ACC Age	and	sex	had	no	significant	influence	on	the	ANCOVA	model	and	were	subsequently	excluded.	There	 was	 no	 group	 difference	 in	 corrected	 glutamate	 levels	 ANOVA	 (F(3,	 132)=0.97,	 p=0.41,	Figure	2).	There	was	no	influence	of	 IQ	(p=0.61),	 total	CPRS	ADHD	severity	T-score	(p=0.56),	inattentive	 CPRS	 T-score	 (p=0.70),	 hyperactive	 CPRS	 T-score	 (p=0.48),	 CSBQ	 core	 autism	symptom-score	(p=0.64)	or	RBS	compulsivity	score	(p=0.92).	Current	medication	use	showed	no	 significant	 effect	 on	 glutamate	 levels	 when	 any	 current	 medication	 (p=0.65),	 current	stimulant	medication	(p=0.28)	or	current	antipsychotic	medication	(p=0.56)	were	investigated.		There	were	no	correlations	in	those	with	tics	between	corrected	glutamate	concentrations	and	tic	severity	(total	p=0.77,	motor	p=0.40,	vocal	p=0.53),	duration	since	(p=0.38)	or	age	of	onset	(p=0.16).	 A	 significant	 positive	 correlation	 (rho=0.35)	 between	 ACC	 glutamate	 and	 CY-BOCS	total	score	(p=0.02)	was	found.	This	correlation	was	also	present	for	the	obsessions	(rho=0.30,	p=0.045)	 and	 compulsions	 (rho=0.31,	 p=0.04)	 severity	 scales	 separately.	 However,	 the	 two	subscales	were	highly	correlated	(rho=0.55,	p<0.001).	However,	none	of	the	correlations	with	glutamate	 concentration	 survived	 correction	 for	 multiple	 comparisons	 (12	 correlation	analyses).	 The	 analysis	 was	 limited	 to	 the	 participants	 that	 were	 administered	 the	 CY-BOCS	(n=44,	all	with	TD).		
Striatum Similarly	 for	 the	 striatal	 analysis	 there	were	 no	 significant	 effects	 of	 age	 or	 sex	 on	 glutamate	levels.	Group	analysis	revealed	no	difference	in	striatal	corrected	glutamate	levels	(F(3,	121)=0.59,	p=0.62,	 Figure	 2).	 Again	 there	was	 no	 influence	 of	 IQ	 (p=0.63),	 total	 CPRS	ADHD	 severity	T-score	 (p=0.78),	 inattentive	CPRS	T-score	 (p=0.80),	hyperactive	CPRS	T-score	 (p=0.75),	CSBQ	core	autism	symptom	score	(p=0.37),	RBS	compulsivity	score	(p=0.25)	or	current	medication	use	 (any	 p=0.73,	 stimulant	 p=0.80	 or	 antipsychotic	 p=0.06).	 There	 were	 no	 correlations	between	corrected	glutamate	concentrations	and	tic	severity	(total	p=0.34,	motor	p=0.46	vocal	p=0.22),	duration	since	(p=0.19)	or	age	of	onset	(p=0.08).	There	was	no	association	between	glutamate	and	CY-BOCS	total	score	(rho=-0.25,	p=0.11).		
Glx There	were	 also	 no	 group	 differences	 in	 Glx	 concentration	 in	 either	 the	ACC	 or	 striatum	 (see	supplementary	material	for	details).		 	
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	Figure	 2	 Glutamate	 concentrations	 per	 group	 in	 the	 anterior	 cingulate	 cortex	 (ACC)	 and	 striatum.	 No	group	differences	in	glutamate	levels	were	seen.	Error	bars	represent	the	standard	error.	(ACC,	anterior	cingulate	cortex;	ADHD,	attention-deficit/hyperactivity	disorder;	i.u.,	institutional	units).				
		Figure	3	Correlation	of	ACC	glutamate	concentration	with	obsessive-compulsive	symptoms	(CY-BOCS	total	score)	 in	 participants	 with	 Tourette’s	 disorder.	 The	 line	 represents	 the	 total	 fit-line.	 (ACC,	 anterior	cingulate	cortex;	CYBOCS,	Children’s	Yale-Brown	Obsessive	Compulsive	Scale;	i.u.,	institutional	units).			  
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DISCUSSION 	This	is	the	first	study	to	investigate	glutamate	concentrations	in	both	TD	and	ADHD	together.	We	found	no	group	differences	 in	ACC	or	 left	 striatal	glutamate	concentrations.	The	 findings	were	not	 confounded	 by	 any	 demographic	 differences	 between	 the	 groups,	 spectral	 quality,	medication	 use	 or	 OC-symptoms.	 Glutamate	 levels	 in	 the	 ACC	 correlated	 with	 OC-symptoms	within	 the	 participants	with	 TD	 (n=44)	 but	 did	 not	 relate	 to	 either	 tic	 or	 ADHD	measures	 of	severity.		Only	one	previous	study	examined	glutamate	concentrations	 in	TD	by	 investigating	the	combined	Glx	signal	in	children	and	adolescents	and	they	were	unable	to	find	Glx	differences	in	the	 brain	 regions	 investigated.	 In	 corroboration	 with	 results	 presented	 here	 (both	 Glx	 and	glutamate	 analyses)	 they	 found	 no	 difference	 in	 the	 putamen	 but	 unfortunately	 did	 not	 also	examine	 the	 ACC	 (DeVito	 et	 al.	 2005).	 Previous	 studies	 did,	 however,	 suggest	 glutamate	involvement	 in	 TD	 although	 the	 nature	 of	 this	 is	 yet	 unclear	 with	 both	 hyper-	 and	 hypo-glutamatergic	 states	 being	 hypothesized	 (Singer	 et	 al.	 2010).	 For	 instance,	 a	 post-mortem	analysis	by	Anderson	and	colleagues	(Anderson	et	al.	1992)	showed	reduced	glutamate	levels	in	the	 GP	 and	 substantia	 nigra	 of	 those	 with	 TD,	 while	 a	 study	 investigating	 serum	 glutamate	concentrations	showed	 increased	 levels	 in	adult	TD	patients	compared	to	controls	(Janik	et	al.	2010).	Our	current	findings	do	not	support	the	hypothesis	of	glutamatergic	involvement	in	the	fronto-striatal	network	in	TD.	The	current	study	found	no	difference	in	those	with	ADHD	compared	to	healthy	controls	or	 any	 association	 between	 glutamate	 levels	 and	 ADHD	 severity	 scores	 in	 either	 the	 ACC	 or	striatum.	 Previous	 studies	 have	 been	 confounded	 by	 methodological	 issues	 but	 do	 appear	 to	show	 increased	 Glx	 levels	 in	 both	 these	 regions	 in	 paediatric	 ADHD	 compared	 to	 controls	(Naaijen	et	al.	2015),	an	observation	not	replicated	here,	and	reduced	striatal	Glx	in	adults	with	ADHD	 (Maltezos	 et	 al.	 2014).	 Associations	 with	 symptom	 severity	 have	 been	 reported	previously	 in	adults	with	ADHD	 in	which	negative	correlations	between	 inattentive	 symptoms	and	 glutamate-to-creatine	 ratios	 in	 the	ACC	 (Dramsdahl	 et	 al.	 2011)	or	Glx	 levels	 in	 the	basal	ganglia	(Maltezos	et	al.	2014)	were	reported.	However,	these	studies	were	performed	in	adults,	who	differ	in	both	ADHD	symptoms	(Polanczyk	et	al.	2007)	and	glutamate	levels	(Horska	et	al.	2002)	compared	to	children.		Possibly	 the	 most	 interesting	 finding	 of	 the	 current	 study,	 however,	 is	 the	 potential	positive	 correlation	between	ACC	glutamate	 levels	 and	OC-symptoms	within	participants	with	TD.	 The	 correlation	 was	 present	 also	 for	 both	 the	 obsessions	 and	 compulsions	 subscales	separately.	 This	 suggests	 the	 association	 with	 ACC	 glutamate	 concentration	 relates	 to	 the	severity	 of	 OC-symptoms	 irrespective	 of	 these	 dimensions.	 Elevated	 ACC	 glutamate	 may	 be	
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associated	with	cognitive	control	deficits	related	to	obsessions	and	compulsions	(Botvinick	et	al.	2004).	However,	these	findings	failed	to	survive	correction	for	multiple	comparisons	so	should	be	 interpreted	 with	 caution.	 Previous	 literature	 investigating	 associations	 with	 symptom	severity	 in	OCD	samples	have	also	shown	positive	correlations	with	glutamatergic	compounds.	For	 instance,	correlations	between	Glx	 levels	 in	dorsal	and	rostral	ACC	(Yücel	et	al.	2008)	and	caudate	 nucleus	 (Gnanavel	 et	 al.	 2014)	 and	 total	 symptom	 severity	 as	measured	 with	 the	 Y-BOCS	were	reported	before,	although	only	in	adult	samples.	Our	findings	should,	however,	only	be	 interpreted	 in	 relation	 to	 OC-symptoms	 within	 TD.	 No	 studies	 so	 far	 have	 examined	glutamatergic	compounds	in	childhood	TD	and	OCD	together.	Further	studies	are	required	to	see	if	 the	 current	 trend-findings	 extend	 to	 OC-symptoms	within	 paediatric	 OCD	 and	 across	 other	disorders	 that	 exhibit	 similar	 behaviours,	 such	 as	 ASD.	 Furthermore,	 this	 is	 a	 child	 sample	 of	participants	and	how	these	findings	relate	to	OC-symptoms	in	adult	TD	will	remain	unclear	until	further	research	is	conducted.		The	current	study	ranks	among	the	first	to	use	MRS	to	investigate	brain	neurochemical	concentrations	in	TD	and	is	the	very	first	to	investigate	glutamate	concentrations	in	both	TD	and	ADHD	 together.	However,	 the	 study	was	 limited	 by	 the	 small	 number	 of	 TD	 participants	who	presented	without	ADHD/sub-threshold	ADHD,	 these	 figures	are	 in	 line	with	what	 is	expected	given	the	high	comorbidity	rates	of	ADHD	in	TD	(Hirschtritt	et	al.	2015).	It	is	unlikely	that	this	significantly	hindered	the	study	as	our	null	findings	regarding	tics	and	ADHD	are	supported	by	the	 lack	of	 correlations	between	 symptom	severity	 and	glutamate	 levels.	These	 results	 should	not	be	extrapolated	to	adults	as	glutamate	concentrations	change	with	age	(Horska	et	al.	2002)	and	adult	ADHD	and	TD	may	well	constitute	specific	presentations	of	TD	and	ADHD	that	persist	from	childhood.	Many	participants	were	medicated,	which	may	alter	glutamate	levels.	However,	as	the	effect	of	current	medication	use	did	not	influence	glutamate	concentrations	in	either	the	ACC	or	striatum	medication	use	was	unlikely	to	have	confounded	our	results.	There	are	several	additional	 factors	 that	may	 influence	 glutamatergic	 signalling	 such	 as	 time	 of	 day,	 sleep,	 food	intake	etc.	for	which	we	unfortunately	could	not	control	(Yuen	et	al.	2009;	Zlotnik	et	al.	2011).	Future	 work	 is	 needed	 to	 confirm	 the	 influence	 of	 these	 factors.	 Most	 questionnaires	 were	answered	about	an	un-medicated	period,	however,	a	small	number	of	parents	opted	to	answer	about	a	medicated	period	as	they	were	more	familiar	with	this	behaviour,	this	may	have	led	to	inconsistent	measures	of	symptom	severity	in	a	few	cases.	Finally,	due	to	low	spatial	resolution	in	 MRS	 studies	 (i.e.	 large	 ROIs)	 it	 is	 difficult	 to	 determine	 regionally	 specific	 glutamatergic	alterations.	 This	 is	 particularly	 relevant	 for	 the	 striatum	 ROI,	 which	may	 contain	 functionally	independent	areas	with	regard	to	caudate	nucleus	and	putamen.	Further	investigation	should	be	undertaken	 to	 confirm	 the	 relation	 of	 OC-symptoms	 and	 glutamate	 concentrations	 in	 other	
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disorders	 (OCD,	 ASD)	 and	 also	 in	 adult	 cohorts	 to	 determine	 if	 the	 association	 within	 TD	 is	limited	to	children	with	TD	or	also	present	in	adult	TD.		 In	conclusion,	we	found	no	support	 for	alterations	 in	glutamatergic	transmission	in	the	fronto-striatal	circuit	of	children	with	either	ADHD,	TD	or	a	combined	diagnosis.	However,	 the	current	study	suggests	glutamatergic	alterations	in	the	ACC	in	relation	to	OC-symptoms	within	children	with	TD.				 	
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SUPPLEMENTARY MATERIAL CHAPTER 6 	
Glx Uncorrected	p-values	are	reported	below	for	Glx	analysis	in	the	ACC	and	striatum.	No	p-values	were	significant	following	correction	for	multiple	comparisons.			
ACC Age	and	sex	had	no	significant	influence	on	the	ANCOVA	model	and	were	subsequently	excluded.	There	was	no	group	difference	in	corrected	Glx	levels	ANOVA	(F(3,	132)=0.56,	p=0.64).	There	was	no	 influence	 of	 IQ	 (p=0.79),	 total	 CPRS	ADHD	 severity	 T-score	 (p=0.81),	 inattentive	 CPRS	T-score	(p=0.98),	hyperactive	CPRS	T-score	(p=0.55),	CSBQ	core	autism	symptom-score	(p=0.28)	or	RBS	compulsivity	score	(p=0.45).	Current	medication	use	showed	no	significant	effect	on	Glx	levels	when	any	current	medication	(p=0.89),	current	stimulant	medication	(p=0.47)	or	current	antipsychotic	medication	(p=0.46)	were	investigated.		There	were	no	correlations	in	those	with	tics	between	corrected	Glx	concentrations	and	tic	severity	(total	p=0.86,	motor	p=0.48,	vocal	p=0.70),	duration	since	(p=0.16)	or	age	of	onset	(p=0.07).	There	were	also	no	correlations	between	ACC	Glx	and	CY-BOCS	total	score	(p=0.35).	The	analysis	was	limited	to	the	participants	that	were	administered	the	CY-BOCS	(n=44,	all	with	TD).		
Striatum	Similarly	 for	 the	 striatal	 analysis	 there	were	 no	 significant	 effects	 of	 age	 or	 sex	 on	 Glx	 levels.	Group	 analysis	 revealed	 no	 difference	 in	 striatal	 corrected	 Glx	 levels	 (F(3,	 121)=2.58,	 p=0.06).	Again	 there	 was	 no	 influence	 of	 IQ	 (p=0.99),	 total	 CPRS	 ADHD	 severity	 T-score	 (p=0.57),	inattentive	 CPRS	 T-score	 (p=0.47),	 hyperactive	 CPRS	 T-score	 (p=0.79),	 CSBQ	 core	 autism	symptom	 score	 (p=0.78),	 RBS	 compulsivity	 score	 (p=0.66)	 or	 current	 medication	 use	 (any	p=0.52,	 stimulant	 p=0.77	 or	 antipsychotic	 p=0.08).	 There	 were	 no	 correlations	 between	corrected	 Glx	 concentrations	 and	 tic	 severity	 (total	 p=0.22,	 motor	 p=0.21	 vocal	 p=0.43),	duration	since	(p=0.30)	or	age	of	onset	(p=0.01).	There	was	no	association	between	Glx	and	CY-BOCS	total	score	(rho=-0.34,	p=0.02).		 	
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		Figure	 S1	 Glx	 concentrations	 per	 group	 in	 the	 anterior	 cingulate	 cortex	 (ACC)	 and	 striatum.	 No	 group	differences	 in	 glutamate	 levels	 were	 seen.	 Error	 bars	 represent	 the	 standard	 error.	 (ACC,	 anterior	cingulate	cortex;	ADHD,	attention-deficit/hyperactivity	disorder;	i.u.,	institutional	units).		 	
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CHAPTER 7 
 
Glutamatergic and GABAergic gene-sets in attention-
deficit/hyperactivity disorder: Association to overlapping traits in 
ADHD and autism 
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ABSTRACT 	Attention-deficit/hyperactivity	disorder	(ADHD)	and	autism	spectrum	disorders	(ASD)	often	co-occur.	 Both	 are	 highly	 heritable,	 but	 it	 has	 been	 difficult	 to	 discover	 genetic	 risk	 variants.	Glutamate	 and	GABA	 are	main	 excitatory	 and	 inhibitory	 neurotransmitters	 in	 the	 brain;	 their	balance	is	essential	for	proper	brain	development	and	functioning.	In	this	study	we	investigated	the	 role	 of	 glutamate	 and	 GABA	 genetics	 in	 ADHD	 severity,	 autism	 symptom	 severity,	 and	inhibitory	performance,	based	on	gene-set-analysis,	an	approach	to	investigate	multiple	genetic	variants	 simultaneously.	 Common	 variants	 within	 glutamatergic	 and	 GABAergic	 genes	 were	investigated	 using	 MAGMA	 software	 in	 an	 ADHD	 case-only	 sample	 (n=931),	 in	 which	 we	assessed	 ASD	 symptoms	 and	 response	 inhibition	 on	 a	 Stop	 task.	 Gene-set	 analysis	 for	 ADHD	symptom	 severity,	 divided	 into	 inattention	 and	 hyperactivity/impulsivity	 symptoms,	 autism	symptom	 severity,	 and	 inhibition	 were	 performed	 using	 principal	 component	 regression	analyses.	Subsequently,	gene-wide	association	analyses	were	performed.	The	glutamate	gene-set	showed	association	to	severity	of	hyperactivity/impulsivity	(p=0.00015)	and	autism	symptoms	(p=0.0000003).	 Association	 with	 inattention	 was	 nominally	 significant	 (p=0.012).	 The	association	 of	 glutamate	with	 hyperactivity/impulsivity	was	 robust	 to	 correcting	 for	 genome-wide	 association	 levels	 (p=0.009).	 The	 GABA	 gene-set	 showed	 significant	 association	 with	autism	severity	(p=0.005)	and	nominally	significant	association	with	inhibition	(p=0.034),	the	latter	also	when	compared	to	genome-wide	association	levels	(p=0.04).	None	of	single	gene	or	single	variant	associations	was	significant	on	their	own.	By	analyzing	multiple	genetic	variants	within	 candidate	 gene-sets	 together,	we	were	 able	 to	 find	 genetic	 associations	 supporting	 the	involvement	of	excitatory	and	inhibitory	neurotransmitter	systems	in	ADHD	and	ASD	symptom	severity	in	ADHD.		 	
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INTRODUCTION 	Attention-deficit/hyperactivity	 disorder	 (ADHD)	 is	 one	 of	 the	 most	 common	neurodevelopmental	 disorders,	 characterized	 by	 age-inappropriate	 inattentiveness	 and/or	increased	hyperactivity	and	impulsivity	(American	Psychiatric	Association.	2000).	ADHD	is	often	accompanied	 by	 comorbidities,	 one	 of	 them	 being	 autism	 spectrum	 disorder	 (ASD).	 ASD	 is	defined	by	 impaired	 communication	and	 social	 interaction	as	well	 as	 repetitive	 and	 restricted	behaviours	 and	 interests	 (American	Psychiatric	Association.	2000).	ADHD	and	ASD	 frequently	co-occur,	with	 the	presence	of	ADHD	within	ASD	 ranging	 from	30-80%,	while	 the	presence	of	ASD	in	ADHD	is	estimated	at	20-50%	(Ronald	et	al.	2008;	Rommelse	et	al.	2010).	Both	disorders	are	highly	heritable,	with	estimates	of	90%	for	ASD	and	around	76%	for	ADHD	(Pamplona	et	al.	2009;	van	Steijn	et	al.	2012;	Gaugler	et	al.	2014).	In	addition,	about	50-70%	of	the	contributing	genetic	factors	are	overlapping	between	ADHD	and	ASD	(Lichtenstein	et	al.	2010),	but	also	see	(Lee	et	al.	2013).	Despite	their	high	heritability,	finding	genetic	risk	variants	for	both	disorders	has	been	challenging	so	far.	Several	candidate	genes	have	been	associated	with	ADHD	and	ASD	symptoms	(Gizer	et	al.	2009;	Poelmans	et	al.	2011;	Poelmans	et	al.	2013;	Chiocchetti	et	al.	2014),	but	genome-wide	association	studies	(GWASs)	have	not	yielded	many	genome-wide	significance	findings	(Wang	et	al.	2009;	Poelmans	et	al.	2011;	Poelmans	et	al.	2013).	ADHD	and	ASD	are	very	heterogeneous	 and	 polygenic	 disorders,	 which	 may	 explain	 the	 difficulties	 in	 identifying	 the	underlying	 genetic	 factors	 (Rommelse	 et	 al.	 2011;	 Consortium	 2013).	 One	 characteristic	 that	ADHD	 and	 ASD	 have	 in	 common	 is	 impairments	 in	 behavioural	 inhibition	 (Chantiluke	 et	 al.	2015),	 for	 review	see	 (Wang	et	al.	2009).	This	overlapping	 trait	 in	both	disorders	 is	 linked	 to	deficits	 in	 fronto-striatal	 brain	 areas.	 Studying	 an	 overlapping	 trait	 in	 ADHD	 and	 ASD	 may	complement	 the	 search	 for	 genetic	 variants	 involved	 in	 the	disorders	 themselves	 (Glahn	et	 al.	2014).	 Glutamate	 is	the	most	abundant	excitatory	neurotransmitter	 in	the	human	brain	and	is	involved	 in	 many	 neuronal	 functions	 including	 synaptic	 transmission,	 neuronal	 migration,	excitability,	plasticity,	and	long-term	potentiation	(Pittenger	et	al.	2011).	Because	of	these	wide-ranging	 functions,	 altered	 glutamatergic	 neurotransmission	 has	 been	 implicated	 in	 many	different	nervous	system	processes	(Nakanishi	et	al.	1998).	Gamma-aminobutyric	acid	(GABA),	on	 the	 other	 hand,	 is	 the	 most	 abundant	 inhibitory	 neurotransmitter	 of	 the	 human	 brain	involved	in	long-range	signalling	responsible	for	inhibition	of	behaviour.	Both	neurotransmitters	are	involved	in	fronto-striatal	signalling,	related	to	the	dysfunctions	in	inhibition	seen	in	ADHD	and	ASD	(Rommelse	et	al.	2008;	Thakkar	et	al.	2008).		The	balance	between	glutamate	and	GABA	is	essential	for	proper	brain	development	and	functioning	 in	 these	 fronto-striatal	 circuits	 (Wu	 and	 Sun	 2014;	 Keunen	 et	 al.	 2015).	 The	
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pathophysiology	of	ASD	has	been	proposed	to	be	characterized	by	a	glutamate-GABA	imbalance	(Fatemi	2008).	Abnormalities	in	the	expression	of	glutamate	transporters,	GABA-A	and	GABA-B	receptors	have	been	shown	in	post-mortem	brains	of	patients	(Fatemi	et	al.	2009a;	Fatemi	et	al.	2009b).	In	addition,	clinical	trials	of	glutamate	receptor	antagonists	and	GABA	receptor	agonists	in	 Fragile	 X	 syndrome,	 which	 has	 many	 characteristics	 in	 common	 with	 ASD,	 have	 shown	improvement	 of	 social	 impairments	 (Berry-Kravis	 et	 al.	 2012).	 In	 ADHD,	 an	 imbalance	 in	glutamate	 and	 GABA	 signalling	 has	 not	 been	 reported	 before.	 MR	 spectroscopy	 studies	investigating	GABA	and	glutamate	 in	ADHD	have,	however,	 shown	decreased	prefrontal	GABA	levels	 in	 children,	 while	 in	 another	 study	 increased	 glutamatergic	 levels	 were	 found	 in	comparable	prefrontal	brain	 areas	 (MacMaster	 et	 al.	 2003;	Edden	et	 al.	 2012).	A	 recent	 study	showed	a	role	for	GABA	in	impulsivity	and	response	inhibition	(Silveri	et	al.	2013).	Additionally,	BOLD	activity	during	response	inhibition	has	been	related	to	striatal	glutamate	levels,	mediating	the	effect	of	dopamine	synthesis	on	inhibition	(Lorenz	et	al.	2015).		Genes	encoding	glutamate	and	GABA	receptors	and	transporters	are	candidate	genes	for	several	neuropsychiatric	disorders	 (Williams	et	 al.	2002;	Schizophrenia	Working	Group	of	 the	Psychiatric	 Genomics	 Consortium	 2014;	 Purkayastha	 et	 al.	 2015),	 including	 ADHD	 and	 ASD.	Deficits	in	inhibition	can	be	linked	to	fronto-striatal	deficits	in	glutamate	and	GABA	levels,	which	is	 consistent	with	 findings	 in	 ADHD	 and	 ASD	 showing	 altered	 glutamate	 and	 GABA	 signalling	(Naaijen	et	al.	2015).	Genetic	associations	have	been	 found	 for	several	candidate	genes	within	the	glutamatergic	system.	For	instance,	associations	have	been	found	for	variation	in	the	GRIN2B	gene	with	both	inattention	and	hyperactivity	symptoms	in	ADHD	(Dorval	et	al.	2007),	and	both	GRIN2A	 and	GRIN2B	 have	 been	 associated	with	 ASD	 (Yoo	 et	 al.	 2012).	 A	 genome-wide	 study	investigating	rare	variants	found	overrepresentation	of	variants	belonging	to	the	metabotropic	glutamate	receptor	genes	in	several	ADHD	cohorts	(Elia	et	al.	2012).	GABA	transporter	subtype	1	 (GAT1)	 gene	 knockout	 mice	 have	 been	 shown	 to	 have	 decreased	 attention	 and	 increased	impulsive	behaviour,	 relating	 this	 gene	 to	ADHD-symptomatology	 and	difficulties	 in	 inhibiting	impulses	(Yang	et	al.	2013b).	 In	addition,	mutations	 in	 the	GABA-A	receptor	subunit-encoding	genes	 GABRQ	 and	 GABRA3	 have	 been	 found	 in	 two	 different	 families	 with	 ASD	 (Piton	 et	 al.	2013).		Both	 ADHD	 and	 ASD	 are	 polygenic,	 with	 multiple	 genetic	 variants	 with	 small	 effects	assumed	 to	 play	 a	 role	 in	 a	 major	 part	 of	 the	 patient	 population.	 Identifying	 single	 genetic	variants	with	a	small	effect	size	can	be	challenging.	Considering	multiple	genetic	variants	within	the	same	analysis	can	potentially	increase	the	total	explained	phenotypic	variance	and	thereby	boost	 the	power	of	a	genetic	study.	Earlier	studies	on	cognitive	disorders	 focusing	on	multiple	variants	within	 the	same	gene	or	within	candidate	genetic	pathways	already	showed	potential	for	this	approach	(Walsh	et	al.	2008;	Bralten	et	al.	2011;	Bralten	et	al.	2013).	Additionally,	top-
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findings	 within	 genome-wide	 association	 studies	 of	 psychiatric	 disorders	 have	 been	 found	 to	converge	 onto	 common	 underlying	 biological	 processes,	 suggesting	 that	 multiple	 genetic	variants	within	 interacting	 sets	 of	 genes	 are	 involved	 in	 the	 aetiology	of	 psychiatric	disorders	(Stergiakouli	and	Thapar	2010;	Poelmans	et	al.	2011;	Poelmans	et	al.	2013;	Yang	et	al.	2013a).	In	 the	 present	 study	 we	 explored,	 whether	 genes	 for	 glutamate	 and	 GABA	neurotransmission	are	associated	with	ADHD	and	ASD	traits.	This	was	investigated	by	looking	at	the	 two	 symptom	dimensions	 hyperactivity/impulsivity	 and	 inattention	 of	 ADHD.	 In	 addition,	because	of	 the	evidence	of	a	genetic	overlap	between	ADHD	and	ASD	and	the	glutamate-GABA	imbalance	 hypothesis,	 we	 also	 investigated,	 whether	 these	 neurotransmission	 gene-sets	moderate	symptoms	of	ASD	within	an	ADHD	case-only	sample.	We	used	quantitative	measures	of	 ADHD	 and	 ASD	 symptom	 severity	 to	 characterize	 the	 disorders	 in	 terms	 of	 continuous	distributions	(Chabernaud	et	al.	2012).	Such	an	approach	may	help	to	better	take	into	account	the	heterogeneity	of	 the	disorders	as	well	 as	 the	extent	of	overlap	between	 them	(Castellanos	and	Tannock	2002;	Rommelse	et	 al.	 2011).	Complementary,	 because	of	 the	 common	deficit	 of	inhibitory	 control	 in	 ADHD	 and	 ASD	 and	 because	 of	 its	 regulation	 by	 fronto-striatal	glutamatergic	and	GABAergic	signalling,	we	also	investigated	in	a	subsample,	whether	the	genes	for	glutamate	and	GABA	neurotransmission	are	involved	in	 inhibitory	control.	We	made	use	of	the	stop-signal	reaction	time	(SSRT)	of	a	behavioural	response	inhibition	task,	which	is	related	to	 excitatory	 and	 inhibitory	 signalling	 in	 the	 fronto-striatal	 circuit.	 We	 investigated	 multiple	genetic	 variants	 within	 glutamatergic	 and	 GABAergic	 genes	 simultaneously	 using	 a	 gene-set	approach	 with	 the	 MAGMA	 software.	 Subsequently	 we	 investigated	 gene-wide	 associations	within	this	data	set.		
METHODS AND MATERIALS 	
Sample The	 present	 study	 is	 part	 of	 the	 International	Multi-centre	ADHD	Genetics	 (IMAGE)	 study,	 an	international	 collaborative	 study	 in	 7	 European	 countries	 (Belgium,	 Germany,	 Ireland,	 Spain,	Switzerland,	The	Netherlands,	and	the	United	Kingdom)	and	Israel	(Müller	et	al.	2011a;	Müller	et	 al.	 2011b).	 The	 IMAGE	 study	 was	 designed	 to	 identify	 genes	 that	 increase	 ADHD	susceptibility.	Participants	were	5	to	17	years	old	and	of	European	Caucasian	descent.	Exclusion	criteria	 included	an	 IQ	below	70,	 the	presence	of	a	classical	autism	diagnosis,	epilepsy,	known	neurological	 disorders,	 and	 any	 genetic	 or	 medical	 disorder	 associated	 with	 externalizing	behaviours	that	might	mimic	ADHD.	Details	of	the	IMAGE	sample	have	been	described	elsewhere	(Brookes	and	Faraone	2006).		
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ADHD symptom severity A	 semi-structured,	 standardized,	 investigator	 based	 interview	 (Parental	 Account	 of	 Children’s	Symptoms	(Taylor	1986))	and	questionnaires	(parent	and	teacher	Conners’	long-version	rating	scales	 (Conners	 1998)	 and	 parent	 and	 teacher	 strengths	 and	 difficulties	 questionnaires	(Goodman	 1997))	 were	 used	 to	 establish	 an	 ADHD	 diagnosis	 in	 children	 that	 were	 clinically	diagnosed	 previously	 (see	 Rommelse	 et	 al.,	 (Rommelse	 et	 al.	 2007))	 for	 the	 standardized	algorithm	that	was	applied	to	derive	the	DSM-IV	symptoms).	To	investigate	symptom	severity,	a	4-point	 scale	 was	 used	 for	 the	 questions	 of	 the	 subscales	 for	 inattention	 and	hyperactivity/impulsivity	 of	 the	 Conners	 parent	 rating	 scale.	 Severity	 was	 defined	 as	 the	summed	value	of	the	questions	per	subscale.		
Autism symptom severity Autism	 spectrum	 symptoms	were	 determined	 by	 administration	 of	 the	 Social	 Communication	Questionnaire	 (SCQ;	 (Lord	 et	 al.	 2000))	 filled	 in	 by	 the	 parents.	 This	 validated	 questionnaire	consists	 of	 40	 yes/no	 items	 determining	 autistic	 symptom	 severity	 based	 on	 the	 following	domains:	(i)	reciprocal	social	interaction,	(ii)	communication,	and	(iii)	restricted,	repetitive,	and	stereotyped	interests	and	patterns	of	behaviour.	Here,	the	score	(ranging	from	0	to	39)	was	used	as	 a	 continuous	 measure	 of	 autism	 symptom	 severity.	 Since	 a	 DSM-IV	 diagnosis	 of	 autistic	disorder	or	Asperger	 syndrome	was	an	exclusion	 criterion	 for	 the	 IMAGE	study	 (see	Sample),	the	autism	symptoms	could	not	exceed	the	threshold	for	clinical	diagnosis.		
Inhibition Response	 inhibition	 was	 measured	 using	 a	 Stop-task	 in	 which	 participants	 are	 required	 to	withhold	their	response	to	a	stop-signal	as	opposed	to	the	more	frequently	occurring	go-trials.	This	task	was	part	of	a	larger	neuropsychological	assessment	battery	used	in	the	Dutch	part	of	the	 IMAGE	 study	 (Rommelse	 et	 al.	 2008).	 The	 latency	 of	 the	 stop-process,	 the	 stop	 signal	reaction	 time	 (SSRT)	 is	 a	 reliable	 measure	 of	 inhibition,	 which	 has	 shown	 group	 differences	between	 ASD	 and	 ADHD	 cases	 compared	 to	 controls,	 while	 unaffected	 siblings	 showed	 an	intermediate	pattern	and	SSRT	correlates	between	siblings	(Rommelse	et	al.	2008).		
Genotyping Genome-wide	 genotyping	 of	 the	 IMAGE	 probands	 was	 performed	 as	 part	 of	 the	 Genetics	Association	 Information	 Network	 study	 using	 the	 Perlegen	 genotyping	 platform,	 described	previously	(Neale	et	al.	2008).	An	imputation	approach	was	used	with	the	Hapmap	II	release	22	dataset	 (Li	 et	 al.	 2010).	 The	 imputed	 data	 underwent	 quality	 control,	 in	which	 SNPs	with	 an	
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imputation	 score	 lower	 than	 0.5	 and	 minor	 allele	 frequency	 (MAF)	 lower	 than	 0.01	 were	excluded.	 After	 this	 step,	 2.182.904	 SNPs	 across	 the	 genome	 were	 retained,	 excluding	 the	 X-chromosome.	 	Selection	 of	 the	 glutamate	 (48	 genes)	 and	 GABA	 (36	 genes)	 gene-sets	 was	 based	 on	Ingenuity	Pathway	Analysis	software	(http://www.ingenuity.com).	This	is	a	frequently	updated	genetic	 database	 for	 genetic	 pathway	 analysis.	 Ingenuity	 generates	 these	 ‘canonical’	 pathways	based	on	experimental	evidence	from	the	scientific	literature	and	many	other	sources,	including	gene	 expression	 and	 gene	 annotation	 databases,	 to	 assign	 genes	 to	 different	 groups	 and	categories	of	functionally	related	genes.	We	selected	genes	that	are	known	to	have	a	distinct	role	in	 either	 glutamate	 or	 GABA	 signalling	 (see	 tables	 S1	 and	 S2	 and	 figure	 S1	 and	 S2	 for	 an	overview	of	genes	from	the	Ingenuity	Pathway	Analysis,	their	functions	and	which	of	those	were	included	 in	 the	 analysis).	 SNPs	 in	 all	 selected	 genes	were	 selected	 from	 the	quality-controlled	genome-wide	 dataset.	 As	 evidence	 suggests	 that	 genetic	 variants	 surrounding	 a	 gene	 can	influence	gene	expression,	we	extracted	a	second	set	of	SNPs	based	on	the	selected	genes	plus	a	100	 kilo	 base	 pair	 (kb)	 upstream	 and	 downstream	 flanking	 region	 (Veyrieras	 et	 al.	 2008;	Gherman	et	al.	2009;	Nicolae	et	al.	2010;	Pickrell	et	al.	2010).	Analyses	were	performed	for	the	SNPs	 within	 all	 genes	 only	 (no	 flanking)	 and	 for	 the	 SNPs	 within	 the	 genes	 plus	 the	 100	 kb	flanking	region.	Additionally,	we	investigated	association	with	genes	encoding	glutamate/GABA	receptors	and	transporters	only	because	of	their	most	central	role	in	neurotransmitter	signalling	(e.g.	Galvan	et	al.	2006).	In	this	way,	we	wanted	to	check	whether	our	results	are	mainly	driven	by	these	genes.		
Data analysis Association	 analysis	 to	 symptom	 severity	 was	 performed	 separately	 for	hyperactivity/impulsivity	 symptoms	 and	 inattention	 symptoms	 (n=931)	 and	 for	 autism	symptoms	 (n=922).	 Post-hoc	 to	 the	 analysis	 of	 association	 to	 symptoms,	 in	 a	 subsample	(n=162;	see	Table	1)	we	also	performed	association	analysis	of	behavioural	inhibition	with	the	glutamate	and	the	GABA	gene-sets,	to	investigate	potential	association	of	these	gene-sets	with	a	common	 trait	 in	 ADHD	 and	 ASD.	 All	 phenotypic	 variables	 were	 normalized	 using	 Blom	transformation	 (SPSS	 20;	 SPSS,	 Inc.,	 Chicago,	 Illinois).	 Gender	 and	 age	 were	 included	 as	covariates.	Associations	were	assessed	using	MAGMA	software	(Multi-marker	Analysis	of	GenoMic	Annotation,	http://ctglab.nl/software/magma	 (de	 Leeuw	 et	 al.	 2015)).	 To	 account	 for	 linkage	disequilibrium	(LD)	within	our	data,	we	used	a	principal	components	regression	model,	which	projects	 the	SNP	matrix	 for	 a	 gene	onto	principal	 components	 (PCs)	 and	 then	prunes	out	PCs	with	too	small	eigenvalues.	By	default	only	0.1%	of	the	variance	in	the	SNP	data	matrix	is	pruned	
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away.	The	 remaining	PCs	are	 then	used	as	predictors	 for	 the	phenotype	 in	a	 linear	 regression	model	to	calculate	a	gene-wide	p-value.		Subsequently	we	tested	whether	the	genes	 in	the	gene-set	were	 jointly	associated	with	the	phenotype.	This	 analysis	 consists	 of	 a	 self-contained	 test,	 examining	 association	of	 the	 set	with	 the	 phenotype	 under	 a	 null	 hypothesis	 of	 no	 effect.	 A	 competitive	 test	 can	 then	 be	performed	to	test,	whether	a	certain	gene-set	of	interest	is	more	strongly	still	associated	with	a	phenotype	 than	 all	 other	 genes	 in	 the	 genome,	 corrected	 for	 gene-size	 and	 density.	 In	 the	competitive	test	the	effect	of	the	gene-set	is	compared	to	the	background	signal	of	all	genes	that	are	not	in	your	gene-set.		Initial	 testing	 considered	 self-contained	 gene-set	 associations	 with	 the	 phenotypes	inattention	 severity,	 hyperactivity/impulsivity	 severity	 and	 autistic	 symptom	 severity.	 The	association	 to	 inhibition	 was	 performed	 post-hoc	 in	 a	 sub-sample,	 due	 to	 availability	 of	behavioural	 data	 only	 for	 a	 small	 group.	 These	 self-contained	 gene-set	 associations	 were	accompanied	by	another	gene-set	analysis	approach	 to	 investigate	whether	similar	results	can	be	 derived	 with	 a	 slightly	 different	 approach	 (Purcell	 et	 al.	 2007).	 PLINK	 uses	 association	statistics	 of	 observed	 and	 permuted	 data	 and	 compares	 the	 number	 of	 times	 the	 observed	summed	statistic	(of	single	SNP	associations	combined)	 is	smaller	than	the	permuted	summed	statistic,	which	results	in	an	empirical	p-value	of	association	with	a	certain	phenotype.	With	this	additional	 approach	we	want	 to	provide	additional	 support	 for	 the	presence	of	 an	association	with	the	phenotype	under	a	null-hypothesis	of	no	association.		Additionally,	competitive	tests	were	included,	and	gene-wide	and	single	SNP	associations	were	considered.	Because	of	the	correlations	between	the	phenotypic	variables,	corrections	for	multiple	 comparisons	 were	 based	 on	 the	 effective	 number	 of	 tests	 calculated	 by	 using	 the	eigenvalues	 of	 the	 correlation	 matrix.	 Taking	 the	 correlations	 into	 account,	 our	 number	 of	effective	 tests	 was	 2.5.	 For	 the	 gene-sets,	 a	 p-value	 of	 <0.01	 was	 considered	 statistically	significant	 (pcorrected=0.05/#gene-sets/#effective	 tests).	For	gene-wide	association,	a	p-value	of	0.0003	was	considered	statistically	significant	(pcorrected	=	0.05/#genes/#effective	tests).		
RESULTS 	Table	 1	 lists	 the	 general	 characteristics	 of	 the	 sample.	 Moderate	 correlations	 were	 found	between	the	 two	symptom-domains	of	ADHD	(r=.506,	p<0.01),	weak	correlations	were	 found	between	 hyperactivity/impulsivity	 symptom	 severity	 and	 autism	 symptom	 severity	 (r=.077,	p<0.05).	 No	 significant	 correlation	 was	 observed	 between	 inattention	 and	 autism	 symptom	severity	(r=-.006,	p=0.86).	Similarly,	no	significant	correlations	were	found	between	any	of	the	clinical	ADHD	or	autism	symptom	scores	and	the	SSRT	(r=-.008	to	.094,	all	p	values	>0.1).	
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The	 selection	 of	 glutamate	 and	GABA	 genes	 yielded	 a	 total	 of	 84	 genes	 (Table	 2.	 Four	genes	positioned	on	the	X	chromosome	(GRIA3	in	the	glutamate-set,	GABRA3,	GABRE,	GABRQ	in	the	 GABA-set)	 were	 not	 included	 in	 the	 analysis	 due	 to	 unavailability	 of	 the	 X-chromosome	variation	 in	 this	 sample.	 Dependent	 on	 whether	 flanking	 regions	 were	 included,	 the	glutamatergic	gene-set	included	42	(no	SNPs	in	CALML5,	GRIN1,	GRINA,	GRM2,	and	SLC7A7)	or	47	 genes,	 consisting	 of	 9287	 and	15466	 SNPs,	 respectively.	 For	GABA,	 the	 gene-set	without	 a	flanking	region	consisted	of	30	genes	and	3047	SNPs	(not	captured	were	GABARAP,	GABRD,	and	SLC32A21),	 while	 for	 the	 100	 kb	 condition	 the	 set	 consisted	 of	 33	 genes	 (7534	 SNPs).	 See	Supplemental	Tables	S1	and	S2	 for	SNPs	per	gene.	The	more	specific	association	analyses	 that	included	only	genes	encoding	for	glutamate/GABA	receptors	and	transporters	are	described	in	the	supplemental	material	(Table	S6).			Table	1	Demographic	characteristics	of	the	study	sample.		 Value	 N	Age:	y,	m	(SD)	 10,9	(2,8)	 946	Male:	%	 87,5	%	 946	Conners	parent	hyperactive/impulsive	T-scores:	mean,	median	(SD)	 78,67;	80	(10,67)	 931	Conners	parent	inattentive	T-scores:	mean,	median	(SD)	 71,08;	71	(9,62)	 931	Social	Communications	Questionnaire	total	scores:	mean,	median	(SD)	 8,33;	8	(6,11)	 922	Stop-signal	reaction	time	in	milliseconds:	mean,	median	(SD)	 299,23;	280,08	(92,54)	 162	y	=	years,	m	=	months,	SD	=	standard	deviation			 	
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Table	2	Glutamatergic	and	GABAergic	genes	selected	for	analysis.	Glutamate	genes	 	 GABA	genes	CALM1	 GRIA4	 GRIK5	 GRIN3B	 GRM5	 PICK1	 SLC1A2	 ABAT	 GABRA1	 GABRB2	 GABRP	 GPHN	 UBQLN1	CALML5b	 GRID1	 GRIN1b	 GRINAb	 GRM6	 SLC17A1	 SLC1A3	 ALDH5A1	 GABRA2	 GABRB3	 GABRQa	 NSF	 	CAMK4	 GRID2	 GRIN2A	 GRIP1	 GRM7	 SLC17A2	 SLC1A4	 ALDH9A1	 GABRA3a	 GABRDb	 GABRR1	 SLC32A1b	 	GLS	 GRIK1	 GRIN2B	 GRM1	 GRM8	 SLC17A6	 SLC1A6	 DNM1	 GABRA4	 GABREa	 GABRR2	 SLC6A1	 	GRIA1	 GRIK2	 GRIN2C	 GRM2b	 HOMER1	 SLC17A7b	 SLC1A7	 GABARAPb	 GABRA5	 GABRG1	 GABRR3	 SLC6A11	 	GRIA2	 GRIK3	 GRIN2D	 GRM3	 HOMER2	 SLC17A8	 SLC38A1	 GABBR1	 GABRA6	 GABRG2	 GAD1	 SLC6A12	 	GRIA3a	 GRIK4	 GRIN3A	 GRM4	 HOMER3	 SLC1A1	 	 GABBR2	 GABRB1	 GABRG3	 GAD2	 SLC6A13	 	a.	gene	positioned	on	the	X-chromosome.	b.	no	SNPs	for	analysis	when	no	flanking	region	was	used		 	
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Glutamate	As	 shown	 in	 Table	 3,	 the	 glutamate	 set	 showed	 a	 significant	 self-contained	 association	 with	autism	symptom	severity	(p=0.0000003)	and	with	hyperactivity/impulsivity	symptom	severity	(p=0.0000015).	 Association	 to	 inattention	 symptom	 severity	 was	 nominally	 significant	(p=0.012).	No	association	was	found	with	inhibition.	Although	with	higher	p-values,	the	results	from	 using	 PLINK	 revealed	 similar	 results	 for	 autism	 symptom	 severity	 (p=0.0013)	 and	hyperactivity/impulsivity	symptom	severity	(p=0.0014).	Single	gene	analyses	did	not	show	any	significant	associations	(Supplementary	table	S5	shows	the	list	of	included	genes	in	both	gene-sets	and	their	association	p-values).	In	addition,	no	associations	were	found	at	the	single	variant	level	(data	not	shown).			 The	 competitive	 tests	 did	 not	 show	 significant	 associations	 with	 autism	 symptom	severity	 and	 inattention	 severity	 (p=0.176	 and	 p=0.144,	 respectively).	Hyperactivity/impulsivity	symptom	severity	was	more	strongly	associated	with	the	glutamate-set	 compared	 to	 the	 genes	 that	 were	 not	 in	 the	 gene-set	 (p=0.009),	 which	 also	 survived	correction	for	multiple	comparisons.		 When	using	a	100	kb	flanking	region	to	capture	regulatory	gene	elements,	associations	between	 autism	 symptom	 severity	 and	 hyperactivity/impulsivity	 symptom	 severity	 remained	significant	(p=0.0000009	and	p=0.00061,	respectively).			
GABA The	GABA	gene-set	was	significantly	associated	with	autism	symptom	severity	(p=0.0054),	but	not	with	ADHD	symptom	severity	or	 inhibition.	The	 results	 from	using	PLINK	results	 also	did	not	 show	 any	 association	 between	 ADHD	 symptoms	 and	 the	 GABA	 gene-set,	 although	 the	association	with	autism	symptom	severity	was	 significant	at	 trend-level	 (p=0.05).	 Single	gene	analyses	 did	 not	 show	 any	 significant	 associations	 (Supplementary	 table	 S5	 shows	 the	 list	 of	included	 genes	 in	 both	 gene-sets	 and	 their	 association	 p-values).	 In	 addition,	 no	 associations	were	found	at	the	single	variant	level	(data	not	shown).	The	competitive	test	for	association	with	autism	symptom	severity	did	not	reach	significance	(p=0.465).		When	 using	 a	 100	 kb	 flanking	 region,	 the	 association	 with	 autism	 symptom	 severity	remained	 significant	 (p=0.00077).	 The	 competitive	 test	 was	 also	 not	 significant	 (p=0.769).	Table	 3	 summarizes	 the	 results.	 Although	 non-significant	 when	 no	 flanking	 region	 was	 used,	nominally	significant	associations	were	 found	with	 inhibition	 in	 the	analysis	 including	the	100	kb	flanking	region	(p=0.034).	Also	the	competitive	test	was	nominally	significant	(p=0.04),	but	did	not	survive	correction	for	multiple	comparisons.			 	
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Table	3	Association	result	p-values	for	the	discovery	and	post-hoc	tests.			 GLUTAMATE	 Self-contained	 Competitive		 0	kb	 100	kb	 0	kb	 100	kb	Autism	symptom	severity	 .0000003	 .0000009	 .176	 .873	Hyperactivity/impulsivity	severity	 .0000015	 .00061	 .009		 .263	Inattention	severity	 .012	 .163	 .144	 .566		 	 	 	 	Inhibition	(SSRT)	 .064	 .201	 .037	 .345			 GABA	 Self-contained	 Competitive		 0	kb	 100	kb	 0	kb	 100	kb	Autism	symptom	severity	 .005	 .00077	 .465	 .769	Hyperactivity/impulsivity	severity	 .200	 .276	 .473	 .618	Inattention	severity	 .475	 .115	 .827	 .434		 	 	 	 	Inhibition	(SSRT)	 .15	 .034	 .178	 .040	Bold	 marking	 indicates	 significance	 after	 correction	 for	 multiple	 comparisons	 (Meff-corrected,	 adjusted	 p-value=	0.01);	italics	show	nominally	significant	associations.			  
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DISCUSSION 	The	present	study	investigated	the	combined	effects	of	multiple	genetic	variants	from	glutamate	and	 GABA	 gene-sets	 with	 ADHD	 and	 ASD	 traits.	 The	 glutamate	 gene-set	 was	 associated	 with	hyperactivity/impulsivity	 symptoms	 and	 autism	 symptoms.	 The	 association	 with	hyperactivity/impulsivity	 symptoms	 was	 robust	 even	 when	 comparing	 to	 the	 rest	 of	 the	genome.	 For	 GABA,	 an	 association	 with	 autism	 symptoms	 was	 found,	 but	 not	 with	 ADHD	symptom	severity.	The	association	with	autism	symptoms	was	not	significantly	larger	than	the	background	signal	in	genes	that	do	not	fall	in	the	GABA	gene-set.	This	indicates	that	although	the	comparison	of	this	gene-set	to	no	effect	showed	that	the	gene-set	might	capture	genetic	variants	associated	 to	 autism	 symptoms,	 this	 effect	 was	 not	 larger	 than	 the	 background	 effect	 that	captures	the	polygenic	nature	of	this	trait.	Although	a	significant	competitive	test	could	reflect	a	lack	in	power,	it	indicates	that	GABA	is	not	more	associated	than	random	gene-sets	capturing	a	part	 of	 the	 polygenic	 nature	 of	 this	 trait.	 GABA	 was	 furthermore	 nominally	 significantly	associated	with	inhibition,	both	in	the	self-contained	and	the	competitive	test.	Single	genes	did	not	 show	 significant	 association,	 suggesting	 that	 the	 results	 are	 due	 to	 the	 combined	 effect	 of	genetic	variants	across	several	genes.	This	 is	 the	 first	 study	 to	 study	 the	 combined	 effects	 of	 glutamate	 and	 GABA	 genes	 on	ADHD	 and	 ASD	 quantitative	 traits.	 Previous	 investigations	 of	 other	 traits,	 which	 included	multiple	 variants	 in	 one	 analysis,	 have	 been	 mainly	 performed	 based	 only	 on	 so-called	 self-contained	tests.	Recent	research	suggests	that	such	tests	might	harbor	the	risk	of	type	I	errors,	because	 in	 polygenic	 phenotypes	 one	will	 probably	 never	 find	 no	 association.	MAGMA	 allows	performance	 of	 competitive	 testing	 in	 addition	 to	 self-contained	 testing,	 in	 which	 it	 can	 be	investigated,	whether	 the	observed	association	 is	 likely	 to	be	more	 specific	 to	 this	gene-set	 (a	significant	 test)	 or	 whether	 association	 to	 other	 genes	 or	 sets	 is	 equally	 possible	 (a	 non-significant	 test)	by	comparing	 it	 to	 the	effect	of	genes	that	are	not	part	of	your	gene-set	 in	the	entire	 genome.	A	 significant	 competitive	 test	 emphasizes	 the	 association	 to	be	 specific	 for	 the	tested	gene-set	while	a	non-significant	test	indicates	that	the	self-contained	test	captured	a	part	of	the	polygenic	nature	of	the	trait.	Self-contained	tests	do	not	take	into	account	the	overall	level	of	association	across	the	genome,	the	gene	size	(the	number	of	principal	components,	or	SNPs)	and	 the	 gene	 density.	 Competitive	 testing	 therefore	 has	 more	 merits.	 Nevertheless,	 self-contained	testing	indicates	whether	a	signal	is	present	in	the	aggregated	set	of	SNPs	(genes)	in	the	selected	set	compared	with	a	signal	being	present	by	random	chance.	The	 strongest	 finding	 in	 the	 current	 study	 was	 for	 the	 association	 of	 glutamate	signalling-linked	 genetic	 variation	 with	 hyperactivity/impulsivity	 symptoms	 both	 in	 the	 self-contained	 and	 the	 competitive	 tests.	 This	 finding	 is	 in	 accordance	 with	 results	 from	 studies	
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showing	 increased	 glutamate	 release	 from	 the	 prefrontal	 cortex	 PFC	 of	 the	 spontaneously	hypertensive	 rat	 (SHR),	 an	 animal	 model	 showing	 ADHD-like	 hyperactive	 behaviour	 (Russell	2011;	Burton	and	Fletcher	2012;	Miller	et	al.	2014).	Furthermore,	glutamate	has	been	related	to	self-reported	impulsivity	 in	other	disorders	(Hoerst	et	al.	2010)	and	to	 impulsive	behaviour	in	healthy	 adolescents	 (Gleich	 et	 al.	 2014).	 Previous	 work	 in	 the	 same	 sample	 showed	 that	 the	hyperactivity/impulsivity	domain	of	ADHD	was	also	associated	with	candidate	genetic	pathways	involved	in	dopamine/norepinephrine	and	serotonin	signalling	(Bralten	et	al.	2013)	suggesting	that	 several	 genetic	 mechanisms	 contribute	 to	 hyperactivity/impulsivity	 symptoms	 in	 ADHD	cases.		 Inattention	is	not	only	a	characteristic	of	ADHD	but	is	present	in	ASD	as	well	(Christakou	et	al.	2013).	The	(near	significant)	association	of	the	glutamate	set	with	inattention	but	not	with	previous	candidate	pathways	suggests	a	potential	involvement	of	glutamatergic	mechanisms	in	inattention.	This	needs	to	be	further	investigated.	In	our	study,	we	investigated	the	genetic	underpinnings	of	autism	symptom	severity	 in	an	 ADHD-only	 sample.	 ASD	 itself	 has	 been	 linked	 to	 glutamate	 and	 GABA	 by	 the	excitatory/inhibitory	 imbalance	hypothesis	(Fatemi	2008).	The	observed	association	of	autism	symptoms	with	the	glutamate	gene-set	–	in	addition	to	the	hyperactivity/impulsivity	domain	of	ADHD	 –	 is	 consistent	 with	 candidate	 gene	 studies	 showing	 association	 of	 glutamatergic	 gene	variation	 with	 both	 ADHD	 (Dorval	 et	 al.	 2007)	 and	 ASD	 (Yoo	 et	 al.	 2012).	 Our	 results	 thus	provide	 an	 interesting	 hypothesis	 for	 further	 investigating	 the	 underlying	 mechanism	 of	 the	overlap	between	ADHD	and	ASD.	Although	symptoms	co-exist	across	ADHD	and	ASD,	only	weak	correlations	 were	 found	 between	 hyperactivity/impulsivity	 symptom	 severity	 and	 ASD	symptoms,	 and	 no	 correlations	 were	 found	 between	 inattention	 and	 ASD	 symptoms.	 The	associations	 found	 in	 the	current	 study	could	 therefore	not	be	 related	 to	 the	mere	correlation	between	the	studied	phenotypes.		The	 GABA	 gene-set	 was	 also	 significantly	 associated	 with	 autism	 symptom	 severity,	which	can	be	related	to	previous	findings	of	GABA	involvement	in	ASD	(Piton	et	al.	2013;	Yang	et	al.	2013b).	Competitive	testing	did	not	reveal	a	significant	association	of	the	GABA	gene-set,	but	this	might	be	due	to	the	low	power	of	this	test	(see	above).	The	excitatory/inhibitory	imbalance	theory	on	autism	was	supported	by	the	fact	that	both	glutamate	and	GABA	showed	association	with	 autism	 symptom	 severity.	 A	 previous	 study	 indicated	 excitatory/inhibitory	 gene-expression	to	be	disturbed	in	ASD,	suggesting	reduction	of	the	expression	of	inhibitory	genes	to	be	more	pronounced	compared	to	genes	related	to	excitation	and	that	the	imbalance	was	mainly	due	to	GABA	disturbances	(van	de	Lagemaat	et	al.	2014).	 In	the	present	study,	GABA	was	also	nominal	significantly	related	to	inhibition,	which	might	also	reflect	this	disturbance	of	inhibitory	
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factors.	 This	 finding	 is	 limited	 by	 the	 small	 sample	 size	 used	 and	 needs	 replication	 in	independent	dataset	before	any	conclusions	can	be	drawn.		The	 current	 results	 support	 the	hypothesis	 that	 glutamate	and	possibly	 also	GABA	are	associated	 with	 ADHD	 and	 ASD	 traits.	 Unfortunately,	 current	 gene-set	 association	 analysis	cannot	reveal	 the	direction	of	 the	observed	effects,	or	whether	the	directions	for	the	gene-sets	differ,	which	makes	the	interpretation	of	the	findings	in	this	study	more	difficult	in	terms	of	the	imbalance	 theory	 for	 GABA	 and	 glutamate.	 In	 future	 studies,	 it	 would	 be	 interesting	 to	 add	information	on	the	neural	mechanisms	underlying	inhibition	by	using	imaging	studies	focusing	on	the	fronto-striatal	circuitry.		Our	findings	should	be	viewed	in	light	of	certain	strengths	and	limitations.	An	important	strength	of	the	current	study	is	the	combination	of	multiple	genetic	variants,	which	enables	us	to	better	 take	 into	 account	 the	 small	 effect	 sizes	 for	 single	 variants	 and	 genetic	 heterogeneity.	 A	second	 strength	 is	 the	 inclusion	 of	 a	 competitive	 test	 which	 tests	 association	 of	 the	 selected	gene-set	against	the	background	signal	of	other	genes.	Gene-set	selection	is,	however,	limited	by	the	 fact	 that	 the	 currently	 available	 databases	 are	 still	 incomplete	 and/or	 not	 sufficiently	annotated.	For	the	current	study,	we	took	a	conservative	approach	and	only	included	genes	that	could	 be	 selected	 by	 using	 the	 well-established	 canonical	 pathway	 database	 from	 Ingenuity.	Other	 approaches	 would	 have	 been	 selection	 based	 on	 literature	 on	 glutamatergic	 and	GABAergic	 genes	 with	 a	 possible	 role	 in	 ADHD,	 or	 using	 proteomic	 studies	 (e.g.(Kirov	 et	 al.	2012))	which	both	have	 their	drawbacks	as	well.	Therefore,	with	our	approach,	we	may	have	missed	 genes	 that	 are	 involved	 in	 glutamatergic	 and/or	 GABAergic	 signalling	 but	 we	 are	confident	that	the	genes	that	we	did	include	are	directly	involved	in	glutamate/GABA	signalling.		Since	the	studied	sample	consisted	of	ADHD	patients	only,	the	current	results	should	not	be	viewed	as	related	to	disorder	risk	either	for	ADHD	or	ASD.	To	this	end,	a	case-control	study	should	first	be	performed.	In	addition,	a	diagnosis	of	autistic	disorder	or	Asperger	disorder	was	an	exclusion	criterion	in	the	IMAGE	study.	We	could	therefore	not	directly	compare	overlapping	genetic	underpinnings,	but	could	only	 investigate	 the	presence	of	autism	behaviour	within	 the	ADHD	sample.	It	would	be	interesting	for	the	future	to	replicate	these	findings	in	an	ASD	sample	and	 to	 include	patients	with	ASD	with	 comorbid	ADHD.	Lastly,	 differences	 in	 results	occurred	based	 on	 the	 flanking	 region	 we	 used.	 Although	 inclusion	 of	 the	 100	 kb	 flanking	 regions	 of	selected	 genes	 did	 not	 seem	 to	 lead	 to	more	 explained	 variance	 in	most	 cases,	 the	 difference	between	using	the	flanking	region	and	not	using	it	should	be	highlighted.	The	gene-sets	without	flanking	region	capture	 the	SNPs	 in	 the	genes,	while	 in	 the	gene-sets	with	 the	100	kb	 flanking	region,	 there	 were	 4487	 and	 6179	 extra	 SNPs	 present	 in	 the	 GABA	 and	 glutamate	 set,	respectively,	 which	 are	 not	 part	 of	 the	 gene	 itself	 (see	 supplemental	 Tables	 S3	 and	 S4	 for	number	 of	 SNPs	 per	 gene).	 In	 addition	 to	 including	 regulatory	 regions	 important	 for	 gene	
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activity	(Veyrieras	et	al.	2008;	Gherman	et	al.	2009;	Nicolae	et	al.	2010;	Pickrell	et	al.	2010),	this	flanking	 region	may	 also	 include	 neighboring	 genes	 that	may	 dilute	 effects	 of	 variants	 in	 the	selected	genes.	We	therefore	reported	both	approaches	in	the	current	manuscript.	In	 conclusion,	 the	 current	 study	 supports	 the	 hypothesis	 that	 genes	 involved	 in	glutamate	 neurotransmission	 are	 involved	 in	 ADHD	 as	 they	 were	 associated	 to	hyperactivity/impulsivity	 severity.	 Genes	 of	 both	 glutamate	 and	 GABA	 neurotransmitter	systems	were	 found	 related	 to	 autism	 severity	within	 the	ADHD	 sample.	 An	 overlapping	 trait	between	 ADHD	 and	 ASD,	 altered	 response	 inhibition,	 may	 show	 association	 to	 GABA,	 but	additional	 research	 is	 necessary	 to	 clarify	 this.	 Additionally	 the	 present	 study	 shows	 that	studying	 the	 aggregated	 effect	 of	multiple	 genetic	 variants	may	 overcome	 power	 problems	 in	genetic	association	testing.		 	
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SUPPLEMENTARY MATERIAL CHAPTER 7 	Table	S1	Ingenuity	Pathway	Analysis	(IPA)	list	of	genes	included	in	the	glutamatergic	signalling	pathway,	their	functions	and	inclusion	in	the	gene-set	analysis.	Gene	 Function	 Included	GRIA1	 glutamate	receptor	1	 Yes	GRIA2	 glutamate	receptor	2	 Yes	GRIA3	 glutamate	receptor	3	 No		GRIA4	 glutamate	receptor	4	 Yes	GRID1	 glutamate	receptor	ionotropic,	delta-1	precursor	 Yes	GRID2	 glutamate	receptor	ionotropic,	delta-2	precursor	 Yes	GRIK1	 glutamate	receptor	ionotropic,	kainate	1	precursor	 Yes	GRIK2	 glutamate	receptor	ionotropic,	kainate	2	precursor	 Yes	GRIK3	 glutamate	receptor	ionotropic,	kainate	3	precursor	 Yes	GRIK4	 glutamate	receptor	ionotropic,	kainate	4	precursor	 Yes	GRIK5	 glutamate	receptor	ionotropic,	kainate	5	precursor	 Yes	GRIN1	 glutamate	receptor	ionotropic,	NMDA	1	precursor	 Yes	GRIN2A	 glutamate	receptor	ionotropic,	NMDA	2A	precursor	 Yes	GRIN2B	 glutamate	receptor	ionotropic,	NMDA	2B	precursor	 Yes	GRIN2C	 glutamate	receptor	ionotropic,	NMDA	2C	precursor	 Yes	GRIN2D	 glutamate	receptor	ionotropic,	NMDA	2D	precursor	 Yes	GRIN3A	 glutamate	receptor	ionotropic,	NMDA	3A	precursor	 Yes	GRIN3B	 glutamate	receptor	ionotropic,	NMDA	3B	precursor	 Yes	GRINA	 protein	lifeguard	1	 Yes	GRIP1	 glutamate	receptor-interacting	protein	1		 Yes	GRM1	 metabotropic	glutamate	receptor	1	 Yes	GRM2	 metabotropic	glutamate	receptor	2	 Yes	GRM3	 metabotropic	glutamate	receptor	3	 Yes	GRM4	 metabotropic	glutamate	receptor	4	 Yes	GRM5	 metabotropic	glutamate	receptor	5	 Yes	GRM6	 metabotropic	glutamate	receptor	6	 Yes	GRM7	 metabotropic	glutamate	receptor	7	 Yes	GRM8	 metabotropic	glutamate	receptor	8	 Yes	SLC17A1	 sodium-dependent	phosphate	transport	protein	1	 Yes	SLC17A2	 sodium-dependent	phosphate	transport	protein	3	 Yes	SLC17A6	 vesicular	glutamate	transporter	2	 Yes	SLC17A7	 vesicular	glutamate	transporter	1	 Yes	SLC17A8	 vesicular	glutamate	transporter	3	 Yes	SLC1A1	 excitatory	amino	acid	transporter	3	 Yes	SLC1A2	 excitatory	amino	acid	transporter	2	 Yes	
 193		
SLC1A3	 excitatory	amino	acid	transporter	1	 Yes	SLC1A4	 neutral	amino	acid	transporter	A	 Yes	SLC1A6	 excitatory	amino	acid	transporter	4	 Yes	SLC1A7	 excitatory	amino	acid	transporter	5	 Yes	SLC38A1	 sodium-coupled	neutral	amino	acid	transporter	1	 Yes	HOMER1	 homer	protein	homolog	1	 Yes	HOMER2	 homer	protein	homolog	2	 Yes	HOMER3	 homer	protein	homolog	3	 Yes	GLS	 glutaminase	kidney	isoform,	mitochondrial	isoform	precursor	 Yes	CALM1	 Calmodulin	 Yes	CALML5	 calmodulin-like	protein	5	 Yes	CAMK4	 calcium/calmodulin-dependent	protein	kinase	type	IV	 Yes	PICK1	 PRKCA-binding	protein	 Yes	GNB1	 guanine	nucleotide-binding	protein	G(I)/G(S)/G(T)	subunit	beta-1		 No	GNB3	 guanine	nucleotide-binding	protein	G(I)/G(S)/G(T)	subunit	beta-3		 No	
GNG11	 guanine	nucleotide-binding	protein	G(I)/G(S)/G(O)	subunit	gamma-11	precursor	 No	
GNG2	 guanine	nucleotide-binding	protein	G(I)/G(S)/G(O)	subunit	gamma-2	precursor	 No	
GNG5	 guanine	nucleotide-binding	protein	G(I)/G(S)/G(O)	subunit	gamma-5	precursor	 No	
GNG7	 guanine	nucleotide-binding	protein	G(I)/G(S)/G(O)	subunit	gamma-7	precursor	 No	
GNG10	 guanine	nucleotide-binding	protein	G(I)/G(S)/G(O)	subunit	gamma-10	precursor	 No	
GNG12	 guanine	nucleotide-binding	protein	G(I)/G(S)/G(O)	subunit	gamma-12	precursor	 No	
GNG13	 guanine	nucleotide-binding	protein	G(I)/G(S)/G(O)	subunit	gamma-13	precursor	 No	GNG3	 guanine	nucleotide-binding	protein	G(I)/G(S)/G(O)	subunit	gamma-3	 No	GNG4	 guanine	nucleotide-binding	protein	G(I)/G(S)/G(O)	subunit	gamma-4	 No	GNB1L	 guanine	nucleotide-binding	protein	subunit	beta-like	protein	1	 No	GNB2	 guanine	nucleotide-binding	protein	G(I)/G(S)/G(T)	subunit	beta-2	 No	GNB2L1	 guanine	nucleotide-binding	protein	subunit	beta-2-like	1	 No	GNB4	 guanine	nucleotide-binding	protein	subunit	beta-4	 No	GNB5	 guanine	nucleotide-binding	protein	subunit	beta-5	 No	GLUL	 glutamine	synthetase	 No	DLG4	 disks	large	homolog	4	isoform	precursor	 No	
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GRIA3	 was	 initially	 included	 in	 the	 gene-set	 but	 not	 taken	 into	 account	 in	 the	 association	analysis	 because	 of	 the	 location	 on	 the	 X-chromosome.	 Other	 non-included	 genes	were	 those	encoding	 for	 the	 complex	 guanine	 nucleotide-binding	 proteins	 (G	 proteins)	 because	 of	 their	general	 involvement	 in	 regulating	 metabolic	 enzymes,	 ion	 channels,	 and	 transporters	 that	extends	 far	 beyond	 their	 involvement	 in	 glutamatergic	 signalling	 (Neves	 et	 al.	 2002).	Additionally	GLUL	was	not	included	because	it	is	involved	in	the	synthesis	of	glutamine	instead	of	glutamate	while	DLG4,	which	encodes	postsynaptic	density	protein	95,	has	an	important	role	in	 regulating	 multiple	 processes	 in	 addition	 to	 glutamatergic	 signalling	 such	 as	 synaptic	plasticity	(Meyer	et	al.	2014).				 	
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Table	S2	 Ingenuity	Pathway	Analysis	 (IPA)	 list	 of	 genes	 included	 in	 the	GABA-ergic	 signalling	pathway,	their	functions	and	inclusion	in	the	gene-set	analysis.	Gene	 Function	 Included	ABAT	 4-aminobutyrate	aminotransferase,	mitochondrial	precursor	 Yes	ADCY1	 adenylate	cyclase	type	1		 No	ADCY10	 adenylate	cyclase	type	10		 No	ADCY2	 adenylate	cyclase	type	2		 No	ADCY3	 adenylate	cyclase	type	3		 No	ADCY4	 adenylate	cyclase	type	4	 No	ADCY5	 adenylate	cyclase	type	5		 No	ADCY6	 adenylate	cyclase	type	6	 No	ADCY7	 adenylate	cyclase	type	7		 No	ADCY8	 adenylate	cyclase	type	8	 No	ADCY9	 adenylate	cyclase	type	9	 No	ALDH5A1	 succinate-semialdehyde	dehydrogenase,	mitochondrial	isoform	 Yes	ALDH9A1	 4-trimethylaminobutyraldehyde	dehydrogenase	 Yes	AP1B1	 AP-1	complex	subunit	beta-1	isoform	 No	AP1G2	 AP-1	complex	subunit	gamma-like	2	isoform	 No	AP2A1	 AP-2	complex	subunit	alpha-1	isoform		 No	AP2A2	 AP-2	complex	subunit	alpha-2	isoform	 No	AP2B1	 AP-2	complex	subunit	beta	isoform		 No	AP2M1	 AP-2	complex	subunit	mu	isoform	 No	AP2S1	 AP-2	complex	subunit	sigma	isoform		 No	DNM1	 dynamin-1	isoform		 Yes	GABARAP	 gamma-aminobutyric	acid	receptor-associated	protein	 Yes	GABBR1	 gamma-aminobutyric	acid	type	B	receptor	subunit	1	precursor	 Yes	GABBR2	 gamma-aminobutyric	acid	type	B	receptor	subunit	2	precursor	 Yes	GABRA1	 gamma-aminobutyric	acid	receptor	subunit	alpha-1	precursor	 Yes	GABRA2	 gamma-aminobutyric	acid	receptor	subunit	alpha-2	precursor	 Yes	GABRA3	 gamma-aminobutyric	acid	receptor	subunit	alpha-3	precursor	 No		GABRA4	 gamma-aminobutyric	acid	receptor	subunit	alpha-4	precursor	 Yes	GABRA5	 gamma-aminobutyric	acid	receptor	subunit	alpha-5	precursor	 Yes	GABRA6	 gamma-aminobutyric	acid	receptor	subunit	alpha-6	precursor	 Yes	GABRB1	 gamma-aminobutyric	acid	receptor	subunit	beta-1	precursor	 Yes	GABRB2	 gamma-aminobutyric	acid	receptor	subunit	beta-2	precursor	 Yes	GABRB3	 gamma-aminobutyric	acid	receptor	subunit	beta-3	precursor	 Yes	GABRD	 gamma-aminobutyric	acid	receptor	subunit	delta	precursor	 Yes	GABRE	 gamma-aminobutyric	acid	receptor	subunit	epsilon	precursor	 No		GABRG1	 gamma-aminobutyric	acid	receptor	subunit	gamma-1	precursor	 Yes	GABRG2	 gamma-aminobutyric	acid	receptor	subunit	gamma-2	precursor	 Yes	GABRG3	 gamma-aminobutyric	acid	receptor	subunit	gamma-3	precursor	 Yes	GABRP	 gamma-aminobutyric	acid	receptor	subunit	pi	precursor	 Yes	GABRQ	 gamma-aminobutyric	acid	receptor	subunit	theta	precursor	 No		GABRR1	 gamma-aminobutyric	acid	receptor	subunit	rho-1	precursor	 Yes	GABRR2	 gamma-aminobutyric	acid	receptor	subunit	rho-2	precursor	 Yes	GABRR3	 gamma-aminobutyric	acid	receptor	subunit	rho-3	precursor	 Yes	
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GAD1	 glutamate	decarboxylase	1	isoform	GAD25	 Yes	GAD2	 glutamate	decarboxylase	2	 Yes	GNAS	 protein	GNAS	isoform		 No	GPHN	 gephyrin	isoform	 Yes	GPR37	 prosaposin	receptor	GPR37	precursor	 No	KCNH2	 potassium	voltage-gated	channel	subfamily	H	member	2	 No	KCNN1	 small	conductance	calcium-activated	potassium	channel	protein	1	 No	KCNN2	 small	conductance	calcium-activated	potassium	channel	protein	2	 No	KCNN3	 small	conductance	calcium-activated	potassium	channel	protein	3	 No	KCNN4	 small	conductance	calcium-activated	potassium	channel	protein	4	 No	KCNQ2	 potassium	voltage-gated	channel	subfamily	KQT	member	2	 No	KCNQ3	 potassium	voltage-gated	channel	subfamily	KQT	member	3	 No	MRAS	 ras-related	protein	M-Ras	precursor	 No	NSF	 vesicle-fusing	ATPase	 Yes	SLC32A1	 vesicular	inhibitory	amino	acid	transporter	 Yes	SLC6A1	 sodium-	and	chloride-dependent	GABA	transporter	1	 Yes	SLC6A11	 sodium-	and	chloride-dependent	GABA	transporter	3	 Yes	SLC6A12	 sodium-	and	chloride-dependent	betaine	transporter	 Yes	SLC6A13	 sodium-	and	chloride-dependent	GABA	transporter	2	 Yes	UBQLN1	 ubiquilin-1	isoform	 Yes			GABRA3,	GABRE,	and	GABRQ	were	initially	included	in	the	gene-set	but	not	taken	into	account	in	the	association	analysis	because	of	their	location	on	the	X-chromosome.	All	other	genes	were	not	included	 in	 the	 association	 analysis	 because	of	 their	non-specific	 role	 in	GABAergic	 signalling.	The	 ADCY	 genes	 encode	 the	 enzymes	 of	 the	 adenyl-cyclase	 complex,	 that	 catalyses	 the	conversion	of	 adenosine	 triphosphate	 into	 cyclic	AMP	and	pyrophosphate,	which	 is	 important	for	 a	 large	 number	 of	 biological	 processes	 other	 than	 GABA	 signalling	 (see	 for	 instance	(Schröder-Lang	 et	 al.	 2007;	 Rahman	 et	 al.	 2013)).	 The	 AP-1	 and	 AP-2	 genes	 are	 general	transcription	factors	that	are	central	for	regulating	the	expression	and	activity	of	multiple	genes	in	 response	 to	 stimuli	 (Latchman	 1997).	 The	 genes	 that	 code	 for	 the	 complexes	 of	 small	conductance	 calcium-activated	 potassium	 channels	 and	 potassium	 voltage-gated	 channels	 are	involved	 in	 the	 regulation	of	 action	potentials	 that	 are	generated	 through	 the	actions	of	many	neurotransmitters.	 GNAS	 encodes	 the	 stimulatory	 G-protein	 alpha	 subunit	 that	 is	 involved	 in	multiple	signalling	pathways	other	than	GABA	signalling.	MRAS	codes	for	a	member	of	the	Ras	family	of	small	GTPases	and	functions	as	a	signal	transducer	in	many	‘generic’	processes	such	as	cell	 growth	 and	 differentiation.	 Lastly,	 GPR37	 is	 a	member	 of	 the	 G	 protein	 coupled	 receptor	family	 and	 has	 a	 more	 general	 role	 in	 regulating	 neuronal	 and	 glial	 physiology	 (Meyer	 et	 al.	2013).		
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Table	S3	Glutamatergic	genes	and	the	number	of	SNPs	within	the	genetic	boundaries	as	well	as	including	a100-kbp	flanking	region.	Number	of	SNPs		Glutamatergic		Genes	 No	flanking	 100-kbp	flanking		CALM1	 11	 125	CALML5	 Not	captured		 93	CAMK4	 230	 458	GLS	 41	 172	GRIA1	 438	 600	GRIA2	 54	 205	GRIA4	 265	 427	GRID1	 617	 768	GRID2	 746	 862	GRIK1	 381	 523	GRIK2	 658	 789	GRIK3	 90	 192	GRIK4	 276	 430	GRIK5	 6	 30	GRIN1	 Not	captured		 15	GRIN2A	 622	 899	GRIN2B	 516	 707	GRIN2C	 7	 76	GRIN2D	 6	 55	GRIN3A	 264	 443	GRIN3B	 1	 50	GRINA	 Not	captured		 9	GRIP1	 323	 475	GRM1	 277	 373	GRM2	 Not	captured		 14	GRM3	 165	 254	GRM4	 87	 199	GRM5	 531	 654	GRM6	 10	 172	GRM7	 910	 1106	GRM8	 1002	 1300	HOMER1	 57	 169	HOMER2	 52	 158	HOMER3	 1	 48	PICK1	 4	 111	SLC17A1	 67	 311	SLC17A2	 23	 214	SLC17A6	 42	 134	
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SLC17A7	 Not	captured		 71	SLC17A8	 29	 83	SLC1A1	 103	 312	SLC1A2	 187	 431	SLC1A3	 71	 256	SLC1A4	 13	 156	SLC1A6	 20	 154	SLC1A7	 29	 190	SLC38A1	 55	 193			 	
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Table	S4	GABAergic	genes	and	the	number	of	SNPs	within	the	genetic	boundaries	as	well	as	including	a	100-kbp	flanking	region.	Number	of	SNPs	GABAergic	genes	 No	flanking	 100-kbp	flanking	ABAT	 107	 217	ALDH5A1	 33	 278	ALDH9A1	 23	 199	DNM1	 16	 46	GABARAP	 Not	captured	 27	GABBR1	 37	 406	GABBR2	 438	 630	GABRA1	 42	 138	GABRA2	 89	 166	GABRA4	 92	 195	GABRA5	 1	 133	GABRA6	 15	 116	GABRB1	 281	 413	GABRB2	 235	 439	GABRB3	 204	 311	GABRD	 Not	captured	 24	GABRG1	 71	 165	GABRG2	 60	 178	GABRG3	 397	 494	GABRP	 39	 204	GABRR1	 58	 185	GABRR2	 51	 216	GABRR3	 45	 260	GAD1	 16	 114	GAD2	 77	 238	GPHN	 335	 484	NSF	 22	 60	SLC32A1	 Not	captured	 178	SLC6A1	 48	 212	SLC6A11	 123	 290	SLC6A12	 5	 144	SLC6A13	 45	 168	UBQLN1	 42	 206			 	
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Table	S5	Gene-wide	associations	for	all	genes	in	the	glutamate	and	GABA	gene-sets	when	using	no	flanking	region.	
	
p-value		
Gene	 Autism	 Hyperactivity/	Impulsivity	 Inattention	 SSRT	ABAT	 0.042434	 0.31612	 0.24602	 0.083319	ALDH5A1	 0.7891	 0.7891	 0.57201	 0.72101	ALDH9A1	 0.78195	 0.78195	 0.86688	 0.42879	CALM1	 0.41265	 0.146	 0.57994	 0.16367	CAMK4	 0.19204	 0.19599	 0.027561	 0.28852	DNM1	 0.72472	 0.058169	 0.10288	 0.88154	GABBR1	 0.5605	 0.1913	 0.51159	 0.16366	GABBR2	 0.14454	 0.39925	 0.32814	 0.34161	GABRA1	 0.13219	 0.48784	 0.67771	 0.14433	GABRA2	 0.031425	 0.30973	 0.88334	 0.89916	GABRA4	 0.075928	 0.24566	 0.3076	 0.82527	GABRA5	 0.14466	 0.67609	 0.50877	 	GABRA6	 0.72933	 0.36216	 0.083129	 0.44964	GABRB1	 0.20314	 0.21505	 0.61332	 0.12673	GABRB2	 0.73361	 0.79601	 0.45283	 0.25295	GABRB3	 0.69721	 0.31011	 0.5056	 0.27433	GABRG1	 0.22105	 0.66393	 0.55156	 0.12318	GABRG2	 0.25422	 0.42516	 0.78009	 0.14987	GABRG3	 0.072438	 0.37534	 0.37946	 	GABRP	 0.55742	 0.23738	 0.76089	 0.97273	GABRR1	 0.48654	 0.8643	 0.67558	 0.002711	GABRR2	 0.009981	 0.252	 0.23001	 0.27485	GABRR3	 0.73867	 0.34703	 0.40097	 0.78523	GAD1	 0.089976	 0.065136	 0.26791	 0.27496	GAD2	 0.74339	 0.61291	 0.84593	 0.15477	GLS	 0.28723	 0.44964	 0.61708	 0.41282	GPHN	 0.28728	 0.51668	 0.19869	 0.28563	GRIA1	 0.38966	 0.96735	 0.24693	 0.37766	GRIA2	 0.74009	 0.43772	 0.39849	 0.60788	GRIA4	 0.81754	 0.3927	 0.053213	 0.38408	GRID1	 0.21933	 0.001118	 0.031218	 0.19266	GRID2	 0.53641	 0.35917	 0.37622	 0.67539	GRIK1	 0.18663	 0.001896	 0.019578	 0.076858	GRIK2	 0.19569	 0.67005	 0.74299	 0.018062	GRIK3	 0.01249	 0.62494	 0.40432	 0.25893	GRIK4	 0.68156	 0.085049	 0.41807	 0.93647	GRIK5	 0.57929	 0.79235	 0.9764	 0.9381	GRIN2A	 0.27403	 0.029114	 0.16522	 0.73415	GRIN2B	 0.032321	 0.003961	 0.26166	 0.43811	GRIN2C	 0.003591	 0.4957	 0.84738	 0.58948	GRIN2D	 0.069227	 0.1425	 0.67259	 0.3701	
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GRIN3A	 0.004415	 0.92314	 0.4459	 0.41118	GRIN3B	 0.81048	 0.29934	 0.7626	 	GRIP1	 0.9239	 0.27626	 0.93598	 0.78818	GRM1	 0.60144	 0.009834	 0.38045	 0.17429	GRM3	 0.045247	 0.26292	 0.85492	 0.61897	GRM4	 0.03293	 0.055035	 0.49976	 0.9425	GRM5	 0.046871	 0.012371	 0.008675	 0.96713	GRM6	 0.51535	 0.49984	 0.13321	 0.42513	GRM7	 0.005357	 0.15944	 0.16338	 0.018695	GRM8	 0.41442	 0.39432	 0.48456	 0.62174	HOMER1	 0.3697	 0.021477	 0.43092	 0.20995	HOMER2	 0.046795	 0.22071	 0.59626	 0.049371	HOMER3	 0.090184	 0.12773	 0.013209	 0.97673	NSF	 0.96393	 0.47128	 0.57376	 0.65425	PICK1	 0.5665	 0.076444	 0.79132	 0.30745	SLC17A1	 0.002141	 0.33591	 0.61055	 0.19426	SLC17A2	 0.000836	 0.44624	 0.44113	 0.10304	SLC17A6	 0.029701	 0.5957	 0.34497	 0.20135	SLC17A8	 0.5728	 0.14257	 0.10432	 0.56923	SLC1A1	 0.28616	 0.63595	 0.25859	 0.098161	SLC1A2	 0.57846	 0.027963	 0.5857	 0.55119	SLC1A3	 0.45549	 0.2894	 0.77059	 0.40146	SLC1A4	 0.57935	 0.86356	 0.29662	 0.054852	SLC1A6	 0.17501	 0.57592	 0.2298	 0.15728	SLC1A7	 0.052445	 0.69654	 0.11126	 0.56859	SLC38A1	 0.18621	 0.57486	 0.043368	 0.25299	SLC6A1	 0.33775	 0.63242	 0.26363	 0.74692	SLC6A11	 0.69155	 0.33054	 0.65268	 0.92536	SLC6A12	 0.39626	 0.94597	 0.57484	 0.85674	SLC6A13	 0.019078	 0.28369	 0.19009	 0.28581	UBQLN1	 0.19503	 0.36137	 0.87032	 0.6647	
	
	None	of	the	genes	was	significantly	associated	with	any	of	the	phenotypes	after	correction	for	multiple	comparisons	(corrected	p-value	=	0.0003).	
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Table	S6	Association	result	p-values	for	the	discovery	and	post-hoc	tests	when	only	including	receptor	and	transporter	genes.		 GLUTAMATE	 Self-contained	 Competitive		 0	kb	 100	kb	 0	kb	 100	kb	Autism	symptom	severity	 .00000000006	 .	00000000002	 .0898	 .996	Hyperactivity/impulsivity	severity	 .044	 .003	 .044	 .997	Inattention	severity	 .217	 .210	 .569	 .768		 	 	 	 	Inhibition	(SSRT)	 .122	 .281	 .118	 .339		 	 		 GABA	 Self-contained	 Competitive		 0	kb	 100	kb	 0	kb	 100	kb	Autism	symptom	severity	 .0004	 .00007	 .500	 .721	Hyperactivity/impulsivity	severity	 .565	 .324	 .867	 .643	Inattention	severity	 .231	 .077	 .619	 .092		 	 	 	 	Inhibition	(SSRT)	 .310	 .052	 .398	 .194			With	a	more	restricted	gene-set	 including	only	glutamatergic	(n=35	when	no	 flanking	 is	used,	n=39	when	100kb	 flanking	 is	used)	or	GABAergic	 (n=19,	or	n=22	respectively)	 receptor	and	transporter	encoding	genes,	we	found	similar	results.	Only	the	competitive	test,	which	revealed	significant	 associations	with	 hyperactivity/impulsivity	 severity	 in	 the	 larger	 gene-set,	 did	 not	survive	multiple	comparison	testing	in	this	more	specific	analysis.	This	result	suggests	that	the	glutamate	 and	 GABA	 gene-sets	 associations	 with	 ADHD	 and	 autism	 phenotypes	 are	 mainly	driven	by	the	more	restricted	gene-set,	but	that	adding	additional	genes	does	not	only	add	noise,	but	 further	 increase	 the	 association	 signal.	 Thus,	 including	 less	 SNPs	 decreases	 the	 explained	variance.		
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				Figure	S1	Unique	genes	included	in	the	glutamatergic	signalling	pathway.	(Adapted	from	www.ingenuity.com).	
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					Figure	S2	Unique	genes	included	in	the	GABAergic	signalling	pathway.	(Adapted	from	www.ingenuity.com).
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The	overall	aim	of	this	thesis	was	to	gain	insight	into	shared	and	unique	underlying	neural	and	genetic	mechanisms	of	ADHD,	ASD,	OCD	and	(to	a	lesser	extent)	TD,	with	a	specific	focus	on	the	fronto-striatal	 systems	 and	 the	 role	 of	 the	 glutamate	 neurotransmitter	 system.	 In	 this	 thesis	previous	studies	were	complemented	by	examining	a	set	of	rather	common	neurodevelopmental	disorders	 with	 onset	 in	 childhood	 and	 with	 clinical	 overlap	 (i.e.	 comorbidity)	 using	 MR	spectroscopy,	 structural	 MRI	 and	 a	 genetic	 systems	 approach.	 The	 role	 of	 compulsivity	 was	explored	not	 only	 in	 terms	 of	 binary	 psychiatric	 classification	 but	 also	 in	 a	more	 dimensional	cross-disorder	 manner.	 This	 is	 in	 accordance	 with	 the	 recent	 development	 of	 the	 Research	Domain	 Criteria	 approach	 (RDoC;	 Cuthbert	 2014),	 which	 promotes	 the	 application	 of	dimensional	 constructs	 to	 (neurodevelopmental)	 disorders	 in	 addition	 to	 the	 classical	 case-control	divisions.	In	this	sense,	we	can	better	investigate	state	versus	trait	markers	for	disorders.		State	markers	refer	to	a	transient	clinical	manifestation,	while	a	trait	marker	could	play	a	causal	role	in	the	predisposition	for	developing	a	disorder	and	is	usually	considered	long-lasting.	To	gain	more	insight	into	the	role	of	glutamate	in	compulsivity,	we	conducted	a	series	of	studies	 that	 were	 described	 in	 the	 empirical	 chapters	 (4–7)	 within	 this	 thesis.	 In	 this	 final	chapter,	 I	 provide	 an	 overall	 summary	 of	 the	 findings	 of	 these	 chapters.	 I	 describe	 how	 these	findings	relate	to	each	other	and	how	this	work	complements	and	advances	existing	literature.	Strengths	and	limitations	of	this	thesis	are	discussed	as	well	as	(potential)	clinical	implications	and	suggestions	for	future	research.		
SUMMARY OF THE CHAPTERS 	In	chapter	2	the	design	used	and	cohort	recruited	for	use	in	subsequent	chapters	4,	5	and	6	was	described.	 This	 chapter	 provided	 an	 overview	 of	 the	 characteristics	 of	 participants	 in	 the	COMPULS	study	and	all	measures	that	were	collected	in	terms	of	cognitive	functioning,	genetics,	and	neuroimaging.	In	 chapter	 3,	 I	 reviewed	 the	 MRS	 literature	 regarding	 fronto-striatal	 glutamate	concentrations	 in	 children,	 adolescents	 and	 adults	with	 ADHD,	 ASD	 and	OCD	 published	 up	 to	2014.	 These	 studies	 together	 suggested	 alterations	 in	 glutamate	 concentrations	 in	 all	 three	disorders	in	the	anterior	cingulate	cortex	(ACC)	and	striatum.	In	children	and	adolescents	with	ADHD	 and	 ASD,	 mainly	 increased	 glutamate	 concentrations	 compared	 with	 controls	 were	reported	 throughout	 the	 studies,	 while	 in	 adults	 with	 ADHD	 and	 ASD	 mostly	 decreased	concentrations	 were	 found.	 Within	 the	 striatum,	 several	 studies	 pointed	 to	 increased	glutamatergic	 concentrations	 in	 all	 three	 disorders,	 regardless	 of	 age,	 but	 several	 studies	 also	found	no	differences.	What	became	clear	from	this	review	was	that	ADHD,	ASD	and	OCD	indeed	show	 overlapping	 glutamatergic	 alterations	 in	 certain	 brain	 regions.	 After	 summarizing	 the	
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previous	 literature,	 several	 studies	were	 conducted	 using	 the	 COMPULS	 cohort	 to	 investigate	disorder	groups	collectively	in	larger	samples	than	described	in	the	published	literature.	In	chapter	4	we	used	MRS	to	study	glutamate	concentrations	in	the	ACC	and	left	dorsal	striatum	of	children	with	ASD	and	OCD.	We	investigated	glutamate	concentrations	categorically	–	 comparing	 children	 with	 ASD	 and	 OCD	 with	 healthy	 controls.	 In	 addition,	 we	 used	 a	dimensional	comparison,	 in	which	we	examined	whether	continuous	measures	of	compulsivity	was	associated	with	glutamate	concentrations.	Individuals	with	ASD	and	OCD	showed	increased	glutamate	concentrations	in	the	ACC,	but	not	the	striatum,	compared	with	controls.	Importantly,	the	 two	 disorder	 groups	 did	 not	 differ	 from	 each	 other.	 Furthermore,	 the	 increase	 in	 ACC	glutamate	was	associated	with	increased	limited	interests	in	both	ASD	and	OCD.	The	findings	of	this	study	support	the	idea	of	a	common	underlying	mechanism	of	compulsivity	across	the	two	disorders.		 In	 chapter	5,	we	extended	 the	 study	described	 in	 chapter	4	by	 investigating	glutamate	concentrations	 in	 relation	 to	 striatal	 volume.	 We	 also	 investigated	 NAA	 concentrations	 and	striatal	shape.	Although	we	had	not	found	any	differences	between	disorder	groups	and	controls	in	 chapter	 4	 regarding	 glutamate	 concentrations	 in	 striatum,	 several	 studies	 have	 pointed	 to	structural	 abnormalities	 in	 this	 brain	 region	 in	 ASD	 and	 OCD	 before.	 Additionally,	 structural	abnormalities	 may	 be	 associated	 with	 neurochemical	 abnormalities.	 Here,	 we	 investigated,	whether	ASD	and/or	OCD	were	associated	with	differences	 in	striatal	volume	(and	shape)	and	whether	 this	 was	 related	 to	 striatal	 glutamate	 concentration	 and	 N-Acetylaspartate	 (NAA)	concentration.	The	latter	is	assumed	to	be	a	measure	of	neuronal	integrity.	No	group	differences	were	 found	 in	 striatal	volume	or	 shape,	but	a	diagnosis	by	hemisphere	 interaction	was	 found,	indicating	 different	 volumetric	 asymmetry	 (right	 larger	 than	 left)	 of	 the	 striatum	 in	 ASD	 and	OCD	compared	with	controls.	Again,	the	disorders	did	not	differ	from	each	other.	In	addition,	in	ASD	 only,	 we	 found	 decreased	 NAA	 concentrations	 in	 the	 striatum	 compared	 with	 controls.	Striatal	 volume	 was	 associated	 with	 NAA	 and	 glutamate	 concentrations	 within	 this	 group	 as	well,	 pointing	 to	possible	 reduced	neuronal	 integrity	 and/or	 impaired	neuronal	 functioning	of	the	striatum.		 Chapter	6	described	an	MRS	study	with	similar	methods	to	those	described	in	chapter	4,	but	 this	 time	 investigating	 paediatric	 ADHD	 and	 Tourette’s	 disorder	 (TD).	 Children	 with	 a	diagnosis	 of	 both	 disorders	 were	 also	 included.	 No	 differences	 in	 ACC	 or	 striatal	 glutamate	concentrations	were	found	between	any	of	the	groups.	However,	in	children	with	TD,	we	found	a	positive	 association	 between	 ACC	 glutamate	 concentrations	 and	 obsessive	 and	 compulsive	behaviour,	similar	to	those	found	in	compulsivity	in	ASD	and	OCD	(chapter	4).	This	was	the	first	study	 investigating	 glutamatergic	 concentrations	 in	 paediatric	 TD.	 Interestingly,	 TD	 is	 highly	
 211		
comorbid	 with	 OCD,	 and	 the	 findings	 of	 this	 chapter	 and	 chapter	 4	 point	 to	 glutamatergic	involvement	in	compulsivity	across	several	disorders.		 Finally,	in	chapter	7,	to	investigate	the	involvement	of	glutamatergic	signalling	in	ADHD	in	more	 detail,	 we	made	 use	 of	 part	 of	 the	 IMAGE	 cohort	 that	 encompasses	 a	 large	 group	 of	children	 and	 adolescents	 with	 combined-type	 ADHD	 recruited	 for	 genetic	 studies.	 We	investigated	 the	 involvement	 of	 common	 genetic	 variants	 related	 to	 glutamatergic	 as	 well	 as	GABAergic	 signalling	 in	 explaining	 variance	 in	 measures	 of	 ADHD	 and	 ASD	 symptoms	 in	 the	IMAGE	 sample.	 A	 genetic	 aggregation	 (gene-set)	 approach	 was	 used,	 in	 which	 the	 combined	association	of	multiple	variants	with	the	phenotype	was	tested.	ADHD	symptom	severity,	autism	symptom	severity	(within	this	ADHD-only	sample)	and	inhibitory	control	were	investigated.	We	observed	 association	 of	 variants	within	 the	 glutamate	 gene-set	with	 hyperactivity/impulsivity	(but	not	with	inattention),	and	with	overall	autism	symptom	severity,	which	includes	severity	of	repetitive	behaviours	and	compulsivity.	Variation	in	GABAergic	genes	was	also	associated	with	autism	severity	and	at	trend-level	with	inhibitory	control.	This	study	pointed	to	a	possible	role	of	 excitatory-inhibitory	 imbalance	 in	 autism-symptoms	 within	 ADHD	 and	 to	 glutamatergic	involvement	in	hyperactivity/impulsivity.			The	 literature	 available	 to	 date	 has	 provided	 us	with	 several	 studies	 investigating	 the	 role	 of	glutamate	 in	 neurodevelopment,	 which	 supported	 a	 role	 for	 this	 neuro-metabolite	 in	 both	compulsivity-	and	 impulsivity-related	disorders.	However,	 these	studies	 lack	the	 integration	of	disorders	 in	 one	 design	 to	 specifically	 study	 cross-disorder	 overlapping	 traits.	 The	 studies	described	 in	 this	 thesis	 advance	 existing	 literature	 regarding	 this.	 As	 the	 currently	 used	diagnostic	system	has	difficulties	 in	dealing	with	comorbidities	across	disorders	(Kessler	et	al.	2011;	Caspi	et	al.	2014),	investigating	comorbid	disorders	together	might	provide	us	with	more	insight	 into	 how	 these	 comorbidities	 come	 about	 by	 identifying	 what	 the	 disorders	 have	 in	common.	 Comorbidities	 can	 be	 concurrent	 but	 also	 sequential,	 where	 having	 one	 disorder	increases	the	chance	of	developing	the	second.	An	idea	that	has	arisen	recently	is	that	there	is	a	general	 factor	 in	 psychiatric	 disorders	 (referred	 to	 as	 “p”)	 that	 influences	 vulnerability	 to	symptoms	of	all	 types	of	disorders	(Caspi	et	al.	2014).	These	symptoms,	aggregated	 in	several	different	diagnoses,	can	be	captured	in	two	domains;	internalizing	and	externalizing	symptoms.	However,	 this	 is	 based	 on	 the	 most	 common	 psychiatric	 disorders	 in	 adulthood.	 In	 the	neurodevelopmental	disorders	described	 in	 this	 thesis	 a	more	general	psychopathology	 factor	may	be	composed	of	vulnerability	to	impulsivity	and	compulsivity	or	a	combination	of	the	two.	Comorbidity	 across	 the	 disorders	 associated	with	 these	 traits	 suggests	 a	 positive	 relationship	between	 impulsivity	 and	 compulsivity,	 where	 higher	 impulsivity	 is	 associated	 with	 higher	
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compulsivity,	or	where	high	 impulsivity	may	possibly	 lead	 to	compulsivity	 (Koob	and	Le	Moal	1997).		Although	only	ASD	is	defined	in	such	way,	all	disorders	investigated	in	the	current	thesis	can	be	considered	as	spectrum	disorders	(Fineberg	et	al.	2014;	Robbins	et	al.	2012;	Stein	2000;	Hollander	 et	 al.	 2014).	 Impulsivity	 and	 compulsivity	 are	 behavioural	 traits	 that	 cut	 across	multiple	 psychiatric	 spectrum	 disorders	 but	 additionally	 exist	 in	 the	 general	 population	(Chamberlain	 et	 al.	 2016).	 One	 conceptualization	 is	 that	 impulsivity	 and	 compulsivity	 are	opposing	 ends	 of	 the	 same	 spectrum	 (Hollander	 1996;	Berlin	 and	Hollander	 2014),	while	 the	two	are	also	seen	as	overlapping,	both	implying	problems	with	cognitive	control	(Chamberlain	et	 al.	 2006;	 Fineberg	 et	 al.	 2014).	 The	 studies	 described	 in	 this	 thesis	 point	 to	 a	 role	 for	glutamate	in	compulsivity,	directly	in	the	MRS	studies	and	indirectly	in	the	genetic	study.	A	role	for	glutamate	in	(disorders	associated	with)	impulsivity	was	only	shown	in	the	genetics	study	of	this	 thesis.	 Fronto-striatal	 alterations	 with	 regard	 to	 glutamate	 thus	 possibly	 differ	 between	impulsivity	and	compulsivity	and	its	related	disorders.				
FRONTO-STRIATAL GLUTAMATE 	
Autism spectrum disorder and obsessive compulsive disorder ASD	and	OCD	are	the	two	neurodevelopmental	disorders	described	in	this	thesis	that	are	mostly	associated	 with	 compulsivity	 (Ruzzano	 et	 al.	 2015).	 Although	 the	 psychological	 mechanisms	underlying	the	compulsivity	may	be	different	for	ASD	(self-soothing)	and	OCD	(reducing	stress),	poor	behavioural	 inhibition	has	been	 linked	 to	both	disorders	 (Robbins	 et	 al.	 2012),	which	 in	turn	is	linked	to	fronto-striatal	functioning.	It	has	therefore	been	suggested	that	changes	in	the	fronto-striatal	 circuit	may	 be	 involved	 in	 the	 compulsivity	 seen	 in	 both	 disorders	 (Voon	 et	 al.	2014;	Fuccillo	2016).	In	chapter	4	we	provided	evidence	for	glutamatergic	alterations	in	children	with	ASD	and	OCD,	 extending	 the	 previous	 literature	 by	 directly	 comparing	 the	 two	 disorders.	 More	specifically,	 the	 disorders	 both	 showed	 increased	 ACC	 glutamate,	 which	 was	 associated	 with	limited	 interests.	 Certain	 compulsivity	 behaviours	 seen	 in	 both	 disorders	 might	 thus	 be	associated	with	similar	alterations	in	fronto-striatal	glutamate.	The	ASD	group	was	almost	twice	as	 large	 as	 the	 OCD	 group,	 but	 the	 latter	 also	 separately	 had	 increased	 ACC	 glutamate	 levels	compared	with	 the	controls,	 showing	 that	 this	was	not	driven	by	 the	 larger	sample	size	of	 the	ASD	 group.	 An	 increase	 in	 glutamate	 levels	 in	 the	 ACC	measured	 by	 spectroscopy	 suggests	 a	hyper-glutamatergic	 state,	 as	 previously	 hypothesized	 for	 ASD	 (Fatemi	 2008).	 This	 is	additionally	 supported	 by	 genetic	 studies	 pointing	 to	 the	 involvement	 of	 genes	 encoding	glutamate	 receptors	 (e.g.	Alonso	 et	 al.	 2012).	These	 receptors	may	be	upregulated	 in	 children	
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with	ASD	(Carlson	2012),	causing	a	hyper-glutamatergic	state,	that	may	be	reflected	in	increased	glutamate	signal	 in	 the	ACC	 in	our	studies.	Elevated	glutamate	concentrations	may	also	be	 the	result	of	reductions	 in	proteins	that	convert	glutamate	 into	GABA,	which	reduce	the	 inhibitory	GABAergic	 tone	 and	 therefore	 enhance	 glutamate	 concentrations	 (Pizzarelli	 and	 Cherubini	2011).	Although	we	found	alterations	in	ACC	glutamate,	we	did	not	find	any	evidence	for	striatal	glutamatergic	alterations.	Compulsivity	disorders	may	 thus	be	a	result	of	deficits	 in	regulation	by	 the	 frontal	 cortex	 and	 not	 so	 much	 of	 subcortical	 dysfunction	 (e.g.	 (Dalley,	 Everitt,	 and	Robbins	 2011;	 Fineberg	 et	 al.	 2010)).	 Although	 we	 did	 not	 find	 any	 differences	 in	 striatum	glutamate,	 this	 does	 not	 per	 definition	 rule	 out	 a	 role	 for	 subcortical	 alterations	 regarding	cognitive	control	in	compulsivity.	The	striatum	itself	is	not	glutamatergic	and	thus	does	not	have	any	excitatory	output	 (Pittenger	 et	 al.	 2011).	However,	 via	GABAergic	 inhibition	of	 the	globus	pallidus	 which	 in	 turn	 disinhibits	 the	 thalamus	 the	 striatum	 is	 indirectly	 involved	 in	 PFC	excitation	(Van	den	Heuvel	et	al.	2010).	It	seems	that	in	ASD	and	OCD	the	ACC	is	over-excited	via	this	system	leading	to	continuation	of	behaviour	and	to	less	inhibition.	This	can	additionally	be	the	 result	of	deficits	 in	 striatal	GABAergic	output.	An	 imbalance	between	glutamate	and	GABA	has	 been	hypothesized	before	 and	 is	 the	 core-idea	 of	 one	 of	 the	models	 described	 for	 autism.	According	 to	 this	 model	 an	 excitation/inhibition	 imbalance	 exists	 in	 key	 brain	 regions	(Rubenstein	and	Merzenich	2003;	Tebartz	Van	Elst	et	al.	2014;	Uzunova	et	al.	2015;	Lee	et	al.	2016).	This	 imbalance	possibly	causes	ASD-like	behaviour,	 including	compulsivity,	but	has	not	been	 shown	 in	 OCD	 before.	 Regarding	 the	 results	 of	 this	 thesis,	 an	 excitation/inhibition	imbalance	 might	 be	 underlying	 the	 cross-disorder	 trait	 compulsivity.	 To	 be	 able	 to	 link	glutamatergic	 and	 GABAergic	 alterations	 to	 brain	 function	we	 need	 future	 studies	 integrating	MRS	with	functional	imaging	in	which	top-down	fronto-striatal	signalling	related	to	self-control	can	be	investigated	in	relation	to	glutamate	and	GABA	concentrations.		Having	 found	 no	 evidence	 for	 glutamate	 alterations	 in	 the	 striatum	 in	 chapter	 4,	 in	chapter	5	we	investigated	whether	possible	striatal	volume	or	shape	alterations	in	ASD	and/or	OCD	 were	 related	 to	 glutamate	 concentrations	 and	 N-Acetylaspartate	 (NAA),	 a	 marker	 of	neuronal	 integrity.	 Neuronal	 loss	 in	 the	 striatum	may	 be	 a	 result	 of	 excitotoxicity	 caused	 by	increased	 afferent	 glutamatergic	 projections	 from	 the	 prefrontal	 cortex	 to	 the	 striatum	(Engelsen	 1986;	 Choi	 1988),	 as	 previously	 shown	 in	 schizophrenia	 (Plitman	 et	 al.	 2014).	However,	 we	 found	 a	 positive	 relationship	 between	 glutamate	 concentrations	 and	 striatal	volume	 and	 between	 NAA	 and	 striatal	 volume	 in	 children	 with	 ASD,	 which	 contradicts	 this	excitotoxicity	 hypothesis.	 Levels	 of	 glutamate	 need	 to	 be	 excessive	 before	 they	 become	 toxic,	which	was	not	 the	 case	 in	our	 samples	and	has	also	not	been	shown	 in	ASD	before.	While	we	found	 no	 reductions	 in	 striatal	 volume,	 shape	 or	 glutamate	 concentrations,	 we	 did	 find	decreased	NAA	 levels	 in	children	with	ASD.	NAA	 levels	were	associated	with	striatum	volume,	
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suggesting	reduced	neuronal	 integrity	or	 impaired	neuronal	 functioning	 in	the	striatum	within	ASD	 (Devito	 et	 al.	 2007).	 In	 addition,	 we	 found	 hemispheric	 asymmetry	 in	 striatal	 volume	 in	both	ASD	and	OCD	(right	larger	than	left)	compared	with	controls,	which	was	the	first	study	to	show	this	overlap.	Altered	striatal	structure	may	thus	be	present	in	children	with	both	disorders	underlying	their	overlap	in	behaviour,	but	this	needs	replication	in	an	independent	sample.		
 
Attention-Deficit/Hyperactivity Disorder and Tourette’s Disorder In	chapter	6	I	investigated	two	other	highly	comorbid	disorders,	ADHD	and	TD.	ADHD	is	mainly	associated	with	 impulsivity	but	 is	often	comorbid	with	ASD,	while	TD	 is	highly	comorbid	with	both	impulsivity	(ADHD)	and	compulsivity	(OCD)	disorders	and	is	associated	with	both	traits	on	itself	 (Kano	 et	 al.	 2015).	 Both	 ADHD	 and	 TD	 have	 been	 hypothesized	 to	 be	 related	 to	glutamatergic	 deficits	 (Singer	 et	 al.	 2010;	Naaijen	 et	 al.	 2015),	 although	 in	 TD,	 this	 has	 never	been	reported	before	using	MRS	(DeVito	et	al.	2005).	Because	of	the	immense	overlap	between	ADHD	and	TD	and	because	of	the	confounding	factors	caused	by	their	comorbidity	 in	previous	studies,	we	 investigated	 the	disorders	 together	 in	chapter	6,	using	TD-	and	ADHD-only	groups	and	 a	 group	with	 both	diagnoses.	We	 found	no	differences	 in	 fronto-striatal	 glutamate	within	ADHD,	 TD	 and	 ADHD+TD	 compared	 with	 controls.	 Within	 the	 TD	 group	 (with	 and	 without	ADHD)	 we	 found	 an	 association	 between	 ACC	 glutamate	 and	 obsessive	 and	 compulsive	behaviour.	 In	 line	 with	 findings	 in	 ASD	 and	 OCD	 in	 chapter	 4,	 it	 might	 be	 the	 case	 that	glutamatergic	projections	from	the	ACC	to	subcortical	regions	are	associated	with	compulsivity	behaviours	 in	 TD	 as	 well.	 Cognitive	 control	 deficits	 related	 to	 obsessive	 and	 compulsive	behaviour	may	be	associated	with	elevated	ACC	glutamate	(Botvinick	et	al.	2004).	Here	we	can	only	 speculate	 on	 OCD-symptoms	 within	 TD.	 No	 studies	 have	 investigated	 glutamatergic	alterations	 in	children	with	TD	and	OCD	 together.	One	has	hypothesized	 that	TD	without	OCD	and	TD+OCD	are	actually	different	types	of	tic-disorders	(Lebowitz	et	al.	2012;	Yu	et	al.	2015).	The	 difference	 in	 compulsivity	 between	 these	 groups	 may	 therefore	 be	 responsible	 for	differences	 in	 glutamatergic	 alterations	 in	TD.	 Previous	 studies	 that	 suggested	 involvement	 of	glutamate	 in	 TD,	 however,	 have	 not	 been	 able	 to	 detect	 the	 nature	 of	 this	 involvement;	 both	hyper-	 and	 hypo-glutamatergic	 states	 have	 been	 hypothesized	 (Singer	 et	 al.	 2010).	 Previous	MRS	studies	 investigating	ADHD	did	not	specifically	focus	on	the	role	of	 impulsivity,	but	found	correlations	between	glutamate	alterations	and	memory	disability	(Courvoisie	et	al.	2004)	and	inattention	 (Dramsdahl	 et	 al.	 2011;	Maltezos	 et	 al.	 2014).	 In	 this	 first	 study	 comparing	ADHD	and	 TD	 and	 investigating	 both	 measures	 of	 compulsivity	 and	 impulsivity	 we	 found	 no	association	with	impulsivity.		
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In	summary,	based	on	the	spectroscopy	studies	in	this	thesis	we	found	more	evidence	for	a	role	for	glutamate	in	compulsivity	than	in	impulsivity	across	neurodevelopmental	disorders.	OCD	is	mainly	associated	with	compulsivity,	while	ADHD	is	more	associated	with	impulsivity.	ASD	and	TD	both	show	overlap	with	compulsivity	and,	to	a	lesser	extent,	also	with	impulsivity	(see	Figure	1).	 The	 distinction	 across	 disorders	 is,	 however,	 not	 so	 clear-cut,	 with	 compulsivity	 and	impulsivity	present	in	all	four	disorders	at	some	point	during	development	(Robbins	et	al.	2012;	Fineberg	 et	 al.	 2010;	 Huisman-van	 Dijk	 et	 al.	 2016).	 Further,	 TD-ASD	 and	 ADHD-OCD	comorbidities	 also	 occur	 (Geller	 et	 al.	 2000;	 Cath	 and	 Ludolph	 2013),	 which	 complicates	 the	compulsivity-impulsivity	association	even	more.				
		Figure	1	Schematic	overview	of	the	relation	between	the	developmental	disorders	described	in	this	thesis	and	 the	 association	 with	 impulsivity	 and	 compulsivity;	 the	 dashed	 line	 represents	 the	 ambiguous	distinction	 between	 these	 two	 traits.	 The	 arrows	 represent	 the	 (frequent)	 comorbidities	 across	 the	disorders.	In	this	thesis	I	found	support	for	an	association	between	compulsivity	and	glutamate	both	at	the	brain-	and	genetics	level;	for	impulsivity	this	was	only	supported	within	the	genetics	study.			We	were	not	able	 to	compare	all	 four	disorders	with	each	other	 in	 the	main	chapters	directly,	because	of	the	immense	reduction	in	participants	we	would	have	faced	due	to	the	multi-centre	nature	of	several	of	the	samples.	However,	for	this	general	discussion	I	aggregated	all	the	data	to	meta-analyse	the	patterns	we	observed	in	the	separate	chapters.	This	overall	analysis	is	used	as	an	 illustration	 of	 the	 findings	 across	 all	 disorders	 investigated	 within	 this	 thesis,	 using	glutamate-,	 compulsivity-	 and	 impulsivity	 measures	 from	 the	 chapters	 combined.	 Here	 I	 use	multi-centre	data	and	non-multi-centre	data,	which	is	a	less	stringent	approach	than	we	used	for	
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the	separate	chapters.	Using	all	participants	together	(n=255	and	n=237	for	ACC	and	striatum,	respectively),	we	find	the	same	results	as	described	in	chapters	4	and	6.	In	the	ACC,	I	found	an	overall	 diagnosis	 effect	 (F(4,247)=3.39,	 p=0.01).	 This	 effect	 was	 split	 up	 into	 diagnosis-control	comparisons,	which	showed	that	this	was	driven	by	the	ASD	and	OCD	group;	in	ASD	(p<0.001)	and	 OCD	 (p=0.04)	 significantly	 increased	 glutamate	 concentrations	 compared	 with	 controls	were	found,	while	no	differences	were	found	for	ADHD	and	TD	(both	p-values	>0.05)	(Figure	2).	None	 of	 the	 disorder	 groups	 differed	 from	 each	 other	 (p-values	 >0.05).	 Using	 the	 limited	interests	 subscale	 of	 the	 Repetitive	 Behaviour	 Scale	 (RBS;	 Lam	 and	 Aman	 2007))	 as	 a	compulsivity	 measure	 (taken	 from	 chapter	 4),	 we	 found	 an	 association	 with	 ACC	 glutamate	concentrations	 across	 the	 four	 disorder	 groups	 (rho=0.22,	 p=0.005;	 Figure	 3).	 However,	 as	shown	in	the	previous	chapters,	this	was	driven	by	ASD	and	OCD.	For	the	participants	for	whom	we	 had	 impulsivity	 measures	 available	 from	 the	 hyperactivity/impulsivity	 subscale	 from	 the	Conners	Parent	Rating	Scale	(Conners	et	al.	1998),	we	found	no	association	with	ACC	glutamate	(rho=-0.07,	p=0.38;	Figure	3),	confirming	the	findings	of	chapter	6.	In	the	striatum	we	did	not	find	any	differences	between	the	disorder	groups	and	controls	and	no	 associations	with	 either	 compulsivity	 or	 impulsivity.	 Interestingly,	 the	 impulsivity	 and	compulsivity	measures	themselves	were	positively	correlated	(rho=0.21,	p=0.007),	confirming	the	 positive	 relation	 between	 impulsivity	 and	 compulsivity	 behaviours.	 Additionally,	concentrations	 in	 the	 ACC	 were	 positively	 correlated	 with	 concentrations	 in	 the	 striatum	(rho=0.32,	p<0.001).	Previous	 structural	 and	 functional	 studies	 and	 meta-analyses	 have	 pointed	 to	 unique	patterns	 of	 brain	 alterations	 for	 ADHD,	 ASD	 and	 OCD	 underlying	 similar	 inhibitory	 control	deficits	(Rubia	et	al.	2010;	Rubia	et	al.	2011;	Lim	et	al.	2013;	Carlisi	et	al.	2016;	Norman	et	al.	2016).	 Our	 results	 regarding	 compulsivity	 seen	 in	 ASD	 and	 OCD,	 however,	 point	 to	 shared	underlying	 mechanisms	 in	 fronto-striatal	 signalling	 using	 neurochemical	 measures.	 The	association	 with	 obsessions	 and	 compulsions	 in	 TD	 in	 chapter	 6	 was	 based	 on	 a	 different	measure	 than	 we	 used	 for	 ASD	 and	 OCD;	 for	 the	 measures	 of	 the	 RBS	 we	 did	 not	 find	 an	association	within	TD,	supporting	the	close	resemblance	with	OCD	symptoms	but	less	with	ASD	symptoms.	 ADHD	 seems	 to	 be	 different	 from	 the	 other	 disorder	 groups	 in	 our	 MRS	 studies;	impulsivity	is	probably	less	regulated	by	glutamatergic	alterations	in	the	ACC	and/or	striatum.		 	
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		Figure	2	Effect	sizes	(Cohen’s	d)	for	differences	in	anterior	cingulate	cortex	(ACC)	glutamate	levels	for	the	four	 disorders	 compared	 with	 controls.	 The	 results	 show	 medium	 to	 large	 effect	 sizes	 for	 differences	between	 ASD	 and	 OCD	 patients	 compared	 with	 controls,	 and	 small	 effect	 sizes	 for	 ADHD	 and	 TD,	comparable	with	the	findings	of	the	separate	chapters	4	and	6.	
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			Figure	 3	Association	 between	 anterior	 cingulate	 cortex	 (ACC)	 glutamate	 levels	 and	 compulsivity	 and	 impulsivity	measures	 for	 participants	 from	 chapter	 4	 and	chapter	6	combined.	The	line	represents	the	total	fit.	Compulsivity	was	positively	associated	with	ACC	glutamate,	while	impulsivity	was	not.	
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GENETICS OF GLUTAMATE 	Since	glutamate	is	the	most	abundant	excitatory	neurotransmitter	in	the	human	central	nervous	system	 and	 especially	 in	 fronto-striatal	 circuits,	 investigating	 the	 genetic	 involvement	 in	glutamatergic	 alterations	 across	 neurodevelopmental	 disorders	 is	 of	 importance,	complementing	the	MRS	studies	that	are	only	able	to	investigate	a	small	number	of	brain	regions	within	one	study.	In	chapter	7	we	investigated	the	combined	effects	of	genes	encoding	glutamate	and	GABA	 receptors,	 transporters,	 and	additional	proteins	 involved	 in	 those	neurotransmitter	systems	on	quantitative	traits	of	ADHD	and	ASD.	The	strength	of	our	approach	compared	with	previous	multiple-variant	analyses,	 is	the	addition	of	competitive	testing	next	to	self-contained	testing.	 Recent	 research	 suggests	 that	 self-contained	 tests	 might	 harbour	 the	 risk	 of	 Type	 I	errors,	 because	 of	 an	 increased	 likelihood	 of	 finding	 association	when	 investigating	 polygenic	phenotypes.	A	significant	competitive	test	emphasizes	an	association	to	be	specific	 for	a	tested	gene-set	and	stronger	than	the	polygenic	background	of	the	phenotype,	while	a	non-significant	competitive	 test	 combined	 with	 a	 significant	 self-contained	 test	 indicates	 that	 one	 may	 have	captured	a	part	of	the	polygenic	nature	of	a	trait	(but	an	insufficiently	large	part	of	it).		 In	 line	with	 our	 results	 from	 the	 chapters	 describing	 the	MRS	 findings,	 the	 glutamate	gene-set	was	associated	with	ASD-traits	present	in	ADHD	patients.	The	link	between	glutamate	and	ASD	is	thus	only	indirect,	as	we	did	not	investigate	ASD	patients	in	this	study.	However,	not	in	line	with	what	we	found	in	the	fronto-striatal	circuit	in	ADHD	in	chapter	6,	here	we	did	find	hyperactivity/impulsivity	 symptom	 severity	 to	 be	 associated	 with	 glutamatergic	 variants.	Interestingly,	there	was	no	significant	association	with	inattention.	Although	we	did	not	include	participants	with	ASD,	measures	of	compulsivity-like	behaviour	as	seen	in	ASD	were	associated	with	 glutamate	 in	 the	ADHD-only	 sample	we	 used	 in	 this	 chapter,	 showing	 the	 importance	 of	investigating	 more	 trait-like	 behaviours.	 This	 should	 also	 be	 done	 vice	 versa,	 studying	compulsivity	measures	in	an	ASD	sample	and	investigating	the	possible	association	with	ADHD-traits.	The	international	collaboration	EU-Aims	(European	Autism	Interventions:	a	Multi-centre	Study	(Murphy	and	Spooren	2012))	might	be	suited	for	this.	Additionally,	information	is	needed	about	 associations	 of	 glutamate	 with	 these	 traits	 in	 the	 normal	 population.	 In	 our	 study,	 the	association	with	hyperactivity/impulsivity,	but	not	the	one	with	ASD-traits	showed	significance	in	 the	 competitive	 testing,	making	 strong	 claims	 for	 glutamatergic	 genetic	 involvement	 in	 this	symptom	domain	of	ADHD.	While	this	is	in	contrast	with	the	findings	in	chapter	6,	glutamatergic	genes	and	glutamatergic	brain	concentrations	do	not	necessarily	need	to	be	similarly	affected	in	one	disorder	 and/or	 trait.	Brain	 concentrations	of	 glutamate	 can	only	be	measured	 in	 a	 small	number	of	areas	 in	one	study	and	are	specific	 for	a	certain	 tissue	 type;	 this	 is	not	 the	case	 for	genetics.	The	genetic	make-up	of	all	cells	in	our	body	is	(largely)	the	same.	Gene	expression	and	
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translation	 of	 RNA	 into	 proteins	 is	 influenced	 not	 only	 by	 genetic	 variation,	 but	 also	 by	 the	environment.	 Also,	 gene-environment	 interactions	 have	 proven	 to	 contribute	 to	 several	neurodevelopmental	disorders	(e.g.	Uher	2014).	Thus	there	are	differences	between	the	brain-glutamate	 and	 genetics.	 While	 in	 two	 fronto-striatal	 brain	 regions	 no	 alterations	 were	 found	regarding	 impulsivity,	 this	 does	 not	 per	 definition	 rule	 out	 a	 role	 for	 brain-glutamate	 in	impulsivity	 in	 general.	 In	 chapter	 7	 we	 were	 not	 able	 to	 compare	 the	 association	 between	glutamate	 and	 impulsivity	 in	 ADHD	 with	 a	 matched	 control	 sample	 and	 can	 therefore	 only	speculate	 on	 differences	 between	 ADHD	 participants	 and	 controls.	 The	 scale	 we	 used	 for	impulsivity	 in	 this	study	 is	part	of	an	ADHD	questionnaire	(Conners	et	al.	1998),	which	would	probably	 have	 significantly	 differed	 from	 a	 hypothetical	 control	 group.	 However,	 impulsivity	within	 the	 general	 population,	 measured	 with	 a	 more	 general	 scale	 of	 impulsive	 behaviour,	might	be	associated	with	glutamate	as	well.	As	 described	 in	 the	 introduction,	 compulsivity	 can	 be	 considered	 a	more	maladaptive	perseveration	of	behaviour	which	does	not	so	much	 fall	within	 the	range	of	normal	behaviour	(Robbins	 et	 al.	 2012);	 this	 in	 contrast	 to	 impulsivity.	 This	 may	 explain	 the	 more	 specific	association	 of	 fronto-striatal	 glutamatergic	 alterations	 with	 compulsivity	 and	 compulsivity-disorders.	 The	neural	 correlates	 of	 impulsivity	may	have	 a	more	 indirect	 link	with	 glutamate,	which	may	also	be	present	within	normal	behaviour.	We	therefore	possibly	found	an	association	between	glutamatergic	genetic	variations	and	hyperactivity/impulsivity	specifically	in	ADHD	but	no	evidence	for	altered	brain	glutamate	concentrations	in	ADHD	and	TD.			
METHODOLGICAL CONSIDERATIONS 		Recruiting	participants	for	a	study	from	four	different	disorder	groups	fulfilling	several	in-	and	exclusion	 criteria	 (see	 chapter	 2)	 is	 not	 without	 struggle.	 One	 needs	 to	 consider	 collecting	enough	data	and	having	the	best	quality	available	or	collecting	more	data	with	the	possibility	of	more	confounding	factors.	The	COMPULS	and	IMAGE	cohorts,	used	in	chapters	4	through	7,	are	therefore,	 not	 perfectly	 balanced	 samples	 with	 the	 most	 ideal	 measures.	 The	 studies	 are	observational,	leading	to	the	inclusion	of	both	medication-naïve	and	medicated	participants	and	imperfect	matching	on	age,	sex	and	IQ.	Further,	the	recruitment	of	OCD	patients	in	the	relatively	young	age	groups	has	proven	to	be	difficult,	which	resulted	in	fewer	participants	 in	this	group	than	in	the	ASD	group	in	chapters	4	and	5.	The	studies	are	international	multi-centre	studies,	in	which	 we	 not	 only	 dealt	 with	 complex	 and	 heterogeneous	 disorders,	 but	 four	 different	 MRI	scanners	across	three	countries.	Although	we	were	able	to	disentangle	our	results	from	possible	confounds	related	to	these	differences	in	hardware	(see	the	supplementary	material	of	chapters	4	and	5),	the	variance	induced	by	these	variables	may	have	prevented	us	from	detecting	(other)	
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disorder-related	effects.	I	am	confident	that	the	scanner	variability	did	not	confound	the	results	of	chapter	4	and	5,	but	it	may	have	overruled	some	smaller	effects	we	have	not	been	able	to	pick	up	because	of	this	noise.			 Complementing	previous	literature,	the	approach	of	combining	multiple	disorders	in	one	study	 design	 has	 proven	 to	 be	 very	 informative	 on	 shared	 and	 overlapping	 phenotypes.	Additionally,	 in	 the	 MRS	 studies	 we	 used	 advanced	 methodology	 in	 correcting	 glutamate	concentrations	 for	 partial	 volume	 effects	 and	 tissue	 water	 concentrations	 (Ernst	 et	 al.	 1993;	Provencher	2014).	A	drawback	of	single	voxel	MRS	is	that	the	regions	are	relatively	 large.	Our	striatum	voxel	(see	Figure	1	from	chapter	4)	covered	both	caudate	and	putamen,	while	effects	of	glutamatergic	 alterations	 might	 be	 different	 for	 the	 two	 striatal	 sub-regions.	 Additionally,	scanning	time	is	of	course	limited,	especially	with	young	children.	Therefore	we	could	only	select	a	 few	 regions	 of	 interest	 to	 measure	 neurochemical	 concentrations;	 other	 regions	 related	 to	fronto-striatal	 functioning	 may	 show	 different	 glutamatergic	 alterations	 with	 regard	 to	compulsivity	and	 impulsivity.	Related	 to	 this	scanning	 time	 issue,	we	were	not	able	 to	reliably	measure	GABA	concentrations	because	different	methods	are	required	(MEGA-PRESS;	Mescher	et	al.	1998;	O’Gorman	et	al.	2011).		 In	chapter	7	we	used	a	sample	of	children	and	adolescents	with	combined-type	ADHD	in	which	we	 considered	 not	 only	ADHD	 symptom	 severity	 but	 also	ASD-trait	 severity.	 Since	 this	was	an	ADHD-only	sample	with	no	comorbid	ASD	diagnosis,	the	severity	of	ASD-traits	could	only	be	interpreted	within	ADHD.	The	results	of	this	chapter	cannot	be	viewed	as	related	to	disorder-risk	for	either	ADHD	or	ASD,	because	of	the	lack	of	a	control	group.			 The	aim	of	this	thesis	was	to	investigate	overlap	and	differences	across	disorders	and	use	the	 cross-disorder	 traits	 impulsivity	 and	 compulsivity	 in	 doing	 so.	 Since	 these	 traits	 are	 not	solely	 present	 within	 disorders	 but	 also	 to	 a	 greater	 or	 lesser	 extent	 within	 the	 general	population,	 considering	 not	 only	 the	 disorders	 on	 a	 spectrum	 but	 also	 the	 “healthy	 controls”	would	have	added	to	the	construct	of	dimensional	psychiatry	(Cuthbert	2014;	Heinz	et	al.	2016),	which	we	were	 not	 able	 to	 do	within	 the	 current	 studies.	 The	 questionnaires	we	 used	 in	 this	thesis	 are	 not	 per	 definition	 the	 best	measures	 for	 impulsivity	 and	 compulsivity	 available,	 as	these	are	derived	from	questionnaires	that	have	other	main	outcome	variables	related	to	ADHD	and	repetitive	behaviours.		
CLINICAL IMPLICATIONS 	Doing	scientific	research	is	a	world	unto	its	own	and	being	in	the	lab	making	scans	and	writing	MATLAB-scripts	to	analyse	all	the	data	lies	far	from	actual	clinical	practice.	However,	one	should	keep	 this	 in	mind	when	 doing	 scientific	 research:	 How	will	what	 I	 am	 doing	 help	 the	 clinical	
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practice	in	treatment	and	prevention	of	neurodevelopmental	disorders?	I	wish	to	discuss	some	possibilities	in	how	the	studies	conducted	in	this	thesis	might	contribute	to	this,	even	if	it	is	only	a	small	contribution.		 Clinical	practice	has	to	deal	with	the	sheer	complexity	and	heterogeneity	that	plagues	the	nature	of	neurodevelopmental	disorders.	Diagnosis	and	 treatment,	however,	are	still	based	on	behavioural	observations	and	by	ticking	off	a	list	of	symptoms	that	needs	to	be	fulfilled.	In	this	sense,	 the	heterogeneity	 cannot	 be	 captured	 sufficiently.	 Symptoms	 are	neither	necessary	nor	sufficient	 for	 diagnosis.	 A	 person	 can	 have	 six	 completely	 different	 symptoms	 from	 another	person	and	still	have	the	same	diagnosis.	In	this	thesis	I	have	shown	that	investigating	multiple	disorders	 together	 might	 increase	 the	 insight	 into	 shared	 mechanisms.	 Related	 to	 this,	investigating	 (child	 and	 adolescent)	 psychiatric	 disorders	 in	 a	 dimensional	way	 increases	 this	understanding	 further.	 Instead	 of	 using	 the	 yes/no	 distinction	 in	 diagnosis	 and	 enhancing	parochialism,	 scoring	 behavioural	 traits	 on	 a	 spectrum	 provides	 a	more	 complete	 image	 of	 a	person.	 One	 should	 therefore	 also	 not	 ignore	 the	 biological	 mechanisms	 that	 are	 underlying	these	traits.	Although	we	are	 far	 from	using	neuroimaging	modalities	 as	markers	 for	diagnosis,	 the	reason	for	using	MRI	in	clinical	samples,	I	am	convinced	of	the	fact	that	using	these	techniques	broadens	our	understanding	in	such	way	that	clinical	practice	may	benefit	from	this.	Since	at	the	individual	 level	no	 specific	 alterations	have	been	 found	 for	 the	neurodevelopmental	disorders	described	 in	 this	 thesis,	we	might	 be	 able	 to	 find	 compulsivity-markers	 that	 hold	 true	 across	disorders.	One	approach	 in	the	search	for	diagnostic	markers	uses	pattern	recognition	 in	MRI-data	 sets	 in	 which	 regularities	 are	 extracted	 to	 predict	 outcome	 measures	 (for	 a	 review	 see	Wolfers	et	al.	2015).	This	method	has	shown	promising	proof	of	concept	results	but	so	far	only	in	 research.	 Up	 until	 now	we	 are	 not	 able	 to	 accurately	 diagnose	 based	 on	 imaging	markers.	However,	 we	 might	 still	 be	 able	 to	 predict	 treatment	 response	 or	 clinical	 outcome.	 This	 has	already	been	proven	to	be	effective	in	for	instance	depression	(Fu	et	al.	2008).		There	is	currently	no	medication	treatment	that	completely	cures	people	from	any	of	the	disorders	 described	 in	 this	 thesis.	 Although	 stimulant	 treatment	 has	 shown	 to	 be	 effective	 in	ADHD	(Schweren	et	al.	2013;	Chan	et	al.	2016)	and	cognitive	therapy	and	the	selective	serotonin	reuptake	 inhibitors	 (SSRIs)	 are	 the	 first-line	 treatments	 for	 OCD	 (Grant	 2014),	 a	 significant	proportion	of	people	does	not	benefit	from	these	treatments.	In	addition,	there	are	currently	no	medications	to	effectively	treat	the	core	symptoms	of	ASD.	Taking	into	account	shared	biological	alterations	 in	 several	 disorders	 may	 improve	 treatment-effect	 at	 trait-level	 across	 these	disorders.	 Open	 label	 studies	 have	 shown	 reduction	 of	 OCD	 symptoms	 using	 glutamatergic	medications	 (e.g.	 memantine)	 in	 both	 adults	 and	 children	 (Grant,	 Odlaug,	 and	 Suck	 2007;	Aboujaoude,	Barry,	and	Gamel	2009;	Coric	et	al.	2005).	Clinical	trials	must	further	examine	the	
 	
223			
effectiveness	of	glutamatergic	treatment	in	reducing	compulsive	behaviour	in	both	ASD	and	OCD	(Häge	et	al.	2016).			
FUTURE RESEARCH 	What	 if	 we	 also	 had	 had	 sufficient	 information	 on	 impulsivity	 and	 compulsivity	 in	 healthy	controls;	 what	 if	 we	 had	 additionally	 investigated	 glutamate	 in	 the	 orbitofrontal	 cortex,	thalamus	 and	 globus	 pallidus	 (etcetera);	 what	 if	 we	 had	 collected	 more	 samples	 to	 combine	genetic	 and	neuroimaging	data?	Questions	 I	 am	asking	myself	 now	 that	 I	 have	written	up	 the	results	 of	 all	 separate	 studies	 within	 this	 thesis.	 The	 design	 of	 an	 experiment	 is	 of	 utmost	importance	 for	 its	 success.	 I	 would	 therefore	 like	 to	make	 some	 recommendations	 for	 future	studies	 into	 the	 involvement	 of	 glutamate	 in	 (compulsivity-related)	 neurodevelopmental	disorders.			 First,	 future	 studies	 should,	 at	 least	 in	 addition	 to	 but	 possibly	 instead	 of	 disorder-control	comparisons,	include	dimensional	measures,	which	use	well-defined	instruments	to	also	investigate	a	certain	trait	in	the	healthy	population.	In	addition	to	the	ones	used	in	the	current	thesis,	measures	such	as	the	Barratt	Impulsiveness	Scale	(Patton	et	al.	1995)	could	be	included	to	 measure	 trait-impulsivity.	 For	 compulsivity,	 scales	 are	 often	 disorder-specific	 and	 fewer	measures	 are	 available	 for	 the	 general	 population.	 Related	 to	 this,	 investigating	 multiple	disorders	 in	 one	 study	 has	 been	 proven	 to	 be	 of	 use	within	 this	 thesis	 by	 showing	 the	 same	findings	across	ASD	and	OCD	that	might	be	informative	for	treatment	of	both	disorders.	Future	studies	should	continue	this	 investigation.	Second,	not	only	the	combination	of	several	groups,	but	also	the	combination	of	several	(imaging)	modalities	is	recommended.	MRS	is	very	useful	in	investigating	glutamate	 concentrations	 in	vivo	but	 it	does	not	 tell	us	anything	more	about	 the	structure	 and/or	 functioning	 of	 certain	 brain	 regions	 or	 networks.	 Such	 information	 can	 be	obtained	 by	 combining	 MRS	 with	 functional	 imaging	 and	 by	 subsequently	 correlating	 the	glutamate	concentrations	with	the	BOLD	response.	Alternatively,	one	could	also	use	 functional	MRS,	 in	which	 live	 recordings	of	neurochemicals	 can	be	made,	while	performing	an	 fMRI	 task	(Taylor	 et	 al.	 2015).	 This	 would	 provide	 insights	 into	 the	 relationship	 between	 function	 and	neurochemistry	and	how	this	can	possibly	be	modulated.		As	 shown	 in	 this	 thesis,	 both	 imaging	 and	 genetics	 can	 be	 used	 to	 investigate	 the	involvement	of	glutamate	in	compulsivity.	However,	the	effect	of	glutamatergic	alterations	in	the	brain	and	those	induced	by	genetic	level	variation	may	differ	immensely.	Association	of	genetic	glutamatergic	 variation	 with	 brain	 glutamate	 concentrations,	 in	 other	 words	 using	 imaging	genetics	(Hariri	and	Weinberger	2003;	Durston	2010;	Glahn	et	al.	2015)	may	give	better	insights	into	 glutamatergic	 underpinnings	 of	 compulsivity.	 Further,	 glutamate	 does	 not	 operate	 in	
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isolation.	 Because	 of	 their	 close	 interaction	 within	 fronto-striatal	 circuitry,	 investigating	 the	combined	role	of	glutamate	and	dopaminergic,	serotonergic	and	GABAergic	signalling	will	help	us	 in	 better	 understanding	 the	 neurochemistry	 associated	 with	 compulsivity	 disorders	(Pittenger	et	al.	2011;	Reinhoud	et	al.	2013;	Walls	et	al.	2014;	Pehek	and	Hernan	2015;	Root	et	al.	2016).	Especially	 to	be	able	 to	 further	 look	 into	 the	excitatory/inhibitory	 imbalance	 in	ASD	(but	possibly	also	OCD,	and	therefore	compulsivity),	future	MRS	studies	should	focus	on	reliable	measures	of	both	glutamate	and	GABA.	Third,	in	our	studies,	we	showed	glutamatergic	alterations	in	a	very	specific	age	range	of	8	 to	 13	 years,	 in	 which	 development	 of	 fronto-striatal	 circuits	 is	 still	 ongoing.	 Although	 in	chapter	 3	we	 summarized	 previous	 literature	 showing	 a	 role	 for	 glutamate	 in	 adults	 as	well,	whether	 the	 increase	 in	ACC	glutamate	 is	 a	 stable	effect	within	 these	disorders,	 and	 therefore	possibly	within	compulsivity,	cannot	be	stated	based	on	the	studies	described	in	this	thesis.	To	establish,	 whether	 glutamatergic	 alterations	 in	 ASD	 and	 OCD	 are	 trait	 or	 state	 markers	longitudinal	investigations	are	therefore	warranted.		 	
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Het	 doel	 van	 dit	 proefschrift	 is	 om	 meer	 inzicht	 te	 verkrijgen	 in	 de	 neurale	 en	 genetische	mechanismen	die	onderliggend	zijn	aan	de	relatief	veel	voorkomende	ontwikkelingsstoornissen	attention-deficit/hyperactivity	 disorder,	 autism	 spectrum	 disorder,	 obsessive	 compulsive	disorder	en	Tourette’s	disorder	(afgekort	ADHD,	ASD,	OCD	en	TD).	De	focus	van	dit	proefschrift	ligt	op	de	overlappende	mechanismen	gerelateerd	aan	de	fronto-striatale	hersengebieden	en	de	rol	van	glutamaat	in	deze	stoornissen.		
ONTWIKKELINGSSTOORNISSEN 	ADHD	is	een	van	de	meest	voorkomende	ontwikkelingsstoornissen	en	wordt	gekenmerkt	door	aandacht	 tekort	 en/of	 hyperactiviteit,	 wat	 vaak	 leidt	 tot	 moeilijkheden	 in	 sociaal	 of	professioneel	 functioneren.	 Naast	 de	 kern-symptomen	 wordt	 ADHD	 ook	 gekenmerkt	 door	moeilijkheden	 met	 cognitieve	 controle	 en	 inhibitie	 en	 met	 (over)gevoeligheid	 voor	 beloning.	ASD	 wordt	 gekarakteriseerd	 door	 moeilijkheden	 in	 sociale	 interactie	 en	 communicatie,	abnormale	 sensorische	 ervaringen	 en	 door	 repetitieve	 en	 stereotypische	 gedragingen	 en	interesses.	 Met	 name	 het	 repetitieve	 gedrag	 is	 interessant	 voor	 de	 onderzoeken	 in	 dit	proefschrift.	OCD	gaat	samen	met	repetitieve	gedachten,	impulsen	of	beelden	(obsessies)	en	met	repetitieve	 (mentale)	 gedragingen	 (compulsies)	 die	 stressvol	 zijn	 of	 zorgen	 voor	 beperkt	functioneren.	Compulsies	zijn	vaak	gekoppeld	aan	obsessies	en	worden	uitgevoerd	om	angst	te	verminderen	die	door	de	obsessies	veroorzaakt	worden.	TD	wordt	gekenmerkt	door	meerdere	motorische	tics	en	één	of	meerdere	vocale	tics.	De	klachten	moeten	minimaal	een	jaar	aanwezig	zijn.	Tics	komen	voor	als	plotselinge,	snelle	en	doelloze	motorische	bewegingen	of	geluiden.	Ze	worden	steeds	op	dezelfde	manier	uitgevoerd,	wat	ze	stereotypisch	maakt.		Hoewel	 de	 definities	 van	 deze	 vier	 ontwikkelingsstoornissen	 verschillen	 en	 de	diagnostiek	 anders	 is,	 hebben	 alle	 vier	 de	 stoornissen	 gemeen	 dat	 er	 problemen	 zijn	 in	 de	fronto-striatale	 hersengebieden.	 Daarnaast	 worden	 ze	 allen	 in	 meerdere	 of	 mindere	 mate	gekenmerkt	door	impulsiviteit	en	compulsiviteit.		
IMPULSIVITEIT EN COMPULSIVITEIT 	ADHD,	ASD,	OCD	en	TD	komen	vaak	samen	voor.	Zo	heeft	bijvoorbeeld	30-80%	van	de	kinderen	met	 ASD	 voldoende	 symptomen	 voor	 een	 diagnose	 ADHD.	 De	 meest	 overlappende	eigenschappen	 tussen	 deze	 ontwikkelingsstoornissen	 zijn	 impulsiviteit	 en/of	 compulsiviteit.	Impulsiviteit	 is	 de	 neiging	 om	 in	 reactie	 op	 een	 stimulus	 te	 handelen	 zonder	 na	 te	 hebben	gedacht	wat	de	potentiele	negatieve	gevolgen	zullen	zijn.	Compulsiviteit	wordt	gekenmerkt	door	een	 repetitieve,	 niet	 tegen	 te	 houden	 drang	 om	 gedrag	 uit	 te	 voeren,	 het	 gevoel	 van	
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controleverlies,	het	niet	in	staat	zijn	om	gedragingen	te	stoppen	of	uit	te	stellen	en	de	neiging	tot	het	uitvoeren	van	gedrag	op	een	 stereotypische	manier.	 Zowel	 impulsiviteit	 als	 compulsiviteit	lijkt	het	gevolg	van	defecten	in	respons	inhibitie	of	cognitieve	controle.	Deze	cognitieve	controle	wordt	gereguleerd	door	fronto-striataal	functioneren.		
NEUROBIOLOGIE EN GENETICA VAN ONTWIKKELINGSSTOORNISSEN 	Er	 bestaan	 verschillende	 fronto-striatale	 circuits	 die	 het	 gedrag	 reguleren.	 Deze	 circuits	 zijn	separaat,	maar	werken	toch	intensief	samen.	Ze	zijn	daarnaast	geassocieerd	met	impulsiviteit	en	compulsiviteit.	 Impulsief	of	compulsief	gedrag	ontstaat	wanneer	er	een	disbalans	 is	 tussen	het	initiëren	 en	 continueren	 van	 gedrag	 en	 het	 inhiberen	 en	 veranderen	 van	 gedrag.	 Door	abnormaal	 functioneren	binnen	de	hersengebieden	die	hier	verantwoordelijk	voor	zijn	kan	er,	afhankelijk	van	welke	componenten	aangetast	zijn,	impulsief	of	compulsief	gedrag	ontstaan.	Studies	die	gebruik	maken	van	MRI	hebben	veelvuldig	laten	zien	dat	de	fronto-striatale	gebieden	 betrokken	 zijn	 bij	 ADHD,	ASD,	OCD	 en	TD.	 Veel	 studies	 demonstreren	 dat	 de	 basale	ganglia	kleiner	zijn	 in	ADHD	vergeleken	met	controles,	 terwijl	bijvoorbeeld	 in	ASD	de	caudate	nucleus	groter	is	en	in	TD	juist	weer	kleiner.	Ook	het	functioneren	van	de	gebieden	is	verstoord,	zowel	bij	het	uitvoeren	van	allerlei	cognitieve	taken	als	in	rust.		Deze	 structurele	 en	 functionele	 veranderingen	 in	 de	 fronto-striatale	 gebieden	 zouden	kunnen	samenhangen	met	neuro-chemische	veranderingen.	Meestal	wordt	er	onderzoek	gedaan	naar	 de	 bekende	 neurotransmitters	 dopamine	 en	 serotonine.	 Echter,	 de	 meest	 voorkomende	neurotransmitter	is	glutamaat,	betrokken	bij	bijna	alle	processen	in	het	brein.	Omdat	de	rol	van	glutamaat	zo	groot	is,	 is	het	belangrijk	dat	het	in	de	juiste	mate	op	de	juiste	plaats	op	de	juiste	tijd	 aanwezig	 is.	 Zowel	 te	 veel	 als	 te	weinig	 glutamaat	 kan	 schadelijk	 zijn.	 Glutamaat-signalen	zijn	 erg	 belangrijk	 in	 de	 communicatie	 tussen	 de	 fronto-striatale	 gebieden.	 Impulsiviteit	 en	compulsiviteit	zouden	daarom	wel	eens	deels	verklaard	kunnen	worden	door	een	disbalans	 in	glutamaat.	 Met	 behulp	 van	 MR	 spectroscopie	 is	 al	 eerder	 aangetoond	 dat	 er	 verstoorde	glutamaat	concentraties	zijn	in	de	fronto-striatale	gebieden	bij	ADHD,	ASD	en	OCD.		Samengevat	 kunnen	 we	 dus	 stellen	 dat	 de	 fronto-striatale	 gebieden	 betrokken	 zijn	 in	zowel	 ADHD,	 ASD,	 OCD	 als	 TD,	 aangetoond	 in	 studies	 die	 structurele,	 functionele	 en	 neuro-chemische	veranderingen	laten	zien.	Echter,	er	zijn	tot	nu	toe	nog	geen	studies	gedaan	naar	de	overlap	en	verschillen	tussen	deze	stoornissen	op	basis	van	de	eigenschappen	 impulsiviteit	en	compulsiviteit.		 Uit	 tweeling-	 en	 familie-studies	weten	we	dat	 er	 een	 genetische	 factor	 onderliggend	 is	aan	 ontwikkelingsstoornissen.	 Behalve	 dat	 er	 een	 grote	 mate	 van	 erfelijkheid	 is	 voor	 de	
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afzonderlijke	stoornissen	delen	ze	ook	erfelijke	factoren.	Het	 identificeren	van	deze	genetische	risico	factoren	blijft	echter	ingewikkeld	omdat	ontwikkelingsstoornissen	erg	heterogeen	zijn.	De	comorbiditeiten	 tussen	 de	 stoornissen	 maakt	 dit	 nog	 ingewikkelder.	 Veel	 voorkomende	varianten	 worden	 onderzocht	 met	 associatie-studies	 tussen	 een	 fenotype	 en	 de	 genetische	variatie.	 Dit	 kan	 bijvoorbeeld	 worden	 gedaan	 met	 kandidaat-genen;	 genen	 waarvan	 men	 al	verwacht	dat	ze	geassocieerd	zijn	met	een	fenotype.	Naast	kijken	naar	enkele	genen	of	varianten	kunnen	 er	 ook	 meerdere	 varianten	 worden	 meegenomen	 in	 één	 genetische	 analyse.	 Dit	 kan	zorgen	voor	meer	power	van	een	studie	en	de	kans	groter	maken	dat	we	fenotypische	variantie	kunnen	verklaren.	In	dit	proefschrift	hebben	we	zo’n	kandidaat-genen-set	gebruikt	in	hoofdstuk	7.		 Naast	 veel	 voorkomende	 varianten	 zijn	 er	 ook	 zeldzame	 genetische	 varianten,	 die	 bij	minder	dan	1%	van	de	mensen	voorkomen,	die	moeilijker	te	detecteren	zijn,	maar	die	wel	vaak	meer	variantie	verklaren	en	meer	effect	lijken	te	hebben	op	het	fenotype.	Er	is	veel	bewijs	voor	dat	ook	deze	zeldzame	varianten	een	grote	rol	spelen	bij	ontwikkelingsstoornissen. 	Het	doel	van	dit	proefschrift	was	om	meer	inzicht	te	krijgen	in	de	neurobiologie	en	de	genetica	van	ADHD,	ASD,	OCD	en	TD	en	hoe	zij	hierin	overlappen	of	verschillen,	met	een	specifieke	focus	op	(fronto-striataal)	glutamaat.	De	huidige	 literatuur	heeft	ons	al	 inzicht	gegeven	in	de	rol	van	glutamaat	 in	 ontwikkelingsstoornissen.	 Echter	 hebben	 onderzoeken	 tot	 nu	 toe	 de	 stoornissen	nog	 niet	 geïntegreerd	 in	 één	 studie	 om	 naar	 impulsiviteit	 en	 compulsiviteit	 te	 kijken.	 In	 dit	proefschrift	heb	 ik	dit	wel	gedaan.	De	eerdere	 literatuur	wordt	aangevuld	door	een	aantal	MR	spectroscopie	 studies,	 een	 structurele	MRI	 studie	 en	een	genetische	aggregatie	 studie.	 In	deze	studies	 bekijken	 we	 de	 rol	 van	 compulsiviteit	 (en	 impulsiviteit)	 tussen	 de	 verschillende	stoornissen	op	een	dimensionele	manier.			 	
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SAMENVATTING PER HOOFDSTUK 	In	hoofdstuk	2	wordt	het	 studie-cohort	beschreven	dat	 in	de	hoofdstukken	4,	 5	 en	6	 gebruikt	wordt.	 Het	 is	 een	 overzicht	 van	 de	 deelnemers	 aan	 de	 COMPULS	 studie	 en	 de	maten	 die	 we	verzameld	hebben	over	cognitief	functioneren,	genetica	en	MRI.	In	 het	 volgende	 hoofdstuk,	 hoofdstuk	 3,	 heb	 ik	 een	 overzicht	 gemaakt	 van	 alle	 MRS	literatuur	die	gepubliceerd	is	tot	het	jaar	2014.	Dit	hoofdstuk	is	een	samenvatting	van	59	studies	die	hebben	gekeken	naar	fronto-striatale	glutamaat	concentraties	in	kinderen,	adolescenten	en	volwassenen	met	ADHD,	ASD	en	OCD.	Al	deze	studies	samen	suggereerden	dat	er	veranderingen	in	 glutamaat	 concentraties	 waren	 in	 alle	 drie	 de	 stoornissen	 in	 de	 anterior	 cingulate	 cortex	(ACC)	 en	 het	 striatum.	 In	 kinderen	 en	 adolescenten	 met	 ADHD	 en	 ASD	 werden	 er	 in	verschillende	 studies	 in	 de	 ACC	 verhoogde	 glutamaat	 concentraties	 vergeleken	met	 controles	gerapporteerd,	terwijl	bij	volwassenen	met	ADHD	en	ASD	juist	verlaagde	concentraties	werden	gevonden.	 In	het	striatum	vonden	veel	studies	een	verhoging	in	alle	stoornissen,	onafhankelijk	van	leeftijd,	hoewel	er	ook	veel	studies	waren	die	geen	verschillen	vonden.	Wat	duidelijk	werd	uit	dit	overzichtsartikel	is	dat	er	inderdaad	overlappende	veranderingen	in	glutamaat	waren	in	ADHD,	ASD	en	OCD.	Naar	aanleiding	van	deze	bevindingen	heb	ik	een	aantal	studies	uitgevoerd	binnen	COMPULS	om	de	stoornissen	gezamenlijk	te	onderzoeken.	Hoofdstuk	 4	 beschrijft	 een	MRS	 studie	 naar	 glutamaat	 concentraties	 in	 de	 ACC	 en	 het	striatum	van	kinderen	met	ASD	en	OCD.	We	hebben	dit	op	een	categorische	manier	onderzocht,	door	 ASD,	 OCD	 en	 controles	 met	 elkaar	 te	 vergelijken.	 Daarnaast	 hebben	 we	 ook	 een	dimensionele	 vergelijking	 gedaan,	 waarin	 we	 keken	 of	 continue	 maten	 van	 compulsiviteit	geassocieerd	waren	met	 glutamaat	 concentraties.	Kinderen	met	ASD	en	OCD	 lieten	verhoogde	glutamaat	concentraties	in	de	ACC	zien	vergeleken	met	controles.	Interessant	hieraan	is	dat	we	geen	 verschillen	 vonden	 tussen	 de	 twee	 stoornissen.	 Daarnaast	 was	 deze	 verhoging	 in	 ACC	glutamaat	geassocieerd	met	een	verhoogde	mate	van	compulsiviteit.	De	bevindingen	van	deze	studie	 ondersteunen	 dus	 het	 idee	 van	 een	 gedeeld	 mechanisme	 onderliggend	 aan	 de	compulsiviteit	in	beide	stoornissen.	In	 hoofdstuk	 5	 hebben	 we	 het	 volume	 van	 het	 striatum	 in	 relatie	 tot	 glutamaat	concentraties	 bekeken.	Ook	 al	 vonden	we	 in	 hoofdstuk	 4	 geen	 groepsverschillen	 in	 glutamaat	concentraties,	 in	het	 striatum	zijn	 er	 veel	 studies	die	wijzen	op	 structurele	 abnormaliteiten	 in	ASD	 en	OCD.	 Structurele	 abnormaliteiten,	 zoals	 eerder	 beschreven,	 kunnen	 samenhangen	met	neuro-chemische	 abnormaliteiten.	 In	 dit	 hoofdstuk	 hebben	 we	 onderzocht	 of	 ASD	 en	 OCD	geassocieerd	 waren	 met	 verschillen	 in	 het	 volume	 en	 de	 vorm	 van	 het	 striatum	 en	 of	 dit	gerelateerd	was	 aan	 glutamaat	 concentraties	 en	 N-Acetylaspartate	 (NAA)	 concentraties.	 Deze	laatste	maat	wordt	gebruikt	om	de	 integriteit	 van	neuronen	 te	onderzoeken.	We	vonden	geen	
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groepsverschillen	in	volume	of	vorm,	maar	een	diagnose	×	hemisfeer	interactie	liet	zien	dat	er	een	asymmetrie	was	 in	het	volume	van	het	 striatum	 in	ASD	en	OCD	vergeleken	met	 controles	(rechts	groter	dan	 links).	Ook	hier,	net	als	 in	hoofdstuk	4,	verschilden	de	stoornissen	niet	van	elkaar.	 In	 de	 ASD	 groep	 vonden	we	 lagere	NAA	 concentraties	 in	 het	 striatum	 vergeleken	met	controles.	Het	volume	van	het	striatum	was	daarnaast	gerelateerd	aan	de	hoeveelheid	glutamaat	en	 de	 hoeveelheid	 NAA,	 wat	 mogelijk	 wijst	 op	 een	 verminderde	 neuronale	 integriteit	 of	 een	verminderd	functioneren	van	het	striatum	in	deze	groep.	Hoofdstuk	6	beschrijft	een	MRS	studie	die	in	methode	vergelijkbaar	is	met	hoofdstuk	4.	In	 dit	 geval	 onderzochten	 we	 echter	 kinderen	 met	 ADHD	 en	 TD.	 Daarnaast	 werden	 er	 ook	kinderen	 geïncludeerd	 die	 beide	 stoornissen	 hadden.	 Er	 werden	 geen	 verschillen	 gevonden	tussen	de	groepen	in	glutamaat	concentraties	in	de	ACC	of	het	striatum.	Echter,	in	kinderen	met	TD	vonden	we	een	associatie	tussen	ACC	glutamaat	en	obsessief	en	compulsief	gedrag.	Dit	was	de	 eerste	 studie	 naar	 glutamaat	 concentraties	 in	 kinderen	met	TD.	 Interessant	 is	 dat	TD	 vaak	samen	voorkomt	met	OCD	en	dat	de	bevindingen	van	dit	hoofdstuk	en	hoofdstuk	4	dus	wijzen	op	een	betrokkenheid	van	glutamaat	in	compulsief	gedrag	in	beide	stoornissen.	In	het	laatste	hoofdstuk,	hoofdstuk	7,	hebben	we	gebruik	gemaakt	van	het	IMAGE	cohort,	een	 grote	 groep	 kinderen	 en	 adolescenten	 met	 ADHD.	We	 hebben	 naar	 genetische	 varianten	gekeken	 die	 betrokken	 zijn	 bij	 glutamaat	 of	 GABA.	 In	 deze	 studie	 hebben	 we	 meerdere	genetische	varianten	gecombineerd	en	gekeken	wat	de	gezamenlijke	associatie	met	het	fenotype	was.	De	ernst	van	de	ADHD	symptomen	en	van	autisme	symptomen	werd	bekeken.	Daarnaast	keken	we	of	cognitieve	controle	geassocieerd	was	met	variaties	in	glutamaat	en	GABA	genen.	We	vonden	dat	het	glutamaat	genen-set	geassocieerd	was	met	hyperactiviteit	en	impulsiviteit,	maar	niet	met	aandacht	tekort,	en	met	autisme	symptomen.	GABA	was	ook	geassocieerd	met	autisme	en	met	cognitieve	controle	(maar	met	deze	laatste	niet	significant).	Deze	studie	wijst	op	een	rol	voor	een	glutamaat-GABA	disbalans	 in	autisme-symptomen	 in	ADHD	en	op	betrokkenheid	van	glutamaat	bij	hyperactiviteit	en	impulsiviteit.		
GLUTAMAAT IN IMPULSIVITEIT EN COMPULSIVITEIT 	Dit	proefschrift	bestaat	uit	een	aantal	hoofdstukken	waarin	met	behulp	van	MRS	naar	glutamaat-concentraties	 in	 het	 brein	 is	 gekeken	 (hoofdstuk	 4-6)	 en	 een	 hoofdstuk	 (7)	 dat	 naar	 de	betrokkenheid	van	genen	kijkt.	 Samengevat	vinden	we	 in	hoofdstuk	4	 tot	en	met	6	verhoogde	glutamaat	concentraties	 in	de	ACC	van	kinderen	met	ASD	en	OCD,	die	ook	geassocieerd	waren	met	 een	 maat	 van	 compulsiviteit	 in	 deze	 stoornissen	 en	 in	 TD,	 hoewel	 we	 geen	 verhoogde	waarden	 vonden	 voor	 ADHD	 en	 TD.	 ASD	 en	 OCD	 worden	 het	 meest	 geassocieerd	 met	compulsiviteit	 terwijl	 ADHD	meer	met	 impulsiviteit	 in	 verband	wordt	 gebracht	 en	 TD	 er	 een	
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beetje	 tussenin	 ligt.	 De	 resultaten	 van	 de	 MRS	 studies	 suggereren	 dus	 dat	 glutamaat-veranderingen	in	de	ACC	geassocieerd	zijn	met	compulsiviteit	maar	dat	het	niet	gegeneraliseerd	kan	 worden	 naar	 compulsiviteit	 én	 impulsiviteit.	 Het	 onderscheid	 tussen	 de	ontwikkelingsstoornissen	 is	 echter	 niet	 zo	 zwart-wit.	 Zowel	 compulsieve	 als	 impulsieve	gedragingen	komen	in	zekere	mate	voor	 in	alle	vier	de	stoornissen.	 In	alle	stoornissen	hebben	we	niet	de	bevindingen	uit	eerdere	studies	in	het	striatum	kunnen	repliceren,	wat	suggereert	dat	de	 verandering	 geassocieerd	 met	 compulsiviteit	 ACC-specifiek	 is	 in	 onze	 studies.	 De	 meer	specifieke	associatie	met	compulsiviteit	en	compulsiviteit-stoornissen	komt	misschien	doordat	compulsiviteit	 op	 een	 extremere	 vorm	 van	 gedrag	 duidt	 dan	 impulsiviteit.	 De	 onderliggende	neurobiologie	 met	 impulsiviteit	 is	 misschien,	 indirect,	 tevens	 aanwezig	 in	 normaal	 gedrag.	Daarom	 vonden	we	mogelijk	wel	 bewijs	 voor	 genetische	 variaties	 in	 glutamaat	 en	 een	 relatie	met	impulsiviteit,	maar	geen	verschillen	in	het	brein.			
DE KLINISCHE PRAKTIJK  	Wat	 betekenen	 de	 resultaten	 van	 dit	 proefschrift	 voor	 de	 klinische	 praktijk?	 De	 klinische	praktijk	 heeft	 te	 kampen	 met	 complexiteit	 en	 heterogeniteit	 die	 ten	 grondslag	 liggen	 aan	ontwikkelingsstoornissen.	 Diagnose	 en	 behandeling	 worden	 echter	 nog	 steeds	 gebaseerd	 op	gedragsmatige	observaties	en	door	het	aankruisen	van	een	lijst	met	symptomen.	Op	deze	manier	wordt	 de	 heterogeniteit	 niet	 voldoende	 in	 kaart	 gebracht.	 Symptomen	 zijn	 noch	 noodzakelijk	noch	 voldoende	 voor	 een	 diagnose.	 Een	 persoon	 kan	 zes	 compleet	 verschillende	 symptomen	hebben	 vergeleken	 met	 een	 ander	 persoon	 maar	 toch	 dezelfde	 diagnose	 krijgen.	 In	 dit	proefschrift	heb	 ik	 laten	zien	dat	het	onderzoeken	van	meerdere	stoornissen	tegelijkertijd	kan	zorgen	 voor	meer	 inzicht	 in	 gedeelde	mechanismen.	 In	plaats	 van	het	 gebruik	 van	 een	 ja/nee	dichotomie	 en	 daarmee	 de	 vergroting	 van	 hokjes-denken,	 geeft	 een	 dimensionele	 vergelijking	een	 duidelijker	 beeld.	 Hierbij	 kunnen	 de	 biologische	 onderliggende	 mechanismen	 niet	genegeerd	worden.		Hoewel	we	verre	zijn	van	het	gebruik	van	imaging	modaliteiten	voor	het	stellen	van	een	diagnose,	 ben	 ik	 ervan	 overtuigd	 dat	 het	 gebruik	 van	 deze	 technieken	 ons	 begrip	 zodanig	vergroot	dat	de	klinische	praktijk	hier	voordeel	uit	kan	halen.	Er	 is	momenteel	geen	medicatie	beschikbaar	 die	 een	 stoornis	 volledig	 geneest.	 Voor	 bijvoorbeeld	 ADHD	 is	 gebleken	 dat	stimulantia	 effectief	 zijn,	maar	 een	 grote	 groep	 patiënten	 ondervindt	 geen	 voordeel	 van	 deze	behandeling.	Voor	ASD	 is	zelfs	nog	geen	behandeling	beschikbaar.	Als	de	gedeelde	biologische	mechanismen	 worden	 meegenomen	 zou	 het	 behandelings-effect	 kunnen	 toenemen.	 Klinisch	onderzoek	zal	zich	verder	moeten	richten	op	de	effectiviteit	van	glutamaterge	behandeling	in	het	reduceren	van	compulsiviteit	in	ASD	en	OCD.	
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VERVOLGONDERZOEK 	Het	ontwerp	van	een	onderzoek	is	van	groot	belang	voor	het	succes	ervan.	Ik	zou	daarom	graag	enkele	 aanbevelingen	 doen	 voor	 toekomstig	 onderzoek	 naar	 de	 rol	 van	 glutamaat	 in	compulsiviteit	en	de	hieraan	gerelateerde	stoornissen.		 Ten	eerste	zouden	toekomstige	studies	dimensionele	maten	moeten	includeren	met	goed	gedefinieerde	constructen	die	ook	 in	de	controle-populatie	 te	onderzoeken	zijn.	Ten	 tweede	 is	niet	 alleen	 de	 combinatie	 van	 meerdere	 stoornissen	 in	 één	 studie	 van	 belang,	 maar	 ook	 het	combineren	 van	 meerdere	 meet-modaliteiten.	 MRS	 is	 zeer	 nuttig	 in	 het	 onderzoeken	 van	glutamaat	concentraties	maar	het	vertelt	ons	niets	over	de	structuur	en/of	functie	van	de	regio	of	 zelfs	 de	 netwerken.	 Door	 een	 combinatie	 van	 fMRI	 en	 MRS	 (functionele	 MRS)	 kan	 men	glutamaat	 concentraties	 bekijken	 tijdens	 het	 uitvoeren	 van	 een	 taak.	 Ook	 kan	 de	 associatie	tussen	genetische	maten	en	brein-maten	gerelateerd	aan	glutamaat	ons	meer	 inzicht	 geven	 in	het	onderliggende	mechanisme	van	compulsiviteit.	Vanwege	de	hechte	samenwerking	binnen	de	fronto-striatale	 gebieden	 is	 het	 daarnaast	 zinvol	 om	de	 gecombineerde	 rol	 van	 glutamaat	met	andere	 neurotransmitters	 als	 dopamine,	 serotonine	 en	 GABA	 transmissie	 verder	 te	onderzoeken.	Ten	 derde,	 om	 te	 achterhalen	 of	 glutamaat-veranderingen	 in	 ASD	 en	OCD	 gekenmerkt	worden	door	een	tijdelijk	effect	of	een	permanente	afwijking,	zijn	longitudinale	studies	nodig.	In	de	huidige	studies	hebben	we	een	zeer	specifieke	leeftijdsgroep	onderzocht	(8-13	jaar)	waarin	de	ontwikkeling	van	 fronto-striatale	gebieden	nog	volop	 in	gang	 is.	Hoewel	we	 in	hoofdstuk	3	hebben	 gezien	 dat	 eerdere	 studies	 al	 een	 rol	 voor	 glutamaat	 in	 de	 volwassenheid	 hebben	gevonden,	 kunnen	we	 op	 basis	 van	 de	 studies	 in	 dit	 proefschrift	 niet	 concluderen	 of	 het	 een	stabiele	 bevinding	 is	 die	 geassocieerd	 kan	 worden	 met	 ASD	 of	 OCD	 en	 daarmee	 met	compulsiviteit.		 	
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DONDERS GRADUATE SCHOOL FOR COGNITIVE NEUROSCIENCE 
 For	a	successful	research	Institute,	it	is	vital	to	train	the	next	generation	of	young	scientists.	To	achieve	 this	 goal,	 the	 Donders	 Institute	 for	 Brain,	 Cognition	 and	 Behaviour	 established	 the	Donders	Graduate	School	for	Cognitive	Neuroscience	(DGCN),	which	was	officially	recognised	as	a	national	 graduate	 school	 in	2009.	The	Graduate	 School	 covers	 training	 at	 both	Master’s	 and	PhD	 level	 and	 provides	 an	 excellent	 educational	 context	 fully	 aligned	 with	 the	 research	programme	of	the	Donders	Institute.		The	 school	 successfully	 attracts	highly	 talented	national	 and	 international	 students	 in	biology,	physics,	 psycholinguistics,	 psychology,	 behavioral	 science,	 medicine	 and	 related	 disciplines.	Selective	 admission	 and	 assessment	 centers	 guarantee	 the	 enrolment	 of	 the	 best	 and	 most	motivated	students.	The	DGCN	tracks	the	career	of	PhD	graduates	carefully.	More	than	50%	of	PhD	alumni	show	a	continuation	 in	 academia	 with	 postdoc	 positions	 at	 top	 institutes	 worldwide,	 e.g.	 Stanford	University,	 University	 of	 Oxford,	 University	 of	 Cambridge,	 UCL	 London,	MPI	 Leipzig,	 Hanyang	University	 in	 South	 Korea,	 NTNU	 Norway,	 University	 of	 Illinois,	 North	 Western	 University,	Northeastern	 University	 in	 Boston,	 ETH	 Zürich,	 University	 of	 Vienna	 etc.	 Positions	 outside	academia	 spread	among	 the	 following	 sectors:	 specialists	 in	a	medical	 environment,	mainly	 in	genetics,	geriatrics,	psychiatry	and	neurology.	Specialists	in	a	psychological	environment,	e.g.	as	specialist	 in	 neuropsychology,	 psychological	 diagnostics	 or	 therapy.	 Positions	 in	 higher	education	 as	 coordinators	 or	 lecturers.	 A	 smaller	 percentage	 enters	 business	 as	 research	consultants,	analysts	or	head	of	research	and	development.	Fewer	graduates	stay	in	a	research	environment	 as	 lab	 coordinators,	 technical	 support	 or	 policy	 advisors.	 Upcoming	 possibilities	are	positions	in	the	IT	sector	and	management	position	in	pharmaceutical	 industry.	In	general,	the	 PhDs	 graduates	 almost	 invariably	 continue	 with	 high-quality	 positions	 that	 play	 an	important	role	in	our	knowledge	economy.		For	more	information	on	the	DGCN	as	well	as	past	and	upcoming	defenses	please	visit:	http://www.ru.nl/donders/graduate-school/phd/		
 

